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Ischaemic heart disease (IHD) is a leading cause of morbidity and mortality 
worldwide.  IHD occurs when blood-flow to the heart is occluded, depriving the tissue of 
oxygen and glucose.  Paradoxically, restoration of blood supply can cause further damage, 
termed reperfusion injury. The resultant oxidative stress (OS) causes multiple pathologies 
including profound mitochondrial damage. 
Mitochondrial function is closely linked to their dynamics; continual fission and 
fusion facilitate mitochondrial-trafficking and ATP-distribution.  Mitochondrial fission is 
mediated by the dynamin-like GTPase Drp1, which is recruited to mitochondria by its 
receptor Mff.  Over-expression of Drp1 or Mff results in highly fragmented, dysfunctional 
mitochondria. The regulation of Drp1 by post-translational modifications (PTMs) is well-
established, whereas regulation of Mff PTMs is less defined. 
The aim of this PhD was to determine if, and how, manipulation of Mff PTMs can 
protect against mitochondrial damage incurred by IHD. 
I show that OS causes phosphorylation of Mff, which promotes its SUMOylation.  
Mff SUMOylation subsequently leads to its ubiquitination and degradation.  We propose 
that this is a protective response to limit mitochondrial fragmentation.  Non-SUMOylatable 
Mff mutants have significantly reduced ubiquitination and slower turnover, indicating the 
activity of a SUMO-targeted ubiquitin ligase (STUbL).   
I demonstrate that Mff is ubiquitinated by at least three ligases, and test the 
hypothesis that Parkin, a known ligase of Mff, could be recruited via a SUMO-dependent 
mechanism.  While Parkin interacts non-covalently with SUMO, its recruitment to Mff is 
SUMO-independent.  I then show that Parkin ubiquitinates Mff at its SUMOylatable lysine, 
whereas Fbxo7, a component of the Skp1-Cul1-Fbx ligase complex, mediates ubiquitination 
of Mff at a site independent of both SUMO and Parkin. 
Given its dependence on OS, we propose that specific manipulation of the novel STUbL 
pathway could be a viable clinical intervention in recovery from IHD.  This project therefore 
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Chapter 1 Introduction 
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Chapter 1 Introduction 
1.1 Mitochondrial dynamics regulate their 
function 
The mitochondrion is an organelle found in most eukaryotic cells, but varies 
considerably between cell types in size, structure and number.  For example, red blood 
cells have no mitochondria, but hepatocytes may have more than 2000 (Voet and Voet, 
2011).  Mitochondria are bound by a double membrane and are generally 0.75-3µm in 
diameter (Wiemerslage and Lee, 2016).  These organelles are highly compartmentalised 
with structures for specific processes in the generation of adenosine triphosphate (ATP); 
90% of cellular ATP is generated by mitochondria, resulting in mitochondria colloquially 
being referred to as “the powerhouse of the cell” (Pessayre et al., 2002).   
1.1.1 Mitochondria: discovery and evolution 
As reviewed previously (Ernster and Schatz, 1981), intracellular structures 
retrospectively believed to be mitochondria were first observed in the 1840s, although it 
was not until the late 1800s that they were recognised to be ubiquitously distributed 
throughout cell types, and of functional importance.  The respiratory chain was not 
described until the discovery of cytochromes in 1925, and cellular respiration was not 
attributed specifically to mitochondria until the late 1940s.   
Despite the dependence of most eukaryotic cells on mitochondria for energy 
conversion, it is now widely accepted that they were originally prokaryotic cells, engulfed 
by eukaryotic cells to ultimately form an endosymbiotic relationship (Keeling and Archibald, 
2008).  It is thought that an anaerobic cell endocytosed an aerobic bacterium but was 
unable to digest it.  The cytoplasm of the anaerobic cell, abundant in partially-digested 
carbohydrates, allowed the aerobic bacterium to flourish and generate enough ATP to be 
beneficial to the anaerobic host as well (Gray, 1992, Zimorski et al., 2014).  In support of 
this theory, mitochondria have their own genome, with an alternative genetic code and 
DNA replication and repair machinery, which show significant similarity to those of the 
bacterial species Rickettsia prowazekii (Andersson et al., 1998).  Mitochondria have their 
own ribosomes, which are more like those of bacteria than of eukaryotes (Manuell et al., 
2007).  Furthermore, mitochondria divide only by binary fission, which is also how bacteria 
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and archaea divide, and eukaryotic cells cannot generate de novo mitochondria (Margolin, 
2005). 
1.1.2 Mitochondrial structure 
The mitochondrion has a double membrane comprising proteins and phospholipid 
bilayers.  This creates 5 distinct mitochondrial compartments: outer membrane, 
intermembrane space, inner membrane, cristae (formed by folding of the inner 
membrane) and matrix (the space created between cristae) (Figure 1.1). 
The mitochondrial outer membrane (MOM or OMM) has a protein:phospholipid 
ratio similar to that of the eukaryotic plasma membrane, and is largely composed of 
transmembrane porins, which allow free diffusion of small molecules between the 
cytoplasm and the mitochondrial intermembrane space (Checchetto and Szabo, 2018).  
Larger proteins can translocate into the mitochondria via binding of a signalling sequence 
on their N-termini to a multi-subunit mitochondrial translocase for active transport 
(Herrmann and Neupert, 2000).  Disruption of the MOM allows intermembrane proteins 
to leak into the cytoplasm, resulting in cell death (Chipuk et al., 2006).  As well as being 
crucial to mitochondrial integrity and function, the MOM can also associate with the 
endoplasmic reticulum (ER) (Hayashi et al., 2009). 
The intermembrane space (IMS) is located between the outer and inner membranes 
of the mitochondria.  Due to their free diffusion through the MOM, ions and other small 
molecules are at the same concentration as in the cytoplasm. However, the protein 
composition of the intermembrane space differs from the cytoplasm due to the need for 
specific signalling sequences to translocate.  Cytochrome c, the last enzyme of the 
respiratory transport chain, is localised here, and its leakage into the cytoplasm is often 
used as a marker of cellular stress and/or death (Chipuk et al., 2006). 
The inner mitochondrial membrane (IMM or MIM) is highly impermeable and has a 
membrane potential as a result of the electron transport chain.  The MIM has a very high 
protein:phospholipid ratio, and incorporates enzymes involved in ATP synthesis, oxidative 
phosphorylation, metabolite transport, protein import, and mitochondrial fission and 
fusion.  The MIM extends not only around the internal perimeter of the mitochondrion, 
but also invaginates to create numerous cristae, greatly increasing its available surface for 
ATP production; mitochondria in cells with greater energy-demands have greater numbers 
of cristae (Mannella, 2006). 
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The mitochondrial matrix fills the space between cristae and contains around 60% 
of all mitochondrial proteins, including enzymes required for pyruvate and fatty acid 
oxidation, as well as the citric acid cycle.  Additionally, the matrix contains copies of the 
mitochondrial DNA genome, which encodes the machinery required to generate RNAs and 
proteins, including tRNAs and ribosomal components (Anderson et al., 1981).        
 
1.1.3 Organisation and distribution of 
mitochondria 
In the vast majority of cells, mitochondria form extensive and dynamic networks, 
undergoing continuous cycles of fission (division) and fusion.  This creates a highly 
adaptable and efficient energy transfer system, able to rapidly deliver ATP to where it is 
most urgently needed within the cell (Piquereau et al., 2013).  Fused mitochondria 
(mitochondrial network/reticulum) facilitate delivery of ATP from the cell periphery to the 
core, whereas individual mitochondria can be trafficked rapidly, to meet localised increases 
in energy demand throughout the cell (Hom and Sheu, 2009, Skulachev, 2001).  A growing 
body of work is uncovering an important role for mitochondria at ER contact sites, termed 
mitochondria-associated ER membrane (MAM) (Hayashi et al., 2009).     
1.1.4 Mitochondrial function 
The primary function of mitochondria is ATP production by aerobic respiration.  
Pyruvate and NADH, the main products of glucose glycolysis in the cytoplasm, are actively 
transported through the MIM and oxidised in a reaction that generates 13x more ATP than 
Figure 1.1 Labelled schematic of a mitochondrion.  Mitochondria have an outer (MOM) and 
inner (MIM) membrane, separated by the intermembrane space (IMS).  The MIM is highly 
folded, creating cristae, which increase the surface area for ATP production.  The matrix 
sites between the cristae and is the site of various enzyme-catalysed reactions and the 
mitochondrial genome. 
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anaerobic respiration (Rich, 2003).  However, mitochondria also carry out numerous other 
functions. 
Mitochondria can transiently store Ca2+ ions in the matrix, and can also rapidly 
release Ca2+, allowing them to act as a cytosolic calcium buffer (Rossier, 2006).  The ER is 
the primary site of Ca2+ storage, and the interactions between ER and MOM at MAM 
contact sites allow for significant Ca2+ exchange, and play an important role in Ca2+ 
signalling (Pizzo and Pozzan, 2007). 
Other roles for mitochondria include intracellular signalling, for example via 
mitochondrially generated reactive oxygen species (ROS), which trigger the inflammatory 
response in pathologies including cardiovascular disease (CVD) (Li et al., 2013).  
Mitochondria are also sensitive and responsive to hormones, particularly via mitochondrial 
oestrogen receptors, which have been identified in mitochondria isolated from the brain 
and heart.  Oestrogens have been shown to modulate several mitochondrial functions, 
including mitochondrial DNA transcription and oxygen consumption (Klinge, 2008).  
Mitochondrial fission and fusion proteins have also been shown to contribute to temporal 
regulation of mitochondrial metabolism and the cell-cycle (McBride et al., 2006).  
Additionally, mitochondria play a key part in activation of mammalian apoptosis.  Bcl-2 
proteins regulate the release of pro-apoptotic factors from the mitochondrial IMS to the 
cytosol, where they activate caspases responsible for apoptosis and phagocytosis (Wang 
and Youle, 2009). 
1.1.5 Fission and fusion proteins 
Mitochondria are constantly undergoing balanced cycles of fission and fusion to 
create an extensive reticulum that allows efficient energy transfer and can adapt quickly to 
meet changing energy demands, while also effectively disposing of damaged organelles.  
Fusion and fission events occur roughly every two minutes in a mitochondrion (Nunnari et 
al., 1997).  These are both tightly regulated processes, effected by dynamins and dynamin-
related proteins (DRPs).  Mitochondrial fission will be the primary focus of this thesis. 
1.1.5.1 Mitochondrial dynamics are controlled by Dynamins 
and DRPs 
The 100kDa GTPase Dynamin was first identified in 1989 and was shown to be pivotal 
in fission of endocytic vesicles in both plant and animal cells (Shpetner and Vallee, 1989).  
Dynamin has the ability to self-assemble into helical polymers, which co-assemble with the 
neck of a budding vesicle and co-ordinate membrane severing.  Structurally, Dynamin 
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comprises a GTPase domain, a long stalk made up of a four-helix bundle, a 
phosphoinositide‐4,5‐bisphosphate (PIP2)‐binding pleckstrin homology domain (PH) to 
bind membranes, and a proline‐rich domain (PRD).  In mammals, three Dynamin isoforms 
(Dyn1-3) are expressed; Dyn2 is ubiquitously expressed and Dyn1 and -3 are neuron-
specific (Antonny et al., 2016).   
DRPs are also large GTPases that utilise GTP-dependent self-assembly and the 
resultant GTP hydrolysis-mediated conformational changes to remodel intracellular 
membranous structures (Faelber et al., 2013, Praefcke and McMahon, 2004).  The 
mammalian DRP Drp1 (Dnm1 in yeast) drives fission of mitochondrial membranes, while 
DRPs Mfn1/2 (Fzo1 in yeast) mediate fusion of the MOM and Opa1 (Mgm1 in yeast) 
mediates fusion of the MIM (Hoppins et al., 2007). 
1.1.5.2 Mitochondrial fusion 
Mitochondrial fusion enables communication and contents-sharing between 
mitochondrial compartments.  ATP can be rapidly trafficked through the reticulum, healthy 
mitochondrial components can be re-distributed, and damage to mitochondrial DNA can 
be diluted throughout the network, reducing the effects of genomic mutations.  All of this 
is thought to buffer against transient defects in mitochondrial function, but fusion remains 
a relatively poorly understood mechanism (Chen and Chan, 2010).  Currently, evidence 
supports a process in which MOM and MIM fusion occur in two separable stages, both of 
which require DRPs.  The first stage is the tethering of membranes of two mitochondria 
and is mediated by the self-assembly of fusion DRPs (Song et al., 2009, Meeusen et al., 
2004, Meeusen et al., 2006).  The second stage is induced by DRP-dependent GTP 
hydrolysis and involves conformational changes.  This is proposed to destabilise lipid 
bilayers of the tethered mitochondria and facilitate lipid mixing and ultimately 
mitochondrial fusion.  Electron microscopy has been used to observed assembled fusion 
DRP structures, but it remains unclear if/how they contribute to active fusion complexes 
(Abutbul-Ionita et al., 2012, Rujiviphat et al., 2009).  
Chapter 1 Introduction 
6 
 
1.1.6 Mitochondrial fission 
Fission facilitates transport, distribution, quality control and degradation of 
mitochondria (Lackner and Nunnari, 2009).  Individual mitochondria are far easier to traffic 
around the cell, allowing rapid response to localised changes in energy demands 
(Skulachev, 2001, Hom and Sheu, 2009).  Additionally, unhealthy mitochondria are able to 
sequester damaged proteins/DNA into one daughter mitochondrion during asymmetrical 
fission.  This allows one healthy daughter mitochondrion to function and divide normally, 
while the unhealthy one is simultaneously primed for degradation by the cellular quality 
control machinery (Twig et al., 2008a, Ni et al., 2015).   
Figure 1.2 Schematic of mitochondrial fission.  1. Pre-Drp1 recruitment, contact between 
the mitochondrial membrane and ER constricts the mitochondrial membrane.  2. MOM 
adaptor proteins recruit Drp1.  3. Mitochondrial membrane is maximally constricted by 
Drp1-mediated GTP hydrolysis and oligomerisation.  4. Dyn2 (Dnm2) is recruited to the 
constricted neck.  5. Final scission of the mitochondrial membrane by Dyn2-mediated 
GTP hydrolysis.  Figure adapted from Kraus, F. and M. T. Ryan (2017). "The constriction 
and scission machineries involved in mitochondrial fission." Journal of Cell Science 
130(18): 2953  (Kraus and Ryan, 2017).  
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1.1.6.1 Priming by ER-mediated constriction 
The landmark discovery that ER-extensions physically wrap around mitochondria 
prior to their fission was relatively recent (Friedman et al., 2011).  Friedman et al proposed 
their ER contact-determined model of fission following observation that mitochondria and 
ER have extensive points of contact (MAMs) and tightly coupled dynamics in both yeast 
and mammalian Cos-7 cells.  They went on to show by electron microscopy and live cell-
imaging that fission occurred at sites primed by ER tubule-mediated constriction, and 
suggested that this could provide a ‘geometric hotspot’ conducive to Drp1 polymerisation, 
with a dimeter of ∼150 nm (Friedman et al., 2011).  It was concluded that ER-dependent 
mitochondrial constriction occurs upstream and independently of Drp1-adaptor 
assemblies, as constrictive MAMs were observed even in cells devoid of Drp1 or its 
adaptors (Osellame et al., 2016, Friedman et al., 2011).  At MAMs, actin and myosin 
filaments work together to generate a physical force, which drives initial membrane 
constriction (Figure 1.2, 1) (Hatch et al., 2014, Phillips and Voeltz, 2016).  INF2, an ER-
associated formin, has been shown to serve as a nucleation point to facilitate 
polymerisation of F-actin and recruitment of myosin to MAMs in mammalian cells 
(Korobova et al., 2014, Li et al., 2015).  Spire1C serves as a mitochondrial actin nucleation 
centre, and binds to INF2 to promote actin polymerisation (Manor et al., 2015).  
1.1.6.2 Maximal constriction by Drp1 
For further constriction to proceed, the fission site must be demarcated for binding 
of Drp1.  Unlike the archetypal Dynamin, Drp1 does not have a PH domain so cannot 
independently or directly bind membranes (Yoshida, 2018).  It is therefore necessary for 
Drp1 recruitment to be primed by mitochondrial adaptor proteins (Figure 1.2, 2).  Current 
hypotheses detail an important role for Mitochondrial Fission Factor (Mff) in recruitment 
of oligomerised Drp1.  In addition, Mitochondrial Dynamics Proteins MiD49 and MiD51 
have also been implicated in the assembly of Drp1 contractile oligomers, though other 
studies have asserted that they sequester inactive Drp1 away from Mff (Gandre-Babbe et 
al., 2008, Otera et al., 2010, Losón et al., 2013). 
Once recruited to the MOM, Drp1 monomers self-assemble around the membrane 
into contractile ring structures (Fröhlich et al., 2013, Ingerman et al., 2005, Mears et al., 
2011).  GTP hydrolysis provides the energy to drive Drp1-helix conformational changes, 
resulting in the ring diameter being two-fold reduced and contributing to further 
membrane constriction (Figure 1.2, 3) (Mears et al., 2011, Koirala et al., 2013).  Assembly 
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of Drp1 helices is mediated via the central stalk interface, with spirals nucleating from two 
adjacent starting points to form a two-start helix around the membrane (Fröhlich et al., 
2013, Zhang and Hinshaw, 2001).   
1.1.6.2.1 Drp1 
Drp1 is a 70-80kDa cytosolic GTPase recruited to the MOM to facilitate fission.  At 
steady state, ~3% of total Drp1 is associated with mitochondria (Smirnova et al., 2001).  
Cells lacking functional Drp1 exhibit highly elongated and interconnected mitochondria, 
particularly arranged in perinuclear clusters.  This phenotype is consistent with a perturbed 
equilibrium between mitochondrial fission and fusion; fusion still occurring normally but 
fission being hindered.  Similarly, cells devoid of Drp1 have severely elongated 
peroxisomes, indicative of a role for Drp1 in peroxisomal fission analogous to that of 
mitochondrial fission (Ishihara et al., 2009, Koch et al., 2003).  Peroxisomes are ER-derived 
vesicles and are the site of oxidative degradation of hydrogen peroxide from the cell, as 
well as performing beta-oxidation of fatty acid chains (Hoepfner et al., 2005).  During 
apoptosis, rates of mitochondrial fission are greatly increased, and coincide with 
cytochrome c release.  Mutation or deletion of Drp1 delays release of cytochrome c, 
suggestive of a pro-apoptotic role for Drp1 (Munoz-Pinedo et al., 2006, Frank et al., 2001).   
1.1.6.2.2 Drp1 adaptors 
Without a PH domain to bind phospholipids, Drp1 requires adaptor proteins in the 
MOM for its recruitment, of which several have been characterised.  In yeast, peripheral 
membrane receptors Caf4 and Mdv1 recruit and assemble Dnm1 (Drp1), with Fis1 acting 
as an adaptor on the MOM (Lackner et al., 2009).  In metazoan species, however, there are 
no known homologues of Caf4 or Mdv1, and Fis1 has now been established as dispensable 
for mitochondrial fission (Otera et al., 2010, Osellame et al., 2016). 
Mitochondrial dynamics proteins MiD49 and MiD51 are MOM proteins specific to 
higher eukaryotes (Palmer et al., 2011).  It remains unclear if the MiD proteins facilitate 
mitochondrial fusion or inhibit mitochondrial fission;  over-expression of either or both MiD 
proteins gives rise to fused mitochondrial tubules, but low-level expression of tagged 
MiD49/51 increases Drp1 colocalisation with mitochondria, indicative of a role in stabilising 
Drp1 at the MOM (Palmer et al., 2011).  Both MiD proteins are capable of recruiting Drp1 
to sites of mitochondrial fission, independently of each other and of Mff (Losón et al., 2013, 
Osellame et al., 2016, Otera et al., 2016, Richter et al., 2014).  Unlike Mff, which remains 
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punctate at pre-constriction sites in the absence of Drp1, the MiD proteins diffusely localise 
throughout the MOM (Richter et al., 2014, Friedman et al., 2011, Otera et al., 2010). 
Mff is found in all metazoans and is thought to be the primary adaptor for Drp1.  The 
structure and domain architecture of Mff remain elusive, however the N-terminal domain 
of Mff is essential for its interaction with Drp1 (Otera et al., 2010).  Mff knock out cell lines 
display grossly elongated mitochondria and tubular peroxisomes, consistent with a critical 
role for Mff in recruitment of Drp1, both to mitochondrial and peroxisomal membranes 
(Gandre-Babbe et al., 2008, Losón et al., 2013, Otera et al., 2010).  Down-regulation of Mff 
inhibits mitochondrial Drp1 recruitment, whereas Mff over-expression induces excessive 
mitochondrial fission (Otera et al., 2010).  While Mff and MiD51 have been shown to 
colocalise with Drp1 in MEF cells, suggestive of a functional complex (Osellame et al., 
2016), in vitro studies have shown that incorporation of Mff into liposomes stimulates Drp1 
GTPase activity, but incorporation of MiD51 inhibits it (Osellame et al., 2016, Macdonald 
et al., 2016).  In HeLa cells, silencing of Mff with siRNA can partially rescue fusion defects 
caused by dominant negative mutants. Mff silencing also partially attenuates 
fragmentation upon mitochondrial uncoupling by CCCP treatment, and inhibits apoptosis 
in a similar way to Drp1-silencing (Gandre-Babbe et al., 2008).  Mff, as the master regulator 
of Drp1 recruitment, has a crucial role in maintenance of the mitochondrial network.  Its 
activity must be tightly regulated, as excessive or insufficient mitochondrial fission can have 
deleterious effects on mitochondrial function and cellular viability.          
1.1.6.3 Final scission by Dyn2 
Until recently, it was thought that Drp1 alone drove membrane constriction to full 
scission.  However, a study by Lee et al revealed that siRNA-mediated silencing of Dyn2 
created a highly elongated mitochondrial network phenotype, similar to that observed 
when Drp1 is silenced and indicative of a critical role for Dyn2 in fission (Lee et al., 2016).  
This study was consistent with a previous report that Drp1 could readily tubulate, but not 
sever, liposomes in vitro (Yoon et al., 2001). 
Dyn2 (Dnm2) is a classical, PH domain-containing Dynamin, and directly binds to the 
MOM.  Dyn2 is only recruited to restriction sites after Drp1, suggesting that it requires the 
narrower membrane diameter provided by Drp1-ring constriction to bind (Figure 1.2, 4).  
Unlike Drp1, which is found at ~80% of mitochondrial constriction sites, Dyn2 is recruited 
only transiently, and disassembles immediately after membrane scission (Figure 1.2, 5).  A 
population of Drp1 remains on each of the daughter mitochondria after division, 
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suggesting that Dyn2-dependent scission occurs in the centre of the constriction site 
(Legesse-Miller et al., 2003, Lackner et al., 2009, Lee et al., 2016). 
1.1.7 Mitochondrial dynamics: physiology and 
pathophysiology 
Functional mitochondrial morphology is important in almost all cell types, with 
morphological defects having roles in many human diseases (Hom and Sheu, 2009).  These 
include neurodegeneration, diabetes mellitus, liver diseases, cancers and myopathies 
(Wallace, 1999).  Perturbations to mitochondrial fission can be lethal; a child born with a 
dominant negative mutation in Drp1 survived just 37 days (Waterham et al., 2007).  
Equally, disruptions to mitochondrial fusion can be lethal.  Mutations of Mfn1 or Mfn2 are 
embryonic lethal in mice, while Mfn2 mutation in humans causes peripheral neuropathy-
Charcot–Marie–Tooth subtype 2A (Pareyson, 2004, Züchner et al., 2004, Chen et al., 2003).  
Maintenance of functional mitochondrial networks is particularly critical in cell types with 
high energy demands, including neurons, skeletal muscle and heart. 
1.1.7.1 Cardiac mitochondrial dynamics 
Cardiac myocytes, in particular ventricular cells, are hugely enriched with 
mitochondria, which have been shown in electron micrographs to be compacted and highly 
ordered between contractile filaments.  This begs the question: do adult ventricular 
mitochondria undergo the same continuous fusion, fission and movement as mitochondria 
from other cell types?  This question has yet to be definitively answered (Hom and Sheu, 
2009).  Ventricular mitochondria are anchored by components of the myocyte 
cytoskeleton and surrounded by contractile proteins, which could suggest that there is no 
need or capacity for them to have similar dynamics to mitochondria in other cell types.  
However, mitochondria are limited by their lifespan, and their biogenesis, quality control 
and genomic integrity are all dependent on their ability to undergo fission and fusion, and 
to be motile (Twig et al., 2008b, Diaz and Moraes, 2008). 
 In support of fundamental requirements of mitochondrial dynamics in the heart, 
several studies have confirmed that all major fission/fusion proteins are expressed in the 
adult heart.  Indeed, one study used Western blotting to screen various adult tissues for 
fusion DRP Mfn1 and Mfn2 expression and concluded that Mfn1 protein was expressed in 
greatest abundance in heart tissue.  The same study also found mRNA encoding Mfn2 to 
be highly abundant in heart and muscle compared to other tissues (Santel et al., 2003).  
These data are supported by further studies confirming that Mfn1 and Mfn2 can be 
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detected by RT-PCR in rat and mouse heart tissue (Rojo et al., 2002, Bach et al., 2003).  
Similarly, high expression of mRNA encoding fission-mediating Drp1 has been detected by 
Northern blotting of adult human heart tissue (Imoto et al., 1998).    
Presence of fission/fusion proteins in the adult heart does not confirm a functional 
role for them in the regulation of cardiac mitochondrial morphology, per se.  Limitations in 
the spatial resolution of confocal microscopy make it difficult to distinguish subtle 
morphological differences between mitochondria that are so tightly packed as those in 
cardiac cells (Faulkner et al., 2014).  However, electron micrographs dating back over 30 
years demonstrate that perinuclear mitochondria differ in their morphology and 
distribution from those located between myofibrils or beneath the sarcolemma of 
ventricular myocytes.  For example, perinuclear mitochondria are distributed in a more 
irregular manner and are more variable in shape and size, while interfibrillar mitochondria 
are generally elongated, similar in length to a sarcomere, and aligned in longitudinal rows.  
Some intrafibrillar mitochondria exhibit differing degrees of ‘wrapping’ around 
myofilaments, presumably allowing greater efficiency of ATP delivery to regions of high 
demand (Shimada et al., 1984, Palmer et al., 1985).  The differences in distribution and 
morphology of mitochondria in different ventricular compartments suggest spatial and/or 
temporal heterogeneity in adult ventricular mitochondrial dynamics, but are indicative that 
at least some cardiac mitochondria regularly undergo fission, fusion and motility similar to 
the dynamics of other cell types  (Hom and Sheu, 2009).      
Due to their close proximity to the sarcoplasmic reticulum, many cardiac 
mitochondria are situated inside microdomains of high Ca2+ concentration and flux during 
the excitation-contraction coupling (EC-coupling) required to maintain the heartbeat 
(Sharma et al., 2000).  This charges ventricular mitochondria with regulation of localised 
Ca2+ homeostasis and links energy metabolism to EC-coupling.  Given the changeability of 
heart rate, mitochondrial generation of ATP must be effectively regulated to quickly adapt 
to changes in energy supply and demand.  It has long been known that Ca2+ is used by 
mitochondria as a key regulator of metabolic activity; during cycles of EC, mitochondria 
sequester small concentrations of Ca2+ to activate ATP-generating enzymes and, in doing 
so, ensure bioenergetic homeostasis in the beating heart (McCormack and Denton, 1989, 
Matsuoka et al., 2004). 
More recent studies have identified a role for Ca2+  in regulation of mitochondrial 
dynamics (Hom Jennifer et al., 2007).  Breckenridge et al showed that caspase-mediated 
cleavage of ER protein BAP31 stimulates Ca2+-dependent mitochondrial fission and 
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enhances release of cytochrome c during apoptosis (Breckenridge et al., 2003).  Another 
study linked Ca2+ to kinesin-mediated mitochondrial motility, asserting that kinesin-1 is 
switched to an inactive state by Ca2+-induced binding to MOM protein Miro, halting 
mitochondrial movement (Wang and Schwarz, 2009).  A new role for Mfn2 has also been 
identified, in which it regulates mitochondrial Ca2+-uptake by tethering the mitochondrial 
membrane to the ER (de Brito and Scorrano, 2008). 
In instances of cardiac disease, including end-stage dilated cardiomyopathy, 
myocardial hibernation, and ventricular-associated congenital heart diseases, 
mitochondria have been shown to be abnormally organised and unusually small (Kalra and 
Zoghbi, 2002, Scholz et al., 1994, Schaper et al., 1991).  Additionally, large, defective 
mitochondria have been shown to accumulate in senescent cardiac myocytes, in an age-
correlated manner (Terman et al., 2006). 
On reflection of the evidence discussed here, several aspects of adult ventricular 
mitochondrial dynamics can be proposed: 
• The machinery required for fission and fusion appear to be expressed, and 
the requirement for mitochondrial regeneration, quality control and 
genomic stability indicate a demand for normal fission and fusion. 
• Mitochondrial motility is probably minimal and may be limited to certain 
subcellular populations. 
• Microdomain Ca2+ concentration and mitochondrial tethering to the 
sarcoplasmic reticulum may be critical to regulation of mitochondrial 
dynamics. 
 
1.2 Myocardial ischaemia/reperfusion injury 
The heart is an autonomous muscular organ and the epicentre of the circulatory 
system and, together with the blood and blood vessels, makes up the cardiovascular 
system.  The proper functioning of all other organs is dependent on the heart, which pumps 
blood around the body, delivering oxygen and nutrients and removing carbon dioxide.  
1.2.1 Structure and function of the heart 
The heart is made up of 4 chambers: the left and right atria and the left and right 
ventricles.  The right atrium receives deoxygenated blood via the venae cavae, which 
moves through the tricuspid valve into the right ventricle.  The right ventricle feeds into 
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the left and right pulmonary arteries, which carry blood to the lungs to be re-oxygenated.  
The left atrium receives oxygenated blood back from the lungs via the pulmonary veins, 
which then passes through the mitral valve to the left ventricle.  Oxygenated blood is 
pumped out to the rest of the body via the aorta.  
The wall of the left ventricle is much thicker than that of the right ventricle, owing 
to the pressure required to pump blood around the entire body.  The heart walls comprise 
3 layers: the inner endocardium, myocardium, and the outer epicardium.  The myocardium 
is the cardiac muscle tissue - involuntary striated muscle tissue within a complex collagen 
framework.  Two types of cell make up the myocardium: highly contractile muscle cells 
(cardiomyocytes), which make up 99% of cells in the heart, and smaller pacemaker cells, 
which have limited contractibility.  The pacemaker cells function in a similar way to 
neurons, firing synchronised action potentials to stimulate contraction of the entire heart 
(Lindskog et al., 2015). 
1.2.2 Myocardial cells 
Cardiomyocytes are relatively large cells, with an average volume 150x greater than 
that of a red blood cell.  Healthy cardiomyocytes are cylindrical in shape, with a length of 
~100µm and a 10-25µm  diameter (Li and Liu, 2018).  Their functional contractile unit, the 
sarcomere, comprises thick filaments of myosin which glide along thin actin filaments 
(Figure 1.3, green), arranged in parallel to give a striatal appearance (Bray et al., 2008, 
Mansour et al., 2004).  The plasma membrane, or sarcolemma, periodically invaginates 
perpendicular to the long axis of the cardiomyocyte, forming an extensive tubular network 
referred to as the t-tubule system (Figure 1.3, red) (Göktepe et al., 2010).  There are 
approximately 50 sarcomeres in a myofibril, and 50-100 myofibrils per cardiomyocyte 
(Sanger et al., 2000).  Due to the incredibly high ATP demands of normal cardiac contractile 
function, cardiomyocytes are enriched with mitochondria, which account for around 35% 
of their total volume, as assessed by electron microscopy (Hom and Sheu, 2009). 
Figure 1.3 Adult ventricular cardiomyocyte.  Transmission electron microscope image of 
human ventricular cardiomyocyte (stem-cell derived).  Sarcomeric actin is labelled in 
green; t-tubule system is labelled in red.  Image taken from Göktepe, S., O. J. Abilez, K. K. 
Parker and E. Kuhl (2010).  A multiscale model for eccentric and concentric cardiac growth 
through sarcomerogenesis. Journal of Theoretical Biology 265(3): 433-442.  (Göktepe et 
al., 2010). 
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1.2.3 Cardiac disease and dysfunction 
Cardiovascular disease (CVD) refers to all diseases of the heart and circulatory 
system.  This includes everything from heritable myopathies to developed conditions like 
coronary heart disease, atrial fibrillation, heart failure, and stroke.  In all, CVD accounts for 
a quarter of all UK deaths, or one death every three minutes.  It is estimated that 7 million 
people are living with CVD in the UK, with numbers set to increase with the aging 
population (BHF analysis of latest UK mortality statistics: ONS/NRS/NISRA (2016 data)).   
1.2.3.1    Coronary heart disease 
The most common form of CVD is coronary heart disease, also known as ischaemic 
heart disease (IHD).  This occurs when atheroma (fatty deposits) builds up in the coronary 
arteries, narrowing them.  Myocardial infarction (heart attack) can occur as a result of these 
blockages.  Globally, IHD is the leading cause of death, primarily by induction of heart 
attacks.  In the UK, one person is admitted to hospital because of a heart attack every three 
minutes (BHF analysis of latest UK mortality statistics: ONS/NRS/NISRA (2016 data)). 
Ischaemia occurs when blood flow to the tissue is disrupted/blocked, resulting in 
cellular oxygen-deprivation (hypoxia) and glucose-deprivation.  Hypoxia triggers a switch 
to anaerobic glycolysis, which rapidly acidifies the intracellular milieu (Marban et al., 1987).  
Within just a few minutes, the lack of oxygen severely depletes cellular ATP and causes 
contractile arrest (Sanada et al., 2011).  After 15-30 minutes of ischaemia, cellular bulging 
and rupture of intracellular microstructures cause irreversible structural changes to the 
myocardium (Allen and Orchard, 1987).      
1.2.4 Myocardial Ischaemia/Reperfusion injury is 
largely mitochondrial 
Acute occlusion of blood flow to a dependent region of myocardial tissue causes 
localised ischaemia and defines the ‘at risk area’ for myocardial infarction should the 
occlusion be sustained.  Cardiomyocyte death begins after around 20 minutes of ischaemia, 
spreading from the sub-endocardium toward the epicardium (Reimer et al., 1977).  During 
an incident of tissue ischaemia caused by interrupted blood flow, common clinical practice 
is to restore the flow of blood as quickly as possible.  Paradoxically, with the tissue already 
primed for damage, this can induce further damage through a phenomenon known as 
ischaemia/reperfusion (I/R) injury (Hausenloy and Yellon, 2013, Cadenas et al., 2010). 
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1.2.4.1 Pathophysiology of cardiac ischaemic injury 
During ischaemia, abrupt biochemical and metabolic changes are brought about by 
the sudden restriction of oxygen and nutrients.  Lack of oxygen terminates oxidative 
phosphorylation, which in turn causes depolarisation of the MIM and depletion of ATP, 
ultimately inhibiting contractile function.  At the same time, attempts to maintain 
mitochondrial membrane potential by active pumping of protons (H+) across the 
membrane require ATP hydrolysis, further depleting the limited ATP supply.  Oxygen-
deprivation triggers a switch in cellular metabolism to anaerobic glycolysis, causing 
acidification of the cell as H+ accumulate and inhibiting opening of the mitochondrial 
Permeability Transition Pore (mPTP).  The mPTP is a non-selective pore in the MIM which, 
when open, allows free passage of all molecules under 1.5kDa (Griffiths and Halestrap, 
1995, Halestrap, 2010, Pasdois et al., 2013).  This activates the Na+-H+ ion exchanger, which 
works to extrude intracellular H+ coupled to uptake of Na+.  Na+-overload is further 
exacerbated by the halted function of the ATP-dependent 3Na+-2K+ transporter, which 
reverse-activates the 2Na+-Ca2+ ion exchanger, resulting in Ca2+-overload (Figure 1.4, left) 
(Avkiran and Marber, 2002).          
1.2.4.2 Pathophysiology of cardiac reperfusion injury 
Clinically, rapid reperfusion of ischaemic tissue is required for several reasons: to 
salvage viable tissue, limit infarct size, preserve left ventricular systolic function, and 
prevent heart failure.  Unfortunately, reperfusion can contribute to further myocardial 
damage and cell death (Braunwald and Kloner, 1985, Piper et al., 1998, Yellon and 
Hausenloy, 2007).  There are four recognised forms of myocardial I/R injury: reperfusion-
induced arrhythmias, myocardial stunning, microvascular obstruction, and lethal 
myocardial reperfusion injury.  Of these, only the first two are reversible. 
Lethal myocardial reperfusion injury refers to reperfusion-dependent death of cells 
that were still viable immediately following ischaemia and could be responsible for up to 
50% of the final infarct size.  Major contributing factors to lethal reperfusion injury are 
oxidative stress, Ca2+-overload, opening of the mPTP and hyper-contracture (Yellon and 
Hausenloy, 2007).   
Oxidative stress is brought about by several mechanisms but is particularly potent 
during the first few minutes of reperfusion, when a burst of reactive oxygen species (ROS) 
is produced by the sudden re-introduction of oxygen (Hearse et al., 1973, Zweier et al., 
1987, Ambrosio et al., 1993).  Intracellular overload of Ca2+ starts during ischaemia, but 
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disruption of the plasma membrane and mitochondrial re-energisation can exacerbate the 
problem at reperfusion.  Recovery of the MIM potential upon mitochondrial re-
energisation drives mitochondrial uptake of Ca2+ and induces opening of the mPTP.  Once 
open, the mPTP allows equilibration of all small solutes across the MIM, leaving the 
mitochondrial matrix with high concentrations of proteins.  This exerts osmotic pressure, 
drawing water into the matrix and causing a large increase in its volume, resulting in 
immense swelling of the mitochondrion (Halestrap, 1999, Crompton, 1999).  The sudden 
restoration of physiological intracellular pH upon reperfusion, a result of lactate washout, 
also contributes to mPTP opening, as well as cardiomyocyte hyper-contracture (Figure 1.4, 
right) (Lemasters et al., 1996, Qian et al., 1997, Cohen et al., 2007). 
 
1.3 Protein fate is determined by ubiquitin 
Post-translational modifications (PTMs) refer to a large number of protein 
modifications that can be employed by the cell to alter protein function, stability, sub-
cellular localisation, activity and interactions.  There exists a wide range of PTMs, ranging 
from enzymatic cleavage of peptide bonds (as in propeptide processing), to addition of 
Figure 1.4 Schematic of main proponents of acute myocardial I/R Injury.  Ischaemic pathways are 
shown in red, reperfusion in green, discussed above.  Not discussed in the text is the inflammatory 
response, as it remains unclear whether this contributes to the pathogenesis of lethal myocardial 
reperfusion injury, or whether it is a reaction to the acute myocardial injury.  Figure taken from 
Hausenloy, D. J. and D. M. Yellon (2013). "Myocardial ischemia-reperfusion injury: a neglected 
therapeutic target." The Journal of Clinical Investigation 123(1): 92-100 (Hausenloy and Yellon, 
2013). 
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small reactive groups such as phosphate, to covalent attachment of small modifier proteins 
like SUMO and ubiquitin. 
1.3.1 Discovery of ubiquitin 
Ubiquitination was the first discovered modification of a protein by covalent 
attachment of another protein (Ciechanover et al., 1980).  Ciechanover et al had set out to 
find an explanation for the energy-requirement of mammalian intracellular proteolysis, 
which had first been shown by isotopic labelling of cellular proteins almost 30 years prior 
to this study; proteolysis of a peptide bond is an exergonic reaction, so thermodynamically 
the need for energy made no sense (Simpson, 1953).  It was not until the late 1970s that 
hypotheses were set forward that the energy required was not for proteolysis per se, but 
rather some form of energy-dependent proteolytic regulation (Schimke, 1976).  By 1980, 
Ciechanover et al had recognised that ubiquitin was a critical component of ATP-
dependent proteolytic degradation, and made accurate predictions as to the exact 
mechanism, which were more conclusively demonstrated in the subsequent years 
(Hershko et al., 1980).   
 In the four decades since its discovery, ubiquitin and the ubiquitin-like family of 
modifiers have been implicated in virtually every cellular process, including regulating 
proteolysis, nuclear localisation, chromatin structure, genomic integrity, protein quality 
control and intracellular signalling (Schwartz and Hochstrasser, 2003, Wilkinson, 2005).   
1.3.2 Evolutionary and subcellular distribution 
As one of the most highly conserved eukaryotic polypeptides, ubiquitin was probably 
present in the last common ancestor of eukaryotes (Koonin, 2010).  The “ubiquitin-fold” 
superfamily of proteins, to which ubiquitin belongs based on its structure, is an ancient 
group of proteins of widespread phylogeny (Iyer et al., 2006, Burroughs et al., 2012).  
Prokaryotic genomes do not encode ubiquitin, but do encode two, structurally unrelated, 
small modifying proteins that are conjugated to target proteins via isopeptide bonds 
(Maupin-Furlow, 2014).  Actinobacteria synthesise prokaryotic ubiquitin-like protein (Pup), 
an intrinsically disordered polypeptide which is covalently attached to degradation targets 
via a distinct enzymatic mechanism called pupylation (Barandun et al., 2012, Burns and 
Darwin, 2010).  Small archaeal modifier proteins (SAMPs), synthesised in archaea, are also 
ubiquitin-fold proteins, covalently attached to target proteins via a mechanism reminiscent 
of simplified ubiquitination in its requirement of an E1 activating enzyme, but not an E2 
conjugating enzyme or E3 ligase (Darwin and Hofmann, 2010).  The presence of ubiquitin-
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like proteins and rudimentary conjugation systems in prokaryotes suggests that 
ubiquitination was not a newly acquired function of eukaryotes, but rather an 
amalgamation of several modification systems that had already undergone extensive 
diversification in prokaryotes (Koonin, 2010, Hochstrasser, 2009). 
Ubiquitin is encoded by four genes: UbA52 and RPS27A encode monomeric ubiquitin 
moieties which remain fused to ribosomal subunits, whereas UbB and UbC encode 
polymeric ubiquitin precursors, from which free ubiquitin is cleaved by de-ubiquitinating 
peptidases (DUBs).  UbC is believed to produce the majority of ubiquitin, with knock out 
MEFs having 40% reduced ubiquitin, despite compensatory upregulation of UbB mRNA 
(Heride et al., 2014).  In HEK293 cells, ubiquitin makes up around 0.4% of total protein 
(w/w), of which ~23% is free ubiquitin, ~65% mono-ubiquitinated substrates and ~11% 
poly-ubiquitinated substrates (Kaiser et al., 2011).        
1.3.3 Ubiquitin structure 
Ubiquitin is a compact 76-amino acid polypeptide of around 8.5kDa (Komander, 
2009).  Almost 90% of its polypeptide chain contributes to its compact secondary structure 
via hydrogen-bonding.  The main structural features are 3.5 α-helical turns and a 5-
stranded mixed β-sheet.  Between the α-helix and β-sheet is a hydrophobic core (Vijay-
Kumar et al., 1987).  Ubiquitin is conjugated to target proteins via lysine residues; an 
isopeptide bond is formed between the negatively-charged carboxyl-group of the ubiquitin 
peptide C-terminal glycine residue and the positively-charged amino-group on the target 
protein lysine residue (Johnson, 2004).  Target proteins can be either mono-ubiquitinated 
or poly-ubiquitinated, the latter comprising ubiquitin chains (Hershko and Ciechanover, 
1998).  Ubiquitin itself has 7 lysine residues, all on different surfaces of the molecule and 
all of which can be ubiquitinated, resulting in differently branched ubiquitin chains, which 
have been linked to different molecular functions (Figure 1.5) (Komander, 2009). 
1.3.4 Ubiquitin-like Modifiers (UBLs) 
Ubiquitin-like modifiers (UBLs) are a family of small proteins, similar in structure to 
ubiquitin.  With myriad functions, their conjugation to substrates can drastically modify 
target protein functions, and vastly enhances the complexity of the eukaryotic proteome.  
So far, around 16 ubiquitin-like modifiers have been identified in humans, including NEDD8, 
ISG-15, FAT10 and SUMO.  Like ubiquitin, covalent attachment of these UBLs to substrates 
all rely on a C-terminal di-glycine motif in the UBL being conjugated to the ϵ-amino group 
of a lysine residue in the substrate protein, usually within a consensus motif.  




NEDD8 (neural precursor cell expressed developmentally downregulated protein 8) 
is a predominantly nuclear protein, broadly expressed in most adult tissues (Kamitani et 
al., 1997a).  Of all the known UBLs, it shares the greatest sequence identity to ubiquitin – 
59% for the human orthologues (Whitby et al., 1998).  Despite this, ubiquitin and NEDD8 
are functionally non-interchangeable.  The best understood role of NEDD8 is its 
neddylation of cullin RING Ligases (CRLs), which are the most abundant class of RING E3 
ubiquitin ligases.  Here, NEDD8 conjugation acts as a molecular switch, activating ubiquitin-
transfer activity of the cullin RING ligase by altering its conformation (Duda et al., 2008). 
1.3.4.2 ISG15 
ISG15 (interferon stimulated gene 15) is a 15kDa protein, structurally resembling 
two tandem orientation ubiquitin folds (Daczkowski et al., 2017).  Although constitutively 
expressed at low levels, transcription of ISG15 and its regulatory enzymes is upregulated 
by both interferon (IFN)-α and –β, ischaemic stress, DNA damage and aging, by binding of 
IFN-regulatory factors to IFN-stimulated response element-containing promoters (Sadler 
and Williams, 2008). 
1.3.4.3 FAT10 
Like ISG15, FAT10 (Human Leukocyte Antigen-F adjacent Transcript 10) also consists 
of two tandem array ubiquitin-like domains, of 29% and 36% homology to ubiquitin (Fan 
et al., 1996).  Unlike ubiquitin, however, expression of FAT10 is generally limited to tissues 
of the immune system (Lukasiak et al., 2008).  It is only upon IFN-γ and TNF-α stimulation 
that FAT10 transcription and translation is induced (Raasi et al., 1999).  Unlike ubiquitin 
and other UBLs, the di-glycine motif of FAT10 is readily available for activation and 
conjugation, without the need for C-terminal pre-processing (Chiu et al., 2007).  Like 
ubiquitination, conjugation of FAT10 to substrates also targets them for proteasomal 
degradation (Hipp et al., 2005). 
1.3.4.4 SUMO 
Small ubiquitin like modifier (SUMO, or SMT3 in Saccharomyces cerevisiae) refers to 
an ~11kDa protein with limited yet significant sequence homology to ubiquitin.  Unlike 
ubiquitination, modification of substrates by SUMO (SUMOylation) does not generally 
result in their proteasomal degradation, and so far, has been shown to play roles in cell 
cycle regulation, chromatin remodelling, RNA processing, DNA damage repair, 
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transcriptional regulation, protein quality control and response to various cellular insults, 
including oxidative stress, proteasomal inhibition, heat shock, and viral infections.  Given 
the immense range of functions, it is unsurprising that dysfunction of SUMO and its 
regulatory enzymes have been associated with various pathologies, including cancer 
(Kessler et al., 2012), neurodegenerative disorders (Cho et al., 2015, Krumova et al., 2011) 
and cardiovascular diseases (Kho et al., 2011, Wang et al., 2011b, Zhang and Sarge, 2008).   
         
1.3.5 The ubiquitin cycle 
Ubiquitination is a three-step cascade resulting in the covalent attachment of 
mature ubiquitin to a lysine residue of the target protein, in which the carboxyl group of 
the C-terminal glycine (Gly76) in ubiquitin forms a bond with the ɛ-amino group of a lysine 
residue in the target protein (Pickart, 2001).  The sequential actions of an E1 activating 
enzyme, E2 conjugating enzyme and E3 ligase are required to complete the reaction.  The 
E1 forms a thiol ester with the carboxyl group of ubiquitin Gly76, priming the ubiquitin C-
Figure 1.5 Structure of Ubiquitin, with Lysine residues indicated.  The structure of ubiquitin 
(PDB code: 1UBQ) demonstrates that all seven lysine residues (red) reside on different 
surfaces of the molecule. The C-terminal Gly75-Gly76 motif involved in isopeptide bond 
formation is indicated. Relative abundance of chain linkages (in S. cerevisiae) and their 
tentative roles are indicated.  Figure taken from Komander, D. (2009). "The emerging 
complexity of protein ubiquitination." Biochemical Society Transactions 37(5): 937 
(Komander, 2009). 
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terminus for nucleophilic attack.  The E2 then transiently carries the activated ubiquitin 
thiol ester on a cysteine residue, before the E3 transfers activated ubiquitin from the E2 to 
a lysine residue in the target substrate (Hershko et al., 1983).  The same mechanism is 
utilised by all known ubiquitination reactions, regardless of the fate of the ubiquitinated 
substrate (Figure 1.6) (Pickart, 2001).   
1.3.5.1 E1 activating enzymes 
The human genome encodes two E1 enzymes, UBA1 and UBA6, which are around 
40% identical (Jin et al., 2007).  E1s serve to activate ubiquitin by C-terminal adenylation 
and thiol transfer, and subsequently charge cognate E2 enzymes (Schulman and Harper, 
2009).  The activation of ubiquitin is a two-step process.  First, the E1 binds Mg-ATP and 
ubiquitin, and catalyses C-terminal adenylation of ubiquitin, creating a high-energy 
thioester bond.  Next, the E1 enzyme catalytic cysteine residue nucleophilically attacks the 
ubiquitin-adenylate, forming the activated ubiquitin-E1 complex, bonded between the C-
terminus of ubiquitin and the cysteine sulfhydryl group of the E1  (Schulman and Harper, 
2009, Haas and Rose, 1982).  The E1 subsequently catalyses adenylation of a further 
ubiquitin moiety, resulting in the enzyme being asymmetrically loaded with two ubiquitin 
Figure 1.6 Schematic representation of ubiquitination. (1) An E1 ubiquitin-activating enzyme 
is loaded with two ubiquitin molecules: one at its adenylation domain (orange) and the 
other linked to a cysteine at its active site (green). (2) The activated ubiquitin is transferred 
to the cysteine in the E2 conjugating enzyme active site. (E3) The E2 dissociates from the 
E1 before it can engage with a cognate ubiquitin ligase (E3), which recruits substrates. (4) 
Once ubiquitin has been transferred to the substrate lysine (star), the E2 dissociates from 
the E3, and can be recharged with ubiquitin by E1 (5). ~ represents a thioester bond.   
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molecules;  the first covalently bonded via a thioester bond to the catalytic cysteine, and 
the second non-covalently associated with the adenylation active site (Haas et al., 1982). 
The two steps of E1-dependent activation are independently reversible; advance of 
the ubiquitination cascade is driven by release of PPi during adenylation and AMP during 
nucleophilic attack (Haas and Bright, 1988, Haas et al., 1988).  The reason for E1 double-
loading of ubiquitin is not yet fully understood.  In vitro work has demonstrated that the 
singly-loaded E1-ubiquitin complex bound by a thioester bond is capable of transferring 
ubiquitin to an E2 enzyme, although the authors showed that the transfer is accelerated 
by Mg-ATP or ubiquitin-adenylate (Pickart et al., 1994).  This suggests that the cascade is 
made more energetically or conformationally favourable by coupling of the second 
adenylation to ubiquitin transfer, or that the double-loading somehow prevents the E1 
from becoming stuck in an unfavourable conformation (Schulman and Harper, 2009).       
1.3.5.2 E2 conjugating enzymes 
At least 38 E2 ubiquitin-conjugating enzymes are encoded by the human genome 
(Deshaies and Joazeiro, 2009).  Due to their ability to recruit specific substrates, it was 
previously assumed that E3 ligases were the primary ‘decision makers’ of the ubiquitin 
cycle, while E2s had auxiliary ‘carrier’ roles.  However, more recent studies have indicated 
that E2s play an active part in determining the length/structure of ubiquitin chains, thereby 
having an important role in determination of substrate fate (Ye and Rape, 2009).  Active 
E2s contain a highly conserved ubiquitin-conjugating domain (UBC) at their core, which 
includes the catalytic cysteine residue and is the site of E1 interaction.  The conserved UBC 
comprises four α-helices and a four-stranded anti-parallel β-sheet, with the catalytic 
cysteine sitting in a shallow groove (Lin et al., 2002, Eddins et al., 2006).  E2s will generally 
only bind their cognate E1s with any significant affinity if the E1 is charged with ubiquitin 
(Schulman and Harper, 2009); ubiquitin binding to the E1 induces a conformational change 
that exposes E2-binding sites, facilitating formation of the E1-E2 complex and allowing 
transfer of ubiquitin (Huang et al., 2007, Lee and Schindelin, 2008).  
To generate ubiquitin chains, the E2-E3 complex must distinguish between chain 
initiation and elongation, or ubiquitin conjugation to a substrate protein lysine or a 
ubiquitin lysine.  This ‘decision’ is often made by the E2, and a handful of E2s dedicated to 
ubiquitin-conjugation in the context of initiation or elongation have recently been 
described (Ye and Rape, 2009).  For example, the yeast anaphase-promoting complex uses 
E2 Ubc4 to modify substrate lysine residues, but Ubc1 to extend ubiquitin chains through 
lysine 48 (Rodrigo-Brenni and Morgan, 2007).  In humans, several E2s, such as UBE2W and 
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UBE2E2, act in ubiquitin chain initiation with BARD1 (BRCA1-associated RING domain 1), 
while the E2 heterodimer UBE2N–UBE2V1 and UBE2K specifically promote ubiquitin chain 
elongation in the same system (Christensen et al., 2007).               
1.3.5.3 E3 ligases 
E3 ligases are engaged by ubiquitin-charged E2s to catalyse substrate ubiquitination 
(Ye and Rape, 2009).  In humans, 600-1000 E3s are encoded, several of which can interact 
with each E2 (Deshaies and Joazeiro, 2009).  So far, all characterised E2s recognise E3s via 
their N-terminal loops and α-helix, with subtle variations in this motif contributing to their 
E3-specificty (Zheng et al., 2000).  The E2-E3 interaction is generally weak (micromolar 
dissociation constants) (Yin et al., 2009).  Interaction with the E3 substantially increases the 
E2 active site rate of ubiquitin discharge; it is thought that the E3 induces an E2 
conformational change, positioning an asparagine residue near the active site which 
stabilises an oxyanion intermediate of the transition state (Wu et al., 2003, Ozkan et al., 
2005, Petroski and Deshaies, 2005b). 
Ubiquitin E3 ligases generally fall into one of two groups, although variation and 
crossover do also occur (Figure 1.7).  The two predominant types of E3 ligase are the Really 
Interesting New Gene (RING) ligases and the Homologous to the E6AP Carboxyl Terminus 
(HECT) ligases, described briefly below.  
Figure 1.7 Ubiquitination by different E3 ubiquitin ligases.  RING E3 ligases (top): E2-
ubiquitin complex engages with E3 RING domain to optimally position ubiquitin for transfer 
to a substrate. HECT E3 ligases (bottom): engage E2-ubiquitin complex via their N-terminus 
and form a thioester bond between the C-terminus of ubiquitin and the conserved catalytic 
cysteine residue in the HECT E3. This HECT-ubiquitin intermediate is then poised for 
transfer of ubiquitin to a substrate.  RBR E3 ligases (middle): use a ‘RING–HECT’ hybrid 
mechanism. RING1 engages with the E2-ubiquitin complex in a similar manner to RING E3s, 
and the Rcat (RING required for catalysis) acts in a similar fashion to the C-terminus of HECT 
E3s, forming a thioester bond between the C-terminus of ubiquitin and the catalytic 
cysteine of the Rcat domain of RBR E3.  Figure taken from Spratt D , E., H. Walden and S. 
Shaw G (2014). "RBR E3 ubiquitin ligases: new structures, new insights, new questions." 
Biochem J 458(Pt 3): 421-437 (Spratt D  et al., 2014). 
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1.3.5.3.1 HECT E3 ligases 
The HECT E3 ligases are characterised by a C-terminal HECT domain, containing the 
conserved catalytic cysteine residue, and N-terminal extensions of varying 
lengths/architectures, that determine the E2-binding and substrate specificity of the E3 
(Scheffner and Kumar, 2014, Kee and Huibregtse, 2007).  These ligases directly engage in 
substrate ubiquitination by formation of a catalytic thioester intermediate between their 
catalytic cysteine and the C-terminal ubiquitin glycine (Maspero et al., 2011). 
1.3.5.3.2 RING E3 ligases 
The RING E3 ligases do not directly catalyse substrate ubiquitination, but rather act 
as scaffolds, orienting the substrate protein and E2-ubiquitin thioester to facilitate efficient 
ubiquitin transfer (Deshaies and Joazeiro, 2009, Metzger et al., 2014).  They do this by co-
ordinating two Zn2+ ions via a cross-brace formation of eight cysteine and histidine 
residues, which folds the E3 into a conformation that  correctly positions conserved 
residues required for interaction with their cognate E2-ubiquitin, thus promoting ubiquitin 
transfer to the substrate protein (Plechanovova et al., 2012, Zheng et al., 2000, Pruneda et 
al., 2012).   
1.3.5.3.3 SUMO-targeted ubiquitin ligases 
A novel and relatively recently discovered class of ubiquitin E3 is the SUMO-targeted 
Ubiquitin Ligase (STUbL or E3-S).  Over the last few years, a handful of STUbLs have been 
identified, either by their demonstrable binding to SUMO, possession of a SUMO-
interacting motif (SIM), or by sequence similarity to other STUbLs (Uzunova et al., 2007, 
Sriramachandran and Dohmen, 2014).  Presence of a SIM facilitates STUbL preference for 
SUMOylated substrates, with most of the currently identified STUbLs having multiple SIMs, 
mediating cooperative binding to several SUMO moieties and indicative of a preference for  
substrates with poly-SUMO chains (Weisshaar Stefan et al., 2008, Tatham et al., 2008).  
RNF4, the most extensively studied STUbL to date, contains at least three clear SIMs, which 
engage SUMO-1 and SUMO-2, and confer a preference for substrates with chains of at least 
three SUMO moieties (Tatham et al., 2008, Lallemand-Breitenbach et al., 2008, Sun et al., 
2007).  STUbLs often target their SUMOylated substrates for degradation via the ubiquitin-
proteasome system (UPS), but can also contribute to a novel composite binding motif, that 
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can be recognised by tandem SIMs and ubiquitin-interacting motifs (UIMs) (Figure 1.8) 
(Sriramachandran and Dohmen, 2014).  
1.3.5.4 De-ubiquitinating peptidases 
De-ubiquitinating peptidases (DUBs) are responsible for generation of free ubiquitin 
by cleaving the poly-ubiquitin chain precursors encoded by ubiquitin genes UBB and UBC 
(Ozkaynak et al., 1987, Komander et al., 2009a).  DUBs are also required in the recycling of 
ubiquitin necessary to maintain ubiquitin homeostasis.  For this reason, the proteasome 
and lysosomal sorting machinery both have associated DUBs, which rescue ubiquitin from 
substrates committed to degradation (Clague and Urbe, 2006, Finley, 2009). 
Around 80 active DUBs are encoded by the human genome, most of which fall into 
the category of ubiquitin-specific proteases (USPs).  USPs, as well as most other DUB 
families, are cysteine-proteases (Clague et al., 2012).  DUB-specificity is primarily 
Figure 1.8 Role of SUMO-ubiquitin hybrid conjugates in protein targeting.  Model illustrating 
SUMO-targeting ubiquitin ligation by a STUbL. Poly-SUMO is recognized by multiple SUMO-
interaction motifs (SIMs) on the STUbL, a RING finger protein that, in conjunction with a 
ubiquitin-conjugating enzyme (E2) attaches additional ubiquitin (Ub) moieties to the 
SUMO-modified substrate. The ubiquitin modification may target the substrate to the 
proteasome (lower), or to a SUMO- and ubiquitin-interacting motif (SIM-UIM)-containing 
protein (upper). 
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determined by preferences for ubiquitin chain linkages, via different ubiquitin binding 
domains, and sub-cellular localisation.  Even within the same family, DUBs show high levels 
of discrimination for differing types of chain (Komander et al., 2009b, Bremm et al., 2010, 
Virdee et al., 2010, Licchesi et al., 2011).        
1.3.6 Ubiquitin linkages dictate substrate fate 
Protein ubiquitination is a very diverse modification.  Substrates may be modified at 
one or multiple lysine residues, and substrate-bound ubiquitin can be further ubiquitinated 
at any of its seven lysine residues, resulting in complex chains and branching (Figure 1.9).  
As alluded to in Figure 1.5, different chain linkages target the substrate protein for different 
fates (Komander, 2009). 
Figure 1.9 Types of ubiquitin linkage.  Ubiquitin modification can be: (A) mono-
ubiquitination (single-site), multi-mono-ubiquitination (multiple-sites, singly 
ubiquitinated) or (B) poly-ubiquitination (single-site, multi-ubiquitinated). Examples of 
Parkin-mediated homotypic poly-ubiquitination (Lysine-48- or -63-linked), where each 
chain contains a single type of linkage. Individual linkages result in different chain 
structures. Multiple homotypic ubiquitin chains of the same substrate are also possible. (C) 
Forms of heterotypic poly-ubiquitination. In mixed linkages, a ubiquitin chain has 
alternating linkage types. In branched or poly-ubiquitin chains, a single ubiquitin is 
extended at two or more lysine residues. 
 




Ubiquitin substrates can be singly ubiquitinated on a single lysine residue (mono-
ubiquitination) or at multiple lysine residues (multi-mono-ubiquitination) (Komander, 
2009).  Nuclear mono-ubiquitination of histones and/or PCNA (proliferating-cell nuclear 
antigen) is a well-established part of the response to DNA-damage (Sigismund et al., 2004, 
Alpi et al., 2008).  Both mono-ubiquitination and multi-mono-ubiquitination have been 
shown to trigger internalisation of cell-surface receptors, resulting in their lysosomal 
degradation or recycling (Haglund et al., 2003, Williams and Urbe, 2007). 
1.3.6.2 Poly-ubiquitination 
Each of the seven lysine residues in ubiquitin can be ubiquitinated in their own right, 
resulting in a complex landscape of differently linked chains, the roles of which are still 
being uncovered.  Different types of chain can adopt different conformations, facilitating 
interactions with linkage-specific DUBs and UIMs (Komander, 2009).  Chains can also be 
mixed, involving more than one type of linkage, and branched, when a single ubiquitin 
moiety is ubiquitinated at more than one site.  Furthermore, other ubiquitin-like modifiers, 
like SUMO, can be incorporated into ubiquitin chains.  Established roles of the different 
chain linkages are discussed briefly below. 
1.3.6.2.1 Lys6-linked chains 
The physiological function(s) of this type of linkage remain elusive, although it might 
have a role in DNA repair (Sobhian et al., 2007).  Lys6-linked poly-ubiquitination is mediated 
by a heterodimeric RING-type E3 comprising BRCA1 and BARD1, which are localised at sites 
of DNA damage.  Mutations in BRCA1 predispose individuals to early-onset ovarian and 
breast cancer (Venkitaraman, 2002). 
1.3.6.2.2 Lys11-linked chains 
Lys11-linked chains have long been established as potent signals for proteasomal 
degradation (Baboshina and Haas, 1996, Jin et al., 2008).  However, there is mounting 
evidence for roles in diverse cellular processes, including the endoplasmic-reticulum-
associated degradation (ERAD) pathway (Xu et al., 2009), and the APC/C E3 assembles Lys11-
linked chains in its regulation of the mammalian cell cycle (Jin et al., 2008).    
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1.3.6.2.3 Lys27, 29 & 33-linked chains 
Due to their proximity, Lys27-, Lys29- and Lys33-linked chains are difficult to distinguish 
by mass spectrometry, as the tryptic digest yields such small fragments.  This makes it 
difficult to assign their specific roles (Komander, 2009).  Lys27-linked chains have no known 
cellular function, despite accouting for ~10% of ubiquitination (Xu et al., 2009).  Lys29-linked 
poly-ubiquitination has been associated with three different HECT E3 ligases: KIAA10, Itch 
and Ufd5.  In vitro, KIAA10 mediates predominantly Lys29-linked ubiquitination, along with 
Lys6- and Lys48-linked ubiquitination (You and Pickart, 2001).  Itch assembles Lys29-linked 
chains on the Notch-signalling regulator Deltex, resulting in its lysosomal degradation 
(Chastagner et al., 2006).  Ufd5 assembles Lys29-linked chains as part of the ubiquitin fusion 
degradation (UFD) pathway, in which ubiquitin chains are extended from a ubiquitin moeity 
on the substrate N-terminus, which has been fused with a non-cleavable linear linkage, 
effciently resulting in their degradation (Johnson et al., 1995, Licchesi et al., 2011).        
1.3.6.2.4 Lys48-linked chains 
Lys48-linked poly-ubiquitin chains are the canonical form of poly-ubiquitin, and the 
most-associated with protein degradation.  Ubiquitin tetramers with Lys48-linkages make 
up the minimal recognition motif for the proteasome – a Lys48-linked substrate is typically 
degraded within minutes in the cell (Thrower et al., 2000).  Lys48-linkages are also 
assembled by Ufd5 as part of the UFD pathway (Johnson et al., 1995).   
1.3.6.2.5 Lys63-linked chains 
Lys63-linked ubiquitin chains are associated with a plethora of non-degradative roles, 
the best-understood of which is in cytokine signalling.  Activation of IKK, responsible for the 
phosphorylation of IκB required to activate NF-κB in response to pro-inflammatory 
cytokines, is dependent on Lys63-linked poly-ubiquitin by TRAF (TNF receptor-associated 
factor) E3 ligases (Deng et al., 2000).  Many cell-surface receptors are poly-ubiquitinated 
with Lys63-linked ubiquitin prior to their endocytosis, recognised by the ESCRT (endosomal 
sorting complexes required for transport) machinery (Williams and Urbe, 2007).  AMSH, an 
endocytosis-regulating DUB, has intrinsic Lys63-linkage-specificity (Sato et al., 2008).  Lys63-
linked poly-ubiquitin is also heavily implicated in several aspects of the DNA-damage 
response (Hofmann and Pickart, 1999, Moldovan et al., 2007, Mailand et al., 2007, Doil et 
al., 2009).       
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1.3.6.3 Diversifying ubiquitin chains 
Ubiquitination in itself is already diverse in the ways it can modify proteins.  
However, it is also possible for other post-translational modifications to become involved 
in ubiquitin chains.  This gives rise to an almost infinite number of distinct modifications 
(Swatek and Komander, 2016). 
While STUbLs are now well-established as ubiquitin ligases of SUMO chains, 
ubiquitin has also recently been shown in proteomics studies to be a target of 
SUMOylation, although a ubiquitin-targeted SUMO ligase (‘UbTSL’) has yet to be identified.  
Of the seven ubiquitin lysine residues, five can be SUMOylated – Lys6, 11, 27, 48 and 63 
(Galisson et al., 2011, Lamoliatte et al., 2013, Hendriks et al., 2014).  The physiological roles 
of SUMO-ubiquitin chains have not yet been established, although it has been reported 
that SUMOylation of Lys6 and Lys27 of ubiquitin is up-regulated during the heat shock 
response, or as a result of proteasome inhibition (Hendriks et al., 2014). 
With ubiquitin SUMOylation established, it is conceivable that NEDD8 or other 
ubiquitin-like modifiers (UBLs) could also modify ubiquitin chains.  Indeed, NEDDylated 
ubiquitin can be easily detected upon NEDD8 over-expression, although it remains unclear 
to what, if any, extent ubiquitin NEDDylation occurs under physiological conditions (Singh 
et al., 2012, Hjerpe et al., 2012). 
It has been known for some time that small chemical groups including phosphate, 
methyl, and acetyl groups can modify ubiquitin and other UBLs, but the physiological 
relevance of this has only recently started to be investigated.  For example, 
phosphorylation of ubiquitin at Serine 65 by PINK1 (PTEN-induced protein kinase 1) has 
been shown to recruit and activate Parkin during mitophagy (Caulfield et al., 2015, Wauer 
et al., 2015b).  
 
1.4 SUMO 
1.4.1 Discovery of SUMO proteins 
The discovery of SUMO in the 1990s heralded a new way of thinking about post-
translational modifications by small proteins.  The gene encoding SUMO (SMT3) was first 
identified over twenty years ago in a genetic screen of Saccharomyces cerevisiae (Meluh 
and Koshland, 1995).  Two research groups later independently verified that SMT3 
encoded an as-yet uncharacterised peptide involved in covalent modification of RanGAP1 
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(Matunis et al., 1996, Mahajan et al., 1997).  Ran, a nuclear Ras-like GTPase, is required for 
bidirectional transport of proteins and ribonucleoproteins across the nuclear pore complex 
(NPC).  RanGAP1 (Ran-GTPase-activating protein) is a key regulator of the Ran GTP/GDP 
cycle (Bischoff et al., 1994).  Both groups, Matunis et al and Mahajan et al, identified the 
novel modification as being structurally similar to ubiquitin, and went on to characterise its 
role in the subcellular partitioning of RanGAP1, targeting it to the NPC.  The protein was 
found to colocalise with RanGAP1 at the NPC, and also to be present in the nucleus.  
Initially, the ubiquitin-like protein was referred to as GMP1 (GAP modifying protein 1) 
(Matunis et al., 1996).  The subsequent paper showed that conjugation of the novel protein 
was ATP-dependent, and was required for association of RanGAP1 with RanBP2, a Ran–
GTP-binding protein, at the NPC.  It was from this study that SUMO (small ubiquitin-related 
modifier) took its name (Mahajan et al., 1997). 
1.4.2 SUMO structure 
Despite sharing only 18% sequence homology with ubiquitin (Mahajan et al., 1997), 
the structure of SUMO is very similar to that of ubiquitin, with the addition of an 
unstructured N-terminal extension (Bayer et al., 1998, Martin et al., 2007).  Bayer et al used 
nuclear magnetic resonance (NMR) spectroscopy to solve the structure of SUMO-1 and 
found it to have the same protein fold (“ubiquitin-fold”) as ubiquitin.  Sequence alignment 
and structural representations of SUMO and ubiquitin are shown in Figure 1.10 (Martin et 
al., 2007).  Residues highlighted in red and green are identical or conservatively changed; 
residues identical in the three SUMO paralogues are highlighted in blue. 
The ubiquitin fold is one of 9 “superfolds” (Orengo et al., 1994).  This consists of a 
five-stranded β-sheet, made up of parallel strands, except for β4, which is twisted against 
the main plane. Helix α1 is rotated approximately 45° relative to the first β-sheet (Figure 
1.10, B).  the ubiquitin superfold is found not only in ubiquitin and ubiquitin-like modifier 
such as SUMO, but also in unrelated proteins including ferredoxin and the Ras-binding 
domains of Raf kinase (Tsukihara et al., 1990, Nassar et al., 1995). 
1.4.3 SUMO paralogues 
All eukaryotes express one or more SUMO paralogues.  Lower eukaryotes including 
Saccharomyces cerevisiae and Drosophila melanogaster express only the single SUMO 
paralogue (referred to as Smt3), whereas most mammals express 3 SUMO paralogues 
(Zhou et al., 2004, Smith et al., 2012).  A fourth paralogue, SUMO-4, has more recently 
been described in humans, but is non-conjugatable due to a unique Proline 90 residue 
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preventing its maturation, and has no known function (Bohren et al., 2004, Owerbach et 
al., 2005).  Arabidopsis thaliana, the most commonly used model plant organism, expresses 
up to eight SUMO paralogues (Miura et al., 2007). 
Mammalian SUMOs share around 45% sequence homology with yeast Smt3 (Wang 
and Dasso, 2009).  Mature human SUMO-2 and SUMO-3 share 97% sequence homology, 
making them indistinguishable by Western blotting, and are therefore referred to as 
SUMO-2/3; SUMO-1 shares only 50% sequence homology with SUMO-2/3 (Wilkinson and 
Henley, 2010).  Owing to their sequence and structural similarities, SUMO-1 and SUMO-
2/3 can modify an overlapping group of proteins and are activated and conjugated by the 
same enzymes, which do not significantly discriminate between paralogues.  In mammalian 
cells, SUMO-1 exists almost entirely in its conjugated form, whereas free SUMO-2/3 
predominates.  However, SUMO-2/3 is the preferred modifier, and is expressed 10x more 
than SUMO-1 (Saitoh and Hinchey, 2000).  Owing to the higher intracellular levels of 
SUMO-2/3 and indiscriminate modifying enzymes, SUMO-2/3 conjugation is strongly 
 Figure 1.10 Human ubiquitin and SUMO.  (A) Sequence alignment of ubiquitin and SUMO 
isoforms; identical residues are red, conservative changes are green, SUMO-only identical 
residues are blue. Alignment performed using ClustalW.  (B) Ribbon diagrams of NMR 
structures of ubiquitin (Uniprot 1D3Z) and SUMO (Uniprot 1A5R and 2AWT).  Figure 
adapted from Martin, S., Wilkinson, K. A., Nishimune, A. and Henley, J. M. (2007). Emerging 
extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nature 
reviews. Neuroscience. 8(12): 948-959. (Martin et al., 2007). 
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favoured (Flotho and Melchior, 2013).  To balance this, cleavage of SUMO-2/3 conjugates 
is significantly faster than for SUMO-1 (Kolli et al., 2010).       
1.4.4 Evolutionary importance of SUMO 
SUMOylation has been established as an essential PTM for development and/or 
survival of almost all eukaryotes.  The only currently known organisms whose SUMO-null 
mutants exhibit only a minor phenotype are the yeast Schizosaccharomyces pombe and 
the fungus Aspergillus nidulans (Tanaka et al., 1999, Wong et al., 2008).  Inhibition of 
SUMO-conjugation by replacement of Ubc9 (required for SUMOylation) with a loss-of-
function mutant caused defective cell division, accumulated chromosomal damage and 
apoptotic cell death in cultured DT40 chicken cells (Hayashi et al., 2002).  Additionally, 
Ubc9-null murine embryos in vivo display severe chromosomal condensation and 
segregation defects, as well as aberrant nuclear envelope morphology, disruption of 
nucleoli, and die at the early post-implantation stage (Nacerddine et al., 2005).  These 
studies demonstrating chromosomal and nuclear defects, in vitro and in vivo, in response 
to loss of SUMOylation are supportive of previous works that identified SUMOylation as a 
primarily nuclear PTM (Kamitani et al., 1997b). 
It remains unclear if individual SUMO paralogues are necessary.  Several studies of 
SUMO-1 knockout mice have shown them to be viable and fertile but with various 
phenotypes; some have cleft lip and palates whereas others display increased anti-
inflammatory responses, cardiac defects and impaired adipogenesis (Alkuraya et al., 2006, 
Venteclef et al., 2010, Mikkonen et al., 2013).  The same mice also have normal testis 
development and function, despite SUMO-1 mRNA being highly expressed in testes (Zhang 
et al., 2008).  Collectively, these studies indicate that, while SUMO-1 can be compensated 
for by SUMO-2/3 in most circumstances, there are SUMO substrate proteins with 
paralogue-specific requirements. 
1.4.5 SUMO distribution 
The study by Kamitani et al showed by Western blotting that the majority of 
SUMOylation occurs in the nucleus (Kamitani et al., 1997b).  More recent proteomics 
studies have confirmed this, identifying SUMO substrates with roles in DNA repair, 
transcription and replication (Jackson and Durocher, 2013, Wei and Zhao, 2016). 
Nonetheless, cytoplasmic SUMO has also been detected and shown to modify 
extranuclear proteins (Geiss-Friedlander and Melchior, 2007).  SUMOylated proteins have 
been shown to occur in the mitochondria by Western blotting of subcellular fractions and 
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by immunofluorescence, and have been implicated in maintenance of the fission/fusion 
equilibrium of mitochondria; Drp1 is a SUMO substrate and overexpression of SUMO1 or 
depletion of SENP5 results in mitochondrial fragmentation (Guo et al., 2013, Guo et al., 
2017, Luo et al., 2017, Harder et al., 2004, Zunino et al., 2007).  Protein-tyrosine 
phosphatase-1B was the first identified ER-associated SUMO substrate.  It’s SUMOylation 
is enhanced at the ER-outer membrane and directly inactivates the enzyme, suggesting a 
positive role for SUMO in receptor tyrosine kinase signalling (Dadke et al., 2006).  At the 
plasma membrane, SUMO has been linked to the regulation of channels and receptors.  
The voltage-gated potassium channel Kv1.5, which has crucial roles in tightly regulated 
electrical responses throughout the cardiovascular system, is a SUMO substrate (Benson 
et al., 2007).  Additional SUMO substrates at the neuronal plasma membrane are the 
metabotropic glutamate receptor-8 (mGluR8) and the GluR6 subunit of kainate receptors, 
the latter of which is SUMOylated upon kainate stimulation and is required for kainate-
induced endocytosis of the receptor (Tang et al., 2005, Martin et al., 2007). 
1.4.6  The SUMO cycle 
Like ubiquitination, SUMOylation is a three-step process resulting in the covalent 
attachment of mature SUMO to a lysine residue of the target protein (Figure 1.11). While 
ubiquitin has several E2 enzymes and hundreds of E3 enzymes, SUMO has a specific and 
limited set of enzymes analogous to those required for ubiquitination.  These comprise a 
single E1 activating dimer (SAE1/2), a single E2 conjugating enzyme (Ubc9), and a handful 
of known E3s, which are not essential but are thought to contribute to substrate specificity 
(Gareau and Lima, 2010). 
 
 




1.4.6.1 SUMOylation consensus motifs 
A SUMOylation consensus motif is defined as ψ-K-x-[D/E], where ψ is (usually) an 
amino acid with a large hydrophobic group and x can be any amino acid (Sampson et al., 
2001).  However, proteomics analyses by several groups have shown that more than half 
of all SUMO substrates do not contain a SUMO consensus motif (Zhu et al., 2008, Blomster 
et al., 2009).  Interestingly, many proteins that contain the consensus SUMOylation motif 
are not detectably SUMOylated in vivo (Matic et al., 2010).  SUMOylation motifs (both 
consensus and non-consensus) are described in more detail in Chapter 5. 
Figure 1.11 SUMO conjugation cycle.  SUMO is transcribed and translated as an inactive 
precursor, which is cleaved by SENPs to expose a C-terminal di-glycine motif (1). This 
mature SUMO can then enter the SUMO conjugation cycle, where it is activated by ATP-
dependent thioester bond formation with the active site of the E1 enzyme, a heterodimer 
of SAE1 and SAE2 (2). Activated SUMO is passed to the active cysteine of the E2 conjugating 
enzyme, Ubc9 (3), which catalyses transfer of SUMO to the target protein (5). This may be 
assisted by an E3 ligase (4). De-SUMOylation is mediated by SENP family proteases (6), 
releasing the unmodified target protein and free SUMO, which can re-enter the 
conjugation cycle. 
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1.4.6.2 SUMO-interacting motifs 
The SUMO-interacting motif (SIM) is highly variable, and is the site of non-covalent 
binding between SUMO and a target protein (Kerscher, 2007).  At its most basic, the SIM 
comprises a hydrophobic core, consisting of 3-4 aliphatic amino acid residues, which 
interact with a hydrophobic groove in SUMO (Song et al., 2005).  The SIM hydrophobic core 
is often, but not necessarily, found in juxtaposition with a cluster of acidic residues 
(Hannich et al., 2005, Hecker et al., 2006).  SIMs are described in more detail in Chapter 5. 
1.4.6.3 SUMO maturation and activation 
SUMO proteins are synthesised as inactive precursors and undergo proteolytic 
cleavage by sentrin-specific proteases (SENPs) to expose the C-terminal di-glycine motif 
required for conjugation (Johnson, 2004).  Mature SUMO is then activated by the SUMO 
E1 enzyme heterodimer comprising SUMO activating enzyme (SAE)1 and SAE2, which have 
significant N- and C-terminal sequence homology to their ubiquitin E1 counterpart 
(Johnson et al., 1997, Gong et al., 1999).  The SAE1/SAE2 complex activates SUMO protein 
in a two-step, ATP-dependent reaction in which a cysteine residue of SAE2 forms a 
thioester bond with SUMO (Olsen et al., 2010).  The ubiquitin fold domain of SAE2 then 
interacts with the SUMO E2 enzyme, ubiquitin conjugating enzyme 9 (Ubc9), and SUMO is 
thiol-transferred to a conserved cysteine residue on Ubc9 (Yunus and Lima, 2006). 
1.4.6.4 SUMO conjugation 
SUMOylation requires formation of an isopeptide bond between the negatively-
charged, exposed carboxyl-group of the mature SUMO peptide C-terminal glycine residue 
and the positively-charged amino-group on the target protein lysine residue (Johnson, 
2004).  Unlike ubiquitination, which requires an E3 ligase for the final step in substrate-
conjugation, SUMOylation can occur in an E3-independent or -dependent manner; in vitro, 
SAE1/SAE2, Ubc9 and ATP are sufficient to conjugate SUMO to a substrate (Bernier-
Villamor et al., 2002).   
The E2 conjugating enzyme, Ubc9, can directly SUMOylate substrate proteins via 
two different mechanisms.  Firstly, Ubc9 can recognise a consensus SUMOylation motif on 
a substrate protein and directly conjugate SUMO to the lysine residue.  The structure of 
the Ubc9-RanGAP complex has been shown to contain a continuous interface, within which 
interactions are present between the consensus RanGAP1 SUMOylation motif (LKSE) and 
four surfaces of Ubc9, including its catalytic cysteine (Bernier-Villamor et al., 2002).  
Secondly, Ubc9 can directly SUMOylate SIM-containing substrate proteins.  SIMs can 
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promote protein SUMOylation by non-covalently binding to the same SUMO moiety as 
Ubc9, thus bringing SUMO into proximity with their SUMO-acceptor lysine residue.  As SIMs 
can have SUMO paralogue preferences, SUMOylation via a SIM in an E3-independent 
manner confers greater SUMO-specificity than E3-, consensus motif-dependent 
SUMOylation, which has not been shown to discriminate (Zhu et al., 2008). 
Alternatively, SUMOylation can occur via an E3 ligase, as is the case for the majority 
of SUMO substrates.  Unlike ubiquitin, for which hundreds of E3 ligases have been 
identified, only a handful of SUMO E3s have yet been described.  While they are not 
necessary for SUMO conjugation, SUMO E3 ligases are believed to greatly enhance 
substrate specificity by forming multiple interactions with target proteins (Reverter and 
Lima, 2005).  The SUMO conjugation cycle is graphically depicted in Figure 1.11. 
1.4.6.5 SUMO deconjugation 
Deconjugation of SUMO is the hydrolysis of the isopeptide bond between the C-
terminal carboxyl group of SUMO and the lysyl amino group of the acceptor protein (Wang 
and Dasso, 2009).  The main group of enzymes that deSUMOylate mammalian proteins are 
the SENP family of SUMO proteases, the same family that facilitate SUMO maturation. 
SUMO proteases were first identified in 1999 in the yeast species Saccharomyces 
cerevisiae, where they were shown to have a crucial role in cell-cycle progression at the 
G2/M phase (Li and Hochstrasser, 1999).  Since then, 6 SUMO proteases have been 
discovered in mammals (SENPs1-3 and 5-7) and 7 identified in the model plant organism 
Arabidopsis thaliana (ULP1a-d, ESD4, ULP2a/b) (Mukhopadhyay et al., 2006, Yeh et al., 
2000, Colby et al., 2006). 
Unlike the SUMO conjugating machinery, SENPs have some level of SUMO 
paralogue-specificity.  SENPs 1 and 2 have roles in the maturation and deconjugation of 
both SUMO-1 and SUMO-2/3, whereas SENPs 3 and 5-7 preferentially interact with SUMO-
2/3.   As previously discussed, intracellular levels of SUMO-2/3 far exceed SUMO-1, and 
modifying enzymes are largely indiscriminate, resulting in SUMO-2/3 conjugation being 
strongly favoured (Flotho and Melchior, 2013).   The larger number of SENPs acting to 
deconjugate SUMO-2/3 therefore contributes to the greater rate of SUMO-2/3 
deconjugation required to maintain the balance of SUMO-1- and SUMO-2/3-ylation (Kolli 
et al., 2010, Gong and Yeh, 2006). 
Owing to the large proportion of nuclear SUMOylation, the SENPs are predominantly 
found in and around the nucleus (Kamitani et al., 1997b).  SENP1 and SENP2 mainly localise 
to the nuclear envelope, with SENP1 also able shuttle to the cytoplasm (Bailey and O'Hare, 
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2004, Hang and Dasso, 2002).  SENP3 and SENP5 localise predominantly with the nucleolus 
(Di Bacco et al., 2006), although both have also been shown to have activity at the 
mitochondrial outer membrane (Guo et al., 2013, Luo et al., 2017, Zunino et al., 2007).  
SENP6 and SENP7 are mainly localised to the nucleoplasm, with SENP6 also exhibiting a 
significant cytoplasmic presence (Kolli et al., 2010, Li et al., 2018). 
More recently, proteases outside of the SENP family have been shown to specifically 
deconjugate SUMO.  DeSI1 and 2 (deSUMOylating isopeptidases) are part of the family of 
permuted papain fold peptidases of dsRNA viruses and eukaryotes, and were initially 
thought to be party of the ubiquitin pathway (Iyer et al., 2004).  USPL1 (ubiquitin-specific 
protease-like 1) has significant homology to the family of ubiquitin-specific proteases, but 
preferentially cleaves SUMO over ubiquitin, both in vitro and in vivo (Schulz et al., 2012).  A 
list of SUMO conjugation and deconjugating enzymes is given in Table 1.1. 
 
Table 1.1 Overview of SUMO proteins. 
Protein Mammalian identity Role(s) 
SUMO SUMO-1 Substrate modification 
 SUMO-2/3 Substrate modification 
SUMO E1 SAE1/SAE2 SUMO activation 
SUMO E2 Ubc9 SUMO conjugation 
SUMO E3 (examples) PIAS1, RanBP2 SUMO conjugation, specificity 
SUMO proteases SENP1/2 SUMO-1 and -2/3 maturation and 
deconjugation 
 SENP3/5 SUMO-2/3 deconjugation 
 SENP6/7 PolySUMO chain editing 
 DeSI1/2 SUMO deconjugation 
 USPL1 SUMO deconjugation 
        
1.4.6.6 Regulation of SUMOylation 
SUMOylation is a highly dynamic modification and, as such, must be tightly 
regulated.  The majority of SUMO substrates undergo rapid cycling of SUMO conjugation 
and deconjugation, essential in maintaining steady-state SUMOylation (Mukhopadhyay 
and Dasso, 2007).  The proportion of substrate proteins that are SUMOylated at any given 
time is regulated on a number of levels.  The amount of free SUMO available within the cell 
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dictates potential SUMOylation levels, as does the rate of substrate deSUMOylation.  
Additionally, SUMO proteases add specificity by having defined localisations and SUMO 
paralogue preferences (Flotho and Melchior, 2013). 
Oftentimes, substrates are SUMOylated in response to intracellular stimuli, including 
DNA damage, cell-cycle phases and signal transduction.  It is thought that 3 mechanisms 
regulate stimulus-dependent SUMOylation: 
i. Activity of SUMO E1-3 enzymes and SUMO proteases can be manipulated.  
For example, hydrogen peroxide-dependent low-level oxidative stress has 
been shown to reduce global SUMOylation in two different ways: 
a. Via reversible inhibition of SAE2 and Ubc9 by formation of a 
disulphide bond between their catalytic cysteine residues (Bossis 
and Melchior, 2006). 
b. Via increased specific SUMO-2/3 deconjugation by stabilisation of 
SENP3.  It has been speculated that SENPs may act as redox sensors 
(Huang et al., 2009, Xu et al., 2008). 
ii. Phosphorylation can enhance substrate binding to Ubc9.  Phosphorylation 
of a serine or threonine residue(s) up- or downstream of the substrate 
SUMO acceptor lysine creates a negative charge, similar to that provided by 
the D/E residue in a consensus SUMOylation motif (ψ-K-x-D/E), required to 
stabilise the Ubc9-substrate interaction.  An example of this is GluK2, a 
kainate receptor subunit, in which phosphorylation at serine 868 enhances 
SUMOylation at lysine 886, resulting in kainate receptor endocytosis 
(Konopacki et al., 2011). 
iii. The addition to or removal from the SUMO acceptor lysine of competing 
PTMs, including ubiquitin, acetyl and methyl groups, can inhibit/enhance 
SUMOylation (Ulrich, 2005).       
1.4.7 Roles of SUMOylation 
SUMO modification can have several different outcomes, which are outlined in 
Figure 1.12 (Everett et al., 2013).  Mono-SUMOylation by SUMO-1 or SUMO-2/3 can 
change the substrate protein conformation or create/disrupt allosteric binding sites.  
SUMO-2/3 can form poly-SUMO chains through sequential SUMOylation of an internal 
consensus motif, which is missing from SUMO-1 (Matic et al., 2008).  Poly-SUMO chains 
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can facilitate interactions between SUMO substrate proteins and SIM-containing proteins 
(Kung et al., 2014).  
Interestingly, hybrid SUMO-Ubiquitin (SUMO-Ub) chains also occur, the synthesis of 
which is reliant on SUMO-targeted ubiquitin ligases (STUbLs), which specifically bind to and 
ubiquitinate poly-SUMO chains on substrate proteins.  Originally, SUMO-Ub chains were 
detected on proteins targeted for proteasomal degradation, recognised by ubiquitin 
receptors (Tatham et al., 2008, Kung et al., 2014).  However, subsequent work has 
established that hybrid chains are recognised as a distinct modification by receptors 
containing tandem SUMO-interacting motifs and ubiquitin-interacting motifs (tSIM-UIMs) 
(Guzzo et al., 2012).   
   
1.4.8 SUMO enigma 
An interesting quirk of modification by SUMO is that only a tiny proportion of the 
available substrate pool need be SUMOylated at any given moment to achieve maximal 
effect.  This is often referred to as the ‘SUMO Enigma’ (Hay, 2005).  It remains a poorly 
understood paradox, yet elegant hypotheses have been put forward to explain the 
phenomenon, centring around the highly dynamic nature of SUMOylation and the rapid 
activity of SENPs, with the functional effects of substrate SUMOylation persisting beyond 
SUMO deconjugation (Martin et al., 2007). 
Figure 1.12 Functional consequences of SUMOylation.  SUMO-1 or SUMO-2/3 can mono-
SUMOylate substrates; targets can be poly-SUMO-2/3-ylated (blue S); poly-SUMO-2/3-
ylated and terminated by SUMO1 (purple S). SUMOylated targets can be bound by SUMO 
interaction motif (SIM)-containing proteins; targets may change their conformation as 
SUMO disrupts structure.  Allosteric binding pockets may be formed, or ligand-binding sites 
disrupted. Figure taken from Everett, R.D., Boutell, C. & Hale, B.G., 2013. Interplay between 
viruses and host SUMOylation pathways. Nature Reviews Microbiology, 11(6), pp.400–411.  
(Everett et al., 2013).    
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SUMOylation is an ATP-dependent process, so the rapid SUMOylation, 
deSUMOylation and re-SUMOylation undergone by most SUMO substrates seems an 
unnecessarily energy-inefficient mechanism of modification.  Why SUMO is so rapidly 
cycled on and off of substrate proteins is not yet understood, but it is proposed that having 
such a dynamic system allows for rapid responses to stimuli, and that the adaptability of 
the process makes it ‘cost-effective’ (Guo and Henley, 2014). 
 
1.5 Parkin 
Parkin is perhaps the best-known RING-between-RING (RBR) E3 ligase, notable for 
its significance in manifestation of early-onset Parkinson’s disease.  In contrast with 
traditional RING or HECT E3s, all of the currently acknowledged RBR E3s are complex, 
multidomain proteins (Spratt D  et al., 2014).  RBR E3s contain two Zn2+-co-ordinating 
cysteine-rich domains that were once thought to loosely conform to the RING E3 consensus 
sequence, referred to as RING1 and RING2 (Marin and Ferrus, 2002, Marin et al., 2004).  
Between these domains, a third cysteine-rich domain referred to as the In-Between-RINGs 
(IBR), completes the recognisable RBR motif (Morett and Bork, 1999).    
More recently, it has been shown that ‘RING2’ actually does not conform to the 
canonical RING E3 structure but is essential for RBR E3 ligase activity and is sometimes 
referred to as a Required for Catalysis (Rcat) domain.  It has also been established that, 
unlike classical RING or HECT E3s, RBR E3s utilise an auto-inhibitory mechanism to regulate 
activity, which was first identified in Parkin (Chaugule et al., 2011).  The E3 ligase activity of 
RBRs has now be shown to use a hybrid mechanism, combining aspects of RING and HECT 
E3 activity (Wenzel et al., 2011).  Parkin modifies its substrates with a number of different 
ubiquitin chain linkages, the most common being K63, K48, K11 and K6 (Ordureau et al., 
2014). 
1.5.1 Structure and autoinhibition of Parkin 
In recent years, high-resolution crystal structures of Parkin have revealed many 
intricacies of its regulation and function.  The RBR E3 is now known to comprise an N-
terminal ubiquitin-like domain (Ubl) and four Zn2+-co-ordinating RING-like domains: RING0 
(also referred to as the unique Parkin domain, UPD), RING1, IBR and RING2, collectively 
referred to as the RBR domain (Figure 1.13 (A)) (Trempe et al., 2013, Riley et al., 2013, 
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Wauer and Komander, 2013).  The complex folded structure of Parkin is largely responsible 
for regulation of its activity (Figure 1.13 (B)).   
The Ubl domain is required for substrate recognition, autoinhibition, association 
with the proteasome and regulation of Parkin activity and abundance.  It also binds to the 
RBR domain in cis, inhibiting catalytic activity of Parkin (Chaugule et al., 2011, Finney et al., 
2003).  RING0 (UPD) contains a PINK1-interacting site (Xiong et al., 2009), while RING1 is 
responsible for E2-binding (Wauer and Komander, 2013).  RING2 contains the catalytic 
cysteine residue C431 required for Parkin ligase activity.  An additional structure, often 
referred to as the Repressor element (REP), connects the IBR and RING2 domains, and is 
responsible for holding Parkin in its inactive conformation in the cytosol by bringing RING0 
(UPD) and RING2 together to occlude C431 (Seirafi et al., 2015, Wauer and Komander, 
2013, Wauer et al., 2015b). 
1.5.2 PINK1-dependent activation 
The majority of Parkin exists in an autoinhibited state in the cytosol and is recruited 
to mitochondria only during times of oxidative stress (Geisler et al., 2010).  PTEN-induced 
Figure 1.13 Parkin structure.  (A) cartoon representation of linear Parkin structure, with N-
terminal Ubl and C-terminal RING2 containing C431 (star).  UPD = RING0.  REP is shown in 
red, between IBR and RING2.  (B) cartoon structures of UPD-RBR domains (Ubl not included 
in any high-resolution structures) in autoinhibited state.  REP (linker helix) shown in red.  
C431 indicated (catalytic centre).  Yellow spheres represent Zn2+.  Disordered stretches 
represented as dotted lines.  Figure adapted from Wauer, T. and D. Komander (2013). 
"Structure of the human Parkin ligase domain in an autoinhibited state." Embo j 32(15): 
2099-2112 (Wauer and Komander, 2013).  
Chapter 1 Introduction 
42 
 
protein kinase 1 (PINK1) is targeted to the MOM by its N-terminal mitochondrial targeting 
sequence, but its kinase domain remains facing the cytosol and is known to physically 
interact with Parkin (Zhou et al., 2008, Kim et al., 2008b).  Under basal conditions, PINK1 is 
degraded soon after mitochondrial import, but depolarisation of the mitochondrial 
membrane causes PINK1 to accumulate on the MOM.  Here it phosphorylates 
mitochondrial ubiquitin and Mfn2, which serve as activator and receptor for Parkin, 
respectively (Chen and Dorn, 2013).  Current data support a model for initiation of 
mitophagy in which PINK1-mediated phosphorylation of Mfn2 simultaneously facilitates 
mitochondrial Mfn2 to recruit Parkin, and functionally sequesters the mitochondrion by 
disturbing Mfn2-mediated mitochondrial fusion (Gong et al., 2015).  PINK1 
phosphorylation of ubiquitinated mitochondrial proteins activates Parkin and amplifies its 
mitochondrial activity by helping to retain its mitochondrial localisation (Ordureau et al., 
2015).  This mechanism thereby selectively recruits Parkin to dysfunctional mitochondria 
(Narendra et al., 2008, Narendra et al., 2010, Matsuda et al., 2010).  In SH-SY5Y cells 
treated with mitochondrial uncoupler CCCP, endogenous PINK1 is able to co-
immunoprecipitate more Parkin with longer treatments, compared to no treatment 
(Geisler et al., 2010). 
Activation of Parkin requires the release of several ‘safety belts’ which hold it in 
its autoinhibited conformation (Figure 1.14) (Caulfield et al., 2015).  PINK1-
phosphorylated ubiquitin (pUb) binds to Parkin, forming an extensive interface along 
the RING1-IBR region of Parkin, and also interacting with side chains of RING0.  This is 
proposed to destabilise the Ubl-RBR domain interaction by displacing IBR and 
reconfiguring the IBR-REP linker.  With Ubl partially destabilised from the RBR domain, 
S65 is accessible for phosphorylation by PINK1 (Wauer et al., 2015b).  PINK1 
phosphorylates S65 of the Parkin Ubl, which sits within a cleft formed by the interface 
between Ubl and a flexible linker region, triggering a cascade of structural changes.  
Initially, the Ubl-linker cleft is opened up, eventually facilitating release of the Ubl from 
its close contact with RING1 and IBR.  This opening further propagates more global 
conformational changes, all of which are required for full Parkin activity.  The REP 
element loosens its interaction with RING1 (in silico modelling predicts an increased 
distance between Tyr391 and Cys238), exposing its binding site for a ubiquitin-loaded 
E2, and RING0 is released from its close contact with RING2, allowing increased 
hydration around the catalytic C431.  It is thought that removal of these ‘safety belts’ is 
sequential (Caulfield et al., 2014). 




1.5.3 Parkin: mitochondrial roles and 
consequences 
Through its interplay with PINK1 and pUb, the primary function of Parkin is the 
induction of mitophagy by heavily ubiquitinating proteins in the mitochondrial membrane 
and targeting the mitochondrion for degradation (Figure 1.15).  However, Parkin has a 
number of other mitochondrial and non-mitochondrial roles.  Established mitochondrial 
roles for Parkin are outlined briefly below. 
• In relation to mitochondrial dynamics, Parkin has been shown to ubiquitinate a 
number of MOM proteins, including regulators of mitochondrial fusion, mitofusins 
and OPA1 (optic atrophy 1), and regulators of mitochondrial trafficking, such as Miro 
(Scarffe et al., 2014).  This disrupts the equilibrium of mitochondrial fission and fusion, 
allowing isolation of dysfunctional mitochondria from the mitochondrial network prior 
to mitophagy.   
Figure 1.14 Model of Parkin activation.  Multiple ‘safety belts’ hold Parkin in an 
autoinhibited state (top left).  Inactive Parkin can interact with pUb, ultimately releasing 
Ubl and destabilising inhibitory interactions to ‘open’ Parkin (top row).  Parkin is also 
phosphorylated by PINK1 at S65 of its Ubl, either directly (bottom left) or with greater 
efficiency after pUb binding (bottom middle).  Phosphorylated Ubl undergoes a 
conformational change which probably prevents Parkin from reverting to an autoinhibited 
state.  Phosphorylation of Ubl thereby stabilises an active and open Parkin conformation 
(bottom right).  Figure adapted from Wauer, T., M. Simicek, A. Schubert and D. Komander 
(2015). "Mechanism of phospho-ubiquitin induced PARKIN activation." Nature 524(7565): 
370-374 (Wauer et al., 2015b). 
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• PINK1 and Parkin also co-operate in the repair of mildly damaged mitochondria that 
result from mild oxidative stress.  By sequestering oxidised/damaged proteins in 
mitochondria-derived vesicles, which are then targeted for lysosomal degradation, 
the mitochondrion can be restored to function (Soubannier et al., 2012, McLelland et 
al., 2014).   
• Complementing this, PINK1 and Parkin also contribute to the balancing of 
mitochondrial dynamics by promoting mitochondrial regeneration (Vincow et al., 
2013).  In SH-SY5Y cells, as well as other proliferating cell lines, over-expression of 
Parkin has been shown to increase mitochondrial transcription via interactions with 
TFAM (mitochondrial transcription factor A) (Kuroda et al., 2006, Rothfuss et al., 
2009). 
 
Figure 1.15 How PINK1 and Parkin mediate mitophagy.  PINK1 accumulates on the membrane 
of damaged mitochondria, where it phosphorylates ubiquitinated MOM proteins and the 
Ubl of Parkin, activating the ligase activity of Parkin.  Parkin ubiquitinates MOM proteins, 
which can then be PINK1-phosphorylated, contributing to further recruitment of Parkin.  The 
heavily ubiquitinated mitochondrion is eventually targeted for degradation.  
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1.5.4 Parkin and pathology 
Parkin is most commonly associated with the neurodegenerative disorder 
Parkinson’s disease (PD).  To date, more than 120 pathogenic Parkin mutations have been 
linked to PD (Seirafi et al., 2015).  Clinically, PD is characterised by loss of dopaminergic 
(DA) neurons from the substantia nigra of the midbrain, often accompanied by presence 
of Lewy bodies in surviving DA neurons, resulting in motor deficits (Braak et al., 2003).  DA 
neurons of the substantia nigra are generally very large, highly branched, highly active and 
under oxidative stress (as a result of dopamine oxidation), putting huge pressure on their 
mitochondria.  Given the pivotal role of Parkin in mitochondrial homeostasis, it is 
understandable that Parkin dysregulation can lead to PD-associated DA neurodegeneration 
(Zhang et al., 2015).  Indeed, mitophagy is defective in PD brains (Fiesel et al., 2015).  
Accumulating evidence is also implicating Parkin in the pathology of other 
neurodegenerative disorders, including Alzheimer’s disease and Amyotrophic lateral 
sclerosis (Nemes et al., 2004, Lagier-Tourenne et al., 2012).  
Beyond its mitochondrial functions, Parkin has been reported to have roles in cellular 
metabolism and regulation of the cell cycle, with at least 25 substrates or putative 
substrates described so far (Zhang et al., 2015).  Through its non-covalent interactions with 
SUMO-1, Parkin has been shown to shuttle between the cytosol and nucleus, with its 
nuclear import increased by association with SUMO (Um and Chung, 2006).  The zinc-finger 
protein PARIS (Parkin-interacting substrate) is a major transcriptional repressor of PGC 
(Peroxisome proliferator-activated receptor-γ coactivator)-1α expression and regulator of 
transcription of many metabolism-associated genes and has been identified as a target of 
Parkin-mediated degradation.  Accordingly, studies of post-mortem brains showed that 
PARIS accumulates in brain tissue of Autosomal Recessive Juvenile Parkinsonism (ARJP) and 
sporadic PD patients.  PARIS also was shown to accumulate in the ventral midbrain of mice 
in which Parkin had been conditionally ablated (Shin et al., 2011).  Parkin has also been 
shown to interact with co-activators of the anaphase-promoting complex (APC/C), 
mediating APC/C-independent degradation of key mitotic regulators, with Parkin-
deficiency resulting in mitotic defects, genomic instability and tumorigenesis (Lee et al., 
2015).  Additionally, Parkin dysfunction has been implicated in the progression of several 
types of cancer (Cesari et al., 2003, Tay et al., 2010, Yeo et al., 2012).   
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1.5.5 Parkin in the heart    
Despite having been repeatedly shown to be expressed in cardiac tissue and 
cardiomyocytes, the role(s) of Parkin in the heart remains little-understood and often-
debated (Wu et al., 2016, Bhandari et al., 2014, Dorn, 2016).  Given the huge abundance 
of mitochondria in the mammalian heart, and the resulting need to prevent cardiotoxicity 
caused by damaged/senescent mitochondria, it is interesting that adult mouse hearts have 
so little Parkin (Dorn, 2013, Song et al., 2015).  Current opinion is that Parkin plays little (if 
any) role in normal maintenance of homeostatic mitophagy in hearts, but that Parkin-
mediated mitophagy is a critical stress-response and Parkin could be central in perinatal 
cardiac metabolic remodelling. 
In Drosophila melanogaster, individual or combined knock out of Parkin and PINK1 
provokes a Parkinson’s-like phenotype, characterised by locomotor defects and skeletal 
myopathy associated with mitochondrial dysmorphology, indicative of impaired 
mitochondrial maintenance (Greene et al., 2003).  Equally, cardiac-specific Parkin knock 
out in Drosophila heart tubes showed that Parkin is required for the maintenance of normal 
mitochondrial morphology and membrane polarisation, as well as the prevention of 
abnormal ROS production (Bhandari et al., 2014).  However, orthologous germline gene-
ablation in mice yields minimal phenotypes (Lee et al., 2012b).  This could be the result of 
upregulation of hundreds of cardiac-expressed mRNAs in the germline Parkin-null mice 
providing a developmentally-incurred opportunistic compensation for loss of Parkin, which 
is not observed in cardiac-specific ablation of Parkin in adult cardiomyocytes (Song et al., 
2015, Bhandari et al., 2014). 
In 2013, Gustafsson’s group used germline Parkin knock out mice to carry out the 
first full phenotypic characterisation of Parkin-deficient hearts (Kubli et al., 2013b).  Under 
normal conditions, these mice did not exhibit cardiac dysfunction or structural 
abnormalities.  Echocardiographic analyses demonstrated that, at least up to 12 months, 
cardiac function of the Parkin-null mice was normal.  Despite maintaining normal function, 
the cardiac mitochondria of Parkin-null mice were smaller and disorganised compared to 
those of WT mice, and over time developed aberrant electron-dense inclusions (Kubli et 
al., 2013a).  Notably, Parkin-null mice were far more sensitive to myocardial infarction than 
WT, developing larger infarcts and having reduced survival rates.  In WT mice, Parkin 
protein expression and mitophagy were increased around the border of the infarct within 
8 hours, and sustained for at least 48 hours, whereas border cardiomyocytes of the Parkin-
null mice had reduced mitophagy, leading to an accumulation of swollen, dysfunctional 
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mitochondria (Kubli et al., 2013b).  The same group went on to show that over-expression 
of WT Parkin, but not Parkinson’s-associated lack-of-function mutants, in isolated adult 
cardiac myocytes was protective against hypoxia-induced cell death, suggesting a critical 
role for Parkin in adapting to stress and/or mitigating stress-related damage (Kubli et al., 
2013b, Kubli et al., 2013a).  
Stress-related up-regulation of Parkin has been linked to pathophysiological 
mitochondrial dynamics; disruption of cardiac mitochondrial fission by cardiomyocyte-
specific ablation of Drp1 concordantly and chronically increases Parkin mRNA and protein 
level (Song et al., 2015).  Additionally, PINK1-deficient hearts exhibit markedly increased 
Parkin expression compared to WT (Kubli et al., 2015).  Regardless of any observable 
cardiac dysfunction, these data indicate that Parkin is upregulated in response to 
mitochondrial stress in the heart.  
Interestingly, several reports have established a role for Mfn2 as a mitochondrial 
receptor for Parkin.  As discussed previously, Mfn2 mRNA is highly abundant in the heart 
(Santel et al., 2003).  Later studies went on to report that Parkin localisation to 
mitochondria is defective in both cardiomyocytes and neurons following in vivo cell type-
specific Mfn2 knock out, suggestive of a role for the Mfn2-Parkin interaction in 
mitochondrial Parkin recruitment (Chen and Dorn, 2013, Lee et al., 2012a).  This finding is 
supported by later work that demonstrates PINK1-dispensibility in the mitochondrial 
recruitment of Parkin and mitophagy activation in cardiomyocytes (Kubli et al., 2015).  
While it is generally understood that PINK1-mediated phosphorylation of Parkin, ubiquitin 
and Mfn2 are required for Parkin activation, it is evident from these data that other kinases 
can compensate for PINK1-deficiency (Chen and Dorn, 2013).  
While basal cardiac expression of Parkin is minimal, the data presented here 
demonstrate three conditions under which cardiac Parkin expression is increased:  
• Following myocardial infarction (Kubli et al., 2013b)  
• In cases of defective mitochondrial fission (Song et al., 2015) 
• In cases of PINK1-deficiency (Kubli et al., 2015)   
It is therefore evident that, under conditions of stress, Parkin plays a pivotal, albeit 
conditional, role in removal of defective cardiac mitochondria (Dorn, 2016). 
 
 




F-box protein 7 (Fbxo7) has a number of roles, most notably as a substrate 
recognition subunit in certain Cullin-RING ligase complexes (CRLs), but also independently 
of CRLs.  Like Parkin, mutations in Fbxo7 have been demonstrated to cause early-onset PD 
(Shojaee et al., 2008, Di Fonzo et al., 2009) and have more recently been linked to defective 
mitophagy (Burchell et al., 2013, Zhou et al., 2015, Skaar et al., 2013). 
1.6.1 Cullin-RING ligases 
Ubiquitin E3 ligases are largely responsible for the spatiotemporal regulation of 
substrate-specific ubiquitination.  A major family of E3 ligases are the CRLs, which mediate 
proteolysis of thousands of proteins across almost every cellular pathway (Petroski and 
Deshaies, 2005a).  The CRLs are multi-protein complexes containing a RING E3 ligase and a 
cullin scaffold (collectively referred to as the E3 ligase module), as well as a variable 
substrate recognition subunit (SRS) that mediates the interaction with cognate substrates 
(Komander and Rape, 2012).  There are 6 main types of CRL, along with at least 2 atypical 
CRLs, with cullin proteins used as the backbone in all cases (Figure 1.16) (Skaar et al., 2013).  
F-box domain containing proteins (FBXO), including Fbxo7, are one type of SRS module that 
interact with the Skp1 (S-phase kinase associated protein 1) adaptor to form Skp1-Cul1-F-
box (SCF)-type CRLs (Ravid and Hochstrasser, 2008).  The carboxyl-terminus of Cul1 recruits 
Rbx (a small RING protein) which acts to direct the E2 enzyme to the E3 complex, while the 
amino-terminus binds Skp1, which can then bind one of 69 F-box proteins (in humans) to 
dictate substrate-specificity (Petroski and Deshaies, 2005a, Skaar et al., 2009).  CRLs are 
activated by NEDDylation of the cullin scaffold (Duda et al., 2008).  




1.6.2 Fbxo7 structure 
Fbxo7 belongs to the family of F-box-containing proteins.  An F-box is a ~40 amino 
acid protein motif which acts as a site of protein-protein interaction (Kipreos and Pagano, 
2000).  In the case of CRLs, the F-box motif links the FBXO to the rest of the E3 complex by 
binding Skp1.  Two Fbxo7 isoforms are expressed in humans; isoform II is a truncated 
protein lacking the N-terminal Ubl of isoform I (Zhou et al., 2016).  Isoform I comprises 5 
functional domains: a Ubl domain, cdk6 domain, dimerization domain, F-box domain and 
a proline-rich domain (Figure 1.17) (Larsen and Bendixen, 2012, Ho et al., 2006).  Isoform 
II of Fbxo7 could not be isolated from pig tissue, suggesting that it may be a very low 
abundance protein (Larsen and Bendixen, 2012).   The dimerization (FP) domain is the site 
of Fbxo7 homo-dimerization and has also been shown to be present in PI31, a regulatory 
subunit of the proteasome which shares a similar structure and FP domain to Fbxo7.  PI31 
does not appear to be a substrate of SCF, as Fbxo7 knock down has no effect on PI31 
expression, and it has been proposed that PI31 could act as an antagonistic regulator of 
SCF activity (Kirk et al., 2008, Bader et al., 2011).  The proline-rich region (PRR) directly 
recruits substrates (Nelson et al., 2013).   
 
Figure 1.17 Domain structure of human Fbxo7.  Full length isoform I comprises an N-
terminal Ubl, a Cdk domain, a dimerization domain (FP), an F-box domain and a C-terminal 
proline-rich domain (PRR).   
  
Figure 1.16 Schematic of Fbxo7-containing SCF-type Cullin-RING ligase (CRL).  Cullin protein 
1 (Cul1) forms the complex scaffold, while Skp1 and an Fbxo7 act as substrate adaptors.  
Fbxo7 binds Skp1 via its F-box domain.  RING-box protein 1 (Rbx1) recruits the E2 
conjugating enzyme, which interacts with the E3 ligase (not shown) to ubiquitinate the 
target protein at a lysine residue (star).  PTM Nedd8 activates the CRL. 
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1.6.3 Fbxo7 and mitophagy 
Fbxo7, like Parkin, has been linked to mitophagy (Burchell et al., 2013).  In their 2013 
study, Burchell et al demonstrated binding between the Fbxo7 Ubl and Parkin and 
significantly reduced localisation of Parkin to depolarised mitochondria in the absence of 
Fbxo7, together indicative of a role for Fbxo7 in Parkin recruitment.  Like Parkin, 
mitochondrial recruitment of Fbxo7 was shown to be PINK1-dependent and over-
expression of Fbxo7 was found to rescue, among other phenotypes, mitochondrial 
dysregulation in Parkin-null Drosophila.  Knock down of Fbxo7 lead to a reduction in Parkin-
dependent p62 recruitment, resulting in delayed lipidation of LC3-I and inhibition of 
autophagosomal recruitment, ultimately impeding CCCP-induced mitophagy in 
mammalian cells (Burchell et al., 2013). 
The role for Fbxo7 in normal mitophagy was later confirmed by an independent 
study, in which the authors used mouse PC12 dopaminergic cells and showed that knock 
down of Fbxo7 impaired FCCP-induced mitophagy, while over-expression of Fbxo7 
promoted mitophagy, even in the absence of mitochondrial stress (Zhou et al., 2015).  
Furthermore, Zhou et al showed that Fbxo7 accumulated under cellular stress and was 
found in aggregates in the post-mortem brains of PD and Alzheimer’s disease (AD) patients, 
diseases which have been strongly linked to aberrant mitophagy.  Disease-linked mutations 
in Fbxo7 also promoted its aggregation and inhibited mitophagy (Onyango et al., 2017).     
1.6.4 Other roles for Fbxo7 
Around 12% of FBXO proteins have so far been shown to have SCF-independent 
functions, with Fbxo7 being one of them.  So far, demonstrable roles have included cell 
cycle-regulation, intracellular trafficking, transcription and mitochondrial dynamics (Nelson 
et al., 2013).  The first-identified SCF-independent role of Fbxo7 was as a regulator of the 
cell cycle via its interactions with viral and cellular D cyclins, as well as cyclin-dependent 
kinase 6 (cdk6), which are regulators of cell cycle-progression (Laman et al., 2005).  These 
interactions took place in vivo (U2OS mammalian cells) and in vitro, providing compelling 
evidence of direct, SCF-independent binding.  The authors went on to show that Fbxo7 
positively regulates these cell cycle proteins, acting as a proto-oncogene, and that Fbxo7 
was upregulated in biopsies of human lung and colon cancers (Laman et al., 2005, Laman, 
2006). 
The capacity for Fbxo7 to bind with high affinity to PI31 via their FP domains has 
raised questions about the potential for Fbxo7 to have a regulatory role in the ubiquitin 
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proteasome system (UPS) (Kirk et al., 2008, Nelson et al., 2013).  PI31 was initially 
characterised biochemically as a proteasome inhibitor, binding to the 20S barrel (Chu-Ping 
et al., 1992), but later in vivo work demonstrated that it does not inhibit proteasome 
activity, but rather regulates maturation of the inducible immunoproteasome (Zaiss et al., 
2002).  So far, there is no clear evidence for Fbxo7 and PI31 interacting to regulate 
mammalian proteasomal activity.  However, work in Drosophila melanogaster (Dm) has 
shown that a partial orthologue of Fbxo7, Nutcracker, stabilises DmPI31 to facilitate 26S 
proteasome function, and that abolishing DmPI31 function results in defective protein 
degradation, cell cycle abnormalities and lethality.  Of note, the authors observed that 
DmPI31 binds Nutcracker via a mechanism conserved in the binding of mammalian PI31 
and Fbxo7 (Bader et al., 2011).    
 
1.7 Regulation of mitochondrial dynamics by 
post-translational modifications 
1.7.1 Fission 
The regulation of mitochondrial fission proteins utilises a diverse range of PTMs, 
including phosphorylation, ubiquitination, SUMOylation and nitrosylation (van der Bliek et 
al., 2013).  The principal mediator of mitochondrial fission, Drp1, is the target of numerous 
PTMs. 
Drp1 activity and subcellular localisation is largely regulated by its phosphorylation 
status.  It has 3 phosphorylation sites, targeted by different kinases at different times.  
Serine 616 can be phosphorylated by protein kinase C (PKC) δ, Rock kinase, CDK1/Cyclin B 
or CAMK-Ia (Taguchi et al., 2007, Han et al., 2008, Qi et al., 2011, Wang et al., 2012c).  
Phosphorylation at S616 promotes Drp1 binding to other fission proteins, including Fis1, so 
is likely to activate mitochondrial fission (Chang and Blackstone, 2010, Han et al., 2008).  
Opposing this, phosphorylation of Drp1 by PKA at S637 inhibits fission by repressing GTPase 
activity and/or hindering mitochondrial translocation (Chang and Blackstone, 2007, Cribbs 
and Strack, 2007).  S693 phosphorylation by GSK3β inhibits mitochondrial fission by 
inactivating Drp1 during apoptosis (Chou et al., 2012).  It is thought that phosphorylation 
at this site affects GTP-hydrolysis or Drp1 oligomerisation (Chang and Blackstone, 2010). 
Ubiquitination is known to regulate a number of mitochondrial dynamics proteins, 
including Drp1 and Fis1, which are both ubiquitinated by the MOM RING E3 ligase March5 
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(Nakamura et al., 2006, Yonashiro et al., 2006).  Initially, ubiquitination of Drp1 was 
proposed to promote mitochondrial fusion (or inhibit fission), but a later study detailed 
evidence for ubiquitination of Drp1 promoting mitochondrial fission, potentially by 
mediating Drp1 trafficking to sites of mitochondrial division (Karbowski et al., 2007).  In this 
study, Karbowski et al showed that expression of non-functional RING mutants of MARCH 
lead to abnormal mitochondrial assembly of Drp1 and aberrant mitochondrial morphology. 
Drp1 was first demonstrated to be a SUMO substrate in 2004, but it was not until 
2009 that its SUMO E3 ligase, mitochondria-associated protein ligase (MAPL), was 
identified (Harder et al., 2004, Braschi et al., 2009).  The role of SUMO in Drp1 regulation 
remains unclear.  It was initially proposed that SUMOylation of Drp1 was promoted by 
Bax/Bak during apoptosis and stabilised Drp1 at the mitochondria (Wasiak et al., 2007), a 
model which later evolved with the discovery of MAPL, which was found to function 
downstream of Bax/Bak and to promote stabilisation of ER/mitochondria contact sites by 
SUMOylating Drp1 (Prudent et al., 2015).  However, other studies have found SUMOylation 
of Drp1 to have the opposite effect, demonstrating that SUMOylated Drp1 is sequestered 
in the cytosol, and that SENP3-mediated deSUMOylation facilitates its translocation to 
mitochondria to initiate cell death following ischaemia, probably by promoting the 
interaction between Drp1 and Mff on the MOM (Guo et al., 2013, Guo et al., 2017). 
It has been proposed that Drp1 activity is also regulated by S-nitrosylation.  Cho et 
al showed that mitochondrial fission was activated by nitric oxide (NO)-induced 
nitrosylation of Drp1 in AD patients, leading to neurodegeneration (Cho et al., 2009).  In 
this study, the authors reported that NO-induced S-nitrosylation facilitated Drp1 
dimerization and enhanced GTPase activity in vitro.  However, this work was later disputed, 
with an independent publication finding no effect of S-nitrosylation on Drp1 GTPase activity 
(Bossy et al., 2010).  Indeed, it has been previously established that Drp1 exists in a 
primarily tetrameric state under physiological conditions, so nitrosylated dimers may 
actually be a degradation/disassembly product (Shin et al., 1999, Zhu et al., 2004).  Bossy 
et al went on to show that NO specifically induced Drp1 phosphorylation at S616, which 
facilitated its mitochondrial recruitment, and that nitrosylation was not specific to Drp1 
nor to AD patients, with no difference in Drp1 nitrosylation between post-mortem brains 
of healthy and AD patients, and nitrosylated OPA1 also readily detected.  A summary of 
Drp1 regulation by PTMs as described here is given in Figure 1.18 (A). 
Mff, the primary receptor for Drp1, remains to be fully structurally annotated (Losón 
et al., 2013).  There is currently little known of its domain architecture, apart from it having 
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an N-terminal Drp1-interacting domain and C-terminal single-pass transmembrane (TM) 
domain.  So far, Mff has been annotated only as a target of post-translational 
phosphorylation at two sites, mediated by AMPK (Toyama et al., 2016). Figure 1.18 (B) 
depicts the Mff phosphorylation sites.  
 
1.7.2 Fusion 
Proteolysis and ubiquitination are the primary post-translational regulators of 
mitochondrial fusion proteins; fusion dynamins of the MIM are largely regulated by 
Figure 1.18 Post-translational modifications of Drp1 and Mff.  (A) Drp1 has four domains: A 
N-terminal GTPase, middle domain, variable domain (VAR) and a C-terminal GTPase 
effector domain (GED).  Parkin-mediated K48-linked ubiquitination targets Drp1 for 
degradation, while March5-mediated K63-linked ubiquitination stabilises the Drp1 pool.  
The sites of ubiquitination are not yet known.  Drp1 can be SUMOylated at four residues 
between the middle and variable domains.  SUMO-2/3-ylation is inactivating, sequestering 
Drp1 in the cytosol, while SUMO-1-ylation by MAPL stabilises Drp1 at mitochondria. O-
linked-N-acetylglucosamine glycosylation at T585 and T586 activates fission.  CDK1/Cyclin 
B-mediated phosphorylation at S616 activates Drp1 activity, whereas PKA-mediated 
phosphorylation at S637 inhibits mitochondrial translocation/GTPase activity and GSK3β-
mediated phosphorylation at S693 inactivates Drp1. C644 S-nitrosylation of Drp1 is 
activating.  (B) Mff is known to be phosphorylated at S155 and S172 by AMPK, promoting 
its function. Mff is characterised by an N-terminal Drp1-interacting domain and C-terminal 
mitochondrial anchoring region comprising a single TM domain.  
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proteolytic cleavage, whereas MOM fusion dynamins are generally inactivated by 
ubiquitin-mediated degradation (van der Bliek et al., 2013). 
The MIM fusion dynamins Mgm1 (yeast) and Opa1 (mammals) are regulated by 
proteolytic cleavage, but with differing effects.  Here, I shall focus on the mammalian 
dynamin.  Opa1, of which there are 8 mammalian isoforms, is cleaved in a complex pattern 
determined by the alternative splicing of mRNA (Olichon et al., 2007).  Different isoforms 
are cleaved depending on the presence or absence of several short exons, which contain 
three distinct proteolytic cleavage sites, near the amino-terminus of Opa1; all isoforms 
contain the S1 cleavage site, while around half contain S2 and S3 sites.  The S2 and S3 sites 
are constitutively cleaved in the intermembrane space by Yme1L, an AAA-protease, 
yielding short and long isoforms (Griparic et al., 2007, Song et al., 2007).  The S1 site is only 
cleaved by the MIM Zn2+-protease Oma-1 if the mitochondrion loses membrane potential, 
has low ATP levels or other quality control mechanisms are disturbed (Head et al., 2009, 
Ehses et al., 2009, Baricault et al., 2007).  Under mitochondrial stress, this mechanism 
cleaves all isoforms of Opa1 within minutes, preventing inner membrane fusion well before 
the triggering of other stress-induced protective mechanisms like the PINK1-Parkin 
pathway (van der Bliek et al., 2013). 
In mammals, MOM fusion dynamins Mfn1/2 are degraded via the UPS in a stress-
induced manner.  Upon loss of mitochondrial membrane potential, Mitofusins are 
degraded by the PINK1-Parkin ubiquitination pathway of mitophagy (Narendra et al., 
2010).  Following ubiquitination, the AAA+ protein p97, which accumulates on the surface 
of Parkin-positive mitochondria, excises Mfns from the MOM before they are degraded by 
the proteasome (Tanaka et al., 2010). 
1.7.3 Mitophagy 
Mitophagy is the ultimate form of mitochondrial quality control.  Mitochondrial 
damage and/or depolarisation triggers Parkin recruitment and the ubiquitin proteasome 
system (UPS), resulting in ubiquitination and proteasomal targeting of MOM proteins for 
degradation.  The remainder of the organelle is then removed via selective autophagy, 
known as mitophagy (Figure 1.19) (Kageyama et al., 2012, Youle and Narendra, 2011). 
PINK1 is generally unstable in the mitochondrial intermembrane space (IMS) and is 
constitutively proteolytically degraded in healthy mitochondria (Jin et al., 2010), with a 
proteolytic C-terminal fragment released into the cytosol and degraded by the UPS 
(Yamano and Youle, 2013).  Loss of membrane potential prevents PINK1 proteolysis and 
Chapter 1 Introduction 
55 
 
allows its accumulation on the MOM, recruiting and activating Parkin (Narendra et al., 
2008, Kim et al., 2008b).  Parkin then poly-ubiquitinates MOM proteins with K48- and K63-
linked chains, triggering their UPS-dependent degradation and reconfiguring the MOM 
protein composition, as well as changing the ubiquitination status of cytosolic domains of 
MOM proteins  (Geisler et al., 2010, Sarraf et al., 2013).  Mass ubiquitination on the surface 
of damaged mitochondria is thought to recruit ubiquitin-binding adaptors, including p62.  
These proteins can interact with the cellular autophagic machinery to mediate clearance 
of the damaged organelle (Ding et al., 2010, Lee et al., 2010, Geisler et al., 2010).       
 Parkin is largely regulated by PINK1 and its own structure, primarily existing in the 
cytosol in an autoinhibited state, as described in 1.5.1 and 1.5.2 (Wauer et al., 2015a).  
While PINK1-mediated phosphorylation of ubiquitin and of the UbL of Parkin are the major 
PTMs contributing to regulation of Parkin activity, further modifications have been 
described in the literature (Figure 1.20) (Chung et al., 2004, Rubio de la Torre et al., 2009, 
Vandiver et al., 2013, Imam et al., 2011).   
Figure 1.19  Mitophagy of dysfunctional mitochondria is ubiquitin-dependent in mammals.   
Recruitment of Parkin to the MOM of depolarised mitochondria causes ubiquitination and 
proteasomal degradation of MOM proteins including Miro, Mfns, and VDAC.  This inhibits 
various processes, including mitochondrial transport (Miro) and fusion (Mfn1/2). It also 
triggers mitophagy by recruiting adaptors of the autophagic machinery, such as p62.  Figure 
taken from Escobar-Henriques, M. & Langer, T. 2014. Dynamic survey of mitochondria by 
ubiquitin. EMBO Rep, 15, 231-43 (Escobar-Henriques and Langer, 2014).  
 




Figure 1.20 Post-translational modifications of Parkin. PINK1 phosphorylation of the UbL at 
S65 contributes to Parkin activation, along with sulphydration at C59, C95 and C182. 
Phosphorylation at S131 by Cdk5 or Y143 by CAbl inhibit Parkin activity. S-nitrosylation at 
C323 initially activates Parkin, but further S-nitrosylation (presumably at other sites) then 
becomes inhibitory. 
1.8 Aims 
The overarching aims of my PhD were to: 
i. Identify mitochondria-associated proteins that are regulated by an ex vivo model 
of cardiac ischaemia/reperfusion (I/R) injury.  
ii. Define the regulation of selected protein(s) in mitochondrial dynamics in cell 
culture models. 
1.8.1 Profiling the ischaemia/reperfusion injury 
proteome 
During ischaemia and reperfusion, the cellular proteome is vastly changed by stress-
induced up- and down-regulation of protein expression.  Mitochondrial dynamics and 
function are heavily perturbed by I/R injury, so the focus of this thesis was on regulators 
and post-translational modifications of these processes (Baines, 2010, Halestrap, 2010).  
I/R injury can be attenuated by ischaemic pre-conditioning (Kalogeris et al., 2014).  
Accordingly, mitochondrial regulators with differential pre-ischaemia/ischaemia 
expression were of particular interest.  The aims of this part of my PhD project were to: 
Chapter 1 Introduction 
57 
 
i. Use an ex vivo model of cardiac I/R injury to generate ischaemic damage in whole 
hearts. 
ii. Generate a protein expression profile of mitochondrial dynamics proteins during 
I/R injury. 
iii. Identify candidate proteins for further study, focussing on those whose 
mitochondrial recruitment/expression was altered by ischaemic pre-conditioning. 
1.8.2 Investigating the interplay between Parkin, 
Fbxo7 and Mff 
Levels of Parkin, Fbxo7 and Mff in the mitochondrial fraction were all altered in 
response to I/R injury.  Parkin has previously been reported to ubiquitinate Mff (Gao et al., 
2015) and to interact with Fbxo7 to mediate mitophagy (Burchell et al., 2013).  I therefore 
wanted to investigate the interplay between these three proteins with regard to 
mitochondrial dynamics.  In light of this, the aims of this part of the project were to: 
i. Generate and/or validate knock down of Parkin and Fbxo7 in mammalian cells. 
ii. Investigate the effects of Parkin/Fbxo7 knock down, focussing on Mff protein level 
and ubiquitination. 
iii. Examine the roles of post-translational modifications in the interactions and 
activities of Parkin, Fbxo7 and Mff. 
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Chapter 2 Materials & Methods 
2.1 Materials 
2.1.1 Chemicals 
All chemicals were obtained from Sigma-Aldrich Company Limited unless otherwise 
stated.  Acids/solvents were purchased from Fisher Scientific unless otherwise stated.   
2.1.2 Glass- and plastic-ware 
0.5mL and 1.5mL microcentrifuge tubes were obtained from Eppendorf, 0.2mL and 
0.5mL thin-walled PCR tubes from Starlabs, 15mL and 50mL conical Falcon tubes from 
Greiner, and 5mL Bijou and 30mL Universal tubes from Greiner.  14mL Cell Culture Tubes 
were from Bio-Rad.  10µL, 20µL, 200µL, 1000µL and 1250µL Gilson pipette tips and sterile 
filter tips were purchased from Starlabs.  5mL, 10mL and 25mL sterile serological pipettes 
were from Greiner.  24-well-, 12-well and 6-well cell culture plates, 35mm, 60mm and 
100mm cell culture dishes and T25, T75 and T175 vented cell culture flasks were obtained 
from Greiner.  Syringes and needles were from Terumo; syringe filters were from Sartorius. 
2.1.3 Cell culture reagents 
2.1.3.1 Cell lines 
Human Embryonic Kidney (HEK293T) cells were obtained from The European 
Collection of Cell Cultures (ECACC).  Stocks containing 1% (v/v) DMSO were stored in liquid 
nitrogen. 
2.1.3.1.1 HEK293T Media and reagents 
Dulbecco’s Modified Eagle’s Medium (DMEM), with Phenol Red, without Glutamine, 
4.5g/L glucose, was acquired from Lonza (HEK293T cell culture) or Sigma (HEK293T viral 
production).  Foetal Bovine Serum (FBS) was obtained from Sigma, as were 
Penicillin/Streptomycin and Poly-L-Lysine Hydrobromide.  Phosphate-buffered Saline 
(PBS), sterile cell culture water, 0.05% Trypsin-EDTA and L-Glutamine were purchased from 
Gibco (Life Technologies).  Lipofectamine 2000 transfection reagent was purchased from 
Invitrogen.  Bortezomib (BTZ) was purchased from Cell Signalling. 
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2.1.4 Molecular Biology Reagents 
2.1.4.1 Kits, enzymes and markers 
RNeasy® RNA extraction kit was from Qiagen.  RevertAid First Strand cDNA Synthesis 
Kit was from Thermo Fisher Scientific.   KOD Hot Start DNA Polymerase kit for polymerase 
chain reaction (PCR) was purchased from Merck Millipore.  Restriction enzymes were from 
New England Biolabs (NEB) and T4 DNA ligase from TaKaRa.  GeneJET™ Mini- and Midi-
prep kits and Gel Extraction kits were purchased from Thermo Scientific; DNA molecular 
weight marker (HyperLadder™ 1kB) was from Bioline. 
2.1.4.2 Oligonucleotides 
Lists of oligonucleotides (primers) generated and used as part of this work can be 
found in Table 2.1 (over-expression) and Table 2.2 (knock-down).  All primers were 
purchased from Sigma-Aldrich. 
2.1.4.2.1 Generating over-expression constructs 
All primers used in the generation of over-expression constructs are listed in Table 
2.1.  Sequence validation of over-expression constructs was performed by Eurofins 
Genomics, either using primers listed in this table or using standard primers provided by 
Eurofins Genomics.  All over-expression constructs encode the Homo sapiens protein 
(Parkin accession number: O60260).  Oligonucleotide sequences are given in the 5’-3’ 
direction, with any restriction sites underlined. 
Table 2.1 Oligonucleotides used to generate mammalian over-expression constructs 
Primer (cloning) Sequence (5’-3’) Restriction site 




















Primer (sequencing) Sequence Restriction site 
Fwd Seq Parkin 250 GAGGCGACGACCCCAGAAACG - 
Fwd Seq Parkin 484 CTCAGGGTACAGTGCAGCACC - 
Fwd Seq Parkin 635 GTGGAGCACACCCCACCTCTG - 
Fwd Seq Parkin 1189 GCCGCCGAGCAGGCTCGTTGG - 
 
2.1.4.2.2 Generating knock-down constructs 
All primers used in the generation of knock-down constructs (shRNAs) are listed in 
Table 2.2.  Sequence validation of knock-down constructs was performed by Eurofins 
Genomics using standard primers.  Parkin knock-down constructs were generated to target 
both Homo sapiens and Rattus norvegicus DNA sequences.  Oligonucleotide sequences are 
given in the 5’-3’ direction, with DNA target sequences underlined. 
Table 2.2 Oligonucleotides used to generate knock-down constructs 










2.1.4.2.3 Bacterial expression of proteins 
All primers used in the generation of bacterial expression constructs are listed in 
Table 2.3.  Sequence validation of expression constructs was performed by Eurofins 
Genomics, using standard primers provided by Eurofins Genomics.  All expression 
constructs encode the Homo sapiens protein (Parkin accession number: O60260).  
Oligonucleotide sequences are given in the 5’-3’ direction, with restriction sites underlined. 
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Table 2.3 Oligonucleotides used to generate bacterial expression constructs 
Primer Sequence (5’-3’) Restriction site 
His-Parkin fwd GCGGGATCCATGATAGTGTTTGTCAGGTTCAAC BamHI 
His-Parkin rev CGCAAGCTTCTACACGTCGAACCAGTGGTCCCC HindIII 
 
2.1.4.3 Plasmids 
2.1.4.3.1 Mammalian over-expression plasmids 
All plasmids used to over-express proteins in mammalian cells are listed in Table 2.4.  
Over-expression constructs all encoded the human sequence of the protein of interest and 
were used for over-expression of desired proteins in HEK293T cells.  Accession numbers: 
Parkin - O60260, SUMO-1 - P63165, SUMO-2 - P61956, Mff - Q9GZY8. 
Table 2.4 Plasmids generated to over-express mammalian proteins 
Protein Backbone Tag Cloning sites 
Parkin pcDNA3.1(+) - 5’ HindIII, 3’ BamHI 
Parkin pcDNA3.1(+) Myc 5’ HindIII, 3’ BamHI 
Parkin pET28a His 5’ BamHI, 3’ HindIII 
SUMO-1 pET28a GST 5’ BamHI, 3’ HindIII 
SUMO-2 pET28a GST 5’ BamHI, 3’ HindIII 
SUMO-1 pEYFP  YFP 5’ KpnI, 3’ BamHI 
SUMO-1 ΔGG pEYFP YFP 5’ KpnI, 3’ BamHI 
SUMO-2 pEYFP YFP 5’ KpnI, 3’ BamHI 
SUMO-2 ΔGG pEYFP YFP 5’ KpnI, 3’ BamHI 
E1E2-SUMO1 pE1E2-SUMO-1 - 5’ KpnI, 3’ BamHI 
E1E2-SUMO2 pE1E2-SUMO-2 - 5’ KpnI, 3’ BamHI 
Mff WT pECFP CFP 5’ KpnI, 3’ BamHI 
Mff K151R pECFP CFP 5’ KpnI, 3’ BamHI 
Mff E153A pECFP CFP 5’ KpnI, 3’ BamHI 
Mff S155A pECFP CFP 5’ KpnI, 3’ BamHI 
Mff S155D pECFP CFP 5’ KpnI, 3’ BamHI 
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2.1.4.3.2 Mammalian knock-down plasmids 
 All plasmids used to knock-down proteins in mammalian cells are listed in Table 
2.5.  Knock-down constructs contained sequences targeted to either human and rat DNA 
or only human DNA, as indicated.  esiRNA was purchased from Sigma-Aldrich and was 
targeted to only the human DNA sequence.  XhoI and BglII restriction sites were used to 
clone into pSUPER. 
Table 2.5 Plasmids generated to knock-down mammalian proteins 
Protein Target sequence (5’-3’) Backbone Tag Species 
Parkin shRNA ACCAGCATCTTCCAGCTCAAG pSUPER mCherry Human, Rat 
Parkin shRNA ACCAGCATCTTCCAGCTCAAG pXLG3 GFP Human, Rat 
Fbxo7 siRNA esiRNA pool  - - Human 
Fbxo7 shRNA CCTTTGGGAAAGCTCATCATG pXLG3 GFP Rat 
PINK1 siRNA esiRNA pool - - Human 
 
2.1.4.3.3 Bacterial expression plasmids 
All plasmids used to express proteins in bacterial cells (BL21 (DE3)) are listed in Table 
2.6.  All constructs encoded the human form of the protein of interest.  Accession numbers: 
Parkin - O60260, SUMO-1 - P63165, SUMO-2 - P61956. 
Table 2.6 Plasmids generated to express proteins in bacteria 
Protein Region Backbone Tag Cloning sites 
Parkin UbL + RING0 pET28a His 5’ BamHI, 3’ HindIII 
Parkin RING0 + RING1 pET28a His 5’ BamHI, 3’ HindIII 
Parkin RING-1 + IBR pET28a His 5’ BamHI, 3’ HindIII 
Parkin IBR + RING2 pET28a His 5’ BamHI, 3’ HindIII 
SUMO-1 Full-length pGEX-4T1 GST 5’ BamHI, 3’ XhoI 
SUMO-2 Full-length pGEX-4T1 GST 5’ BamHI, 3’ XhoI 






Chapter 2 Materials & Methods 
63 
 
2.1.5 Bacterial reagents 
2.1.5.1 Escherichia coli (E. coli) 
Table 2.7 Competent E. coli strains 
Strain Genotype Supplier 
DH5α F– endA1 glnV44 thi-
1 recA1 relA1 gyrA96 deoR nupG purB20 φ80dlacZΔM15  
Δ(lacZYA-argF)U169, hsdR17(rK–mK+), λ– 
Thermo Fisher 
XL1-Blue endA1 gyrA96(nalR) thi-1 recA1 relA1 lac glnV44 F'[ ::Tn10 proAB+ 
lacIq Δ(lacZ)M15] hsdR17(rK- mK+) 
Thermo Fisher 
BL21 (DE3) B F– ompT gal dcm lon hsdSB(rB–mB–) λ(DE3 [lacI lacUV5-T7p07 
ind1 sam7 nin5]) [malB+]K-12(λS) 
Stratagene 
 
2.1.5.2 Bacterial growth media 
Luria-Bertani (LB) Broth (1% (w/v) tryptone, 0.5% (w/v) yeast extract and 0.5% (w/v) 
NaCl) was used for cultivation of E. coli for plasmid propagation.  2xYT Broth (1.6% (w/v) 
bacto-tryptone, 1% (w/v) Bact yeast extract, 0.5% (w/v) NaCl, pH7.0) was used for 
expression of recombinant proteins in BL21 (DE3).  LB Agar (LB Broth containing 1.5% (w/v) 
agar) was used to plate E. coli for single colony selection.  100µg/mL ampicillin, 25µg/mL 
kanamycin or 34µg/mL chloramphenicol were added to media to enable antibiotic 
resistance-dependent selection.  Protein expression was induced by addition of Isopropyl 
β-D-1-thiogalactopyranoside (IPTG, Sigma Aldrich) to a final concentration of 0.2mM. 
2.1.6 Protein Biochemistry 
2.1.6.1 Cell/tissue lysis, immunoprecipitation 
N- Ethylmaleimide (NEM) was purchased from Sigma Aldrich, cOmplete™ Protease 
Inhibitor Cocktail Tablets were purchased from Roche Diagnostics GmbH, and Phosphatase 
Inhibitor Cocktail 2 was purchased from Sigma Aldrich.  Pierce® BCA Protein Assay Kit was 
purchased from Thermo Fisher Scientific.  Glutathione Sepharose® 4 Fast Flow and Ni-NTA 
Sepharose® 4 Fast Flow were obtained from GE Healthcare Life Sciences.  GFP-Trap® beads 
were bought from Chromotek. 
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2.1.6.2 SDS-PAGE and Western blotting 
Prestained molecular weight marker PageRuler was purchased from Thermo 
Scientific.   30% (v/v) 37.5:1 acrylamide:bis-acrylamide mix was purchased from Geneflow 
Limited.  Immobilon-PVDF membrane (0.45μm) and Whatman blotting paper (3CHR) were 
obtained from Millipore and GE Healthcare Life Sciences respectively.  Non-fat milk powder 
was from The Co-operative (own brand) and Bovine Serum Albumin (BSA) was from Sigma-
Aldrich.  SuperSignal™ West-Pico and –Femto Chemiluminescence substrates were 
purchased from Thermo Scientific and Luminata™ Crescendo and Forte were purchased 
from Millipore.  CL-Xposure™ X-ray film was obtained from Thermo Scientific and 
Hypercasettes™ were bought from Amersham Biosciences. 
2.1.6.3 Antibodies 
2.1.6.3.1 Primary antibodies 
Primary antibodies were diluted in TBS-T (1x Tris-buffered saline, 0.1% (v/v) tween) 
containing 5% (w/v) milk, apart from phospho-ubiquitin, SENP3 and SUMO antibodies, 
which were diluted in 4% (w/v) BSA in TBS-T.  A complete list of antibodies, dilutions and 
suppliers can be found in Table 2.8. 
Table 2.8 Primary antibodies used for Western blotting 
Antibody Species Dilution Supplier Cat. No. 
β-actin Mouse 1:10,000 Sigma-Aldrich A5441 
Cleaved Caspase 3 Rabbit 1:1000 Cell Signalling 5A1E 9664S 
Drp1 Mouse 1:1000 BD Biosciences 611112 
Dyn2 Mouse 1:1000 Sigma-Aldrich SAB4200661 
Fbxo7 Rabbit 1:5000 Aviva Systems Biology ARP43128_P050 
Fis1 Rabbit 1:1500 ProteinTech 10956-1-AP 
FLAG Mouse 1:10,000 Sigma-Aldrich M2 F1804 
GAPDH Mouse 1:20,000 Abcam 6C5 Ab8245 
GFP Rat 1:10,000 Chromotek 3H9 
GST Goat 1:10,000 GE Healthcare 27-4577 
HA Mouse 1:1000 Sigma-Aldrich H3663 HA-7 
Hexokinase II Rabbit 1:1000 Cell Signalling C64G5 2867S 
His Rabbit 1:1000 Santa Cruz H-15 sc-803 
Lamin B Goat 1:1000 Santa Cruz C20 sc-6216 
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LC3 A/B Rabbit 1:1000 Cell Signalling D3U4C 12741S 
MAPL Rabbit 1:1000 Abcam Ab155511 
Mff Mouse 1:2000 Santa Cruz C11 sc-398731 
Mitofusin II Rabbit 1:1000 Cell Signalling D2D10 9482S 
c-Myc Mouse 1:1000 Santa Cruz 9E10 sc-40 
Parkin Mouse 1:1000 Santa Cruz PRK8 sc-32282 
PINK1 Rabbit 1:1000 Novus Biologicals BC100-494 
PINK1 Rabbit 1:1000 Cell Signalling D83G 6946 
SUMO-1 Rabbit 1:1000 Cell Signalling 4930S 
SUMO-2/3 Rabbit 1:1000 Cell Signalling 18H8 4941S 
T7 Mouse 1:10,000 Novagen 69522 
Ubiquitin Mouse 1:1000 Cell Signalling P4D1 3936S 
VDAC-1/2/3 Rabbit 1:1000 Santa Cruz FL-283 sc-98708 
 
2.1.6.3.2 Secondary antibodies 
 Anti-goat, -mouse, -rabbit and –rat Horseradish Peroxidase (HRP)-conjugated IgG 
secondary antibodies were purchased from Jackson ImmunoResearch and diluted 1:10,000 
in 5% (w/v) milk or 4% (w/v) BSA in TBS-T, depending on primary antibody. 
2.1.6.4 Electrical Equipment 
 Sterile cell cultures hoods and cell culture incubators were from Holten LaminAir 
and RS Biotech, respectively.  Bacterial incubators were from New Brunswick Scientific and 
LTE Scientific.  Gel electrophoresis power packs were from Bio-Rad Laboratories.  
Centrifuges were from Beckman-Coulter and Jouan; benchtop microcentrifuges were from 
Eppendorf.  PCR Thermocycler (PTC-2000) was from MJ Research.  The automated medical 
X-ray film developer (SRX-101A) was from Konica.  Cell imaging was performed on a SP5-II 
confocal laser scanning microscope attached to a DMI 6000 inverted epifluorescence 
microscope, both from Leica. 
  




2.2.1 Eukaryotic Cell Culture  
 All cell culture techniques were performed using aseptic technique and under 
sterile conditions in a laminar flow hood (Holten LaminAir).  Media and other reagents 
(unless otherwise stated) were pre-heated to 37°C in a water bath prior to use.  Cells were 
incubated at 37°C in a humidified cell culture incubator (RS Biotech), supplied with 5% CO2 
and 95% O2. 
2.2.1.1 Culture of HEK293T cells 
 Aliquots of frozen HEK293T (Human Embryonic Kidney 293 with mutant version of 
the SV40 large T antigen, (Lebkowski et al., 1985)) cells were taken from the cryostore, 
thawed at 37°C in a water bath and transferred into a 15mL Falcon tube with 9mL 
Dulbecco’s Modified Eagle’s Medium (DMEM), supplemented with 2mM L-Glutamine, 10% 
(v/v) Foetal Bovine Serum (FBS) and 1% (v/v) Penicillin/Streptomycin (‘complete DMEM’).  
The cell suspension was centrifuged at 1000 x g for 2 minutes at room temperature (RT).  
DMEM was aspirated (to remove DMSO) and the cells re-suspended in 1mL complete 
DMEM.  This suspension was transferred to a T25 flask containing 5mL complete DMEM.  
This was incubated for 24 hours and then passaged into a T75 containing 20mL complete 
DMEM.   HEK293T cells were subsequently cultured in a T75 flask with 20mL complete 
DMEM and passaged approximately twice per week. 
2.2.1.1.1 Passaging of HEK293T cells 
 HEK293T cells were passaged upon reaching 80-90% confluency.  Complete DMEM 
was aspirated from the flask and the cell monolayer was gently washed with 10mL 1x 
Phosphate Buffered Saline (PBS).  PBS was then aspirated and 1mL Trypsin-EDTA was added 
to the cells and the flask returned to the incubator for 3 minutes.  Individual cells were 
detached from the flask by gentle tapping before 9mL complete DMEM was added to 
quench the trypsin digest.  The cell suspension was then centrifuged in a 15mL Falcon tube 
at 1000 x g for 2 minutes to pellet the cells.  DMEM was then aspirated and the cells 
resuspended by gentle trituration in 10mL fresh complete DMEM.  For maintenance of 
HEK293T stock flask, this suspension was diluted 1:20 in complete DMEM in a new T75.  
For transfection, cells were plated on 35mm (120-150µL cell suspension in 2mL DMEM) or 
60mm (250-350µL cell suspension in 5mL DMEM) plastic cell culture dishes pre-coated 
with 0.1mg/mL poly-L-lysine. 
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2.2.1.1.2 Transfection of HEK293T cells 
 Cells were transfected 20-24 hours after plating (at around 70% confluency).  
Depending on construct expression levels, ≤3µg DNA was transfected in 35mm dishes and 
≤8µg DNA in 60mm dishes.  DNA was added to 100µL plain DMEM in a 1.5mL Eppendorf 
tube, and 1.5µL Lipofectamine 2000 per µg DNA were added to 100µL plain DMEM in 
another 1.5mL Eppendorf tube (e.g. 3µL Lipofectamine 2000 for 2µg DNA) and left to 
equilibrate at room temperature (RT) for 5 minutes.  The Lipofectamine 2000 suspension 
was then added to the DNA suspension and mixed by inversion, then incubated at RT for a 
further 20 minutes to allow complex formation.  During this time, cells were gently washed 
twice in plain DMEM and thereafter cultured in ‘transfection DMEM’ (DMEM 
supplemented with 2mM L-Glutamine and 10% (v/v) FBS).  The transfection mix was then 
added drop-wise and cells incubated for 48-72 hours. 
2.2.1.1.3 Poly-L-Lysine coating of dishes 
 For transfection of HEK293T cells, cell culture dishes were first coated with 
0.1mg/mL poly-L-lysine (PLL), to promote cell adhesion.  PLL was diluted to 0.1mg/mL in 
sterile cell culture water and used to coat the bottom of dishes.  Dishes were incubated at 
37°C for ≥ 1 hour, then washed 4 times with sterile cell culture water prior to cell plating. 
2.2.1.2 Oxygen-glucose deprivation 
Oxygen-glucose deprivation (OGD) was used as a cell model of ischaemia.  Cells were 
transferred into an anaerobic chamber (95% N2, 5% CO2) at 37°C, washed once with de-
oxygenated 1x PBS, and incubated in de-oxygenated, glucose-free media.  Control cells 
were washed once in 1x PBS and incubated in fresh, oxygenated, glucose-containing media 
in a normal cell culture incubator at 37°C for the same period of time.  Cells were lysed or 
fixed in the anaerobic chamber to prevent reperfusion.   
2.2.2 Molecular Biology 
2.2.2.1 RNA Extraction from cells 
 RNA was purified from cells using the RNeasy® kit (Qiagen), according to the 
manufacturer’s protocol.  RNA concentration was quantified using the NanoDrop™ ND-
1000 (LabTech) and its corresponding software. Distilled water (dH2O) was used for 
reference and absorbance was measured at wavelengths of 260 and 280nm to ascertain 
purity in accordance with the Beer-Lambert law. 
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2.2.2.2 cDNA synthesis 
 cDNA was synthesised from RNA using the RevertAid First Strand cDNA Synthesis 
Kit (Thermo Fisher Scientific), in accordance with the manufacturer’s protocol.  Oligo(dT)18 
primers were used to selectively bind to the poly(A) tail of mRNAs and generate a cDNA 
library.  DNA concentration was quantified using the NanoDrop™ ND-1000 (LabTech) and 
its corresponding software. Distilled water (dH2O) was used for reference and absorbance 
was measured at wavelengths of 260 and 280nm to ascertain purity in accordance with the 
Beer-Lambert law. 
2.2.2.3 Polymerase Chain Reaction 
 Polymerase Chain Reaction (PCR) was used to amplify DNA fragments or interest 
using custom oligonucleotide primers synthesised by Sigma Aldrich.  PCR reactions were 
mixed in 0.5mL PCR tubes using the high fidelity KOD Hot Start DNA Polymerase kit.  
Reactions were prepared as indicated in Table 2.9.   
Table 2.9 PCR components 
Component Volume (µL) Final Concentration 
10 x Buffer 5 1x 
dNTP mix (2mM each) 5 0.2mM 
MgSO4 (25mM) 3 1.5mM 
DMSO 2.5 5% 
Sense (5’) primer (10µM) 1.5 0.3µM 
Antisense (3’) primer (10µM) 1.5 0.3µM 
Template DNA (1ng/µL) 10 0.2ng/µL 
dH2O 20.5 - 
KOD Hot Start Polymerase (1.0 
U/µL) 
1 0.02U/µL 
Total Volume (µL) 50  
 
The PCR reaction was carried out in a thermocycler under the conditions outlined in 
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Table 2.10 PCR conditions 
 Target Size 
Step <500bp 500-1000bp 1000-3000bp >3000bp 
1. Polymerase 
activation 









55°C for 10 seconds 
 
70°C for 10 
s/kb 
70°C for 15     
s/kb 
70°C for 20     
s/kb 
70°C for 25     
s/kb 
5. Repeat steps 
2-4 




70°C for 5 minutes 
7. Cooling 
 
10°C for 5 minutes 
 
2.2.2.4 Site-Directed Mutagenesis 
 Site-Directed Mutagenesis (SDM) was used to insert point substitution mutations 
into DNA constructs.  Sense and antisense oligonucleotides including the mutated codon 
and 21bp either side were used in a standard, 20-cycle PCR reaction (as described in 
2.2.2.3), with the extension time calculated for the full length of the plasmid.  Wild-type 
(WT) DNA was removed by digest of methylated plasmid within the PCR products with DpnI 
(20U, 1 hour, 37°C).  5µL of the cleaned PCR product were then used to transform 50µL 
DH5α, which were then plated on LB agar plates containing 25 μg/mL kanamycin or 100 
μg/mL ampicillin to obtain single colonies.  Several colonies were screened for the mutation 
by DNA sequencing following DNA Mini-Prep. 
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2.2.2.5 Agarose Gel Electrophoresis 
 0.8 - 1.5% (w/v) agarose gels containing 0.5µg/mL ethidium bromide were used to 
resolve cleaned DNA products.  6x DNA loading dye (30% (v/v) glycerol, 0.25% (v/v) xylene 
cyanol, 0.25% (w/v) bromophenol blue) was diluted in the DNA sample to a final 
concentration of 1x.  The gel was immersed in 0.5x TAE buffer (20mM Tris acetate, 0.5mM 
EDTA) in a Mupid-exU electrophoresis system (Mupid Co. Ltd) and samples loaded 
alongside HyperLadder™ 1kb molecular weight marker.  Samples were run under constant 
voltage (135V) for 20 minutes, and bands visualised on a UV transilluminator (Ultra-Violet 
Products Ltd). 
2.2.2.6 PCR Product Purification 
 DNA was cleaned up following PCR using the GeneJET Gel Extraction kit (Thermo 
Scientific) in accordance with the manufacturer’s protocol and eluted in 50µL dH2O. 
2.2.2.7 Restriction Digest 
 Plasmid DNA (1µg) or cleaned PCR product (50µL) were incubated with 20U of the 
appropriate restriction enzyme at 37°C for 2 hours as indicated in Table 2.11, then re-
purified and eluted in 25µL dH2O.  
Table 2.11 Restriction digest components 
Component Volume (µL) Final Concentration 
DNA 50 plasmid DNA (0.02µg/µL)  
or 50 PCR product 
0.5µg/µL plasmid DNA                      
Restriction 
enzyme 
2 (10U/µL) 0.2U/µL 
NEB Buffer 10 (10x) 1x 
dH2O 38 - 
Total Volume (µL) 100 
 
2.2.2.8 Sticky end Ligation 
 Equal volumes of digested and cleaned PCR product and plasmid DNA were 
resolved on 0.8 – 1.5% (w/v) agarose gels containing 0.5µg/mL ethidium bromide to 
approximate the insert:vector ratio.  DNA was diluted appropriately in dH2O to obtain a 
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3:1 insert:vector molar ratio for efficient ligation.  1µL each of insert and vector DNA were 
added to 2µL TaKaRa T4 ligase Solution I (2x concentrate), mixed and incubated for 30-60 
minutes at RT.  A separate ligation with dH2O in place of insert DNA was carried out to 
control for vector re-ligation.       
2.2.2.9 E. coli Transformation 
 To amplify DNA constructs, 1µL mini-/midi-prep DNA or 4µL ligation mix were 
mixed with 10µL or 50µL, respectively, competent E. coli.  XL-1 Blue E. coli were used for 
amplification of pXLG3 constructs.  DNA/E. coli mix was incubated on ice for 30 minutes, 
heat shocked at 42°C for 90 seconds and placed back on ice for 2 minutes.  In the case of 
kanamycin-resistant plasmids, 100µL plain LB broth were added to the mix and incubated 
at 37°C for 1 hour, to allow expression of the antibiotic resistance.  E. coli cells were then 
plated on LB agar plates containing the appropriate selection antibiotic (100µg/mL 
ampicillin, 25µg/mL kanamycin or 34µg/mL chloramphenicol) and incubated overnight at 
37°C.  The following day, single colonies were picked for mini-prep and insert-screening 
(ligated DNA), or midi-prep (amplification of plasmid DNA). 
2.2.2.10 DNA Mini-Prep and screening 
 Single bacterial colonies were picked from an agar plate the day after 
transformation.  Colonies were streaked on a fresh agar plate containing the appropriate 
selection antibiotic (100µg/mL ampicillin, 25µg/mL kanamycin or 34µg/mL 
chloramphenicol) and dropped into a cell culture tube containing 2mL LB broth and 
selection antibiotic.  Agar plates were incubated overnight at 37°C, and culture tubes were 
incubated overnight at 37°C in a shaking incubator.  Plasmid DNA was isolated from the 
bacterial suspension culture using the GeneJET™ Plasmid Mini-Prep kit in accordance with 
the manufacturer’s protocol.  DNA was eluted in 50µL dH2O and screened for presence of 
a correctly sized insert by restriction digest and agarose gel electrophoresis.  DNA 
containing an appropriately sized insert was validated by DNA sequencing. 
2.2.2.11 Plasmid DNA Sequencing 
 Prior to use in experiments, all DNA constructs were validated by DNA sequencing.  
This was carried out by Eurofins Genomics.  Plasmids containing the correct sequence were 
amplified by midi-prep. 
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2.2.2.12 DNA Midi-Prep 
 The streak colony corresponding to mini-prep DNA validated by sequencing was 
picked and cultured overnight at 37°C in 100mL LB broth containing the appropriate 
selection antibiotic (100µg/mL ampicillin, 25µg/mL kanamycin or 34µg/mL 
chloramphenicol) in a shaking incubator.  DNA was purified according to the 
manufacturer’s protocol using the GeneJET™ Plasmid Midi-Prep kit.  DNA was eluted in 
350µL dH2O, and its concentration and purity measured using a NanoDrop™ ND-1000 prior 
to transfection into cells. 
2.2.2.13 shRNA Synthesis 
 Protein knockdown was achieved using shRNAs targeted to regions within the gene 
of interest.  5’-phosphorylated oligonucleotides (custom-made, Sigma Aldrich) were 
dissolved in TE Buffer (1M Tris pH8.0, 100mM EDTA) to a final concentration of 100µM.  
2µL each of the sense and antisense oligonucleotides were mixed, heated at 95°C for 4 
minutes to denature any secondary structures, and left at RT for 30 minutes to anneal.  1µg 
pSUPER was digested with restriction enzymes corresponding to restriction sites that 
would allow the target sequence to be in-frame and match the overhang of the annealed 
primers, as described in 2.2.2.7.  The annealed primers were diluted 1:250 in dH2O, then 
1µL primer mix, 1µL cut vector and 2µL TaKaRa DNA Ligase T4 Solution I were mixed and 
incubated for 30 minutes at RT.  The ligation mix was then transformed into 40µL 
competent DH5α, plated on agar containing 100µg/mL Ampicillin, and incubated overnight 
at 37°C.  Single colonies were picked for screening as described in 2.2.2.10/11, and DNA 
amplified as described in 2.2.2.12. 
 
2.2.3 Biochemical Methods 
2.2.3.1 Cell Lysis 
 Cells were lysed on ice and in the presence of protease inhibitors (cOmplete™ 
Protease Inhibitor Cocktail Tablets, Roche) to minimise protein degradation.  The cell 
monolayer was washed twice with ice-cold 1x PBS and lysed in 200µL (35mm dish) or 500µL 
(60mm dish) lysis buffer (25mM HEPES pH7.4, 150mM NaCl, 1% (v/v) Triton X-100, 0.1% 
(w/v) SDS, 1x protease inhibitors) and the lysate scraped into a 1.5mL Eppendorf tube.  
When SUMO-conjugates were of interest, N-Ethylmaleimide (NEM, Sigma Aldrich), a 
cysteine protease inhibitor which irreversibly inhibits SENPs, was added to a final 
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concentration of 20mM.  Lysates were sonicated (5x 1-second pulses) and incubated on 
ice for 15 minutes.  Lysates were then centrifuged at 16,000 x g at 4°C from 15 minutes to 
pellet insoluble debris.  The cleared lysate was then added to an equal volume of 2x 
Laemmli sample buffer (4% SDS (w/v), 10% glycerol (v/v) 125mM Tris-HCl pH6.8, 0.004% 
bromophenol blue (w/v), 10% (v/v) 2-β-mercaptoethanol) to give a final concentration of 
1x Laemmli sample buffer.  Samples were heated at 95°C for 10 minutes and centrifuged 
at 16,000 x g for 1 minute prior to use for SDS-PAGE. 
2.2.3.2 Immunoprecipitation by GFP-Trap® 
 60mm dishes of cells were lysed in 500µL lysis buffer (20mM Tris pH7.4, 137mM 
NaCl, 2mM sodium pyrophosphate, 2mM EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 
25mM β-glycerophosphate, 10% glycerol (v/v), 1x cOmplete™ protease inhibitors, 20mM 
NEM) and the lysate scraped into a 1.5mL Eppendorf tube.  Lysates were sonicated briefly 
(5x 1-second pulses) and incubated on ice for 30 minutes.  Lysates were then centrifuged 
at 16,000 x g at 4°C from 15 minutes to pellet insoluble debris.  5µL GFP-Trap® bead 
suspension were aliquoted into a 1.5mL Eppendorf tube per sample and washed twice with 
500µL wash buffer (20mM Tris pH7.4, 137mM NaCl, 2mM sodium pyrophosphate, 2mM 
EDTA, 1% (v/v) Triton X-100, 0.1% (w/v) SDS, 25mM β-glycerophosphate, 10% glycerol 
(v/v)).  Washes were carried out by gently inverting tubes to mix and centrifuging at 1180 
x g for 2 minutes to pellet beads.  20µL cleared lysate were kept on ice as an input sample, 
and the remaining lysate was added to the washed GFP-Trap® beads.  The bead/lysate 
suspension was then incubated on a spinning wheel at 4°C for 90 minutes.  Beads were 
pelleted and washed 3 times as before.  Wash buffer was aspirated and 40µL 2 x Laemmli 
sample buffer added to the beads.  20µL 2 x Laemmli sample buffer were added to the 
input samples and all samples were briefly vortexed and heated at 95°C for 10 minutes.  
Samples were then centrifuged at 16,000 x g for 1 minute prior to use for SDS-PAGE.  
2.2.3.3 BCA Assay 
 BCA assays were performed in duplicate in 96-well plate format.  Albumin 
standards were prepared by serial dilution as described in the manufacturer’s protocol.  
Sufficient working reagent for 200µL/well was prepared by mixing 50 parts BCA reagent A 
with 1-part BCA reagent B.  10µL each unknown sample and BSA standards were pipetted 
into the wells of a 96-well plate.  200µL working reagent were then added to each well and 
the plate shaken for 30 seconds, before being covered and placed in a 37°C incubator for 
30 minutes.  Absorbance was measured at 570nm using a VersaMax Microplate Reader 
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(Molecular Devices).  The blank value was subtracted from all sample/standard values and 
a standard curve plotted as the average measurement from each BSA standard vs. its 
concentration (µg/mL).  This was then used to determine the concentration in µg/mL of 
the unknown samples. 
2.2.3.4 SDS-PAGE 
 Proteins were resolved according to their molecular weight (MW) using previously 
described methods (Laemmli, 1970) by Sodium Dodecyl Sulphate-Polyacrylamide Gel 
Electrophoresis (SDS-PAGE).  10-15% resolving gels (375mM Tris-HCl pH8.8, 10-15% (w/v) 
acrylamide, 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate (APS), 0.01% (v/v) 
tetramethylethylenediamine (TEMED, Bio-Rad Laboratories Inc.)) were cast in 1.5mm glass 
plates according to the manufacturer’s protocol (Bio-Rad).  The resolving gel was overlaid 
with butan-1-ol and left at room temperature (RT) to polymerise.  Following removal of 
butan-1-ol, the 4% stacking gel (125mM Tris-HCl pH6.8, 4% (w/v) acrylamide, 0.1% (w/v) 
SDS, 0.1% (w/v) APS, 0.01% (v/v) TEMED) was cast on top of the resolving gel and a 10- or 
15-well comb inserted into the stacking gel, which was then left at RT to polymerise. 
 Polymerised gels were mounted into the electrophoresis tanks (BioRad Mini-
Protean II) in accordance with the manufacturer’s protocol.  Running Buffer (25mM Tris 
base, 250mM glycine, 0.1% (w/v) SDS) was used to fill the central and bottom tank 
reservoirs.  Protein samples in Laemmli buffer were loaded into the wells alongside 5µL 
molecular weight marker (PageRuler™ Prestained Protein Ladder, Thermo Scientific).  SDS-
PAGE was carried out at 80V until samples had cleared the stacking gel, and then at 180V 
until the dye front reached the bottom of the gel.  Gels were then removed from the glass 
plates and used either for staining with Coomassie Brilliant Blue or transferred to 
membrane for immunoblotting. 
2.2.3.5 Coomassie Brilliant Blue Staining 
 Proteins in acrylamide gels following SDS-PAGE were fixed and stained in 
Coomassie Brilliant Blue stain (50% (v/v) methanol, 10% (v/v) glacial acetic acid, 0.25% 
(w/v) Coomassie Brilliant Blue) for 1 hour at room temperature (RT), gently shaking.  Excess 
stain was then removed by incubation overnight at RT, shaking, in De-staining solution 
(50% (v/v) methanol, 10% (v/v) glacial acetic acid), leaving only protein-bound stain. 
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2.2.3.6 Western Blotting 
2.2.3.6.1 Wet Transfer 
 Following SDS-PAGE, proteins were transferred onto 0.45µm Immobilon-Polyvinyl 
Difluoride (PVDF, Millipore) by wet transfer.  PVDF membrane was activated in methanol 
for 5 minutes and then equilibrated in Transfer Buffer (50mM Tris base, 40mM glycine, 
20% (v/v) methanol) for 5 minutes.  6 sheets of filter paper (Whatman™) and 2 sponges 
per transfer were also soaked in Transfer Buffer.  Bio-Rad Wet Transfer apparatus was used 
according to the manufacturer’s protocol.  The acrylamide gel was excised from the glass 
plates and laid carefully on top of 3 sheets of filter paper and a sponge, adjacent to the 
cathode.  PVDF membrane was then laid over the gel, followed by a further 3 sheets of 
filter paper and another sponge, so that the membrane was adjacent to the anode.  The 
Bio-Rad cassette was then placed back into the electrophoresis tank, which was filled with 
Transfer Buffer.  Transfer was performed at 400mA for 70-90 minutes, with constant 
cooling and stirring of the buffer. 
2.2.3.6.2 Immunoblotting 
 Following transfer, PVDF membranes were briefly washed in TBS-T (200mM Tris, 
137mM NaCl, 0.1 (v/v) Tween-20, pH7.4).  Membranes were then blocked at room 
temperature (RT) for 1 hour in 5% (w/v) non-fat dry milk or 4% (w/v) Bovine Serum Albumin 
(BSA) in TBS-T, shaking, according to manufacturer’s directions for use of the antibody 
required.  Primary antibodies were diluted to an appropriate concentration (1:1000-
1:20,000), according to manufacturer’s directions in 2.5% (w/v) non-fat dry milk or 2% 
(w/v) BSA in TBS-T and incubated with membranes at 4°C overnight, or RT for 1 hour, 
shaking.  Excess primary antibody was removed from the membrane by washing 3 times (3 
x 5-minute washes in TBS-T, shaking), and Horseradish Peroxidase- (HRP-) conjugated 
secondary antibody, diluted 1:10,000 in 5% (w/v) non-fat dry milk or 4% (w/v) BSA in TBS-
T, incubated with the membrane at RT for 1 hour.  The membrane was then washed again 
3 times in TBS-T, as before. 
2.2.3.6.3 Developing 
 Membranes were developed using enhanced chemiluminescence (ECL) as a 
substrate for the HRP-conjugated secondary antibody.  Membranes were incubated face-
down in ECL substrate for 2 minutes, then excess ECL substrate was removed and 
membranes sealed between two sheets of transparency film in a developing cassette 
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(Amersham).  Signal was detected by exposing CL-Xposure™ X-ray film (Thermo Scientific) 
to the membrane in a dark room and processing in an automated X-ray film developer 
(Konica SRX-101A medical film processor).  Up to 4 ECL substrates were used, 
depending on sensitivity required.  These are listed in Table 2.12 in order of increasing 
sensitivity.  
Table 2.12 Substrates for chemiluminescence 
ECL Substrate   
SuperSignal® West-Pico (Thermo Scientific)  
Luminata™ Crescendo (Millipore) 
Luminata™ Forte (Millipore) 
SuperSignal® West-Femto (Thermo 
Scientific) 
 
2.2.3.6.4 Stripping blots 
 To re-probe the blot for further proteins, the membrane was stripped of bound 
antibody in Restore™ PLUS Western Blot Stripping Buffer (Thermo Fisher Scientific) at 60°C 
for 20 minutes.  The membrane was then was 3 times in TBS-T, re-blocked in 5% (w/v) non-
fat dry milk or 4% (w/v) BSA in TBS-T for 1 hour before incubation with the appropriate 
primary antibody. 
2.2.3.6.5 Quantification of Immunoblots 
 Films were scanned, and blots analysed by scanning densitometry.  Pixel intensity 
of bands was quantified using ImageJ software (NIH).  Relative band intensity was reported 
as the area under each peak.  Numerical values were exported to Microsoft Excel, where 
raw values were normalised to appropriate controls.  These data were then exported to 
GraphPad Prism for statistical analysis.  As appropriate, two-tailed unpaired Student’s t-
tests (with or without Welch’s correction, depending on reported group variance), one-
way analysis of variance (ANOVA) with Bonferroni’s or Welch’s correction for multiple 
comparisons or two-way ANOVA with appropriate correction were performed.  Error bars 
represent Standard Error of the Mean (SEM).  Unless otherwise stated, statistical 
significance is reported as: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
  
Increasing sensitivity 
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Chapter 3 Ex vivo modelling of 
Ischaemia/Reperfusion injury 
3.1 Introduction 
Cardiovascular diseases (CVD) are a primary cause of morbidity and 
mortality worldwide, with more than 7 million people living with CVD in the UK alone 
(Mittal et al., 2018).  Of the CVDs, Ischaemic Heart disease (IHD) is the most common, and 
the leading cause of death worldwide (Mozaffarian et al., 2015).  IHD occurs when build-
up of atheroma narrows the coronary arteries.  This can result in angina and, if the arterial 
occlusion is great enough, myocardial infarction. 
3.1.1 Ischaemia/reperfusion injury is largely 
mitochondrial  
Disruption of blood-flow to tissue causes oxygen- and glucose-deprivation (OGD), 
triggering a switch from aerobic to anaerobic respiration.  This causes intracellular 
acidification, energy depletion and perturbations to ion homeostasis, leading to cardiac 
dysfunction and cell death.  Low levels of residual oxygen during ischaemia also contribute 
to generation of reactive oxygen species (ROS) within the myocardium. 
Paradoxically, rapid restoration of glucose and oxygen to the tissue may lead to 
greater damage, known as Ischaemia/reperfusion injury (I/R injury) (Kalogeris et al., 2014). 
I/R injury is multifactorial; however, mitochondrial dysfunction is thought to play a 
fundamental role, triggering a cascade of events which may ultimately result in cell death 
(Baines, 2010).  A burst in ROS production, along with elevated levels of Ca2+ ions, lead to 
opening of the mitochondrial Transition Permeability Pore (mPTP).  The mPTP is a non-
selective channel which plays a crucial role in reperfusion injury.  mPTP opening greatly 
increases the permeability of the mitochondrial membrane to solutes, resulting in release 
of cytochrome c from the mitochondrion and permanent loss of Adenosine Triphosphate 
(ATP), thus driving cell death (Halestrap, 2010).  Some of the mitochondrial effects of I/R 
injury are illustrated in Figure 3.1 (Cadenas, 2018). 




3.1.2 Ischaemic Preconditioning is protective 
against I/R injury 
Interestingly, short bursts of ischaemia and reperfusion, termed ischaemic 
preconditioning (IPC), prior to prolonged ischaemia have a protective role against I/R injury, 
though the reasons for this are not yet fully understood (Pinheiro et al., 2016, Koch et al., 
2014).  IPC was first described by Murry et al and is among the most potent 
cardioprotective strategies that can be employed against I/R injury (Murry et al., 1986). 
The protective effects of IPC have been demonstrated by a large number of separate 
studies and is not limited to cardiac tissue.  Curiously, the protective effects of IPC can be 
conferred even when the site of preconditioning is distal to the site of ischaemic injury (Ren 
et al., 2009).  IPC followed by I/R, compared to I/R insult alone, has been shown to decrease 
Figure 3.1 ROS generation and mPTP opening during reperfusion. Mitochondrial ROS are 
generated by electrons leaking from the electron transport chain, resulting in incomplete 
reduction of oxygen to superoxide (O2•-). During early reperfusion, reverse electron 
transport (driven by succinate) causes superoxide production. Mitochondrial NOX4 
contributes to generation of H2O2. mPTP formation is promoted by ROS and Ca2+ but 
inhibited by acidosis. Ischaemia-effected low pH inhibits transition pore formation but, 
upon reperfusion, restoration of pH, Ca2+ overload and excessive ROS induce pore 
formation, leading to cell death. CyP-D enhances pore Ca2+-sensitivity. Figure taken from 
Cadenas, S. 2018. ROS and redox signaling in myocardial ischemia-reperfusion injury and 
cardioprotection. Free Radic Biol Med, 117, 76-89  (Cadenas, 2018). 
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cytolysis and lipid peroxidation, resulting in improved renal function in a study of ischaemic 
kidneys in rats (Mahfoudh-Boussaid et al., 2012).  In the case of cardiac ischaemia, IPC has 
been shown to improve several different clinical outcomes of I/R injury.  In a randomised 
controlled clinical trial of 180 cardiac bypass patients, the extent of perioperative 
myocardial injury was significantly reduced by remote IPC prior to surgery.  In addition to 
reducing the magnitude of injury, IPC also decreased the incidence of post-operative atrial 
fibrillation and acute kidney injury and reduced the length of recovery required in an 
intensive care unit (Candilio et al., 2015).  IPC alleviates cardiac contractile dysfunction 
upon reperfusion by preserving end-ischaemic ATP levels (Kaplan et al., 1994).  It also 
prevents ventricular arrhythmia (Parratt and Vegh, 1994, Hagar et al., 1991).  Most notably, 
infarct size is limited in IPC treated rat and pig hearts, both in cases of I/R injury and in cases 
where the subsequent ischaemia was lethal (Shintani-Ishida et al., 2006, Yellon et al., 1992, 
Schott et al., 1990).   
3.1.3 Molecular mechanisms of IPC cytoprotection 
Clinically, the effects of IPC are biphasic, with an early phase of protection occurring 
almost immediately post-IPC, and a second, late phase 12-24 hours later, although the late 
phase was not explored within this PhD.  Early phase IPC has been linked ROS; whereas 
large-scale ROS production is detrimental to cellular viability, sub-lethal levels of ROS, such 
as those generated by IPC, may contribute to cardio-protection by acting as messengers in 
signal transduction to modify redox-sensitive proteins (Chen et al., 1995, Otani, 2004).   
During ischaemia, fatty acid oxidation is replaced by glycolysis as the primary method 
of energy metabolism, allowing maintenance of cellular viability over a longer period.  This 
metabolic switch is directly regulated by HIF (hypoxia-inducible factor), a redox-sensitive 
transcription factor (Cadenas, 2018).  HIF is a heterodimeric protein comprising HIF-α and 
HIF-β; expression of the latter is constitutive, whereas accumulation of the former 
(comprising 3 subunits - HIF-1α, HIF-2α and HIF-3α) is oxygen-sensitive, with hypoxia 
inhibiting its degradation (Kim et al., 2006a). 
Sub-lethal intracellular levels of ROS, such as those generated by short bursts of 
ischaemia and reperfusion during IPC, inhibit prolyl hydroxylases.  Under normoxic 
conditions, prolyl hydroxylases are responsible for the hydroxylation of HIF-α, resulting in 
its ubiquitination and subsequent proteasomal degradation (Bruick and McKnight, 2001, 
Srinivas et al., 1999).  During IPC, low levels of ROS facilitate HIF-α accumulation and 
translocation to the nucleus, where it dimerises with HIF-β.  The HIF dimer can then bind 
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to hypoxia response elements, recruit the transcriptional co-activator CBP/p300 and 
induces gene transcription (Epstein et al., 2001, Lando et al., 2002, Mahon et al., 2001).  
HIF-induced transcriptional changes are responsible for initiation of various protective 
mechanisms, including endothelial/vascular remodelling and activation of the RISK 
(reperfusion injury signalling kinase) pathway (Holscher et al., 2011, Martin-Puig et al., 
2015, Tsang et al., 2004). 
Interestingly, there is accumulating evidence that IPC confers protection of cardiac 
mitochondria via cytosol-independent mechanisms.  Sub-lethal I/R in isolated rat hearts 
reduced complex-I and -II-mediated respiration in sub-sarcolemmal (SS) mitochondria, but 
not interfibrillar (IF) mitochondria, an effect which was attenuated by IPC.  Connexin-43 is 
a protein present in SS, but not IF, mitochondria, and is thought to modulate mitochondrial 
respiration via complex-I.  Replacement of connexin-43 with connexin-32 abolished the 
protective effect of IPC, both in whole hearts and in isolated mitochondrial preparations 
(Ruiz-Meana et al., 2014, Rodriguez-Sinovas et al., 2018).  
3.1.4 Mitochondrial dynamics are critical in I/R 
injury outcome 
Because of its constitutive activity the heart has very high energy demands.  To meet 
this requirement, cardiomyocytes are enriched with mitochondria, which account for 30-
35% of their volume.  Mitochondria are highly dynamic organelles, undergoing continuous, 
tightly regulated fission and fusion events, creating an adaptable and efficient energy 
transfer system, crucial to deliver ATP to where it is most urgently needed within the cell 
(Piquereau et al., 2013).  Fused mitochondria (a mitochondrial network or reticulum) 
facilitate efficient delivery of ATP from the cell periphery to the core, whereas individual 
divided mitochondria can be trafficked rapidly to meet changing energy demands around 
the cell.  Under conditions of oxidative stress, this fragile equilibrium is be perturbed, 
resulting in mitochondrial fragmentation, mitophagy, and apoptosis (Hom and Sheu, 2009, 
Skulachev, 2001).  
To co-ordinate the tightly regulated processes of mitochondrial fission and fusion, a 
huge number of different proteins and pathways are required.  However, stresses such as 
ischaemia and I/R injury can alter the expression, turnover and post-translational 
modifications of various fission and fusion proteins.  My PhD work has focused primarily 
on changes to proteins associated with mitochondrial fission.  There are a growing number 
of proteins known to be involved in mitochondrial fission, both under physiological and 
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pathophysiological conditions.  Defining how these proteins are recruited and regulated is 
intrinsic to advancing our understanding of I/R injury and could lead to the identification 
of potential therapeutic targets.  Brief introductions to the proteins assayed are given 
below, listed according to their primary function. 
3.1.4.1 Mitochondrial fission proteins 
Dynamin II (Dyn2) and Dynamin-related protein I (Drp1) 
Mitochondrial fission is a tightly regulated process involving an ever-growing 
number of known proteins.  Key players identified so far include dynamin II (Dyn2, also 
Dnm2) and dynamin-related protein I (Drp1).  Knock out of Drp1, causes mass fusion of 
mitochondria and extended networks and is embryonic lethal, indicating a crucial role in 
development.  However, cultured Drp1-knock out  cells are viable and can divide, 
suggestive of a compensatory mechanism (Ishihara et al., 2009).  It was previously assumed 
that final scission of the mitochondrial membranes during fission was achieved by Drp1-
induced constriction forces.  However, recent work has demonstrated that this task is 
actually carried out by the conventional dynamin Dyn2 (Lee et al., 2016).  Electron 
microscopy and 3D tomography revealed that cells treated with siRNA targeting Dyn2 
displayed stalled and elongated super-constricted mitochondrial membranes, which were 
not present in control cells (Lee et al., 2016).  Drp1 is capable of constricting membranes 
of a greater diameter than Dyn2 but requires Dyn2 to constrict them far enough for 
scission.  Lee et al proposed a model in which Drp1-dependent mitochondrial fission 
requires the sequential action of Drp1, which constricts the mitochondrial membrane to a 
diameter conducive to Dyn2 action, followed by recruitment of Dyn2 and complete 
membrane scission. 
Mitochondrial Fission Factor (Mff) and Fission I (Fis1) 
Mff has been previously identified as the main receptor for Drp1  (Lee et al., 2004, 
Alirol et al., 2006), and is discussed in greater detail in 1.1.6.  It is a single-pass 
transmembrane protein with an N-terminal Drp1-interacting domain (Figure 1.18).  Fis1 
has previously been reported to bind Drp1 in an interaction which is at least partly stress-
dependent (Joshi et al., 2018).  Drp1-independent roles for Fis1, however, must also be 
considered, as knock down of Fis1 inhibits cell death significantly more than inhibition of 
Drp1, and Fis1 is not exclusively localised to sites of mitochondrial scission (Suzuki et al., 
2003, Yoon et al., 2003).   
Mitochondria-anchored protein ligase (MAPL) 
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MAPL (mitochondria-anchored protein ligase) is a SUMO-1 ligase and is currently the 
only known SUMO ligase that is mitochondria-bound (Neuspiel et al., 2008).  MAPL has 
been shown to play a part in regulating mitochondrial fission via SUMOylation of Drp1, 
which is thought to stabilise the endoplasmic reticulum (ER)/mitochondrial interface that 
acts as a hotspot for constriction of the mitochondrial membrane, calcium flux, cristae 
remodelling and cytochrome C release (Braschi et al., 2009, Prudent et al., 2015).   
3.1.4.2 Mitochondrial fusion proteins 
Mitofusin II (Mfn2) 
Mitochondrial morphology and integrity stems from a delicate balance of fission and 
fusion.  Although fission was the main interest of this project, it was still important to 
consider any perturbations to mitochondrial fusion.  We therefore also probed for 
Mitofusin II (Mfn2) in the mitochondrial samples.  Stress-induced phosphorylation of Mfn2 
by JNK, leading to ubiquitination and proteasomal degradation, has been shown to 
facilitate mitochondrial fragmentation and apoptosis (Leboucher et al., 2012).    Conversely, 
it has recently been reported that Mfn2 plays a protective role in I/R injury by increasing 
the rate of autophagy; over-expression of Mfn2 was shown to ameliorate I/R injury by 
increasing formation of autophagosomes and promoting their fusion to lysosomes, whilst 
down-regulation of Mfn2 had the opposite effect (Peng et al., 2018).   
3.1.4.3 Mitophagy proteins 
PTEN-induced kinase I (PINK1) 
PINK1 is a mitochondrial serine/threonine kinase that is constitutively cleaved from 
the mitochondrial membrane under physiological conditions, accumulating only upon 
mitochondrial membrane depolarisation (Geisler et al., 2010, Whitworth et al., 2008).  
PINK1 knock out has been shown to cause defects in mitochondrial morphology and 
increased sensitivity to several cellular stresses, including oxidative stress (Clark et al., 
2006).  However, mitochondrial dysfunction caused by lack of PINK1 can be compensated 
for by Parkin over-expression in Drosophila melanogaster (Park et al., 2006).  This is thought 
to be because PINK1 loss-of-function causes not only abnormal mitochondrial morphology, 
but also altered mitochondrial membrane potential, which can be rescued by activation of 
autophagy by Parkin (Exner et al., 2007). 
PINK1 is cytosolically synthesised as a 63kDa protein, which undergoes at least two 
cleavage events in the mitochondrial inter-membrane space (IMS), first by mitochondrial 
processing peptidase (MPP) to remove the mitochondrial targeting sequence, then by 
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presenilin-associated rhomboid-like protease (PARL) and m-AAA protease, resulting in 
55kDa and 48kDa species (Greene et al., 2012).  It has previously been shown that, upon 
dissipation of the mitochondrial membrane potential, the full-length PINK1 protein 
accumulates (Jin et al., 2010).   
Parkin and F-box only protein 7 (Fbxo7) 
Parkin is well established as playing an important role in mitophagy, through its 
selective recruitment to damaged mitochondria and dramatic changing of the 
ubiquitination status of the mitochondrial proteome (Sarraf et al., 2013, Chan et al., 2011).  
Parkin is a primarily cytosolic ubiquitin ligase, canonically recruited to depolarised 
mitochondrial membranes by accumulation of PINK1 (PTEN-induced putative kinase 1) 
(Matsuda et al., 2010, Narendra et al., 2010, Narendra et al., 2008) which has been 
previously reported to ubiquitinate Mff, promoting its association with the autophagic 
receptor p62 (Gao et al., 2015).  Fbxo7, an adaptor protein of the Skp1-Cul1-Fbx Cullin RING 
ligase complex, has also been shown to play a part in mitophagy, in a role thought to be 
linked to its direct interactions with Parkin (Burchell et al., 2013).  Further detail on Parkin 
and Fbxo7 is given in 1.5 and 1.6, respectively. 
3.1.5 Aims 
Several previous studies have identified increased SUMOylation as a protective 
mechanism against ischaemic stress, including that experienced by ground squirrels during 
torpor (Lee et al., 2007), neurons subjected to OGD (Guo et al., 2013, Guo et al., 2017) and 
HEK293T cells in a heavy metal-induced model of ischaemia (Luo et al., 2017).  Additionally, 
a recent study has implicated the SUMO-protease SENP3 as a key influencer of myocardial 
infarct outcomes, showing that cardiac-specific knock down of SENP3 in vivo reduces 
infarct size, and over-expression of SENP3 increases infarct size upon induced I/R injury 
(Gao et al., 2018). 
The aim of this part of my PhD was to investigate whether the global changes in 
SUMOylation observed by other groups studying ischaemic stress were also apparent in 
our model of cardiac ischaemia.  Additionally, given the importance of mitochondria in I/R 
injury, potential SUMO target proteins and fission/fusion proteins  at the mitochondrial 
outer membrane (MOM) were also of interest in this study.  
 




3.2.1 Ex vivo retrograde perfusion 
250-274g male Wistar rats were anaesthetised with isofluorane and killed by cervical 
dislocation in accordance with Schedule 1 Guidance on the Operation of the Animals 
(Scientific Procedures) Act, 1986.  The aorta was cannulated in vivo and retrograde 
perfusion started immediately using Langendorff apparatus (Figure 3.2).  Hearts were 
perfused under constant flow (12 mL/min) at 37°C with continuously oxygenated (95% O2, 
5% CO2) Krebs Henseleit Buffer (KHS: 118mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 1.25mM 
CaCl2, 1.2 mM KH2PO4, 25 mM NaHCO3, 11mM glucose) at pH 7.4.  A ~15-minute 
stabilisation period allowed hearts to recover to physiological levels of function prior to 
commencement of perfusion protocols.    Ischaemia was achieved by submerging the heart 
in de-oxygenated KHS and cessation of perfusion.   
 
The pre-ischaemic group was continuously perfused for 30 minutes.  Ischaemia  was 
performed by submersion in de-oxygenated KHS with no perfusion for 30 minutes, and the 
Figure 3.2 Schematic of Langendorff retrograde perfusion apparatus. Hearts were perfused 
under constant flow at 37°C with continuously oxygenated Krebs-Henseleit solution (KHS).  
Ischaemia was achieved by submerging the heart in perfusion buffer and cessation of 
perfusion. 37°C water was continuously circulated around the system (black arrows).  KHS 
was perfused with a 95% O2, 5% CO2 mixture to maintain oxygen supply to cardiac tissue 
and pH of KHS (red arrow).  Oxygenated KHS was driven through the Langendorff apparatus 
under constant flow by a pump (X and blue arrows).   
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ischaemia & reperfusion group was then perfused for a further 120 minutes.  Ischaemic 
pre-conditioning consisted of 3 x 2-minute bursts of ischaemia, separated by 3 minutes 
reperfusion.  This was followed by 30 minutes of ischaemia.  The schematic in Figure 3.3 
illustrates the 4 conditions used.  An extended pre-ischaemia group (150 minutes of 
perfusion) was not significantly different from the 30 minutes pre-ischaemia group and was 
excluded from datasets for clarity.  Left ventricular tissue was immediately subjected to 
subcellular fractionation.  For each of the experimental conditions, 6 independent animals 
were used i.e. 6 hearts.   
 
3.2.2 Subcellular fractionation of Left Ventricular 
tissue 
The protocol for isolation of cellular fractions from rat left ventricular tissue was 
adapted from a previously published protocol (Pasdois et al., 2013) and performed at 4°C.  
A schematic of the protocol is shown in Figure 3.4. 
 Left ventricular tissue was immersed in 6mL ice cold isolation buffer (300mM 
sucrose, 3mM EGTA, 10mM Tris-HCl, pH7.1) supplemented with 20mM NEM, 1x complete 
protease inhibitors (Roche) and 1x phosphatase inhibitors.  Tissue was rapidly chopped into 
fine pieces (Figure 3.4, 1) before homogenisation using a Polytron tissue disruptor 
(Kinematica) at 10,000rpm with 2 bursts of 5 seconds followed by 1 burst of 10 seconds.  
Tissue homogenate was diluted to 20mL total volume with isolation buffer supplemented 
with 1x complete protease inhibitors (2) and further homogenised by hand for 2 minutes 
using a glass Potter homogeniser and Teflon pestle (3).  A small volume of homogenate 
was stored at -80°C as whole homogenate (4, A).  The homogenate was centrifuged at 
7500g for 7 minutes (5) and the soluble fraction (supernatant) stored at -80°C as a cytosol-
containing fraction (B).  The pellet was rinsed twice with 5 mL isolation buffer, resuspended 
Figure 3.3 Schematic of retrograde perfusion protocols. 
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in 20mL isolation buffer and further hand-homogenised for 2 minutes (6).  The 
homogenate was then centrifuged at 600g for 10 minutes (7) and the pellet resuspended 
in isolation buffer and stored at -80°C as a nucleus-containing fraction (C).  The supernatant 
was centrifuged at 7000g for 10 minutes (8) to yield a crude mitochondrial pellet, which 
was resuspended in isolation buffer and stored at -80°C (D).  All fractions were assayed for 
protein concentration using a standard BCA assay protocol prior to use for Western 
blotting. 
3.2.3 Lactate Dehydrogenase (LDH) Assay 
The Pierce™ LDH Cytotoxicity Assay Kit was purchased from Thermo Fisher and used 
according to the manufacturer’s protocol.  Briefly, one volume each of perfusate and 
Substrate Solution were mixed in a 96 well plate, and incubated for 30 minutes at RT, 
protected from light.  One volume Stop Solution was then added, and the absorbance read 
in a spectrophotometer at 490nm and 680nm.  LDH activity was calculated by subtracting 
the 680nm reading (background) from the 490nm reading. 
 
Figure 3.4 Schematic of cardiac tissue subcellular fractionation. 






To accurately assess protein levels within subcellular compartments, it was vital to 
ensure that the fractionation protocol followed yielded sufficiently clean fractions.  Most 
importantly, due to the high proportion of SUMO proteins within the nucleus compared to 
the rest of the cell (Takahashi and Kikuchi, 2008), nuclear contamination of other cell 
compartments could significantly distort SUMO measurements from other compartments. 
To assess the purity of mitochondrial samples, mitochondrial and total lysate 
samples were run side-by-side by SDS-PAGE, and Western blotted for markers of 
intracellular compartments (Figure 3.5).  Lamin B is an integral structural constituent of the 
nuclear lamina, and its absence from mitochondrial fractions indicates that the nucleus has 
been largely excluded.  GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) is an enzyme 
involved in glycolysis partitioned to the cytosol, so its absence from the mitochondrial 
fractions is indicative of cytosolic exclusion.  VDACs (Voltage-dependent anion-selective 
channels) are components of the outer mitochondrial membrane but are synthesised at 
endoplasmic reticulum (ER)-associated ribosomes.   
Figure 3.5 Purity of mitochondrial fractions.  Following subcellular fractionation of perfused 
left ventricular tissue, total lysate (Total) and mitochondrial (Mito.) samples were 
subjected to SDS-PAGE and Western blotting side-by-side.  Membranes were blotted for 
Lamin B (nuclear), GAPDH (cytosolic) and VDAC (mitochondrial).  For each condition, two 
Total samples (independent hearts) were run alongside their mitochondrial fractions. 
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 Langendorff apparatus ischaemia and reperfusion 
It was also important to check that the ischaemia protocols in the Langendorff 
experiments were effective in damaging the cardiac tissue, thereby modelling true 
ischaemia/reperfusion (I/R) injury.  To validate this, known cellular stress responses were 
examined by Western blotting.  Cytosolic protein samples from the Langendorff perfused 
hearts were probed for cleaved Caspase-3 and Microtubule-associated protein 1A/1B-light 
chain 3 (LC3).   
 Caspase 3 
The caspase protein family are a group of cysteine proteases with important roles in 
the regulation of apoptosis, broadly categorised as apoptosis initiator- and apoptosis 
executioner-caspases (of which Caspase-3 falls into the latter group) (Degterev et al., 
2003).  Their function must be tightly regulated to avoid inappropriate activation of the 
programmed cell death cascade, and as such, all of the 11 mammalian caspases are 
synthesised as inactive zymogens comprised of N-terminal pro-domain, a large subunit 
(p20) and a C-terminal small subunit (p17) (Yamin et al., 1996).  Activation of the caspase 
only occurs via a series of cleavage events, with executioner caspases typically being 
processed and activated by upstream caspases.  The appearance of cleaved caspase-3 
within a cell therefore serves as an indicator of cellular stress and initiation of apoptotic 
pathways. 
LC3 
LC3 is the mammalian homologue of Atg8 (Autophagy-related protein 8).  Post-
translationally, LC3-I exists as cytosolic polypeptide, and its proteolytic cleavage yields LC3-
II, which is membrane-bound at autophagosomes (Kabeya et al., 2000).  An increase in the 
ratio of LC3-II to LC3-I (i.e. lower molecular weight to higher molecular weight LC3-reactive 
species) is therefore indicative of greater presence of autophagosomal membranes and 
autophagic activity (Aparicio et al., 2016). 
In the Langendorff perfused hearts, cytosolic levels of cleaved caspase-3 were 
significantly increased (p < 0.0001) only during reperfusion, compared to pre-ischaemia 
and ischaemia (Figure 3.6 (A, C)).  Similarly, the only significant (p < 0.001) increase in LC3-
II/LC3-I ratio was also observed upon reperfusion (Figure 3.6 (A, B)).  Taken together, these 
data confirm previous reports that the damage incurred as a result of I/R injury primarily 
occurs during reperfusion. 




 In addition to probing cytosolic fractions for markers of intracellular stress, 
perfusate from the hearts was collected to measure extracellular stress responses.  A 
lactate dehydrogenase (LDH) assay was used to quantify cytotoxicity by colorimetric 
measurement. 
 LDH is a cytosolic enzyme that converts lactate to pyruvate by reduction of NAD+ 
to NADH in a reversible, coupled reaction (Everse and Kaplan, 1973).  Cytotoxic conditions 
damage the plasma membrane, releasing LDH from the cytosol.  LDH is then found in the 
perfusate collected during Langendorff perfusion.  In an LDH assay, release of LDH can be 
quantified from a two-step reaction.  LDH first reduces NAD+ to NADH (coupled to 
deprotonation of lactate to pyruvate).  Diapharose then uses NADH to reduce a tetrazolium 
salt to a formazan product, which is red and can be measured at a wavelength of 490nm 
by spectrophotometry.  In this assay, formation of formazan is directly proportional to 
amount of released LDH, and thereby cytotoxicity. 
Figure 3.6 Intracellular stress response during ischaemia and reperfusion. Following 
subcellular fractionation of perfused left ventricular tissue, cytosolic samples were used for 
Western blotting.  Samples were probed with LC3 and cleaved Caspase-3 antibodies.  Blots 
performed by Nadiia Rawlings. N = 6 (blot shows 3 replicates of each condition).  Analysed 
using ordinary one-way ANOVA with Sidak’s correction for multiple comparisons with a 
pooled variance. Data presented as mean ± SEM.  *** p < 0.001**** p ≤ 0.0001.   
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During the Langendorff experiments, perfusate was collected at three different time 
points: after 30 minutes of normal perfusion (pre-ischaemia control), within the first 
minute of reperfusion following 30 minutes ischaemia (ischaemia), or within the first 
minute of the 3rd reperfusion of pre-conditioning (ischaemic pre-conditioning).  As shown 
in Figure 3.7, only the perfusates collected immediately after 30 minutes of ischaemia had 
significant amounts of LDH, compared to the pre-ischaemic control or pre-conditioning 
group.  We would expect that the largest LDH release would occur during reperfusion.  
However, by the end of 2 hours reperfusion, any extracellular LDH has been washed out 
and so cannot be collected in the perfusate. 
 
3.3.2 Post-Translational Modifications 
Post-translational modifications (PTMs) are a broad class of small molecular 
additions that can alter the subcellular location, efficiency, function, stability and activation 
status of target proteins.  Under stress conditions, PTMs can rapidly and reversibly alter 
large portions of the proteome in an attempt to protect against cellular damage. 
Global up-regulation of ubiquitination is a well characterised consequence of  
cellular stress that participates in triggering the Unfolded Protein Response (UPR) and 
targeting damaged proteins for proteasomal degradation en masse (Lindholm et al., 2017).  
It was therefore expected that this model of I/R injury would result in changes in total 
proteome ubiquitination.  As shown in Figure 3.8, ischaemia resulted in a trend of 
decreased global ubiquitination, which became statistically significant with ischaemic pre-
Figure 3.7 Cytotoxicity during ischaemia.  Perfusate from the hearts was collected at various 
points during the ischaemia/reperfusion modelling and subjected to a lactate 
dehydrogenase (LDH) assay as a measure of cytotoxicity.  The LDH assay provided a 
colorimetric readout of cytotoxicity, measured in absorbance units (AU).  N = 4-6.  Analysed 
using ordinary one-way ANOVA with Sidak’s correction for multiple comparisons with a 
pooled variance. Data presented as mean ± SEM.  *** p < 0.001. 
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conditioning.  However, there was significant up-regulation of global ubiquitination upon 
reperfusion, consistent with the stress responses shown in Figure 3.6. 
 
Protein SUMOylation is globally upregulated during ischaemic stress in neurons and 
in embryonic anoxia (Guo et al., 2013, Meller et al., 2014).  Therefore, it was hypothesised 
that a similar pattern might be expected in cardiac tissue having undergone ischaemia or 
ischaemia/reperfusion.  I therefore assessed left ventricular tissue lysate by SDS-PAGE and 
Western blotting for SUMO-1 and SUMO-2/3 conjugated proteins.  As shown in Figure 3.9, 
no global changes were detected in SUMO-2/3 conjugates (A, C) (analysis of whole lanes).  
However, a small but significant increase was seen in SUMO-1 conjugates when hearts 







Figure 3.8 Total Ubiquitination during ischaemia and reperfusion. Prior to subcellular 
fractionation of perfused left ventricular tissue, whole homogenate samples were 
prepared to be used for Western blotting.  Samples were probed with Ubiquitin antibody. 
Representative blots are of 3 samples per condition.  N = 6.  Analysed using ordinary one-
way ANOVA with Sidak’s correction for multiple comparisons with a pooled variance. Data 
presented as mean ± SEM.  * p < 0.05, **** p < 0.0001. 




Mitochondria are particularly susceptible to acute damage in I/R injury, largely due 
to localised oxidative stress (Jasova et al., 2017, Hassanpour et al., 2018). Changes in 
mitochondrial SUMOylation may have been masked in the total lysate by the presence of 
high levels of nuclear SUMO-conjugates (Takahashi and Kikuchi, 2008). I therefore 
separately assessed mitochondrial fractions for changes in SUMOylation.  Additionally, the 
mitochondrial fractions were blotted for Ubiquitin-conjugates, to determine whether 
ubiquitination of mitochondrial proteins followed the same pattern as the total proteome. 
Figure 3.9 Total SUMOylation during ischaemia and reperfusion. Prior to subcellular 
fractionation of perfused left ventricular tissue, whole homogenate samples were 
prepared to be used for Western blotting.  Samples were probed with SUMO-1 and SUMO-
2/3 antibodies. Representative blots are of 3 samples per condition.  Total protein stain 
was used as a loading control.  Blots performed by Nadiia Rawlings.  N = 6.  Analysed using 
ordinary one-way ANOVA with Sidak’s correction for multiple comparisons with a pooled 
variance. Data presented as mean ± SEM.  *** p < 0.001. 




 As shown in Figure 3.10, no significant changes were detected in global SUMO-1-
ylation or SUMO-2/3-ylation of the mitochondrial proteome (A, B, D).  This is not to say that 
subsets of the mitochondrial proteome did not have their SUMOylation status altered by 
I/R.  For example, an approximately 55kDa SUMO-1-ylated species was significantly 
upregulated under ischaemia, compared to pre-ischaemia, but was not upregulated during 
ischaemia in tissue that had been pre-conditioned (A (highlighted), C).   
Figure 3.10 Mitochondrial post-translational modifications during ischaemia and 
reperfusion.  Following subcellular fractionation of perfused left ventricular tissue, 
mitochondrial samples were used for Western blotting.  Samples were probed with SUMO-
1, SUMO-2/3 or ubiquitin antibodies. Representative blots are of 3 samples per condition.  
N = 6.  Analysed using ordinary one-way ANOVA with Sidak’s correction for multiple 
comparisons with a pooled variance. Data presented as mean ± SEM.  * p ≤ 0.05, ** p < 
0.01**** p ≤ 0.0001. 
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The most notable change in mitochondrial PTMs was that of ubiquitin (Figure 3.10 
(A, E)).  As in the total lysate, ubiquitination of mitochondrial proteins was significantly 
increased during ischaemia and reperfusion, compared to ischaemia alone.  This was 
consistent with Figure 3.6, in which significant cellular stress occurred primarily during 
reperfusion. 
 
3.3.3 Mitochondria-associated proteins 
Mitochondrial integrity is critical to the survival of cells following ischaemic insult or 
I/R injury (Ambrosio et al., 1993, Griffiths and Halestrap, 1995, Schaller et al., 2010).  
Proteins associated with mitochondrial structure and dynamics were therefore a primary 
focus in this study.  Particular attention was paid to proteins involved in mitochondrial 
fission, both under physiological and pathophysiological conditions, especially those which 
appeared to be differentially expressed or recruited between ischaemia and ischaemic pre-
conditioning groups, as this may provide some insight into the molecular mechanisms 
underpinning the cytoprotective effects of pre-conditioning. 
Hexokinase II  
Hexokinase II (HK2) catalyses the phosphorylation of glucose to glucose-6-
phosphate (G-6-P), which is sequestered in the cytosol and primed for further metabolism 
(Halestrap et al., 2015).  Despite its role in glycolysis, HK2 is found not only in the cytosol, 
but can also bind to the outer mitochondrial membrane (MOM), depending on the 
prevailing metabolic conditions; high (G-6-P) concentration favours dissociation of HK2 
from the mitochondrial membrane (Pastorino and Hoek, 2008, Wilson, 2003, Murry et al., 
1990).  Bound HK2 inhibits opening of the mPTP and reduces mitochondrial membrane 
permeability to cytochrome C.  This could be through stabilisation of mitochondrial-
endoplasmic reticulum (ER)-contact sites and antagonization of pro-apoptotic Bcl-2 family 
members, potentially through association with VDAC (Pastorino and Hoek, 2008, Pastorino 
and Hoek, 2003).  Glycogen metabolism during ischaemia produces G-6-P, and previous 
studies have shown that pre-ischaemic levels of glycogen in the heart determine the extent 
of reperfusion injury (Finegan et al., 1995, McNulty et al., 1996).  No significant changes 
were detected in total HK2 under the conditions of this study, however a small loss of HK2 
from the mitochondrial membrane was evident during ischaemia, with a statistically 
significant dissociation of HK2 upon ischaemia of the pre-conditioned group (Figure 
3.11(B)). 
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Dynamin related protein 1 (Drp1) and Dynamin2 (Dyn2)  
Given the mitochondrial fragmentation associated with ischaemia and reperfusion, 
we predicted an increase in association of proteins involved in fission (Chen et al., 2009).  
In our model of I/R injury, mitochondrial association of both Drp1 and Dyn2 was slightly, 
but not significantly, increased during ischaemia (Figure 3.11 (C, D)).  Interestingly, 
association of Dyn2 during ischaemia was significantly reduced by IPC, suggestive of 
reduced ischaemic mitochondrial fission following IPC.  The significant decrease in 
mitochondria-associated Drp1 during reperfusion was unexpected, as we would predict 
that the I/R-induced fragmentation of mitochondria depends on increased/dysregulated 
fission.  However, we cannot rule out decreased mitochondrial fusion as the predominant 
driving force of fragmenting the mitochondrial network during I/R injury. 
Parkin and Fbxo7  
It has been widely reported that Parkin is recruited to mitochondria under conditions 
of oxidative stress, setting in motion a chain of events resulting in large-scale mitophagy 
(Matsuda et al., 2010, Vincow et al., 2013, Caulfield et al., 2015, Gong et al., 2015).  
Consistent with this, I observed that Parkin is heavily recruited to mitochondria during 
ischaemia, an effect which is partially offset by ischaemic pre-conditioning (Figure 3.11 (F)). 
Intriguingly, recruitment of Fbxo7 to mitochondria during ischaemia was also 
attenuated by pre-conditioning (Figure 3.11 (E)), which could be indicative of a co-
dependent mechanism of recruitment for Parkin and Fbxo7, as put forth in the publication 
by Burchell et al (Burchell et al., 2013).  For this reason, Parkin and Fbxo7 were both chosen 
for further study in Chapter 4. 
 




To determine if the apparent recruitment and dissociation of proteins to/from the 
mitochondrial membrane was due to changes in total levels of those proteins, the same 
proteins were also probed for in samples of the total lysates (Figure 3.12). 
No significant changes were detected in total levels of HK2 (Figure 3.12 (B)), Dyn2 
(C) or Parkin (F) over the course of ischaemia and reperfusion.  These data suggest that 
changes of these proteins at the mitochondrial membrane were due to translocation, 
rather than changes to translation or degradation rates.  In the case of Drp1, however, the 
Figure 3.11 Mitochondrial recruitment during ischaemia and reperfusion.  Following 
subcellular fractionation of perfused left ventricular tissue, mitochondrial samples were 
used for Western blotting.  Samples were probed with HK2, Dyn2, Drp1, Fbxo7 or Parkin 
antibodies. Representative blots are of 3 samples per condition.  N = 6.  Analysed using 
ordinary one-way ANOVA with Sidak’s correction for multiple comparisons with a pooled 
variance. Data presented as mean ± SEM. * p < 0.05, ** p < 0.01, **** p < 0.0001. 
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observed decrease in the mitochondrial fraction following reperfusion (Figure 3.11 (D)) 
likely stems from a decrease in its total abundance (Figure 3.12 (D)).  Similarly, the presence 
of Fbxo7 at the mitochondrial membrane was decreased by ischaemic pre-conditioning, 
compared to ischaemia alone, an effect which is mirrored in the total level of Fbxo7 within 
cells, and which is suggestive of IPC-induced degradation of Fbxo7, rather than 
perturbations to its recruitment (E). 
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3.3.4 Mitochondrial membrane proteins 
Recruitment of predominantly cytosolic proteins to mitochondrial membranes is 
undoubtedly a critical aspect of mitochondrial fission pathways. In addition, changes to 
abundance of membrane resident proteins are also important.  In the recruitment of Drp1, 
for example, several membrane-bound adaptor proteins play key roles (Kraus and Ryan, 
2017). 
Figure 3.12 Total changes to recruited proteins during ischaemia and reperfusion.  Prior to 
subcellular fractionation of perfused left ventricular tissue, total protein samples were 
collected, which were then used for Western blotting.  Samples were probed with HK2, 
Dyn2, Drp1, Fbxo7 or Parkin antibodies.  Representative blots are of 3 samples per 
condition.  N = 6.  Analysed using ordinary one-way ANOVA with Sidak’s correction for 
multiple comparisons with a pooled variance. Data presented as mean ± SEM. * p < 0.05, 
** p < 0.01, **** p < 0.0001. 
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3.3.4.1 Fission/fusion proteins 
Unlike Dyn2 and other members of the conventional dynamin family, Drp1 does not 
contain a phospholipid-binding pleckstrin homology (PH) domain, so cannot directly bind 
to the MOM.  To facilitate binding of Drp1, mitochondria present several known Drp1 
adaptor (receptor) proteins on the outer surface of the membrane.  Fission-associated 
Drp1 adaptors Identified so far include Mff, Fis1, Mid49 and Mid51.  Due to a lack of reliable 
antibodies to the rat proteins, Mid49 and Mid51 were not included in this screen. 
Mitochondrial fission factor (Mff) 
As described in 1.1.6, Mff is the Drp1 adaptor thought to have the greatest role in 
mitochondrial fission (Lee et al., 2004, Alirol et al., 2006).   We therefore reasoned that Mff 
abundance at the mitochondrial membrane would follow a similar pattern to 
mitochondrial recruitment of Drp1.  However, a significant decrease was observed in Mff 
upon ischaemia (Figure 3.13 (D)).  This appears to be at odds with the small increase in 
mitochondria-associated Drp1 under the same conditions.  This could be due to increased 
Drp1-recruitment by other receptors (e.g. Mid49 and Mid51) which were not screened in 
this assay.  
Fission 1 (Fis1) 
A similar pattern was observed with Fission 1 (Fis1; Figure 3.13 (E)) as for Mff; a small 
decrease in abundance during ischaemia, which is furthered by reperfusion.  However, the 
importance of these data is unclear, with Fis1 not currently thought to have any detectable 
role in mitochondrial fission (Otera et al., 2010, Osellame et al., 2016) 
Mitofusin II (Mfn2) 
As shown in  Figure 3.13 (B), Mfn2 was significantly reduced upon reperfusion, but 
unchanged by ischaemia alone.  This would indicate a decrease in total mitochondrial 
fusion; Mfns regulate MOM fusion, so their action is required prior to Opa1-mediated 
fusion of the MIM.   
3.3.4.2 Mitochondrial modifying proteins 
Mitochondria-anchored protein ligase (MAPL) 
Although no total changes in mitochondrial SUMOylation were detected, the 
SUMOylation status of some individual proteins was altered (Figure 3.10).  These proteins 
were not identified during this project, but it was predicted that their 
SUMOylation/deSUMOylation during ischaemia and/or reperfusion might be the result of 
changes to levels of SUMO ligases or SUMO proteases.  No significant changes were 
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detected in MAPL abundance at mitochondria (Figure 3.13 (C)), although this does not rule 
out possible changes in activity. 
PINK1 
As shown in Figure 3.11 (F), Parkin was heavily recruited to mitochondria during 
ischaemia.  Canonically, Parkin is only recruited to the membranes of depolarised 
mitochondria in a PINK1-dependent manner.  Therefore, we reasoned that Parkin 
recruitment should align with PINK1 expression during ischaemia. 
In these experiments (Figure 3.13), a significant increase of the 48kDa species (H) 
was seen during ischaemia, while a significant decrease of the 55kDa species (G) was 
observed upon reperfusion, while the 63kDa species remained unchanged (F).  These data 
are difficult to interpret, as our fractionation protocol does not allow us to discriminate 
between proteins on the MOM of mitochondria, or in the lumen/IMS.  
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Figure 3.13 Mitochondrial membrane proteins during ischaemia and reperfusion.  Following 
subcellular fractionation of perfused left ventricular tissue, mitochondrial samples were 
used for Western blotting.  Samples were probed with Mfn2, PINK1, MAPL, Mff or Fis1 
antibodies. Representative blots are of 3 samples per condition.  N = 6.  Analysed using 
ordinary one-way ANOVA with Sidak’s correction for multiple comparisons with a pooled 
variance. Data presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 
0.0001. 
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3.3.4.3 Mff is a novel SUMO substrate 
Of all mitochondrial membrane proteins studied in this project, Mff was of particular 
interest for two reasons.  Firstly, during ischaemia, loss of Mff from the mitochondrial 
membrane coincided with recruitment of Parkin to mitochondria.  This loss of Mff was also 
partially attenuated by ischaemic pre-conditioning, as was Parkin recruitment.  Secondly, 
GFP-Trap immunoprecipitation of CFP-Mff from HEK293T cells revealed that Mff can be 
SUMOylated (Figure 3.14), both by SUMO-1 (A) and SUMO-2/3 (B).  Mutation of lysine 151 
of Mff to non-SUMOylatable arginine completely abolishes both SUMO-1- and SUMO-2/3-
ylation of Mff, indicating that this is the only SUMO-modified residue.  These same higher 
molecular weight species can also be observed in the CFP blot (C), indicating that it is Mff, 
rather than a co-immunoprecipitated protein, which is SUMOylated.  Based on these 
observations we postulated that Mff SUMOylation, which has not been shown previously, 
could play a role in Mff stability and turnover.   
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 To validate the finding that Mff can be SUMOylated, further purification assays 
were performed, in the presence or absence of over-expressed deSUMOylating enzymes 
(SENPs).  In these assays, GST or GST-Mff was transfected into HEK293T cells, with or 
without a tagged SENP.  GST-tagged protein was then purified and probed for GST.  By 
probing for the purified, tagged protein, the possibility of false-positive data as a result of 
covalent modification of another co-purified protein can be avoided.  Additionally, the 
over-expression of a SENP allows us to distinguish genuine SUMO-modifications from any 
Figure 3.14 Mff is SUMOylated at Lysine 151 only.  GFP-Trap immunoprecipitation and 
Western blotting of CFP-Mff reveals high levels of endogenous SUMO-1- (A) and SUMO-
2/3-ylation (B).  Mutation of Lysine 151 to Arginine (K151R) abolishes both SUMO-1- and 
SUMO-2/3-ylation of Mff. Over-exposure of the CFP blot from similar experiments reveals 
that the same higher molecular weight, SUMO-reactive bands are also CFP-reactive (C), 
indicating that we are observing SUMOylated CFP-Mff. 
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SUMO cross-reactive species, as it is well characterised that SENPs are highly specific for 
SUMO (Reverter and Lima, 2004). 
Figure 3.15 shows Western blots of GST-Mff purified from HEK293T cells co-
transfected with FLAG-SENP2 (A) or GFP-SENP5 (B).  In both cases, co-transfection with a 
SENP eliminates the higher molecular weight GST-reactive species that we believe 
corresponds to mono-SUMOylated GST-Mff (labelled GST-SUMO-Mff, ~100kDa) which is 
apparent in the absence of SENP.   
 
    
 
 
Figure 3.15 Mff is a SENP substrate.  HEK293T cells were transfected with GST-Mff with or 
without FLAG-SENP2 (A) or GFP-SENP5 (B).  GST-tagged protein was then purified using 
glutathione beads and the pull down (PD) probed for GST (WB).  In the absence of SENP, 
GST-Mff exists at its unmodified molecular weight (~65kDa) and as a band-shifted species 
(~100kDa).  In the presence of SENP, the 100kDa species is removed. 
 




3.4.1 Mitochondrial fraction was adequately clean 
For the purposes of this study, highly purified mitochondrial fractions were neither 
necessary nor desirable; it has been shown previously that purified mitochondrial protein 
preparations are devoid of low affinity or fleetingly-bound associated proteins (Pasdois et 
al., 2013).  Given that a number of proteins of interest are only transiently recruited to the 
MOM from the cytosol, crude mitochondrial fractions were used.  However, owing to the 
large proportion of SUMOylation that is nuclear, it was important to adequately separate 
the nucleus-containing fraction from the mitochondria-enriched fraction, lest any 
mitochondrial changes in SUMOylation be contaminated and obscured by nuclear SUMO. 
Sufficient purity of the mitochondrial fraction was determined by probing for 
cytosolic and nuclear markers.  As shown in Figure 3.5, very little GAPDH (cytosolic) was 
detected by Western blotting of the mitochondrial samples, compared to the total 
ventricular lysate.  Similarly, no Lamin B (nuclear) was detected in the same samples, 
indicating that purification had removed at least most traces of nuclear contaminants. 
VDAC is typically considered to be a mitochondrial marker, being the most abundant 
protein of the MOM (Simamura et al., 2008).  However, like most mitochondrial proteins, 
it is synthesised on ribosomes at the ER prior to its translocation and insertion into the 
MOM (Dubey et al., 2016).  Interestingly, far more VDAC species were found to be present 
in the total lysate that the mitochondrial fraction (Figure 3.5).  This suggests that the 
reasonable purity of the mitochondria-enriched fraction was achieved at the expense of 
mitochondrial yield.  There are three isoforms of VDAC (VDAC-1, -2 and -3) in mammals, 
encoded on homologous genes, with VDAC-1 being the most abundant (Shoshan-Barmatz 
et al., 2010).  All isoforms are subject to modification by phosphorylation and acetylation, 
resulting in the wide range of detected molecular weights species (Choudhary et al., 2009, 
Gauci et al., 2009, Kerner et al., 2012).  The VDAC-1, -2, -3 antibody has been widely used 
in the literature, and has been previously validated (Zou et al., 2014, Quast et al., 2013, 
Plotz et al., 2012). 
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3.4.2 Reperfusion is the primary cause of cellular 
damage 
It has long been known that reperfusion incurs greater cellular damage than the 
ischaemic insult itself.  In particular, apoptotic mechanisms are almost exclusively brought 
about by reperfusion (Griffiths and Halestrap, 1995, Halestrap, 2010, Kalogeris et al., 2014).  
It was important that the ex vivo model of I/R injury employed in this study reflected this.  
To confirm this, various markers of cellular stress and/or cell death were probed. 
As shown in Figure 3.6, no significant differences were observed in markers of 
apoptosis (cleaved Caspase 3) or autophagy (LC3-II/LC3-I ratio) between pre-ischaemic and 
ischaemic groups, indicating that little or no cell death was detectable during ischaemia 
alone.  However, on reperfusion, both the cleaved Caspase 3 and LC3-II/LC3-I ratio were 
increased and were significantly different from both the pre-ischaemic and ischaemic 
controls, indicative of activation of apoptotic and autophagic mechanisms.  As would be 
expected, IPC did not contribute to increase in either marker of cell death. 
Although cell death brought on by I/R injury occurs almost exclusively on 
reperfusion, many of the mechanisms of cellular stress are set in motion during the 
ischaemic phase, often as a result of the accumulation of cytotoxic by-products of 
glycolysis, initiated under anoxic conditions.  Lactate Dehydrogenase (LDH) catalyses the 
final step of anaerobic glycolysis, converting pyruvate to lactate via coupled oxidation of 
NADH to NAD+ (Everse and Kaplan, 1973).  Damage to the plasma membrane, brought 
about by ischaemic stress, releases cytosolic LDH from the cell, where it can be collected 
from the perfusate. 
Ischaemic pre-conditioning involves a series of short bursts of ischaemia.  Ideally, 
this is not damaging to the tissue.  However, too many or too long IPC cycles incur the same 
cellular damage as real ischaemic insult.  To exclude the possibility that the IPC performed 
in this study contributed to cellular damage, perfusate was collected immediately after 
start of the final reperfusion dung IPC and subjected to LDH assay (Figure 3.7).  The results 
of this were compared to perfusate samples taken before any ischaemic events, and to 
those taken immediately after start of perfusion following 30-minute ischaemic insult.  As 
shown in Figure 3.7, LDH assay results from the IPC group were not significantly different 
from those of the pre-ischaemic group.  The end-ischaemia group, however, had 
significantly higher LDH assay values than both the pre-ischaemic and IPC groups.  These 
data indicate that the IPC protocol we used did not induce any detectable cellular damage. 
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3.4.3 Global ubiquitination, but not SUMOylation, 
changes during I/R Injury 
Global protein SUMOylation has been reported to be upregulated as a result of 
hypoxia (Guo et al., 2013, Meller et al., 2014, Lee et al., 2007).  Surprisingly, in this ex vivo 
study (Figure 3.9) very little change was observed in global conjugation of SUMO-1 or 
SUMO-2/3, although a small but significant increase was observed in SUMO-1-ylation of 
the IPC, compared to ischaemia alone.  This could fit with the established narrative of 
SUMOylation as a cytoprotective modification (Guo et al., 2013, Guo et al., 2017, Lee et al., 
2007, Luo et al., 2017), raising the possibility of SUMOylation as a protective influencer of 
IPC. 
Nevertheless, a lack of global changes to the SUMOylated proteome does not 
preclude the possibility that the SUMOylation status of subsets of proteins may be altered 
under these conditions.  Indeed, a clear example of this is the mitochondrial 55kDa SUMO-
1-ylated species shown in Figure 3.10 (C).  Whilst the total mitochondrial proteome 
mirrored the total proteome in lacking global changes to SUMOylation levels, this 
mitochondria-associated 55kDa species was significantly more abundant during ischaemia 
and after reperfusion compared to pre-ischaemia.  Interestingly, IPC prevented this 
increase in abundance, potentially indicating that SUMO-1-ylation of this protein is in fact 
detrimental to recovery from I/R injury. 
Much of the previous work on SUMOylation and ischaemia has made use of isolated 
cell cultures and cell lines (Guo et al., 2013, Luo et al., 2017).  We speculate that cells in 
culture may be more receptive to stress/cytotoxicity due to the lack of supporting cells, 
extracellular matrix (ECM) and extracellular signalling pathways.  One study showed that, 
in both a mouse model and infarct patients, extracellular vesicles of myocardial origin could 
be found in blood and tissues following myocardial infarct.  In in vitro experiments, these 
vesicles could modulate endothelial function, indicative of an active role in post-ischaemic 
cardiac repair (Rodriguez et al., 2018). 
Although no large-scale changes were observed in SUMOylation, this was not the 
case for ubiquitination.  As shown in Figure 3.8 and Figure 3.10, global conjugation of 
ubiquitin was significantly increased upon reperfusion, compared to both pre-ischaemia 
and ischaemia alone.  This is unsurprising, given the critical role of ubiquitin-targeted 
proteasomal degradation in the Unfolded Protein Response (UPR), triggered under 
cytotoxic conditions (Lindholm et al., 2017).   
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3.4.4 I/R recruits mitochondrial fission-associated 
proteins to the MOM 
Due to their dynamic nature and the previously reported importance of 
mitochondrial fission in I/R injury cellular survival, proteins associated with fission were of 
particular interest (Ambrosio et al., 1993, Griffiths and Halestrap, 1995, Schaller et al., 
2010). 
Mitochondrial fission is a necessary part of cell division, maintenance of cellular 
integrity, and adaptability.  In particular, due to their huge energy requirements, the 
mitochondria of cardiac myocytes undergo constant remodelling by fission and fusion, with 
networked mitochondria allowing efficient ATP transfer from the cell core to the periphery, 
and independent mitochondria being easily trafficked to more energy-demanding regions 
of the cell (Piquereau et al., 2013).  Perturbation of the fission/fusion equilibrium as a result 
of ischaemia or reperfusion can drastically impact upon cellular recovery from I/R injury.  
By identifying differences in recruitment patterns between ischaemia and IPC groups, we 
hoped to identify potential protective proteins. 
Drp1 and Dyn2 
Drp1 is a key regulator of mitochondrial fission, facilitating membrane scission at ER 
junction sites (Prudent et al., 2015, Braschi et al., 2009, Lee et al., 2004).  In addition, 
Dynamin II (Dyn2) has more recently been identified as another critical player in 
mitochondrial fission, without which organelle membranes become stuck at an elongated, 
pre-scission point (Kraus and Ryan, 2017, Lee et al., 2016).  Both Drp1 and Dyn2 were 
probed for in the mitochondrial fractions from this study, as Dyn2 cannot act upon 
membranes not pre-constricted by Drp1 (Kraus and Ryan, 2017). 
As shown in Figure 3.11, both Dyn2 and Drp1 appeared to be slightly more abundant 
on the MOM of ischaemic samples compared to pre-ischaemia, although this increase did 
not reach statistical significance.  Interestingly, MOM levels of Drp1 were significantly 
increased by IPC, whereas Dyn2 abundance was significantly decreased by the same 
treatment.  Taken alone, these data could be indicative of there being no net change in 
mitochondrial fission upon IPC, as the increase in one component of the fission machinery 
is counterbalanced by the decrease in the other.  From these data it seems that other 
factors are also involved, and further investigation of fission-associated proteins would be 
required.  For example, the primary Drp1 receptor, Mff, was unchanged by IPC, but this 
does not preclude the possibility that other, unidentified Drp1 receptors are not up- or 
down-regulated by IPC.  




Parkin  is known to be recruited to depolarised mitochondrial membranes by 
accumulation of PINK1, where it sets in motion the various mechanisms of mitophagy 
(Berger et al., 2009, Clark et al., 2006, Exner et al., 2007, Geisler et al., 2010).  It was 
therefore unsurprising that such a large increase in Parkin was detected at the MOM during 
ischaemia (Figure 3.11).  With Parkin activated and in place at the MOM, damaged 
mitochondrial proteins can be marked for proteasomal degradation by Parkin-mediated 
poly-ubiquitination.  One observation that was particularly intriguing was the decreased 
level of Parkin detected at the MOM of mitochondria subjected to IPC prior to ischaemia.  
This difference implicates the PINK1/Parkin pathway as a potential candidate for a role in 
IPC. 
Fbxo7 
With Parkin identified as a protein of interest, we reasoned that Parkin-related or 
functionally similar proteins might also prove interesting.  We therefore tested if Fbxo7 co-
localises with Parkin to the MOM in ischaemia.  As shown in Figure 3.11, there was a hint 
that Fbxo7 abundance at the MOM was slightly increased by ischaemia, although this was 
not statistically significant.  Interestingly, prior IPC did significantly reduce Fbxo7 
mitochondrial presence compared to ischaemia alone, thereby marking it as another 
protein of interest for this study. 
 
From the mitochondrial fractions alone, it is difficult to definitively discriminate 
between  increased recruitment of proteins of interest to the MOM and increases in total 
expression.  To that end, the total lysate was also probed for all candidate proteins.  
Although total levels of these proteins were often very variable between the different 
animals, no significant differences were detected in Dyn2 or Parkin over the course of I/R 
injury modelling (Figure 3.12).  These data indicate that the large increase in Parkin at the 
MOM during ischaemia is attributable to enhanced recruitment rather than increased 
protein expression.  In the case of Drp1, however, the significant decrease in abundance at 
the MOM on reperfusion seems to reflect a loss of total Drp1 from the cell, presumably a 
result of its degradation, given the short timeframe of the experiment.  Similarly, the 
decrease in Fbxo7 at the MOM brought abought by IPC was also observed at the level of 
the total protein, so is likely due to a net loss of protein, rather than a translocation event.   
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3.4.5 The composition of the MOM is altered by 
I/R Injury 
With various fission-associated proteins being recruited to the MOM over the course 
of I/R injury, it was proposed that the composition of the MOM itself could also be altered.  
Mff is the main fission-associated receptor of Drp1, so was an obvious candidate target 
(Guo et al., 2017).  As shown in Figure 3.13, the Mff content of the MOM was decreased 
by ischaemia, and further decreased upon reperfusion.  IPC appeared to oppose this loss.  
A secondary Drp1 receptor, Fis1, showed a very similar pattern, with a slight loss during 
ischaemia, exacerbated by reperfusion.  Most interesting, however, was that loss of Mff 
from the MOM during ischaemia occurred over the same timescale as recruitment of 
Parkin. IPC blocked or partially blocked both of these events.  It has been previously 
reported that Mff is a target of Parkin-mediated ubiquitination, and these complementary 
events support the previous findings, and also highlight the Parkin/Mff interaction as an 
interesting target in the study of ischaemia and IPC (Gao et al., 2015). 
Moreover, we have shown for the first time that Mff is a target of modification by 
both SUMO-1 and SUMO-2/3.  Taken together, the data presented in Figure 3.14 and 
Figure 3.15 provide compelling evidence for Mff as a bona fide SUMO substrate.  We 
demonstrate that Mff presents not only at its unmodified molecular weight, but also as a 
higher molecular weight species, which is specifically removed in the presence of a 
deSUMOylating enzyme and can be ablated by point mutation of a lysine residue in Mff.  In 
future, denaturing immunoprecipitation experiments could be performed to eliminate the 
possibility of the SUMO conjugates identified in Figure 3.14 being covalently attached to 
another Mff-interacting protein, although the data shown in Figure 3.14 (C), as well as 
Figure 3.15, in which the modified protein is CFP- or GST-positive, go a long way towards 
ruling out that possibility.  The potential implications of this modification are currently 
being investigated, and it has been proposed that the SUMOylation status of Mff may be 
involved in its stability or activation. 
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Chapter 4 Regulation of Mff by Parkin 
and Fbxo7 
4.1 Introduction 
4.1.1 Drp1 requires adaptors for mitochondrial 
fission 
As previously discussed, Drp1 is an intrinsic part of the mitochondrial fission 
machinery.  In a coupled reaction, Drp1 hydrolyses GTP and oligomerises around the 
mitochondrial membrane, constricting the neck to a critical diameter at which Dyn2 can 
perform the final separation (Kraus and Ryan, 2017, Lee et al., 2004, Yoon et al., 2003).  
Receptor proteins expressed on the outer membrane of mitochondria are required to 
recruit Drp1, which cannot bind the mitochondrial outer membrane (MOM) directly due 
to its lack of PH domain (Losón et al., 2013)  A brief overview of known Drp1 receptors is 
given below.  
4.1.1.1 Mff 
Mitochondrial Fission Factor (Mff) is thought to be the primary adaptor for Drp1-
dependent fission, both of mitochondria and peroxisomes (Lee et al., 2004, Alirol et al., 
2006, Gandre-Babbe et al., 2008).  Consistent with this, Mff knock out cell lines exhibit 
greatly elongated mitochondria and peroxisomes (Osellame et al., 2016, Otera et al., 2010). 
Furthermore, Mff-deficient mice are smaller than their WT littermates and die at 
approximately 3 months due to enlargement and inefficiency of the heart (dilated 
cardiomyopathy) leading to heart failure (Gao et al., 2015).  In vitro, incorporation of Mff 
into synthetic liposomes is sufficient to recruit and activate the GTPase activity of Drp1, 
whereas insertion of Mid51 is inhibitory (Osellame et al., 2016, Macdonald et al., 2016).  
4.1.1.2 Fis1 
Fis1 was identified in yeast as an adaptor of the MOM for Mdv1 and Caf4 peripheral 
membrane receptors (Lackner et al., 2009).  These receptors can then recruit and form a 
complex with Dnm1, the yeast homologue of Drp1.  In metazoans, however, there are no 
homologues of Mdv1 or Caf4, and it has more recently been shown that Fis1 is not required 
for fission (Osellame et al., 2016, Otera et al., 2010).  Fis1 knock out murine embryonic 
fibroblast cells (MEF) do not exhibit notable morphological changes to the mitochondrial 
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or peroxisomal networks, casting doubt on the role of Fis1 as a true receptor of Drp1 
(Osellame et al., 2016).  However, they do have some resistance to apoptosis, implicating 
Fis1 in apoptosis-mediated fragmentation, stress—induced fission or mitophagy (Shen et 
al., 2013, Gomes and Scorrano, 2008, Wang et al., 2012a, Yamano et al., 2014). 
4.1.1.3 Mid49/51 
Mid49/Mid51 are chordate-specific mitochondrial proteins that can recruit Drp1 to 
the MOM independently of Mff and appear to modulate Drp1 function differently 
(Osellame et al., 2016, Macdonald et al., 2016).  Whereas Mff is confined to foci associated 
with constriction sites, Mid49 and Mid51 become diffusely localised throughout the MOM 
in the absence of Drp1 (Richter et al., 2014).  It is thought that Mid49 and/or Mid51 form 
part of a fission mechanism distinct from Mff-Drp1-mediated fission. Drp1-mediated fission 
via Mid49 and/or Mid51 is required for cristae opening and cytochrome c release following 
apoptotic induction, whereas Mff-Drp1-mediated fission is not (Otera et al., 2016).  Despite 
this, Mff and Mid51 have been identified together and in proximity of Drp1 in mouse 
embryonic fibroblast (MEF) cells (Osellame et al., 2016).  As well as acting to recruit Drp1 
to the mitochondrial outer membrane, Mid proteins have been shown to assemble with 
Drp1 in vitro, and Mid49-Drp1 heteropolymer rings can constrict to a significantly smaller 
diameter than Drp1 homopolymers, indicating that Mid49 can enhance constriction of 
mitochondrial membranes by Drp1 (Koirala et al., 2013). 
4.1.2 Drp1 activity is regulated by PTMs 
Regulation of proteins by post-translational modifications (PTMs) has a pivotal role 
in most, if not all, cellular processes, including mitochondrial fission.  Drp1 is heavily post-
translationally modified, and this affects its activity as a fission- or fusion-promoting GTPase 
(Figure 1.18 (A)) (Gandre-Babbe et al., 2008).  Phosphorylation of Drp1 by cyclin-dependent 
kinase 1 (Cdk1) serves to activate it during mitosis (Chang and Blackstone, 2007), while 
phosphorylation by cAMP-dependent protein kinase (PKA) inactivates Drp1 in quiescent 
cells and mitochondrial fission is triggered by reversal of PKA-dependent phosphorylation 
by calcineurin (Cribbs and Strack, 2007).   
Drp1 was identified as a SUMO-1 substrate in 2004, by the first group to publish 
evidence of SUMOylation of the mitochondrial proteome (Harder et al., 2004).  The same 
study showed that SUMO-1 is often detected at sites of mitochondrial fission, and that 
over-expression of SUMO-1 protects Drp1 from degradation and leads to an increase in 
mitochondrial fragmentation.  Drp1 was later shown to be a substrate of all 3 SUMO 
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isoforms, despite its lack of consensus SUMOylation motifs, and it was suggested that 
SUMOylation of Drp1 was influenced by its subcellular localisation (Figueroa-Romero et al., 
2009).   
However, a later study by the Henley lab flipped this model around, proposing that 
SUMOylation of Drp1 actually regulates its subcellular localisation.  In this study, it was 
proposed that SUMO-2/3 conjugation sequesters Drp1 in the cytosol, while and SENP3-
mediated deSUMOylation allows Drp1 to translocate to the mitochondria.  The authors 
showed that, in HEK293 cells, replacement of endogenous Drp1 with a non-SUMOylatable 
mutant, but not with WT Drp1, caused substantial release of cytochrome c from the 
mitochondria, indicating that Drp1 SUMOylation is a protective mechanism that reduces 
its ability to elicit cytochrome c release (Guo et al., 2013).  Interestingly, Drp1 SUMO-2/3-
ylation was increased by oxygen-glucose deprivation (OGD), providing further evidence 
that Drp1 SUMOylation may be a cytoprotective mechanism (Guo et al., 2013).  It is 
important to note that the data from the McBride and Henley labs are not necessarily 
incompatible, as the two groups studied Drp1 modification by different SUMO isoforms. 
The Henley lab later published work linking the SENP3-mediated deSUMOylation of 
Drp1 to increased cell death during OGD, by enhancing the interaction of Drp1 with Mff, 
but not Mid49, Mid51 or Fis1.  They also showed that Drp1 binding to Mff is sufficient to 
induce cytochrome c release, and that preventing this interaction is cytoprotective during 
OGD and reperfusion (Guo et al., 2017).        
4.1.2.1 Mff is regulated by Parkin 
Despite its clear importance in maintenance of healthy mitochondrial function, as 
well as in pathophysiological pathways leading to apoptosis, Mff remains a relatively poorly 
characterised protein, with no published structure.  Based on its sequence, it is predicted 
to have a single C-terminal transmembrane domain, and computer algorithms reported a 
region of Mff with high coiled coil-forming propensity, which was later shown to facilitate 
Mff dimerization in vivo (Gandre-Babbe et al., 2008).  The Drp1 binding domain of Mff is at 
the N-terminus.  In humans, there are five known isoforms of Mff (sequence alignment 
shown in Supplementary Figure 1), and a further four predicted, owing to numerous 
translation- start sites and splice-variants.  The constructs used in this project encode 
isoform 1, the full length 342 amino acid protein (Friedman et al., 2011). 
Parkin has previously been reported to ubiquitinate Mff (Gao et al., 2015).  In their 
study, Gao et al showed that HA-Parkin could co-immunoprecipitate FLAG-Mff in HEK293 
cells, and that carbonyl cyanide m-chlorophenyl hydrazine (CCCP)-induced mitochondrial 
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stress enhanced their interaction and induced mitochondrial ubiquitination.  They showed 
that GFP-Parkin WT, but not a ligase-dead mutant (GFP-Parkin C431F), was able to 
ubiquitinate endogenous Mff and FLAG-Mff in HEK293 cells and went on to show that 
lysine 251 (corresponding to lysine 302 in the isoform used in this project) within the 
coiled-coil region was the only site of Parkin-induced ubiquitination on Mff.  Neither CCCP 
treatment nor ubiquitination of K251 by Parkin were found to have any effect on Mff 
oligomerisation.  However, a non-ubiquitinatable K251R mutant of Mff was unable to bind 
p62, which is recruited to damaged organelles during autophagy (Kim et al., 2008a), 
resulting in defective Parkin-induced mitochondrial clearance.  The data presented by Gao 
et al thereby provide intriguing evidence that Mff is essential for Parkin-mediated 
mitophagy. 
4.1.3 Fbxo7 mediates mitophagy 
F-box domain-containing proteins act as adaptors to phosphorylated target 
substrates to SCF (Skp1-Cul1-F-box)-type E3 ubiquitin ligase complexes.  This is usually 
achieved by substrate recruitment through a protein interaction domain and assembly of 
a functional ligase complex by recruitment of a Skp1 adaptor via the F-box domain 
(Skowyra et al., 1997).  Fbxo7 has also been shown to have SCF-independent activity 
(Kuiken et al., 2012, Kirk et al., 2008).    
Burchell et al provide evidence that the N-terminal ubiquitin-like domain (UbL) of 
Fbxo7 interacts with Parkin and PINK1, both in cells (U2OS osteosarcoma cells) and in vitro 
(Burchell et al., 2013).  They also showed that carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP)-mediated mitochondrial membrane depolarisation elicits Fbxo7 recruitment to 
mitochondria. Furthermore, knock down of Fbxo7 significantly reduced recruitment of 
Parkin to depolarised mitochondrial membranes, leading to their hypothesis that Fbxo7 
functions upstream of Parkin in mitophagy.  Like Parkin, Fbxo7 partitioning to mitochondria 
was PINK1-dependent, with recruitment of both Parkin and Fbxo7 significantly reduced by 
knock down of PINK1 (Burchell et al., 2013).  Intriguingly, over-expression of Fbxo7 rescued 
several ‘disease’ phenotypes in Parkin-deficient Drosophila, including locomotor defects, 
dopaminergic neuron loss, muscle degeneration, and mitochondrial disruption.  Knock 
down of Fbxo7 inhibited mitophagy, delaying the lipidation of LC3-I to LC3-II in the 
mitochondrial fraction by reducing Parkin-dependent recruitment of p62, the 
mitochondrial adaptor of LC3-II, thereby inhibiting LC3-II-dependent recruitment of the 
autophagosome to depolarised mitochondria (Burchell et al., 2013).   
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4.1.4 H9c2 cells 
H9c2 cells are a clonal myoblast cell line isolated from embryonic rat ventricular 
tissue (Kimes and Brandt, 1976).  This cell line was chosen for its ventricular origin, as the 
ex vivo fractionated heart samples were also ventricular; other cardiac cell lines, such as 
HL-1, are derived from atrial tissue (Rao et al., 2009).  While H9c2 cardiac myoblasts cannot 
be induced to contract in culture, like HL-1 cells can, they are physiologically more similar 
to primary cardiac myocytes (Watkins et al., 2011).  In culture, their electrophysiological 
properties, as well as their membrane morphology, are largely the same as those of 
primary cells (Sipido and Marban, 1991, Hescheler et al., 1991).   
4.1.5 Aims 
The aims of this part of the project were to investigate the interplay between Parkin, 
Fbxo7 and Mff, and their effects on mitochondrial dynamics.  Specifically, these aims can 
be divided into three parts: 
i. Knock down Parkin and Fbxo7, both individually and together, to study the effects 
on mitochondrial fission proteins Mff and Drp1.   
ii. Parkin has been previously shown to interact with, and ubiquitinate, Mff (Gao et 
al., 2015). Therefore, I attempted to recapitulate and validate these findings.  This 
is important because the functional study by Gao et al focused exclusively on over-
expressed Parkin.  E3 ligases are known to be promiscuous both in their target 
substrates and their preferred lysine residues (Kanner et al., 2017, Danielsen et al., 
2011).  For that reason, over-expression of E3 ligases can have off-target 
artefactual effects.  For functional experiments, I focussed only on activity of 
endogenous Parkin.   
iii. Fbxo7 has not been previously reported to ubiquitinate Mff, but we hypothesised 
that its functional relationship with Parkin and role in mitophagy made it a likely 
candidate regulator of Mff. Therefore, I investigated this possibility.  
iv. Identify any gross morphological changes in mitochondrial networks as a result of 
manipulation of Parkin and/or Fbxo7.  
 




4.2.1 Protein degradation assay 
In order to measure rates of protein degradation in HEK293T cells, protein synthesis 
must be blocked.  Protein translation elongation was inhibited by addition of a drug, 
cycloheximide (CHX).  HEK293T cells were cultured and transfected as described in Chapter 
2.  Protein synthesis was blocked by addition of 25µg/mL cycloheximide (Sigma-Aldrich) for 
up to 24 hours prior to cell lysis.  Western blotting was used to quantify rates of 
degradation. 
4.2.2 Production of Lentivirus 
4.2.2.1 Preparation of HEK293T cells 
 HEK293T cells were cultured only in DMEM from Sigma, supplemented with 10% 
FBS (Sigma), 2mM L-Glutamine and 1% (v/v) Penicillin/Streptomycin (‘complete DMEM’).  
Once confluent, cells were counted and plated in 100mm cell culture dishes at 7,000,000 
cells/dish.  Cells were transfected 24 hours after plating. 
4.2.2.2 HEK293T cell Transfection 
10µg pXLG3 viral vector, 2.5µg pMD2.G (expression of VSV-G envelope protein) and 
7.5µg p8.91 (helper vector) were mixed in a Bijou tube with 2.5mL plain DMEM.  60µL 
1mg/mL Polyethylenimine (PEI) were added to 2.5mL plain DMEM in another Bijou tube 
and mixed by inversion.  The DMEM-PEI mixture was sterile-filtered into a 15mL Falcon 
tube and incubated at RT for 3 minutes.  The DMEM-PEI mixture was then mixed again by 
inversion and added to the DMEM-DNA mixture.  This was inverted several times to mix, 
then incubated at RT for 30 minutes.  Cells were gently washed once with 6mL warm plain 
DMEM.  DMEM was aspirated, and the 5mL transfection mix gently added to the cells.  Cells 
were incubated (37°C in a humidified cell culture incubator, supplied with 5% CO2 and 95%  
O2) for 4 hours, and then the transfection mix was aspirated and replaced with 7mL warm, 
sterile-filtered complete DMEM. 
4.2.2.3 Harvesting Lentivirus 
Virus was harvested 48 hours post-transfection.  Virus-containing DMEM was 
centrifuged at 4000rpm for 10 minutes in a 15mL Falcon tube to remove cell debris.  The 
supernatant was then filtered through a 0.45µm filter pre-wetted with complete DMEM.  
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Viral knock down efficiency was tested by adding a range of volumes to HEK293T or H9c2 
cells in 35mm dishes and lysing 4-5 days later.  Around 100µL was usually found to be 
sufficient to produce ≥80% protein knock down.  Aliquots of lentivirus were stored at -80°C. 
4.2.3 H9c2 cells 
4.2.3.1 Cell culture 
H9c2 rat cardiac myoblast cells were purchased from ATCC.  Stocks containing 1% 
(v/v) DMSO were stored in liquid nitrogen.  Aliquots of frozen H9c2 (subclone of the original 
myoblast clonal cell line derived from embryonic BD1X rat heart tissue (Kimes and Brandt, 
1976)) cells were taken from the cryostore, thawed at 37°C in a water bath and transferred 
into a 15mL Falcon tube with 9mL ‘complete media’ (DMEM with phenol red, without Na-
pyruvate, with stable glutamine, with 3.7 g/L NaHCO3 and 4.5 g/L D-glucose (Merck-
Millipore) supplemented with 10% (v/v) FBS and 0.05% (v/v) Penicillin/Streptomycin.  The 
cell suspension was centrifuged at 1000 x g for 2 minutes at room temperature (RT).  The 
cells were re-suspended in 1mL complete media and transferred to a T75 flask containing 
12mL complete media.  Cells were cultured in T75 flasks and passaged upon reaching ~60% 
confluence.  Cells were not used beyond passage 27. 
4.2.3.1.1 Passaging of H9c2 cells 
H9c2 cells were passaged upon reaching ~60% confluency.  Complete media was 
aspirated from the flask and the cell monolayer was gently washed with 10mL 1x 
Phosphate Buffered Saline (PBS).  PBS was then aspirated and 1mL Trypsin-EDTA was added 
to the cells and the flask returned to the incubator for 3 minutes.  Individual cells were 
detached from the flask by gentle tapping before 9mL complete media was added to 
quench the trypsin digest.  The cell suspension was then centrifuged in a 15mL Falcon tube 
at 1000 x g for 2 minutes to pellet the cells.  Media was then aspirated, and the cells 
resuspended by gentle trituration in 10mL fresh complete DMEM.  For maintenance of 
H9c2 stock flask, this suspension was diluted 1:10 in complete media in a new T75.  For 
infection, cells were plated on 35mm (30,000 cells in 2mL media) plastic cell culture dishes 
pre-coated with laminin for biochemistry or live imaging, or on 13mm glass coverslips (pre-
coated with laminin) in a 12 well dish at 12,000 cells/coverslip for fixed cell imaging. 
4.2.3.1.2 Differentiation of H9c2 cells 
To differentiate H9c2 myoblasts towards a more myocyte-like phenotype, cells in 
35mm dishes or on 13mm coverslips were grown in complete media until they reached 
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confluency.  At this point, media was replaced with complete media containing 1% (v/v) 
Horse serum in place of 10% (v/v) FBS (‘differentiation media’).  Cells differentiated to form 
multinucleated myotubes.  H9c2 cells were kept in this condition for no more than 5 days. 
4.2.3.2 Viral transduction of HEK293T cells and H9c2 cells 
using Lentivirus 
 Lentiviruses were generated to knock down Parkin and Fbxo7 in H9c2 cells.  
Lentivirus was tested in various volumes and for varying lengths of time (1-7 days) to 
optimise target protein knockdown.  The appropriate volume of lentivirus (scrambled or 
knockdown sequence) was added to cells in penicillin/streptomycin-free media.  Cells were 
lysed/fixed 4-5 days post-transduction. 
4.2.3.3 Oxygen-Glucose Deprivation 
Oxygen-Glucose Deprivation (OGD) is a widely used cellular model of ischaemia 
(Singh et al., 2009, Tasca et al., 2015).  For OGD experiments, cells were placed in a 
temperature controlled anaerobic chamber at 37°C, in glucose-free DMEM.  Media and 
1xPBS (used to wash off glucose- and oxygen-containing DMEM) were left to de-oxygenate 
overnight in the chamber.  A mixture of 95% N2 and 5% CO2 was used to remove oxygen 
and maintain carbonate-buffered pH of DMEM.  Control cells were washed in oxygenated 
1xPBS and maintained in oxygenated, glucose-containing DMEM in a normal cell culture 
incubator (95% O2, 5% CO2).  To prevent reperfusion, cells were lysed inside the anaerobic 
chamber.  Samples were then collected for Western blotting. 
4.2.4  Fixed sample confocal imaging 
Confocal images were acquired using a 63x HCX PL APO CS oil-immersion objective 
on a Leica SP5-II confocal laser scanning microscope attached to a Leica DMI 6000 inverted 
epifluorescence microscope.  Images were acquired at 400Hz at a resolution of 1024x1024 
pixels with 3.2x optical zoom.  3 independent experiments were performed, and 6 fields of 
view randomly imaged per coverslip.  1-4 cells were analysed per field of view; cells were 
chosen for analysis only if the nucleus was intact and in focus. 
4.2.4.1  Preparation of coverslips 
4.2.4.1.1 Sterilisation 
13mm glass coverslips (VWR) were submerged in nitric acid overnight with gentle 
agitation.  They were then washed 3 times with cell culture grade water and submerged in 
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70% ethanol overnight with gentle agitation.  Coverslips were washed a further 3 times in 
cell culture grade water before being placed in 12 well plates. 
4.2.4.1.2 Laminin coating 
Laminin (Sigma-Aldrich) was diluted to 50 μg/mL in 1xPBS and used to pre-coat glass 
coverslips (100µL diluted laminin/13mm coverslip) at 37°C for ≥ 1 hour, then washed 4 
times with sterile cell culture water prior to cell plating. 
4.2.4.2  MitoTracker staining 
Mitochondria were stained live using MitoTracker Deep Red (Thermo Fisher 
Scientific).  Mitochondria were stained for 30 minutes prior to the experiment.  
MitoTracker Deep Red was added to the cell culture media to a final concentration of 
100nM and cells returned to the incubator.  After 30 minutes, cells were washed 3 times 
to remove excess stain. 
4.2.4.3  Preparation of glass slides 
After the experiment, coverslips were washed 3 times in 1xPBS and cells fixed in pre-
chilled acetone for 10 minutes at -20°C.  Acetone was then removed, and the coverslips 
washed twice in 1xPBS.  Prior to mounting, coverslips were dipped in cell culture grade 
water.  Coverslips were mounted on glass microscopy slides (Thermo Fisher Scientific) 
using 30µL Fluoromount-G with DAPI (Thermo Fisher Scientific).  Slides were allowed to dry 
overnight at room temperature and then stored at 4°C. 
4.2.5 Mitochondrial network analysis 
MiNA (Mitochondrial Network Analysis) is a freely available pair of macros that work 
in conjunction with existing plugins in ImageJ to provide semi-automated analysis of 
mitochondrial networks (Valente et al., 2017).  This software greatly simplifies analysis and 
quantification of  mitochondrial numbers and networks in an efficient and unbiased way, 
compared to manually assigning morphological features.  The toolset includes optional pre-
processing steps which remove the need to manually enhance, sharpen and apply filters to 
images prior to analysis. 
Sharp images with high contrast and minimal background noise are necessary for 
accurate analysis of mitochondrial networks.  The pre-processing steps within the MiNA 
macros first apply Unsharp Masking to enhance image sharpness, thus contributing to 
deconvolution of the image by subtracting a blurred version of the image from the original.  
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The resulting image is then subjected to CLAHE (contrast limited adaptive histogram 
equalization) to equalize the histogram by adjusting pixel intensities and limiting the 
amount of local change that is allowed, to limit over-amplification of background.  Median 
filtering is then applied to reduce the “salt and pepper” noise, common in fluorescent 
images, which can be amplified by Unsharp Masking and CLAHE. 
Prior to analysis, the image is converted to binary form by thresholding.  This assigns 
foreground pixels the maximum value of 255, and background pixels 0, the minimum value.  
This binary image is then converted to a skeleton, representing the features of the original 
image with a wireframe, the lines of which are just one pixel in diameter.  MiNA then 
requires manual verification that the skeleton is an accurate representation of the original 
image before proceeding. 
Finally, every pixel within the approved skeleton is assigned one of three categories: 
end point pixel, slab pixel, or junction pixel.  The AnalyzeSkeleton ImageJ plugin then uses 
the definition and spatial relation of pixels to measure the number of branches and branch 
lengths within each network. 
 
4.3 Results  
4.3.1 Parkin and Fbxo7 regulate expression of 
mitochondrial fission proteins 
To knock down Parkin in HEK293T cells, an shRNA sequence was designed to target 
human Parkin.   Figure 4.1 (A) shows the open reading frame (ORF) of human Parkin,  taken 
from the NCBI database (https://www.ncbi.nlm.nih.gov/nuccore/AB009973.1).  Four 
different target sequences were selected for shRNA design, highlighted in  (A).  The Human 
(Berger) target sequence has been previously published (Berger et al., 2009).  The other 
three target sequences were selected as they met published criteria for optimal knock 
down.  These included a 5’ A- or AA-, GC-content of <50%, and avoiding repeats of four or 
more A or T nucleotides (Elbashir et al., 2001, Yu et al., 2002).  All sequences were also 
checked for off-target effects by BLAST search of the human genome.  Of the three novel 
shRNA target sequences, one was designed to target only human Parkin, and two designed 
to target both the human and rat Parkin sequences.  All four target sequences were 
generated as shRNAs in pSUPER alongside a scrambled shRNA negative control.  A 
preliminary experiment showed that the Berger sequence and the Human/Rat 1 sequences 
both knocked down endogenous Parkin in HEK293T cells (Figure 4.1 (B)).  It was anticipated 
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that future experiments would be performed in rat H9c2 cells, so the shRNA targeting both 
human and rat Parkin was selected for further use.  Sequence alignment shown in (E) 
demonstrates that this shRNA should target human and rat Parkin.  (C, D) shows the Parkin 
knock down construct almost completely ablates total Parkin (94% knock down) compared 










Figure 4.1 Parkin sequence alignment and shRNA design.  (A) The full coding sequence (open 
reading frame) of the human Parkin gene.  A panel of 4 shRNAs were designed to knock 
down Parkin in HEK293T cells (coloured). The Human (Berger) target sequence was 
previously published (Berger, A. K. et al, 2009); the other sequences were chosen as they 
met various criteria for optimal shRNA target sequences.  HEK293T cells transfected with 
the 4 shRNA constructs targeted to the human Parkin sequence were lysed after 72 hours 
and Western blotted for Parkin.  2 of the 4 tested shRNAs successfully knocked down 
endogenous Parkin (B).  The ‘Human/Rat 1’ shRNA knockdown was quantified and shown 
to significantly reduce endogenous Parkin after 3 days compared to a scrambled shRNA 
control (94% knockdown, C, D). N=4. Analysed using unpaired two-tailed students’ t-test. 
Data presented as mean ± SEM.  p ≤ 0.0001. (E) shows a sequence alignment of the shRNA 
target sequence with human and rat Parkin.  Base mis-matches are highlighted red. 
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 HEK293T cells were transfected with the Parkin-targeted shRNA described in 
Figure 4.1 or a scrambled (SCR) control and lysed 72 hours post-transfection for Western 
blot (Figure 4.2).  Parkin knockdown resulted in  significant reduction of total Drp1 (Figure 
4.2 (B)) and increase of total Mff (D).  Both Drp1 and Mff have previously been reported to 
be targets of Parkin-mediated degradation, so while the increase in Mff was expected, the 
decrease in Drp1 was not (Gao et al., 2015, Wang et al., 2011a).  Interestingly, Fbxo7 was 
also significantly reduced by knock down of Parkin (C), suggestive of a role for Parkin in 
stabilisation of Fbxo7 or Fbxo7-containing CRLs. 
 
  
Figure 4.2 Knockdown of Parkin in HEK293T cells.  Cells were transfected with either shRNA 
targeting human Parkin or a scrambled control (SCR).  Cells were lysed 72 hours later for 
analysis. (A) Western blots for Drp1, Fbxo7, Parkin, Mff and β-actin.  N= 4-7.  (B-D) 
Quantitative analysis  of Drp1, Fbxo7 and Mff levels using Student’s unpaired t-test.  Data 
presented as mean ± SEM.  *** p < 0.001, **** p < 0.0001. 
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Canonically, Parkin is recruited to depolarised mitochondria via a PINK1-dependent 
pathway.  Phosphorylation of S65 within the Ubiquitin-like domain of Parkin by PINK1 
contributes to its activation and ubiquitination of mitochondrial proteins during mitophagy 
(Berger et al., 2009, Xiao et al., 2017). 
To test whether the effects of Parkin knockdown on Drp1 and Mff were PINK1-
dependent, PINK1 was knocked down in HEK293T cells using a commercially available 
siRNA (Figure 4.3).  Compared to a negative control (siRNA targeting Firefly luciferase), the 
PINK1 siRNA significantly reduced total PINK1 in HEK293T cells by 72 hours post-
transfection, as assessed by Western blot (Figure 4.3 (A, B)).  Knock down of PINK1 had no 
significant effect on total cellular levels of Drp1, Fbxo7 or Parkin (Figure 4.3 (C, D, E)), 
indicating that the stability of these proteins is not PINK1-dependent.  Similar to Parkin 
knock down, however, knock down of PINK1 significantly increased total Mff (F), suggestive 
of an upstream role for PINK1 in Parkin-mediated Mff degradation. 
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Figure 4.3 Knockdown of PINK1 in HEK293T cells.  Cells were transfected with siRNA 
targeting either Firefly luciferase (control) or human PINK1.  Cells were lysed 72 hours later.  
(B) Western blots for  Drp1, Fbxo7, PINK1, Parkin, Mff and β-actin.  N=4.  (A, C-F) 
Quantitative analysis of blots using Student’s unpaired t-test.  Data presented as mean ± 
SEM.  ** p < 0.01, *** p < 0.001. 
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Fbxo7 has been previously reported to be involved in mitophagy via its interactions 
with Parkin (Burchell et al., 2013). To examine whether this might be through regulation of 
Mff, Fbxo7 was knocked down in HEK293T cells using a commercially available siRNA 
(Figure 4.4).  Compared to a negative control (siRNA targeting Firefly luciferase), the Fbxo7 
siRNA significantly reduced total cellular Fbxo7 by 72 hours post-transfection (Figure 4.4 
(A, B)).  Knock down of Fbxo7 had no significant effect on total Drp1 or Mff (C, E).  
Interestingly, I observed that different Mff-reactive species responded to Fbxo7 knock 
down in different ways, with a significant reduction in the higher molecular weight species 
and significant increase of the lower molecular weight species (Figure 4.4 (F, G)).  From 
these data, the lower molecular weight Mff species cannot be definitely labelled as 
isoforms or degradation products (further discussed in 4.4.1).  It is also notable that knock 
down of Fbxo7 resulted in a significant reduction of cellular Parkin (D).  This would be 
consistent with a model in which Fbxo7 and Parkin stabilise one another, perhaps forming 
a stable complex, but also confounds the interpretation of these data, as the effects on Mff 
could be ascribed directly to Fbxo7 knock down, or indirectly to Fbxo7 knock down via 
depletion of Parkin.  
  




Figure 4.4 Knockdown of Fbxo7 in HEK293T cells.  Cells were transfected with siRNA 
targeting either Firefly luciferase (control) or human Fbxo7.  Cells were lysed 72 hours later.  
(B) Western blots for Drp1, Fbxo7, Parkin, Mff and β-actin.  N=6. (A, C-G) Quantitative 
analysis using Student’s unpaired t-test.  Data presented as mean ± SEM.  ** p < 0.01, **** 
p < 0.0001. 
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Given that Parkin and Fbxo7 have both previously been linked to mitophagy, and 
that Parkin has been linked to both Mff and Fbxo7 (Gao et al., 2015, Burchell et al., 2013), 
it was important to investigate how knock down of both Parkin and Fbxo7 affects total 
levels of Drp1 or Mff.  Simultaneous knock down of Parkin and Fbxo7 (using shRNA targeted 
to Parkin and siRNA targeted to Fbxo7) significantly reduced total cellular levels of Drp1 
and significantly increased total Mff ( Figure 4.5 (D, E)) compared to a negative control 
(scrambled shRNA and Firefly luciferase-targeted siRNA).  These data follow the same trend 
as knock down of Parkin alone, potentially indicating some functional redundancy of Parkin 
and Fbxo7. 
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Figure 4.5 Knockdown of Parkin and Fbxo7 in HEK293T cells.  Cells were transfected with 
either scrambled shRNA and luciferase siRNA or Parkin shRNA and Fbxo7 siRNA.  Cells were 
lysed 72 hours later. (B) Western blots for Drp1, Fbxo7, Parkin, Mff and β-actin.  N=6.  (A, 
C-E) Quantitative analysis using Student’s unpaired t-test.  Data presented as mean ± SEM.  
* p < 0.05, ** p < 0.01, **** p < 0.0001. 
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4.3.2 Parkin and Fbxo7 mediate degradation of 
Mff 
Next, I wanted to determine whether the loss of Mff from mitochondria during 
ischaemia, which coincides with Parkin recruitment, is attributable to Parkin ubiquitin 
ligase activity.  To test if Parkin binds Mff, CFP-tagged Mff or free GFP (control) were co-
expressed in HEK293T cells with untagged Parkin.  48 hours post-transfection, cells were 
lysed and GFP or CFP-Mff was immunoprecipitated using GFP-Trap beads.  Parkin was 
present in the CFP-Mff co-immunoprecipitation, but not the free GFP co-
immunoprecipitation (Figure 4.6).  These data indicate a specific, albeit not necessarily 
direct, interaction between Mff and Parkin. 
 
Figure 4.6 Parkin specifically binds Mff in HEK293T cells.  Representative Western blot of 
GFP-Trap co-immunoprecipitation from HEK293T total cell lysates.  Exogenously expressed 
untagged Parkin is co-immunoprecipitated with CFP-Mff, but not GFP alone.  N=4.  
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HEK293T cells were co-transfected with GFP/CFP-Mff and shRNA (scrambled or Parkin-
targeting).  72 hours post-transfection, GFP-Trap was used to immunoprecipitate free GFP 
or CFP-Mff.  Post-translational modifications such as ubiquitination and SUMOylation are 
covalent and are therefore not lost under reducing/denaturing conditions used for 
immunoprecipitation and Western blotting.  Immunoblotting of GFP-Trap samples 
revealed that CFP-Mff is highly endogenously ubiquitinated, compared to free GFP.  Knock 
down of Parkin results in a significant ~50% reduction of ubiquitination (Figure 4.7), 
indicating that, at least in HEK293T cells, Parkin has a detectable functional role in Mff 
ubiquitination. 
Figure 4.7 Parkin ubiquitinates Mff in HEK293T cells. (A) Western blots of GFP-pulldowns of 
exogenously expressed CFP-Mff in HEK293T cells reveal high levels of endogenous 
ubiquitination, which is significantly decreased by knockdown of Parkin (B). N=3.  Analysed 
using unpaired two-tailed students’ t-test. Data presented as mean ± SEM.  p < 0.05. 
 
My data demonstrate that Parkin recruitment to mitochondria coincides with the 
loss of Mff, and that knock down of Parkin results in an increase of Mff.  Additionally, the 
GFP-Trap data show that Parkin can both bind Mff, and endogenous levels of Parkin 
ubiquitinate Mff.   
I next assessed the time-course of Mff degradation ± Parkin or Fbxo7 in the presence 
cycloheximide (CHX), a drug that blocks protein synthesis by inhibiting translation 
elongation.  The mechanism of translation inhibition remains largely unknown, but it has 
been proposed that CHX acts via direct binding to the E site of the 60S ribosome (Schneider-
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Poetsch et al., 2010).  By blocking protein synthesis, one can study the rate of protein 
degradation. 
HEK293T cells were transfected with scrambled (control) or Parkin-targeted shRNA, 
or Firefly luciferase (control) or Fbxo7-targeted siRNA and treated with 25µg/mL 
cycloheximide for up to 24 hours prior to their lysis 72 hours post-transfection.  Samples 
were prepared for Western blot and probed for endogenous Mff.  As shown in Figure 4.8, 
knock down of Parkin (B) or Fbxo7 (D) significantly slows the degradation of Mff over 6 or 
12 hours, but only knock down of Parkin significantly prevents loss of Mff by 24 hours, 
suggestive of a greater role for Parkin in Mff degradation than Fbxo7, or that this assay is 
more sensitive to manipulation of Parkin. 
 
Figure 4.8 Parkin and Fbxo7 contribute to Mff degradation.  HEK293T cells were transfected 
with either scrambled shRNA (control, SCR), Parkin shRNA, Firefly luciferase siRNA (control, 
Fluc) or Fbxo7 siRNA.  Prior to lysis 72 hours post-transfection, cells were treated with 
25µg/mL cycloheximide (CHX) for 0, 4, 6, 8, 12 or 24 hours (0-hour CHX received 6-hour 
DMSO treatment; 4 and 8-hour treatments were not included in sufficient replicates to be 
quantified).  Lysates were then Western blotted for Fbxo7, Parkin, Mff and β-actin (A, C).  
(B, D) Quantitative analysis, data presented as mean ± SEM.  Analysed using unpaired two-
tailed Student’s t-tests. N=4.  * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. 
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4.3.3 Parkin and Fbxo7 ubiquitinate Mff via 
independent mechanisms 
Since Parkin knock down reduces cellular levels of Fbxo7, and vice versa (Figure 4.2, 
Figure 4.4), I anticipated knock down of Fbxo7, or of Parkin and Fbxo7 together, would 
have the same effect on Mff ubiquitination as Parkin knock down alone (Figure 4.7).  To 
test this, HEK293T cells were co-transfected with CFP-Mff along with shRNA targeting 
Parkin, siRNA targeting Fbxo7, both, or a scrambled control.  To ensure equal amounts of 
nucleic acids were transfected in all groups, empty pSUPER (shRNA vector) was used as a 
balance.  72 hours post-transfection, GFP-Trap was used to immunoprecipitate CFP-Mff, 
along with its post-translational modifications.  Immunoblotting of GFP-Trap samples 
revealed that CFP-Mff ubiquitination was significantly reduced by knock down of either 
Parkin or Fbxo7 in this experiment.  Surprisingly, simultaneous knock down of Parkin and 
Fbxo7 doubled this effect, suggesting that Parkin- and Fbxo7-mediated ubiquitination of 
Mff is additive and perhaps mediated via different pathways (Figure 4.9). 
 




Figure 4.9 Parkin and Fbxo7 ubiquitinate Mff independently.  (A) Western blots of GFP-
pulldowns of exogenously expressed CFP-Mff WT in HEK293T cells reveal high levels of 
endogenous ubiquitination, which is significantly decreased by knockdown of Parkin 
(shRNA) or knockdown of Fbxo7 (siRNA), compared to a scrambled shRNA control, and is 
further reduced by knockdown of both Parkin and Fbxo7 (B).  N=6.  Analysed using ordinary 
one-way ANOVA with Tukey’s correction for multiple comparisons with a pooled variance. 
Data presented as mean ± SEM.  ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.   
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4.3.4 Parkin and Fbxo7 regulate mitochondrial 
morphology during OGD 
4.3.4.1 Parkin is recruited to mitochondria during OGD in H9c2 
cells 
The initial observations of this study were made in cardiac tissue.  The most notable 
differences were observed in Parkin and Mff, so it was important to study the effects of 
their manipulation in a cardiac or cardiac-like cell type.  In addition, Fbxo7 is of interest 
because it has been reported to interact with Parkin (Burchell et al., 2013) and it mediates 
ubiquitination of Mff (Figure 4.9).  Due to their relative ease of culture and manipulation, I 
used the rat cardiac myoblast cell line H9c2.  However, for H9c2 cells to be a viable model, 
they need to respond to ischaemic stress in a similar way to the cardiac tissue, particularly 
in the recruitment of Parkin to mitochondria, which was the most compelling change 
detected in the ex vivo experiments. 
Figure 4.10 (A) shows Parkin in the whole cell lysate or mitochondrial fraction of 
H9c2 cell samples collected after different lengths of ischaemia.  GAPDH was used as a total 
protein loading control, and VDAC as a mitochondrial loading control.  VDAC is enriched 
and GAPDH is absent from the mitochondrial fraction indicating effective separation of 
subcellular compartments.  Not all timepoints were repeated sufficient times to be 
quantified, but  2 hours of OGD was found to be sufficient to induce a significant (p < 0.05) 
5-fold increase in mitochondria-associated Parkin (B), and was chosen as the length of OGD 
for future experiments.  









4.3.4.2 Validation of lentivirus 
H9c2 cardiac myoblast cells have notoriously low transfection efficiency (Liu et al., 
2011).  I therefore used lentiviral infection to knock down Parkin and Fbxo7. A lentivirus 
containing shRNA to knock down rat Fbxo7 (target sequence: 
CCTTTGGGAAAGCTCATCATG) was already available (Dr Dan Rocca, unpublished work) but 
a Parkin knock down lentivirus had to be made. 
Figure 4.11 (A) shows a sequence alignment of the Fbxo7 shRNA target sequence 
with rat Fbxo7.  H9c2 cells were infected with lentivirus encoding this knock down and 
Figure 4.10 Mitochondrial recruitment of Parkin during OGD in H9c2 cells.  H9c2 cells were 
subjected to oxygen-glucose deprivation (OGD) for 0-24 hours.  Cells were lysed under 
OGD conditions and subsequently underwent subcellular fractionation.  OGD was carried 
out in de-oxygenated, glucose-free DMEM in an anaerobic chamber (95% N2, 5% CO2).  
Control cells were maintained in a standard incubator (95% O2, 5% CO2) in glucose-
containing DMEM.  N=2-6 (2-hour time point n=3). (A) Western blots of Parkin, GAPDH and 
VDAC.  (B) Quantitative analysis using unpaired two-tailed students’ t-test.  Data presented 
as mean ± SEM.  p < 0.05.  OGD and mitochondrial fractionation performed by Dr Nadiia 
Rawlings. 
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were lysed for Western blotting 4 days later.  Figure 4.11 (B) is a representative blot 
showing that endogenous Fbxo7 is knocked down. 
 
The knock down sequence for Parkin was designed to target both human and rat 
Parkin.  A sequence alignment showing the start of the open reading frame of Parkin from 
human and rat, along with the target sequence, is shown in Figure 4.12(A).  This sequence 
was used to create a lentiviral construct in pXLG3-GFP.  H9c2 cells were infected with 
pXLG3-GFP-shParkin or –shSCR (control) and lysed 4 days post-infection.  The Parkin knock 
down virus was highly effective and significantly reduced (p < 0.0001) total Parkin 
compared to the scrambled control (Figure 4.12 (B, C)). 
 
Figure 4.11 Sequence alignment of Fbxo7 shRNA target sequence and rat Fbxo7 sequence.  
The Fbxo7 shRNA targets a sequence starting at 793bp.  The figure shows a partial 
sequence alignment of the relevant section of the rat Fbxo7 coding sequence and the 
shRNA target sequence.  H9c2 cells were infected with lentiviral shRNA with the shown 
target sequence and lysed after 4 days for Western blot.  (B) shows the successful knock 
down of Fbxo7, compared to a scrambled lentiviral shRNA control. 
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Parkin is canonically only recruited to mitochondria under conditions of oxidative 
stress, whereupon PINK1 accumulates on the outer membrane of depolarised 
mitochondria ((Berger et al., 2009, Xiao et al., 2017).  However, the previous experiments 
in HEK293T cells were all conducted under basal conditions, and Parkin still interacted with, 
ubiquitinated and degraded Mff.  This demonstrates that even basally, there could is some 
constitutive activity of Parkin at the mitochondrial outer membrane, an effect which was 
expected, as mitophagy plays an important role in maintenance of the mitochondrial 
reticulum, with unhealthy mitochondria constantly requiring degradation even in healthy 
cells. 
To gain a better understanding of the role Parkin might play in maintenance and/or 
regulation of mitochondrial morphology and the delicate balance between fission and 
Figure 4.12 Human and Rat Parkin sequence alignment and validation of Parkin knockdown 
lentivirus and lentiviral shRNA design.  The figure shows a partial coding sequence alignment 
from the start of the open reading frame of the Rattus norvegicus and Homo sapiens Parkin 
genes (A).  Base mismatches are indicated (red).  The shRNA target sequence, validated 
previously in HEK293T cells, is conserved in rat, and was therefore chosen as the target 
sequence of the lentiviral knockdown. H9c2 cells infected with lentiviral shRNA targeted to 
both human and rat Parkin sequences have significantly reduced endogenous Parkin protein 
levels after 4 days compared to a scrambled lentiviral shRNA control (B, C). N=4. Analysed 
using unpaired two-tailed students’ t-test. Data presented as mean ± SEM. p ≤ 0.0001.       
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fusion, confocal image analysis was used.  Any perturbation of the equilibrium between 
mitochondrial fission and fusion would have an effect on gross mitochondrial network size 
and structure (Sesaki and Jensen, 1999).  H9c2 cells, being muscle cells, have high numbers 
of mitochondria, so an automated analysis tool was employed (Kuznetsov et al., 2015). 
4.3.4.3 Mitochondrial networks and OGD 
Parkin-targeted or Fbxo7-targeted lentivirus described in Figure 4.11 and Figure 4.12 
were used to infect differentiated H9c2 cells.  4 days post-infection, mitochondria were 
stained with MitoTracker, and subjected to 2 hours of OGD (or 2 hours of normoxic 
culture).  The cells were then fixed in acetone and used for confocal imaging (Figure 4.13).  
Various mitochondrial network parameters were analysed, with control and OGD 
conditions compared for each knock down.  As can be seen in Figure 4.13, the proportion 
of mitochondria that were involved in networks tended to decrease during OGD, compared 
to control conditions, although this was not significantly different for either of the knock 
downs (B).  However, the average length of branches within mitochondrial networks was 
significantly decreased by OGD, compared to control, and this difference was exacerbated 
by knock down of Parkin, but not Fbxo7 (C).  This could be interpreted as an increase in 
mitochondrial fission during OGD, which is increased in the absence of Parkin, but opposed 
by absence of Fbxo7.  Interestingly, although there was a non-significant trend towards 
increases in mitochondrial network complexity during OGD (as measured by average 
number of branches within networks), this increase was amplified to statistical significance 
by knock down of Fbxo7, but not Parkin (D), which could indicate that absence of Fbxo7 
inhibits mitochondrial fission or enhances fusion. 
 
 




Figure 4.13 Effects of Parkin or Fbxo7 knockdown on H9c2 mitochondrial networks under 
basal and OGD conditions.  H9c2 cells were infected with lentivirus encoding scrambled 
(control), Parkin or Fbxo7 shRNA.  4 days post-infection, cells were incubated with 
Mitotracker for 30 minutes.  Control cells were washed and returned to normal incubator 
conditions; OGD cells were washed and placed in an anoxic chamber in de-oxygenated, 
glucose-free DMEM.  After 2 hours, cells were washed and fixed in ice-cold acetone.  
Mitochondrial networks were evaluated using Fiji (ImageJ) with the MiNA macro. N=3 (40-
47 cells per group for network analysis, 41-47 cells per group for branch length analysis, 
41-46 cells per group for complexity analysis). Analysed using ordinary two-way ANOVA 
with Sidak’s correction for multiple comparisons. Data presented as mean ± SEM. * p < 
0.05, **** p < 0.0001.  Scale bar = 20µm. 




4.4.1 Parkin and Fbxo7 differentially regulate 
mitochondrial fission proteins 
4.4.1.1 Parkin 
Knock down of Parkin in HEK293T cells was achieved using both a previously 
published (Berger et al., 2009) and a novel shRNA target sequence (Figure 4.1).  The novel 
shRNA (target sequence: ACCAGCATCTTCCAGCTCAAG) produced the most complete 
Parkin knock down, at ~94%, and was used for subsequent experiments.  The effects of 
Parkin knock down were then studied in HEK293T cells. 
Consistent with a previous report that Parkin ubiquitinates Mff (Gao et al., 2015), 
knock down of Parkin significantly increased total expression of Mff (Figure 4.2 (D)).  This 
was indicative of a role for Parkin in Mff degradation and complemented the findings from 
the ex vivo heart experiments in Chapter 3, in which Parkin recruitment to mitochondria 
coincided with a loss of Mff. 
Parkin has previously been reported to ubiquitinate Drp1, contributing to its 
proteasomal degradation (Lutz et al., 2009, Tang et al., 2016, Wang et al., 2011a).  It was 
therefore expected that knock down of Parkin would increase total Drp1.  Surprisingly, 
however, the opposite effect was observed, with knock down of Parkin leading to a ~40% 
reduction in Drp1 (Figure 4.2 (B)).  This would be consistent with Parkin having a protective 
role of Drp1, perhaps by contributing to degradation of another ubiquitin ligase involved 
in Drp1 degradation, or with the cells degrading Drp1 via a proteasome-independent 
mechanism to compensate for the increased Mff and maintain mitochondrial homeostasis. 
Most published studies on Parkin activity rely on cellular stress models, such as 
ischaemia or chemical mitochondrial uncoupling.  However, the experiments presented in 
this chapter were all performed under basal conditions.  Basal mitophagy contributes to 
maintenance of healthy cells.  While inducible stress will exaggerate the effects of Parkin, 
it is reasonable to expect that, at any given time, some cells will contain some dysfunctional 
mitochondria, perhaps a result of localised oxidative stress or ATP-depletion, which need 
to be cleared.  In my functional experiments I only investigated manipulation of 
endogenous Parkin, and the knock down was almost complete.  In contrast, the study by 
Wang et al relied heavily on Parkin over-expression in HeLa and HEK293T cells.  It is notable 
that overexpression studies have been widely criticised for being an unreliable way of 
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identifying substrates due to enzyme promiscuity (Danielsen et al., 2011, Kanner et al., 
2017).  Wang et al also exogenously expressed ubiquitin, further contributing to potential 
off-target effects and/or physiologically irrelevant functional effects.  Moreover, where a 
Parkin knock down was used in SH-SY5Y cells it was only partial (~50%), making it difficult 
to extrapolate the role of Parkin (Wang et al., 2011a).  The work by Tang et al also used 
over-expressed Parkin to report on its degradation of Drp1, and a Parkin knock down 
performed in mouse N2a neuroblastoma cells was also partial (Tang et al., 2016). 
Interestingly, knock down of Parkin also significantly reduced Fbxo7 (Figure 4.2 (C)).  
Although Parkin and Fbxo7 have been shown to interact (Burchell et al., 2013), it has not 
previously been reported that Parkin contributes to stability of Fbxo7.  One possibility 
worthy of future investigation is that Parkin and Fbxo7 form part of a stable SCF-type E3 
ubiquitin ligase complex, and that deletion of Parkin destabilises the other complex 
components. Consistent with this, knock down of Fbxo7 also significantly reduced total 
Parkin (Figure 4.4 (D)). 
4.4.1.2 PINK1 
It is widely-known that Parkin is recruited to mitochondria by PINK1 accumulation, 
triggered by membrane depolarisation (Clark et al., 2006, Geisler et al., 2010, Matsuda et 
al., 2010, Narendra et al., 2010).  Therefore, PINK1 knock down using commercially 
available siRNA was performed, to examine whether the effects of Parkin knock down on 
mitochondrial proteins were PINK1-dependent.  As shown in Figure 4.3, knock down of 
PINK1 had no significant effect on total levels of Drp1, Fbxo7 or Parkin (C-E), though this 
does not preclude effects on protein localisation.  In the absence of PINK1, we would 
expect most, if not all, trafficking of Parkin to the MOM to be blocked.  That PINK1 
knockdown does not have the same effect on Drp1 or Fbxo7 levels as Parkin knockdown 
therefore indicates that regulation of Drp1 and Fbxo7 by Parkin occurs in the cytosol, and 
is independent of PINK1 and/or mitochondrial depolarisation.  Unsurprisingly, a significant 
increase of Mff in the absence of PINK1 was observed (F), similar to the increase observed 
with knock down of Parkin, suggesting that Parkin-mediated degradation of Mff is PINK1-
dependent, with PINK1 being required for mitochondrial recruitment and/or activation of 
Parkin to ubiquitinate Mff.  To further verify this, a Parkin knockdown/replacement strategy 
could be used, replacing endogenous Parkin with WT or a PINK1-insensitive Parkin mutant 
(e.g. non-PINK1-phosphorylatable Parkin S65A (Ordureau et al., 2015)), to see if the effect 
of Parkin knock down on Mff can be rescued. 




 Due to its known involvement in mitophagy and previously reported interaction 
with Parkin (Burchell et al., 2013), I tested if Fbxo7 could also play a role in regulation of 
mitochondrial fission proteins.  No significant difference was detected in total Drp1 
following knock down of Fbxo7 (Figure 4.4 (C)), indicating no substantial role for Fbxo7 in 
Drp1 degradation or protection.  This was unsurprising, as there is no literature available 
on interplay between Drp1 and Fbxo7.   
Knock down of Fbxo7 had no significant effect on total levels of Mff (Figure 4.4 (E)).  
However, different bands of Mff on the Western blots appeared to respond to Fbxo7 knock 
down in different ways.  For that reason, the predominant higher molecular weight species 
and the lower molecular weight species were analysed independently.  This revealed a 
significant decrease in the higher molecular weight species (F) and a significant increase in 
the lower molecular weight species (G).  The Mff antibody used in this study recognises all 
five previously identified isoforms (Supplementary Figure 1), three of which have molecular 
weights between 25 and 28kDa, similar to the lower molecular weight bands shown in 
Figure 4.4 (Gandre-Babbe et al., 2008).  This raises the intriguing possibility  that, rather 
than affect total levels of Mff, Fbxo7 preferentially contributes to degradation of the 
smaller isoforms.  The simultaneous decrease of the main Mff isoform could therefore be 
a compensatory mechanism to protect against excessive mitochondrial fission.  However, 
we cannot rule out the lower molecular weight bands being Mff degradation products, 
which would also be interesting, as it would indicate that Fbxo7 may stabilise Mff, thereby 
opposing the degradative action of Parkin. 
4.4.1.4 Parkin and Fbxo7 
Given that knock down of Parkin also decreased cellular Fbxo7, and knock down of 
Fbxo7 similarly reduced Parkin, it was hypothesised that simultaneous knock down of both 
would have no further effect.  However, knock down of Parkin and knock down of Fbxo7 
had different effects on Drp1 and Mff, so it could be that they have an antagonistic 
relationship with regard to these two proteins.  
Knock down of both Parkin and Fbxo7 resulted in significantly reduced Drp1 and 
significantly increased Mff (Figure 4.5 (D, E)).  This follows the pattern of independent 
knock down of Parkin (Figure 4.2) and suggests that Parkin may be a more dominant 
regulator of Drp1 and Mff than Fbxo7, or that Fbxo7 functions upstream of Parkin in Mff 
regulation.  However, given their demonstrable dependence on one another for stability, 
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it is not possible to dissect out any potential pathway.  Moreover, the effects of Parkin and 
Fbxo7 on Mff are not opposing, so it is unlikely that they have an epistatic relationship. 
Interestingly, although still statistically significant, the effects of Parkin and Fbxo7 knock 
down on Mff and Drp1 were smaller than the effects of Parkin knock down alone; Drp1 
reduction was ~50% with knock down of Parkin alone, compared to just ~10% with the 
double knock down, while Mff abundance was ~100% increased by the single knock down 
and only ~50% increased by the double knock down. 
These data indicate that, at least in the cases of Mff and Drp1, the roles of Fbxo7 
and Parkin are independent of one another, rather than through their possible roles in a 
common E3 ligase complex.  The reduced effect of Parkin knock down with simultaneous 
Fbxo7 knock down is suggestive of Fbxo7 ablation being partially protective against the 
effects of Parkin knock down.  However, it is possible that the effects are smaller simply 
because simultaneous Parkin and Fbxo7 knock downs are less complete than their 
individual knock downs, due to multiple transfections (Figure 4.5 (B, C)).   
4.4.2 Parkin and Fbxo7 regulate Mff degradation 
4.4.2.1 Parkin binds specifically to Mff 
As outlined previously, Parkin has been reported to interact with and ubiquitinate 
Mff (Gao et al., 2015).  Before this could be further explored, it was important to validate 
these findings.  The co-immunoprecipitation data presented in Figure 4.6 use CFP-Mff, 
which can be immunoprecipitated using GFP-Trap beads.  GFP was used as a control and 
differs from CFP by just a single amino acid: Y66W (Day and Davidson, 2009).  As shown in 
the figure, Parkin was co-immunoprecipitated with CFP-Mff, but not GFP alone, providing 
strong evidence that the Parkin-Mff interaction is specific. 
4.4.2.2 Mff is ubiquitinated by Parkin 
The paper by Gao et al reported Parkin-dependent ubiquitination of Mff (Gao et al., 
2015).  In their study, Gao and colleagues expressed Myc-Mff and EGFP-Parkin in HEK293 
Mff -/- cells, then performed immunoprecipitation with an anti-Mff antibody before 
Western blotting with anti-ubiquitin antibodies.  For the data presented in Figure 4.7, the 
ubiquitination capacity of only endogenous Parkin was tested, going some way towards 
ruling out the possibility of enzyme promiscuity and false-positive data.  As shown in Figure 
4.7 (B), near complete knock down of Parkin resulted in a ~50% decrease in endogenous 
ubiquitin immunoprecipitated with Mff.  This provides strong evidence that Mff is a true 
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substrate of endogenous levels of Parkin in HEK293T cells, as well as indicating that Parkin 
is not the only ubiquitin ligase to target Mff.  This raised the question of a role for Fbxo7 in 
ubiquitination of Mff. 
4.4.2.3 Parkin plays a greater role in Mff degradation than 
Fbxo7 
   Demonstrating binding between Mff and Parkin and Parkin-dependent 
ubiquitination of Mff does not conclusively provide evidence of a degradative role for 
Parkin.  To assess rates of Mff turnover and their Parkin-dependence, endogenous Parkin 
was knocked down in HEK293T cells and cycloheximide (CHX), an inhibitor of protein 
synthesis, used to measure rates of Mff decay.  As the role of Fbxo7 in Mff regulation 
remained unclear, the same experiment was also carried out using knock down of Fbxo7. 
As shown in Figure 4.8 (A, B), Mff is degraded over the course of 24 hours to almost 
nothing by inhibition of protein synthesis, reducing by ~50% within around 4 hours.  By 
contrast, knock down of Parkin preserves ~50% of initial Mff until the end of the 
experiment (24-hours CHX treatment).  At 6-, 12- and 24-hours CHX treatment, the Parkin 
knock down cells still contain significantly more Mff than a scrambled control, indicating 
that knock down of Parkin both slows down Mff degradation, and protects from it, 
consistent with a role for Parkin in Mff degradation. 
By contrast, knock down of Fbxo7 did not appear to protect Mff against degradation 
over 24 hours (Figure 4.8 (C, D)).  As with the Parkin knock down experiment, the control 
cells (treated with siRNA targeted Firefly luciferase) have lost almost all initial Mff by 24 
hours CHX treatment, but the Fbxo7 knock down cells did not have significantly higher 
residual Mff.  However, the initial rate of degradation of Mff did appear to be slower in the 
absence of Fbxo7, with significantly higher Mff remaining after 6 and 12 hours of CHX 
treatment.  Taken together, the results of the Parkin and Fbxo7 knock down could be 
indicative of roles for both proteins in degradation of Mff, but with Parkin being the 
dominant regulator of Mff turnover.  Alternatively, partial ablation of Parkin as a result of 
Fbxo7 knock down would also explain the partial occlusion of degradation.  To exclude this 
possibility, the experiment could be performed using Mff mutants that are insensitive to 
Parkin (to study Fbxo7-mediated degradation) or insensitive to Fbxo7 (to study Parkin-
mediated degradation).  However, there are caveats to this method as well.  Degradation 
of over-expressed protein is unlikely to be representative of degradation of the 
endogenous, and the necessary involvement of different Mff mutants would confound 
data analysis.     
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4.4.2.4 Parkin and Fbxo7 ubiquitinate Mff independently 
The data presented previously (Figure 4.7) show that Mff is ubiquitinated by Parkin 
at endogenous levels.  Fbxo7 has not been previously reported to have a role in 
ubiquitination of Mff but has been shown to interact with Parkin in the mediation of 
mitophagy (Burchell et al., 2013).  With Parkin-dependent ubiquitination of Mff having 
already been linked to mitophagy (Gao et al., 2015), we hypothesised that the role of Fbxo7 
might also be linked to Mff.  Given the ability of Fbxo7 over-expression to rescue 
phenotypes of Parkin-null Drosophila, we proposed a level of functional redundancy 
between the two proteins.  
Figure 4.9 shows Western blot data of CFP-Mff immunoprecipitation.  As shown 
previously (Figure 4.7), knock down of Parkin significantly reduced endogenous 
ubiquitination of Mff.  Supportive of a functional redundancy hypothesis in which Parkin 
and Fbxo7 can both ubiquitinate Mff depending on their availability, knock down of Fbxo7 
also significantly reduced Mff ubiquitination by the same amount.  These data are 
suggestive of the two proteins being interchangeable or dependent upon one another in 
their regulation of Mff.  Interestingly, however, simultaneous knock down of Parkin and 
Fbxo7 further reduced Mff ubiquitination, doubling the effect of individual knock down.  
This additive effect is indicative of separate, distinct roles for Parkin and Fbxo7 in Mff 
regulation, via independent pathways.  In light of this, previous discussion that Fbxo7 
functions upstream of Parkin within the same pathway is improbable (4.4.1.4).  It will be 
intriguing to explore the mechanisms and consequences of this by studying the specific Mff 
ubiquitin-chain linkages Parkin and Fbxo7 mediate, as well as the site(s) that they target.  
 
4.4.3 Parkin and Fbxo7 regulate mitochondrial 
networks during OGD 
4.4.3.1 H9c2 cells are a suitable model for cardiac ischaemia     
The data shown in Chapter 3, with Parkin recruitment to mitochondria during 
ischaemia coinciding with a loss of Mff, were informative, but the ex vivo model of heart 
perfusion cannot be readily genetically manipulated. As an alternative to in vivo viral 
infection and ex vivo experiments in whole heart I performed knock down experiments in 
the H9c2 cells, an extensively validated, immortalised rat cell line of cardiac myoblast–like 
cells (Hescheler et al., 1991, Watkins et al., 2011, Kuznetsov et al., 2015).  H9c2 cells  have 
been previously shown to be more similar to primary cardiac cell cultures than other lines, 
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for example HL-1, with respect to their energy metabolism patterns, including cellular ATP 
levels, bioenergetics, metabolism, function and morphology of mitochondria (Kuznetsov et 
al., 2015).  As cardiac-like cells with high energy demands, they also have relatively large 
numbers of mitochondria, making them an ideal model to study mitochondrial networks 
and/or morphology.   
 Cells in culture can respond differently to stress compared to a whole organ it was 
necessary to establish that they would be reflective of the whole heart studies.  The most 
striking effect observed during whole heart ischaemia was the recruitment of Parkin to 
mitochondria, so this was chosen as a bench-mark response to OGD.  The data in Figure 
4.10 show levels of Parkin in whole cell lysate and the mitochondrial fraction of control 
H9c2 cells and cells after varying lengths of OGD.  As can be seen in (A), Parkin is recruited 
to and subsequently lost from the mitochondrial fraction over the course of 24 hours OGD.  
Recruitment of Parkin was significantly increased by 2 hours of OGD (B), so this was chosen 
as an appropriate time for future experiments.   
Although H9c2 cells are relatively straight-forward to culture their transfection 
efficiency is very low (Liu et al., 2011). Despite numerous attempts, I was unable to 
transfect them with various commercially available reagents, so I used lentiviral infection  
to manipulate protein levels in these cells. A lentiviral knock down for Fbxo7 was already 
available in the lab.  Figure 4.11 (A) shows a sequence alignment of the target sequence of 
the knock down with the relevant region of the rat Fbxo7 open reading frame.  Figure 4.11 
(B) shows that Fbxo7 was successfully knocked down within 4 days of transduction, 
compared to a scrambled lentiviral control. 
The Parkin knock down previously used in HEK293T cell experiments was specifically 
generated to target both human and rat Parkin.  Therefore, the functional part of the 
construct could easily be digested out of the mammalian vector and into the lentiviral 
vector.  Figure 4.12 (A) shows a sequence alignment from the start of the open reading 
frames of both human and rat Parkin, along with the shRNA target sequence.  As indicated 
in red, there are a few base pair mismatches between the human and rat sequences, but 
none are within the target sequence of the shRNA.  It was therefore anticipated that this 
sequence would knock down Parkin as efficiently in rat H9c2 cells as it did in HEK293T cells.  
Figure 4.12 (B) and (C) show that this was the case, with an almost complete knock down 
achieved within 4 days of viral transduction.  
The efficacy of Fbxo7 and Parkin knock downs, combined with the OGD-dependent 
mitochondrial recruitment of Parkin, and high mitochondrial content (Kuznetsov et al., 
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2015) made H9c2 cells an ideal model to study protein manipulation and mitochondrial 
effects. 
4.4.3.2 Analysis of mitochondrial networks 
 MiNA (Mitochondrial Network Analysis) was used for all analyses of mitochondrial 
networks (reticula) presented in this study.  This pair of macros have been previously 
published and are freely available online (Valente et al., 2017).  Analysis of mitochondria in 
this way circumvents many of the issues faced in manual analysis of mitochondria.  Most 
previously published studies on mitochondrial morphology involved manual determination 
of structures, by categorising each mitochondrion as round-type or elongated-type.  This 
is a very time-consuming method, and also can be very subjective, as mitochondria rarely 
fit neatly into one of two or three ideological categories.  Performing analysis using the 
MiNA macros removes bias by being fully automated.  It also allows a large number of cells 
to be analysed in a short time frame, allowing for larger numbers of replicates to be 
processed.   
Using the MiNA analysis tools, the effects of knock down of Parkin or Fbxo7 were 
studied, under basal and OGD conditions.  As previously described, 2 hours was chosen as 
an optimal time for OGD.  Control cells were kept in normoxic conditions for the same 
period of time.  To avoid the effects of reperfusion confounding the OGD data, cells were 
fixed in the anoxic chamber.  Figure 4.13 (A) shows representative confocal images of H9c2 
cells under all conditions, and various mitochondrial parameters are analysed in (B) – (D). 
The cells selected for analysis were not all the same size, so the number of 
mitochondria, both total numbers and numbers of individual vs. networked mitochondria, 
are not comparable.  However, this can be controlled for by instead calculating a ratio of 
networked to individual mitochondria within a cell (Figure 4.13 (B)).  Somewhat 
surprisingly, this ratio was not changed by OGD for the control (scrambled) cells or either 
of the knock downs.  However, the ratio not changing does not necessarily mean that 
mitochondrial numbers did not change. 
OGD significantly decreased the average length of branches within the 
mitochondrial reticulum (Figure 4.13 (C)).  This is indicative of an increase in mitochondrial 
fission, or a decrease in mitochondrial fusion.  Interestingly, knock down of Parkin resulted 
in a greater decrease in average network branch length upon OGD (C).  This could suggest 
that the shortening of branch length is a result of increased fission, as opposed to 
decreased fusion.  Consistent with the data presented in this chapter, absence of Parkin 
would result in an increase of Mff, which could in turn facilitate excess fission.  
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Mitochondrial network complexity was measured as the average number of branches 
within the mitochondrial reticulum.  As evident from Figure 4.13 (D), no significant change 
was observed in network complexity as a result of OGD.  However, knock down of Fbxo7 
did result in a significant increase in network complexity upon OGD. 
The meaning of these data is not yet clear, and effects observed through knock down 
of Parkin or Fbxo7 cannot be definitively linked to Mff at this stage.  What is clear, however, 
is that both Parkin and Fbxo7 play roles in the maintenance or regulation of the 
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Chapter 5 SUMO regulates mitochondrial 
dynamics 
5.1 Introduction 
Evidence presented in Chapters 3 and 4 identified Mff as a target of Parkin-mediated 
ubiquitination and showed that Mff can be modified by conjugation of SUMO-1 and SUMO-
2.  A newly emerging group of ubiquitin ligases which identify substrates via SUMO chains 
is generating a lot of interest.  These SUMO-targeted ubiquitin ligases (STUbLs) contain 
SUMO-interacting motifs to bind non-covalently to SUMO.  It has been previously reported 
that Parkin can interact non-covalently with SUMO-1 (Um and Chung, 2006).  I therefore 
wanted to explore the possibility that SUMOylation of Mff may play a part in regulation of 
its interactions with Parkin. 
5.1.1 Identification of non-covalent SUMO 
interactions 
Covalent attachment of one or more SUMO molecules (SUMOylation) to substrate 
proteins has been recognised as an important post-translational modification for more 
than 20 years (Mahajan et al., 1997, Matunis et al., 1996).  However, non-covalent 
interactions of proteins with SUMO remain far less well-characterised (Li et al., 2000, Shen 
et al., 1996).  Since the discovery of SUMO, two-hybrid assays have emerged as a 
convenient tool to differentiate covalent from non-covalent interactions with SUMO; 
proteins which interact with SUMO in the absence of the C-terminal di-glycine motif 
required for covalent conjugation are candidates for non-covalent interactors.  Use of this 
approach has facilitated the identification of many SUMO-interacting proteins and the 
SUMO-interacting motifs (SIMs) which mediate the binding (Hannich et al., 2005, Hecker 
et al., 2006). 
5.1.1.1 Two-Hybrid screen: initial identification of a SIM 
The first specific SUMO-interacting proteins containing conserved SIMs were 
reported in 2000 (Minty et al., 2000).  In their study, Minty et al used a two-hybrid approach 
to show that certain proteins were able to interact with SUMOylated p73 (a member of the 
p53 tumour suppressor family).  A two-hybrid screen relies on the ability of most eukaryotic 
transcription factors (TFs) to still function when their two functional domains, the DNA-
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binding domain (DBD) and the activating domain (AD), are proximal but not directly bound 
to one another (Fields and Song, 1989).  Minty et al fused the DBD of TF LexA to p73α and 
used the resulting fusion protein as bait in a Saccharomyces cerevisiae (strain EGY48, 
containing LEU2 (required for synthesis of leucine (Storms et al., 1981)) under control of 
LexA promoters) based two-hybrid screen.  The p73α-DBD fusion protein was transformed 
into the yeast and a cDNA library from two different cell lines (SK-N-AS neuroblastoma and 
U937 monocytic) was then introduced in plasmids encoding the LexA AD.  Colonies were 
re-plated on agar lacking leucine, to allow selection of successful recombinants.  Using this 
method, the authors isolated cDNA encoding, among others, SUMO-1, Ubc9, SAE2 and 
PIASX (Minty et al., 2000).   
5.1.1.2 SIMs 
With several newly identified SUMO-interacting proteins, Minty et al were able to 
interrogate their sequences for conserved motifs.  A subset of their identified proteins 
contained an 11-amino acid motif, which they proposed to be a SUMO-1 interacting motif 
(SIM).  At its core, the conserved motif comprised of a S-x-S triplet, in which x could be any 
amino acid.  Flanking this core, the authors observed an N-terminal hydrophobic region 
and a C-terminal acidic region (Minty et al., 2000). 
However, a study published a few years later disputed the requirement of the serine 
residues in SUMO-binding, arguing that the hydrophobic region was the principal 
component of the SIM (Song et al., 2004).  The authors of this study used nuclear magnetic 
resonance (NMR) spectroscopy to investigate binding of SUMO-1 to a synthetic peptide 
comprising the previously described SIM of PIASX (PIASX-SIM) (Minty et al., 2000).  The 
NMR data from Song et al revealed that the S-x-S and subsequent acidic residues were not 
directly involved in SUMO-1 binding and showed that the most significant chemical shift 
changes were induced by the hydrophobic residues Val-2 to Ile-9 in their synthetic PIASX-
SIM peptide.  The authors went on to validate this finding by synthesising a new peptide 
comprising just the hydrophobic part of the SIM, Val-2 to Glu-10, and found that this 
peptide induced almost identical chemical shift changes to those detected within the 
PIASX-SIM peptide, suggesting that both the full-length and the reduced synthetic SIM-
containing peptides interacted with SUMO-1 in an identical way (Song et al., 2004). 
Over the subsequent years, a SIM was identified in yeast that shared core 
characteristics of the previously described mammalian SIM, namely a hydrophobic core 
and flanking acidic residues (Hannich et al., 2005, Hecker et al., 2006).  It emerged that this 
hydrophobic core, comprising 3-4 aliphatic residues, was an essential part of the SIM, and 
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that it was often juxtaposed to a cluster of acidic residues.  Despite this, the SIM remains 
an enigmatic and highly variable motif. (Kerscher, 2007). 
5.1.2 The SUMO-SIM interaction 
5.1.2.1 SIM/SUMO hydrophobicity 
NMR spectroscopy was used to solve the structure in solution of SUMO-1 bound to 
a SIM-containing synthetic PIAS peptide, revealing interactions between hydrophobic and 
aromatic residues (Song et al., 2005).  In the case of both SUMO-1 and SUMO-2, these 
hydrophobic and aromatic residues were arranged in a SIM-binding groove between the 
beta-2 strand and alpha-1 helix of SUMO (Figure 5.1 (C)).  In their study, Song et al showed 
that residues 2-8 of the PIAS peptide (V-D-V-I-D-L-T) embed, in an extended conformation, 
in the SIM-binding groove of SUMO. 
The SIM-binding groove of SUMO identified by Song et al is the only concave surface 
of the molecule to comprise patches of hydrophobicity and aromatic residues (His-35, Ile-
34, Phe-36, Val-38, Leu-47, and Tyr-51).  The authors went on to show that mutation of 
Phe-36 to alanine, despite having no effect on the structural integrity of SUMO-1, reduced 
the affinity of the SIM-binding groove for the PIAS peptide to such an extent that 
interaction could no longer be detected, demonstrating the importance of hydrophobicity 
in SUMO-SIM binding (Song et al., 2005).  These data were validated by independent 
studies that also noted the importance of key SUMO-1 hydrophobic residues involved in 
SIM-binding, Phe-36, Val-38 and Leu-47 (Hecker et al., 2006, Baba et al., 2005). 
5.1.2.2 Charge clusters 
Many SIMs contain not only a hydrophobic core, but also a juxtaposed cluster of 
acidic residues (Hannich et al., 2005, Hecker et al., 2006).  These residues promote 
electrostatic interactions, with important roles in affinities, orientation and functionality of 
SUMO-SIM interactions (Hecker et al., 2006, Song et al., 2005).  The binding surface of 
SUMO-1 has a positive electrostatic potential.  In the PIAS peptide, two Asp residues are 
located to interact with Arg-54 and Lys-37 of SUMO-1, likely promoting the SUMO-SIM 
interaction.  Mutation of the equivalent Asp residue in the RanBP2 SIM significantly 
reduced the SUMO-SIM binding affinity (Song et al., 2004). 
Similarly, the hydrophobic core of many SIMs sits near serine and threonine 
residues.  It has been shown that phosphorylation of these residues also regulates SUMO-
SIM binding (Hecker et al., 2006).  The authors in this case propose that phosphorylation 
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of a serine within the PIAS peptide SIM facilitates SUMO binding by introducing a negative 
charge, which Lys-39 of SUMO (conserved in the hydrophobic groove of all three 
mammalian SUMO homologues) can interact with to strengthen the interaction.  Indeed, 
Hecker et al go on to show that the serine residue is phosphorylated in vivo.  These data 
were later validated by an independent study, which showed that phosphorylation of 
serine residues adjacent to the SIM of PIAS1 favoured formation of a non-covalent ternary 
complex comprising PIAS1, SUMO and Ubc9, required for transcriptional repression 
(Mascle et al., 2013). 
5.1.2.3 SUMO orientation 
The hydrophobic core, as shown in Figure 5.1 (A), can be quite variable.  Similarly, 
the cluster of acidic amino acids, if present, can be up- or downstream of the hydrophobic 
core (B).  This allows the SIM to bind SUMO in a parallel or anti-parallel orientation (C).  This 
has been shown in several studies; SUMO binds to the SIMs in thymine DNA glycosylase 
and RanBP2 in an anti-parallel manner, but to the PIAS protein-derived SIM in parallel (Baba 
et al., 2005, Song et al., 2005, Reverter and Lima, 2005).   
5.1.2.4 SUMO preferences 
As previously discussed, the crucial hydrophobic residues involved in SIM binding are 
conserved between the SUMOs.  However, the different SUMO homologues may differ in 
the position of their hydrophobic groove.  It has been shown by crystallographic analyses 
that the hydrophobic groove of SUMO1, SUMO2 and the yeast SUMO paralogue Smt3 is 
surrounded by basic residues, which act as ‘prongs’ to receive the SIM domain and its 
associated negative charges (Chupreta et al., 2005).  However, the positioning of the 
hydrophobic groove relative to the basic residues differs between the SUMOs, indicating 
that the particular arrangement of hydrophobic and acidic residues within SIMs could allow 
them to discriminate between the different SUMO isoforms, which would be of potential 
importance in the case of STUbLs.    
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5.1.3 SUMOylation consensus motifs 
SUMO is attached to a target protein via an ATP-dependent, enzyme-catalysed 
cascade, resulting in formation of an isopeptide bond between an ɛ-amino group on a 
lysine residue of the target protein and the C-terminal carboxyl group of the SUMO protein 
(Desterro et al., 1997).  While all SUMOylation occurs at lysine residues, not all lysine 
residues can be SUMOylated (Matunis et al., 1998, Mahajan et al., 1998, Andre et al., 
1996). 
  It was not until several targets of SUMOylation had been identified and their SUMO-
conjugation sites mapped that a SUMOylation consensus sequence could be established.  
In 1999, Sternsdorf et al identified the SUMOylatable lysine residue of Sp100, a nuclear dot 
(ND) protein (Sternsdorf et al., 1999).  Using this information, along with other published 
SUMOylation sites of IKappaB (Desterro et al., 1998), RanGAP (Matunis et al., 1998, 
Figure 5.1 SUMO interacting motifs are variable.  (A) illustrates the sequence variability 
between core hydrophobic components of SIMs from bona fide SUMO-interacting 
proteins.  (B) possible combinations of hydrophobic (h) core and acidic/phosphorylated 
residues (blue minus symbol).  X can be any amino acid.  (C) SIM-SUMO binding can be 
parallel or anti-parallel, depending on arrangement of (h) to acidic residues. Positively 
charged lysine 78 of SUMO (red plus symbol) may be important in the orientation of 
phosphorylated SIMs.  SUMO shown in blue, SIM-containing peptide in green.  Figure taken 
from Kerscher, O. (2007). "SUMO junction—what's your function? New insights through 
SUMO-interacting motifs." EMBO Reports 8(6): 550-555 (Kerscher, 2007).       
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Mahajan et al., 1998) and PML (Kamitani et al., 1998), they predicted further SUMOylation 
sites in other ND proteins and ND-related proteins.  Their predicted sites all fit a consensus 
sequence similar to one proposed by Desterro et al in 1998 (Desterro et al., 1998).  The 
consensus SUMOylation motif, at its core, comprised 4 amino acids: (I/L)-K-x-E, where x 
could be any amino acid.  This tetrapeptide consensus was later updated to recognise that 
the first position could be any large hydrophobic amino acid, rather than just isoleucine or 
leucine, giving the ψ-K-x-E motif still used in predictions of SUMOylation sites today 
(Sampson et al., 2001).  
5.1.3.1 Non-consensus SUMOylation motifs 
In a proteomics-based approach, Blomster et al used tryptic digestion of proteins 
followed by liquid chromatography-tandem mass spectrometry to perform an unbiased 
screen for identification of post-translational modification sites (Blomster et al., 2010).  
They identified 14 novel SUMOylated peptides, of which only 3 were SUMOylated at 
consensus SUMOylation motifs.  This was in support of previous work carried out by them, 
and by other groups, which had suggested that a considerable proportion of SUMOylated 
proteins do not contain the consensus tetrapeptide SUMOylation motif (Blomster et al., 
2009, Golebiowski et al., 2009, Hsiao et al., 2009, Zhu et al., 2008).  Their previous study 
had identified 382 SUMO-2 targets, of which over half contained non-consensus 
SUMOylation motifs (Blomster et al., 2009).   
5.1.3.2 Phosphorylation-dependent SUMOylation motifs 
A recurrent phosphorylation-dependent SUMOylation motif (PDSM) was first 
reported in 2006 (Hietakangas et al., 2006).  The authors of this study had previously shown 
that phosphorylation of HSF1, a stress-related transcriptional factor, was required for its 
SUMOylation (Hietakangas et al., 2003).  Their 2006 paper identified a conserved motif 
among 48 human proteins, of which 71% were transcriptional regulators, that matched 
with the sites of phosphorylation and SUMOylation in HSF1.  The proteins they identified 
included several known SUMOylation substrates, such as transcription factors GATA-1 and 
MEF2 (Collavin et al., 2004, Gregoire and Yang, 2005).   The consensus sequence, Ψ-K-x-E-
x-(x)-S-P, was termed PDSM (Hietakangas et al., 2006).  
 




The data presented so far have established a role for Parkin in degradation of Mff 
during ischaemia and identified Mff as a novel target of SUMOylation.  A previous study 
has reported that Parkin can associate non-covalently with SUMO-1 (Um and Chung, 2006).  
We therefore hypothesised a role for SUMO in Parkin-dependent regulation of Mff.  The 
aims of this part of my PhD were to: 
i. Validate a previous report of non-covalent interaction between SUMO 
and Parkin. 
ii. Define the nature of the Mff SUMOylation site and determine if this can 
recruit Parkin. 




5.2.1 In vitro co-immunoprecipitation 
5.2.1.1 Fusion protein expression in BL21 (DE3) E. coli 
BL21 (DE3) E. coli were transformed as described in Chapter 2 and plated on LB agar 
containing 100µg/mL ampicillin (pGEX-4T1 constructs: GST-fusions) or 25µg/mL kanamycin 
(pET28a: His-fusions) and incubated at 37°C overnight.  A single colony was then picked 
and incubated in 100mL 2xYT Broth (1.6% (w/v) bacto-tryptone, 1% (w/v) Bact yeast 
extract, 0.5% (w/v) NaCl, pH7.0) containing appropriate selection antibiotic at 37°C 
overnight in a shaking incubator.  Protein expression was induced by addition of Isopropyl 
β-D-1-thiogalactopyranoside (IPTG, Sigma Aldrich) to a final concentration of 0.2mM, and 
further incubation at 25°C, shaking, for 6 hours. 
5.2.1.2 GST-fusion protein purification 
Bacteria were pelleted at 4000rpm for 20 minutes at 4°C, the supernatant removed, 
and the pellet resuspended in 10mL lysis buffer (25mM Tris pH 7.5, 150mM NaCl, 10% (v/v) 
glycerol, 1% (v/v) Triton X-100, 1x protease inhibitors).  Bacterial cells were lysed by 
sonication (6x 10 seconds, with cooling on ice in between) and left to solubilise on ice for 
15 minutes.  Lysates were then centrifuged at 20,000rpm for 25 minutes at 4°C to pellet 
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cell debris.  For each GST-fusion protein, 200µL Glutathione Sepharose® 4 Fast Flow beads 
were washed twice with 10mL wash buffer (25mM Tris pH 7.5, 150mM NaCl, 10% (v/v) 
glycerol, 1% (v/v) Triton X-100) by gently mixing and pelleting at 2000rpm for 2.5 minutes.  
Wash buffer was then aspirated, and the cleared bacterial lysate added to the beads.  
Lysates were incubated on the beads for 2 hours at 4°C, on a spinning wheel.  Beads were 
then pelleted as before and washed 4 times with 10mL wash buffer.  After the final wash, 
beads were resuspended in a small volume (~1mL wash buffer), transferred to a 1.5mL 
Eppendorf tube and pelleted at 4000rpm, 4°C, for 2 minutes.  The supernatant was 
aspirated, and the beads resuspended in 200µL elution buffer (25mM Tris pH 7.5, 150mM 
NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 10mM reduced glutathione, pH 8.0).  Tubes 
were incubated on a rocking platform for 5 minutes at RT, then the beads pelleted at 
4000rpm as before.  The eluate was removed, and the elution process repeated a further 
2 times, giving a total of 600µL GST-fusion protein-containing eluate.  5µL of this were then 
run on an acrylamide gel alongside 1, 2.5, 5 and 10µg BSA standards, so that approximate 
concentration could be ascertained by Coomassie staining.  Eluates were aliquoted and 
stored at -80°C. 
5.2.1.3 His-fusion protein purification 
His-tagged proteins were purified following the GST-fusion protein purification 
protocol, with the exception of buffer components and beads.  Lysis buffer contained 
25mM Tris pH 7.5, 150mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 10mM imidazole 
and 1x protease inhibitors.  Wash buffer was lysis buffer lacking protease inhibitors.  Elution 
buffer contained 25mM Tris pH 7.5, 150mM NaCl and 250mM imidazole, pH 8.0.  Ni-NTA 
Sepharose® 4 Fast Flow beads were used for purification. 
5.2.1.4 Recombinant protein binding assay  
In vitro recombinant protein binding assays were performed using GST-fusion 
proteins and Glutathione Sepharose® 4 Fast Flow beads to co-immunoprecipitate His- 
fusion proteins.  Protein amounts stated are approximations based on BSA standards from 
a Coomassie gel. 
1µg GST, GST-SUMO-1 or GST-SUMO-2 was mixed with 0.01µg His-Parkin in 500µL 
incubation buffer (50mM Tris pH 7.4, 150mM NaCl, 1% (v/v) Triton X-100, 0.1% (w/v) BSA 
and 1x protease inhibitors) in an Eppendorf tube.  The protein suspension was incubated 
on a spinning wheel at RT for 1 hour.  For each tube, 20µL Glutathione Sepharose® 4 Fast 
Flow beads were washed twice in 500µL wash buffer (50mM Tris pH 7.4, 150mM NaCl, 1% 
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(v/v) Triton X-100 and 1x protease inhibitors) by gently mixing and pelleting at 4000rpm, 
4°C, for 2 minutes.  Supernatant was aspirated from the beads and the protein suspension 
added.  The protein/bead suspension was incubated on a spinning wheel at 4°C for 1 hour.  
Beads were then pelleted as before and washed 3 times in 500µL wash buffer by 
resuspension, 10-minute incubation of spinning wheel at 4°C and pelleting as before.  After 
the final wash, supernatant was aspirated, and the beads resuspended in 40µL 2 x Laemmli 
buffer (4% SDS (w/v), 10% glycerol (v/v) 125mM Tris-HCl pH6.8, 0.004% bromophenol blue 
(w/v), 10% (v/v) 2-β-mercaptoethanol) and heated at 95°C, 1200rpm for 10 minutes.  
Samples were then subjected to SDS-PAGE and Western blotting, as described in Chapter 
2. 
5.2.2 Bacterial SUMOylation assay 
5.2.2.1 Fusion protein expression and SUMOylation in BL21 
(DE3) E. coli 
 BL21 (DE3) E. coli were transformed as described in Chapter 2 with either His-tagged 
protein only, or His-tagged protein and pE1E2-SUMO-1/SUMO-2 and plated on LB agar 
containing 25µg/mL kanamycin (single transformations) or 25µg/mL kanamycin and 34 
µg/mL chloramphenicol (double transformations).  Plates were incubated at 37°C 
overnight.  A single colony was then picked and incubated in 3mL 2xYT Broth containing 
appropriate selection antibiotics (25µg/mL kanamycin or 25µg/mL kanamycin and 34 
µg/mL chloramphenicol), at 37°C, shaking, overnight.  Protein expression (and fusion 
protein SUMOylation) was induced by addition of IPTG to a final concentration of 0.2mM, 
and further incubation at 25°C, shaking, for 6 hours. 
5.2.2.2 Assaying for in vitro SUMOylation 
5.2.2.2.1 SUMOylation assay using crude bacterial lysate 
Bacteria were pelleted at 4000rpm for 20 minutes at 4°C, the supernatant removed, 
and the pellet resuspended in 500µL 1x Laemmli buffer (2% SDS (w/v), 5% glycerol (v/v) 
62.5mM Tris-HCl pH6.8, 0.002% bromophenol blue (w/v), 5% (v/v) 2-β-mercaptoethanol).  
The lysate was then sonicated (5x 5 second bursts) and heated at 95°C, 1200rpm for 10 
minutes.  Samples were then subjected to SDS-PAGE and Western blotting, as described in 
Chapter 2. 
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5.2.2.2.2 SUMOylation assay using His-fusion purification 
SUMOylated, His-tagged fusion proteins were purified following a scaled down 
version of the protocol outlined in 5.2.1.3.  Briefly, a 2mL IPTG-induced culture was pelleted 
at 16,000xg for 1 minute and the supernatant discarded.  Each pellet was resuspended in 
500µL lysis buffer (25mM Tris pH 7.5, 150mM NaCl, 10% (v/v) glycerol, 1% (v/v) Triton X-
100, 10mM imidazole, 20mM NEM and 1x protease inhibitors) and sonicated with 2 bursts 
of 5 seconds.  Insoluble material was removed by centrifugation at 16,000xg for 10 
minutes.  2µL 2-β-mercaptoethanol was added to the cleared supernatant to quench 
unreacted NEM, before 30µL Ni-NTA Sepharose® 4 Fast Flow beads were added.  The lysate 
was incubated with the beads at 4°C for 1 hour, on a spinning wheel.  Beads were then 
pelleted (1180xg, 2 minutes) and washed 4 times with wash buffer (lysis buffer lacking 
protease inhibitors and NEM).  Wash buffer was aspirated and the beads resuspended in 
100µL 2 x Laemmli buffer.  Samples were heated at 95°C, 1200rpm for 10 minutes, and 
then subjected to SDS-PAGE and Western blotting, as described in Chapter 2.  This 
SUMOylation assay has been previously described (Wilkinson et al., 2008). 
5.2.3 Protein degradation assay 
In order to measure rates of protein degradation in HEK293T cells, protein synthesis 
must be blocked.  Protein translation elongation was inhibited by addition of a drug, 
cycloheximide (CHX).  HEK293T cells were cultured and transfected as described in Chapter 
2.  Protein synthesis was blocked by addition of 25µg/mL cycloheximide (Sigma-Aldrich) for 
up to 24 hours prior to cell lysis.  Western blotting was used to quantify rates of 
degradation.   
 
5.3 Results 
5.3.1 Parkin interacts with SUMO-1 and SUMO-2 
It was important to first ensure that the non-covalent Parkin-SUMO interaction 
identified previously by Um and Chung could be validated.  In their study, Parkin was shown 
to interact specifically with SUMO-1 and could not be co-immunoprecipitated with SUMO-
2 (Um and Chung, 2006).  I co-transfected HEK293T cells with Myc-Parkin and YFP, YFP-
SUMO-1 or YFP-SUMO-2, both full-length proteins and mutants lacking the C-terminal di-
glycine motif required for their conjugation (ΔGG (Bayer et al., 1998)).  48 hours post-
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transfection, GFP-Trap beads were used to immunoprecipitate YFP or YFP-SUMO, and 
samples were subjected to SDS-PAGE and Western blotting with an anti-Myc antibody to 
identify any co-immunoprecipitated Myc-Parkin.  As shown in Figure 5.2, Myc-Parkin was 
effectively co-immunoprecipitated with both YFP-SUMO-1 (A) and SUMO-2 (B).  
Interestingly, co-immunoprecipitation of Myc-Parkin was significantly less efficient with 
both the SUMO-1 and SUMO-2 ΔGG mutants that cannot be covalently attached to 
substrates (B and D), indicative of a preference for binding to poly-SUMOylated substrates, 
rather than free SUMO. 
 
5.3.2 Parkin may bind directly to SUMO-2 
The data presented in Figure 5.2 demonstrate that Parkin can specifically and non-
covalently interact with both SUMO-1 and SUMO-2.  In a cell-based model, however, it 
cannot be determined whether or not this is a direct interaction, which would be required 
Figure 5.2 Parkin binds SUMO-1 and SUMO-2 in HEK293T cells.  Exogenously expressed YFP- 
SUMO-1 or –SUMO-2 and, to a lesser extent, a non-conjugatable YFP-SUMO-1 or –SUMO-
2 ΔGG mutant, co-immunoprecipitated Myc-Parkin by GFP-Trap from HEK293T lysate, 
whereas YFP alone could not.  N=3. Analysed using unpaired two-tailed students’ t-test. 
Data presented as mean ± SEM.  *** p ≤ 0.001.  
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if Parkin were acting as a STUbL.  To examine the nature of this interaction, the proteins of 
interest need to be expressed within an isolated system. 
His-tagged Parkin and GST-tagged SUMO were expressed in BL21 (DE3) E. coli and 
then purified using Glutathione Sepharose® 4 Fast Flow (GST-proteins) or Ni-NTA 
Sepharose® 4 Fast Flow (His-proteins).   
Initially, GST- or His-tagged proteins were purified and subjected to SDS-PAGE, with 
Coomassie Blue used to stain the gel for total protein.  Known amounts of BSA were loaded 
as a standard, to allow relative estimation of concentration of the purified proteins.  As 
shown in Figure 5.3 (A), GST, GST-SUMO-1 and GST-SUMO-2 expressed well and were 
purified effectively.  However, His-Parkin could not be detected.  At this point, it was not 
known whether the bacteria had failed to efficiently produce His-Parkin, or if it had been 
lost at some point within the Ni-NTA Sepharose® 4 Fast Flow purification protocol.  To 
troubleshoot this, the process was repeated using freshly transformed bacteria, with 
samples removed at various points throughout the purification.  These samples were 
subjected to SDS-PAGE and Coomassie Blue staining as before (Figure 5.3 (B)).  His-Parkin 
could not be identified within the total bacterial lysate, nor did it appear to be within any 
of the eluted fractions or still stuck to the beads, raising concern that the construct was 
not being efficiently expressed.  However, when a 0.8% sample of the supposed purified 
His-Parkin eluate was transferred to PVDF membrane and blotted with a knock down-
validated Parkin antibody, a band of the correct molecular weight (55kDa) was readily 
detected (Figure 5.3(C)).  These results suggest that His-Parkin is expressed at much lower 
levels than the GST-tagged SUMO constructs and was not detected by Coomassie staining 
due to its relative insensitivity. 




Once pure recombinant proteins had been generated, in vitro binding assays were 
performed.  Using the Coomassie staining of GST and GST-SUMO alongside BSA standards, 
protein concentration was estimated so that the volume required for approximately 1µg 
each could be calculated.  This was then used in a binding assay with 0.01µg His-Parkin.  
Figure 5.3 Bacterial expression of GST-SUMO and His-Parkin.  GST, GST-SUMO and His-
Parkin were expressed in BL21 (DE3) E. coli and purified with Glutathione Sepharose® 4 
Fast Flow (GST-proteins) or Ni-NTA Sepharose® 4 Fast Flow (His-proteins).  0.8% samples 
of the eluate were then electrophoresed alongside known standards of BSA, and the gel 
stained with Coomassie (top panel).  His-Parkin could not be detected in the eluate, so the 
purification was repeated, with samples taken at various steps (bottom left panel, a-g (a) 
Bacterial lysate, (b) unbound protein (pre-wash), (c) unbound protein (after wash), (d) 
eluate 1, (e) eluate 2, (f) eluate 3, (g) beads)).  Coomassie was still not sufficient to visualise 
His-Parkin, however, when a 0.8% sample of the eluate was blotted with the Parkin 
antibody, a ~55kDa species was detected (bottom right panel). 
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GST or GST-SUMO was then precipitated using Glutathione Sepharose® 4 Fast Flow, and 
the samples used for SDS-PAGE and Western blotting. 
As shown in Figure 5.4, His-Parkin was co-purified with both GST-SUMO-1 and GST-
SUMO-2 to a greater extent than GST alone, but this difference was only statistically 
significant in the case of SUMO-2 (B).  Under these experimental conditions, it was not 
possible to fully displace the interaction between free GST and His-Parkin, so the data 
cannot be confidently interpreted.  Nonetheless, the binding capacity of GST-SUMO for 
Parkin was between two (SUMO-1) and four (SUMO-2) times that of free GST, so a direct 
interaction cannot be ruled out based on this experiment. 
 
 
5.3.3 Mff K151 is part of a stress-inducible PDSM 
As was shown in chapter 3, Mff is modified by covalent conjugation of both SUMO-
1 and SUMO-2.  The single site of SUMO modification was identified as lysine 151.  Upon 
closer inspection of the SUMOylation site, it became apparent that it is not a regular SUMO 
consensus motif, but rather part of a phosphorylation-dependent SUMOylation consensus 
motif (PDSM). 
In a PDSM, phosphorylation of a nearby serine, in this case at reside 155, facilitates 
SUMOylation at the lysine, 151 in Mff, as shown diagrammatically in Figure 5.5.  To test 
whether this conserved sequence within Mff does act as a PDSM, a series of mutants were 
Figure 5.4 Parkin interacts with SUMO in vitro.  GST-SUMO-2, but not GST-SUMO-1, was 
able to co-immunoprecipitate His-Parkin significantly more than free GST in vitro.  N=6. 
Analysed using ordinary one-way ANOVA with Tukey’s correction for multiple comparisons 
with a pooled variance. Data presented as mean ± SEM.  * p < 0.05, ** p < 0.01. 
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generated.  In addition to the K151R non-SUMOylatable mutant already described, an 
E153A mutant was made to disrupt the SUMOylation consensus motif, whilst preserving 
the SUMOylatable lysine residue.  In this mutant, Ubc9 binding is abolished, rendering the 
protein non-SUMOylatable (Sampson et al., 2001, Gareau and Lima, 2010).  Mutations of 
the phosphorylatable serine were also generated: a phospho-null (S155A) and a phospho-
mimetic, wherein aspartate mimics the charge (S155D).  I then analysed the relative levels 
of SUMOylation of these mutants compared to the WT (Figure 5.6). 
 
Figure 5.5 Schematic of Mff PDSM. 




Figure 5.6 Mff mutants are differentially SUMOylated in HEK293T cells.  CFP-Mff WT and 
mutants were exogenously expressed in HEK293T cells and immuno-precipitated with GFP-
Trap.  Samples were then blotted for endogenous SUMO-1 or SUMO-2/3. N=3.  Analysed 
using one-way ANOVA (each mutant compared to WT) with Dunnett’s correction for 
multiple comparisons.  Data presented as mean ± SEM. ** p < 0.01, *** p < 0.001, **** p 
< 0.0001. 
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As shown in Figure 5.6, the various mutants of Mff were differentially SUMOylated, 
both by SUMO-1 and SUMO-2/3, compared to the WT (B, C).  In the cases of SUMO-1 and 
SUMO-2/3, mutation of K151 or E153 abolished SUMOylation, whilst the phospho-null 
S155A mutation significantly reduced SUMO-2/3-ylation, as would be expected with the 
PDSM model.  The phospho-mimetic mutation, S155D, behaved as expected for SUMO-1, 
resulting in a significant increase in SUMOylation of Mff (B).  Curiously, this was not the 
case for SUMO-2/3, where a significant decrease in SUMOylation compared to WT was 
observed. 
Phosphorylation often occurs as part of a stress response (Wang et al., 2012b, 
Auciello et al., 2014).  In the case of Mff, and other PDSM-containing proteins, 
phosphorylation leads to increased SUMOylation.  This raised the question: does cellular 
stress result increase Mff SUMOylation?  In particular, we were interested in ischaemic 
stress, so we used oxygen and glucose deprivation (OGD) as a stressor. 
HEK293T cells expressing GST-Mff WT were used for immunoprecipitation 
experiments with Glutathione Sepharose® 4 Fast Flow.  Prior to lysis, cells were subjected 
to 2 hours of OGD in de-oxygenated, glucose-free media in an anoxic chamber at 37°C.  
Control cells were incubated in fresh, oxygenated, glucose-containing media in a normal 
cell culture incubator at 37°C for the same period of time.  Western blots were then used 
to quantify endogenous SUMO-1-ylation of Mff.  Figure 5.7 shows a representative blot 
and quantification of this experiment.  Insufficient repeats have been performed so far to 
allow statistical analysis, but preliminary data indicate a ~100% increase in Mff SUMO-1-
ylation during ischaemia (B), indicative of a mechanism whereby stress-induced 
phosphorylation of Mff promotes its SUMOylation. 
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5.3.4 Parkin does not ubiquitinate Mff K151R 
My data show that Parkin can bind to SUMO (Figure 5.2, Figure 5.4 ) and that Mff 
can be SUMOylated (Figure 3.14). Thus, this raised the question: does Mff SUMOylation 
regulate its interactions with Parkin?  Specifically, does SUMOylation of Mff enhance 
Parkin-mediated ubiquitination?  To test this hypothesis, HEK293T cells were co-
transfected with CFP-Mff WT or K151R, along with scrambled (control) or Parkin-targeted 
shRNA.  72 hours post-transfection, cells were lysed, and the lysate used in GFP-Trap 
immunoprecipitation experiments, to identify Mff PTMs. 
Figure 5.8 shows that the non-SUMOylatable Mff mutant K151R has significantly reduced 
ubiquitination compared to the WT (B).  As shown previously, knock down of Parkin 
significantly reduces ubiquitination of WT Mff.  However, knock down of Parkin has no 
significant effect of ubiquitination of Mff K151R, indicating that this mutant is insensitive 
to modification by Parkin. 
Figure 5.7 Mff SUMOylation is increased during ischaemia.  HEK293T cells were transfected 
with GST-Mff (WT) and lysed 48-hours later.  For 2 hours prior to lysis, cells were kept in 
either control or OGD conditions.  Lysates were used for GST-immunoprecipitation (IP) and 
immunoblotted (IB) for endogenous SUMO-1.  Data presented as mean ± SEM.  N = 2.  IP 
and Western blots performed by Richard Seager. 




Figure 5.8 Parkin ubiquitinates WT Mff, but not a non-SUMOylatable mutant of Mff. GFP-
pulldowns of exogenously expressed CFP-Mff WT or K151R in HEK293T cells reveal that the 
K151R mutant has significantly reduced endogenous ubiquitination compared to the WT.  
Knockdown of Parkin significantly reduces ubiquitination of WT CFP-Mff, but not CFP-Mff 
K151R.    N=6.  Analysed using ordinary two-way ANOVA with Tukey’s correction for 
multiple comparisons with a pooled variance.  * p < 0.05,  ** p ≤ 0.01. 
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5.3.5 Fbxo7 does ubiquitinate Mff K151R 
In chapter 4, I demonstrated that Parkin and Fbxo7 contributed equally and 
independently to ubiquitination of Mff WT.  There is no literature available on any 
interactions between Fbxo7 and SUMO, so I tested if Fbxo7 could ubiquitinate the non-
SUMOylatable Mff K151R.  HEK293T cells were co-transfected with CFP-Mff K151R, along 
with shRNA targeted to Parkin, siRNA targeted to Fbxo7, or both.  GFP-Trap was again used 
to immunoprecipitate CFP-Mff, and samples were Western blotted for ubiquitin. 
Consistent with Figure 5.8, Figure 5.9 shows that knock down of Parkin has no effect 
on ubiquitination of CFP-Mff K151R.  However, knock down of Fbxo7 significantly reduces 
ubiquitination of CFP-Mff K151R (B).  Knock down of both Parkin and Fbxo7 does not 
reduce ubiquitination significantly more than knock down of Fbxo7 alone.  This suggests 
that Fbxo7-mediated ubiquitination of Mff is SUMO-independent and occurs at a site other 
than K151. 




Figure 5.9 Fbxo7, but not Parkin, ubiquitinates non-SUMOylatable Mff. GFP-pulldowns of 
exogenously expressed CFP-Mff K151R in HEK293T cells with scrambled (control, SCR) 
shRNA, Parkin-targeted shRNA, Fbxo7-targeted siRNA, or both.  N=4.  Analysed using 
ordinary one-way ANOVA with Tukey’s correction for multiple comparisons with a pooled 
variance.  Data presented as mean ± SEM.  * p < 0.05, ** p ≤ 0.01. 
 
 
Chapter 5 SUMO regulates mitochondrial dynamics 
171 
 
Data presented so far have shown that Fbxo7 contributes to ubiquitination of both 
WT and K151R Mff, whereas Parkin contributes to ubiquitination of only WT Mff.  This 
raised the question of whether Fbxo7 contributes equally to ubiquitination of WT and 
K151R Mff, or if Fbxo7 could have preference for non-SUMOylated Mff.  To answer this 
question, the differences between WT and K151R ubiquitination with or without Fbxo7 
knock down were compared.  However, as can be seen in Figure 5.10, Fbxo7 did not show 
a preference for WT or K151R Mff, contributing equally to ubiquitination of both. 
 
   
5.3.6 Parkin as a proposed STUbL for Mff 
Given the demonstrable interaction of Parkin with SUMO, and the insensitivity of a 
non-SUMOylatable mutant of Mff to Parkin ubiquitination, a model for Parkin as a SUMO-
targeted ubiquitin ligase (STUbL) of Mff was proposed.  A schematic of this model is shown 
in Figure 5.11.  In this model, phosphorylation of Mff at serine 155 enhances/promotes 
SUMOylation at lysine 151.  A SUMO-interacting motif (SIM) in Parkin recognises 
SUMOylated Mff, allowing recruitment of Parkin to Mff to catalyse its ubiquitination via the 
active cysteine, C431.  The only published site of Parkin-mediated ubiquitination of Mff is 
lysine 302, as shown in this model (Gao et al., 2015).  In their study, Gao et al demonstrated 
that K302 is the only ubiquitin-modified reside in Mff, showing that K302 mutation 
completely abolished Mff ubiquitination.  However, this does not rule out the possibility 
that there are additional and/or alternative sites of Parkin-dependent ubiquitination.  
Figure 5.10 Fbxo7 ubiquitinates WT and K151R Mff equally.  The average difference 
between scrambled control samples and Fbxo7 knock down samples for CFP-Mff 
ubiquitination, WT and K151R, were calculated and compared using an unpaired two-tailed 
Student’s t-test.  No significant difference was observed.  N=4-6.  Data presented as mean 
± SEM. 





To test this model, I performed a binding assay in HEK293T cells using expressed 
untagged Parkin and CFP-tagged Mff mutants.  48 hours post-transfection, GFP-Traps were 
used to immunoprecipitate CFP-Mff.  Samples were then Western blotted to see which of 
the Mff mutants were able to co-immunoprecipitate Parkin.  If this model is correct non-
SUMOylatable K151R and E153A mutants would show reduced Parkin binding compared 
to the WT, and the SUMO-enhancing S155D mutant would be increased binding of Parkin.  
However, as can be seen in Figure 5.12, Parkin binding was not significantly different for 
any of the Mff mutants compared to the WT, suggesting that its phosphorylation and/or 




Figure 5.11 Proposed model of Parkin as a STUbL for Mff (1).  Phosphorylation of S155 
of Mff enhances SUMOylation of K151.  SUMOylation of K151 of Mff facilitates 
recruitment and/or binding of Parkin via its SIM.  Recruited Parkin can then 
ubiquitinate Mff at K302, via its catalytic site at C431.  SUMOylation of Mff thereby 
promotes its Parkin-dependent ubiquitination. 





Although the data presented in Figure 5.12, do not fit the proposed model of Parkin 
as a STUbL, previously shown data, namely Figure 5.8, have indicated that Parkin 
preferentially acts upon SUMOylatable Mff.  It was therefore hypothesised that Parkin may 
not require Mff to be SUMOylated for binding, but SUMOylation of Mff might activate or 
enhance Parkin-dependent ubiquitination.  I modified the model such that Parkin could 
bind to Mff directly, but in an inactive conformation, which required binding to SUMO to 
expose the catalytic site.  This model is shown in Figure 5.13. 
Figure 5.12 Parkin binds equally to all CFP-Mff mutants in HEK293T cells. Exogenously 
expressed CFP-Mff WT, K151R, E153A, S155A and S155D were all able to co-
immunoprecipitate untagged Parkin from HEK293T cells using GFP-Trap.  N=9.  Analysed 
using one-way ANOVA (each mutant compared to the WT) with Dunnett’s correction for 
multiple comparisons.  Data presented as mean ± SEM. 





Figure 5.13 Proposed model of Parkin as a STUbL for Mff (2).  Parkin can bind to Mff via a 
site other than its SIM.  However, binding in this manner does not bring the catalytic site 
of Parkin into proximity with its ubiquitination site on Mff, K302 (A).  When Parkin cannot 
bind to SUMO via its SIM, its conformation remains closed such that the catalytic site is 
inaccessible for efficient ubiquitination (B).  Phosphorylation of S155 of Mff enhances 
SUMOylation of K151.  Binding of Parkin to SUMO via its SIM induces a conformational 
change that exposes the catalytic site, allowing ubiquitination of Mff (C). 
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In this new model, binding of Parkin to Mff would be unaffected by the SUMOylation 
status of Mff, with Parkin binding via a site other than its predicted SIM. In this 
conformation, the active cysteine of Parkin is not only spatially sequestered away from the 
site of Mff ubiquitination, but also buried within an inaccessible cleft (Figure 5.13 (A)).  
Similarly, when Parkin is in close proximity to Mff, but not SUMO-bound, the conformation 
of Parkin remains such that the active cysteine is inaccessible (B).  Binding of Parkin to 
SUMOylated Mff, via its SIM, induces a conformational change that opens up the active 
site of Parkin, making the active cysteine both accessible and spatially available to catalyse 
ubiquitination of Mff (C). 
5.3.7 Ubiquitination and turnover of Mff 
This modified model predicts that SUMOylation of Mff would enhance its 
ubiquitination by Parkin.  To see if this was reflected in total ubiquitination of Mff, HEK293T 
cells were transfected with CFP-Mff mutants and lysed 48 hours post-transfection.  GFP-
Traps were used to immunoprecipitate CFP-Mff and its covalent attachments, including 
ubiquitination.   Figure 5.14 shows, as previously shown in Figure 5.8, that the non-
SUMOylatable K151R mutant of Mff has significantly reduced ubiquitination.  This is also 
true of the non-SUMOylatable E153A mutant.  However, the phospho-null (S155A) and 
phospho-mimetic (S155D) mutants do not show significantly different ubiquitination from 
the WT (B).  In the absence of proteasome/autophagy blockers, we cannot rule out the 
possibility that some of these mutants are more heavily ubiquitinated, but then more 
rapidly degraded, resulting in the reduced ubiquitin signal observed. 
 
 




Figure 5.14 shows that non-SUMOylatable mutants of Mff are significantly less 
ubiquitinated than WT Mff.  We therefore hypothesised that non-SUMOylatable Mff could 
be more stable since they would be less susceptible to Parkin-mediated ubiquitin tagging 
and degradation.  To test this, HEK293T cells transfected with either WT or non-
SUMOylatable CFP-Mff (K151R) were treated with cycloheximide (CHX) to block protein 
synthesis.  This allowed the rate of protein degradation to be measured.  The results are 
shown in Figure 5.15.  The experiment has not yet been performed enough times to be 
properly quantified or statistically tested, however, the data obtained so far suggest that 
CFP-Mff K151R is more stable than CFP-Mff WT over 24 hours (Figure 5.15 (B)).    
 
Figure 5.14 Mff mutants are differentially ubiquitinated in HEK293T cells.  CFP-Mff WT and 
mutants were exogenously expressed in HEK293T cells and immuno-precipitated with GFP-
Trap.  Samples were then blotted for endogenous ubiquitin. N=3/4.  Analysed using one-
way ANOVA (each mutant compared to WT) with Dunnett’s correction for multiple 
comparisons. Data presented as mean ± SEM. * p < 0.05. 
 




5.3.8 Parkin ubiquitinates Mff at K151 
None of the data presented thus far preclude the possibility that Parkin may 
ubiquitinate Mff at the same residue as its SUMOylation site, lysine 151, perhaps 
competing with the SUMO ligase.  If this were the case, it might be expected that knock 
down of Parkin would increase SUMOylation of Mff.  To test this possibility, SUMOylation 
of WT Mff in the presence or absence of Parkin was compared. 
HEK293T cells were co-transfected with CFP-Mff WT and shRNA targeted to Parkin, 
or a scrambled shRNA control.  72 hours post-transfection, cells were lysed, and the lysates 
used in GFP-Trap immunoprecipitations.  SDS-PAGE was performed, and samples blotted 
for SUMO-1.  As shown in Figure 5.16, no significant difference was detected in the 
intensity of the primary SUMO band (arrow, (C)).  A significant decrease was observed in 
the higher molecular weight SUMO-reactive smear, consistent with this comprising SUMO 
and ubiquitin mixed chains (bracket, (B)). 
 
Figure 5.15 Stability of WT vs K151R CFP-Mff.  HEK293T cells were transfected with either 
CFP-Mff WT or a non-SUMOylatable CFP-Mff K151R mutant.  Prior to lysis 72 hours post-
transfection, cells were treated with 25µg/mL cycloheximide (CHX) for 0, 4, 6, 8, 12 or 24 
hours (0-hour CHX received 6-hour DMSO treatment).  Lysates were then Western blotted 
for GFP (CFP-Mff) and β-actin.  Data presented as mean ± SEM (where appropriate).  N=2-
4. 




The apparent lack of competition between SUMO and ubiquitin at K151 of Mff does 
not conclusively rule out the possibility that both modifications target the same residue.  
To explore this, HEK293T cells were co-transfected with WT, K151R or E153A CFP-Mff and 
scrambled- or Parkin-targeted shRNA.  CFP-Mff E153A retains the SUMOylatable lysine 
residue, K151, but remains non-SUMOylatable due to disruption of the SUMO consensus 
sequence.  It was shown in Figure 5.8 that CFP-Mff K151R is insensitive to Parkin knock 
down, indicating that Parkin does not ubiquitinate that mutant.  However, this could be 
due to the lack of K151 or the absence of SUMO conjugated to K151. 
Figure 5.17 shows representative Western blots of GFP-Trap immunoprecipitation 
experiments.  As already demonstrated in Figure 5.8, knock down of Parkin significantly 
reduces ubiquitination of WT CFP-Mff, but does not affect CFP-Mff K151R.  However, 
Parkin knock down also significantly reduces endogenous ubiquitination of CFP-Mff E153A 
(Figure 5.17), suggesting that it is the lysine residue, rather than its ability to be 
Figure 5.16 Parkin knock down reduces CFP-Mff SUMO-Ubiquitin chains but not 
SUMOylation. GFP-pulldowns of exogenously expressed CFP-Mff in HEK293T. (B) proposed 
mixed SUMO-Ubiquitin chains (bracket on (A)). (C) primary SUMOylation (arrow in (A)).  
N=6.  Analysed using unpaired two-tailed students’ t-test. Data presented as mean ± SEM. 
* p < 0.05. 
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SUMOylated, that is required for Parkin-dependent ubiquitination of Mff.  Contrary to 
previous work, this suggests that K151 is modified by Parkin (Gao et al., 2015).  
 
5.3.9 Parkin can be SUMOylated 
Parkin is known to be subject to regulation by PINK1-mediated phosphorylation at 
serine 65, within its ubiquitin-like domain, and binding to PINK1-phosphorylated ubiquitin 
Figure 5.17 Parkin ubiquitinates Mff at K151. GFP-pulldowns of exogenously expressed CFP-
Mff in HEK293T cells Total ubiquitination of CFP-Mff WT or CFP-Mff E153A is significantly 
decreased by knockdown of Parkin, but CFP-Mff K151R is not affected. N=8-10. Analysed 
using ordinary two-way ANOVA with Sidak’s and Tukey’s corrections for multiple 
comparisons with a pooled variance. Data represented as mean ± SEM. * p < 0.05, ** p < 
0.01, **** p < 0.0001. 
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(Chaugule et al., 2011, Riley et al., 2013, Trempe et al., 2013, Wauer and Komander, 2013).  
However, Parkin has not previously been shown to be a target of SUMOylation. 
HEK293T cells were transfected with YFP-SUMO and Myc-Parkin and the lysates 
used for GFP-Trap co-immunoprecipitation experiments, as shown in Figure 5.2.  For Figure 
5.18, the non-covalently bound Parkin was allowed to saturate on the Western blots, 
revealing higher molecular weight, Parkin-reactive species, indicated by arrows.  These 
bands were not present in samples containing non-conjugatable -ΔGG SUMO mutants, 
indicating that they represent covalently attached SUMO-1 and SUMO-2 (A and B, 
respectively). 
 
As this has not previously been shown, it was important to validate the finding in 
more than one system.  BL21 E. coli were transformed with DNA encoding His-T7-Parkin, 
either alone, or with a plasmid encoding SUMO-1 or SUMO-2, along with the SUMOylation 
machinery (E1E2-SUMO).  The bacteria were then lysed, and the lysates used for Western 
blotting, using an anti-T7 antibody.  T7 is a small peptide tag, encoded in between the His-
tag and Parkin in the pXLG3 expression plasmid used. 
Figure 5.19 shows a representative blot of the experiment.  His-Parkin was detected 
as a 55kDa band using the T7 antibody in all samples.  Also detected were bands of around 
70kDa with the addition of E1E2-SUMO-1 or -SUMO-2, and two further bands around 
Figure 5.18 Parkin can be SUMO-1-ylated and SUMO-2/3-ylated in HEK293T cells. 
Exogenously expressed YFP-SUMO-1 and -2, but not non-conjugatable YFP-SUMO-1 and -
2 ΔGG mutants, were able to co-immunoprecipitate Myc-Parkin at not only its unmodified 
molecular weight, but also higher (>100 kDa) Parkin- and YFP-reactive molecular weight 
bands by GFP-Trap from HEK293T lysate. N=4 (SUMO-1) and N=3 (SUMO-2). 
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100kDa with the addition of E1E2-SUMO-1, indicated by arrows.  In particular, the bands 




The data presented in this chapter demonstrate a role for SUMO in both Parkin 
activity and Mff stability.  However, it remains unclear if SUMO plays a part in the regulation 
of Mff by Parkin. 
5.4.1 Parkin interacts non-covalently with SUMO 
A 2006 study had reported that Parkin could form a non-covalent interaction with 
SUMO-1, but not SUMO-2, and that this interaction modulates Parkin function (Um and 
Chung, 2006).  To validate these findings, Myc-Parkin and YFP-SUMO-1/-2 were co-
expressed in HEK293T cells and GFP-Trap used to immunoprecipitate YFP-SUMO.  As 
expected, based on the publication by Um and Chung, YFP-SUMO-1 was able to co-
immunoprecipitate Myc-Parkin (Figure 5.2 (A)).  Surprisingly, the same was true of YFP-
SUMO-2 (C).  In both cases, no/minimal binding was detected between Myc-Parkin and 
YFP, precluding the possibility of binding between Myc-Parkin and the GFP-Trap beads or 
YFP alone and indicating that the stringency of the experimental conditions was sufficient 
to exclude non-specific interactions. 
Figure 5.19 Parkin can be SUMO-1-ylated and SUMO-2-ylated in bacteria.  Full length His-
tagged Parkin was expressed in BL21 (DE3) E. coli, either alone, or with a vector encoding 
the SUMOylation machinery and either SUMO-1 or SUMO-2.  Bacteria were lysed, and the 
samples used for Western blotting. 
Chapter 5 SUMO regulates mitochondrial dynamics 
182 
 
In co-immunoprecipitation experiments with YFP-SUMO-1 and YFP-SUMO-2, Myc-
Parkin favoured binding to WT SUMO over the non-conjugatable ΔGG mutant (Figure 5.2 
(B, D)).  As these experiments were performed in cells rather than in a reduced system, WT 
YFP-SUMO can be conjugated to substrate proteins by endogenous SUMOylation 
machinery.  These results could therefore indicate that Parkin preferentially associates with 
SUMOylated proteins, rather than free SUMO. 
While co-immunoprecipitations from HEK293T cells are sufficient to demonstrate 
specific binding between Parkin and SUMO, they cannot discriminate between direct and 
indirect binding on account of the presence of endogenous proteins.  The original study by 
Um and Chung demonstrated Parkin-SUMO binding both in cell lines and in rat cortex, but 
not in a reduced system (Um and Chung, 2006).  For this reason, it was decided that in vitro 
binding assays should be performed to determine the nature of the Parkin-SUMO 
interaction. 
    His-tagged Parkin and GST-tagged SUMO recombinant proteins were expressed 
and purified from BL21 (DE3) E. coli.  These could then be used for in vitro binding assays.  
Glutathione Sepharose® 4 Fast Flow was used to pull down GST, GST-SUMO-1 or GST-
SUMO-2 from an in vitro binding solution containing His-Parkin.  As shown in Figure 5.4, 
GST-SUMO-1 did not bind significantly more His-Parkin than GST alone, whereas GST-
SUMO-2 did.  These data indicate that binding between Parkin and SUMO-2 is likely to be 
direct.  However, the conditions used in these experiments were insufficiently stringent to 
discern direct binding between Parkin and SUMO-1 from non-specific binding of Parkin to 
GST.  This could merely indicate that the experimental set-up was unsuitable, or that Parkin 
can bind directly to SUMO-2, but only indirectly to SUMO-1, either conjugated to a 
substrate protein or as part of a SUMO-chain.  In future, alternative experimental 
conditions could be used to determine whether or not there is a significant binding of 
Parkin to SUMO-1 in vitro by removing non-specific Parkin-GST binding.  This could include 
increasing detergent and/or salt concentration in the binding and wash buffers, increasing 
the length and/or number of washes, decreasing the concentration of proteins, reducing 
the incubation time of the binding reaction or decreasing the temperature of the binding 
reaction.   
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5.4.2 Phosphorylation and ischaemic stress 
regulate Mff SUMOylation 
With K151 of Mff identified as the only SUMOylated residue, we explored the site in 
greater detail.  The residues around K151 were found to conform to a phosphorylation-
dependent SUMOylation consensus motif, or PDSM (Hietakangas et al., 2006).  Figure 5.5 
details the PDSM model, with phosphorylation of Mff at S155 enhancing SUMOylation at 
K151. 
Once the nature of the SUMOylated residue had been identified as part of a PDSM, 
we sought to confirm that it acted as such.  For this, a series of CFP-tagged Mff mutants 
were generated.  These included two non-SUMOylatable Mff mutants, K151R and E153A, 
a phospho-null mutant, S155A, and a phospho-mimetic mutant, S155D (Dr Kevin Wilkinson 
and Richard Seager).  CFP-Mff E153A retains the SUMOylatable lysine residue, K151, but 
cannot be SUMOylated due to disruption of the SUMOylation consensus motif precluding 
binding of the SUMOylation machinery.  The S155A phospho-null mutant replaces 
phosphorylatable serine with non-phosphorylatable alanine, blocking phosphorylation at 
that site; the S155D phospho-mimetic mutant equally cannot be phosphorylated at that 
site, but mimics the charge of a phosphate group by replacement of serine with aspartic 
acid. 
The CFP-Mff mutants were transfected into HEK293T cells, and the CFP-Mff 
immunoprecipitated using GFP-Trap 48 hours later.  Western blotting was used to quantify 
the endogenous SUMOylation of the mutants relative to the WT.  Figure 5.6 shows 
representative blots and quantifications of SUMO-1-ylation and SUMO-2/3-ylation.  As 
expected, both the K151R and E153A mutant have no detectable SUMO-1- or SUMO-2/3-
ylation (B, C).  This is consistent with data shown in Chapter 3 indicating that K151 is the 
sole SUMOylated residue of Mff.  If the region surrounding K151 does conform to a 
functional PDSM, it would be expected that replacement of the phosphorylatable serine, 
S155, with a non-phosphorylatable residue would decrease or abolish SUMOylation at 
K151.  As shown in (C), SUMO-2/3-ylation of CFP-Mff S155A is significantly reduced 
compared to the WT.  A similar pattern is evident for SUMO-1-ylation (B), though this is 
not statistically significant, possibly due to the greater variance in WT SUMO-1-ylation 
compared to SUMO-2/3-ylation observed in the experiments. 
It was unclear whether replacement of S155 with aspartic acid would result in 
enhanced SUMOylation at K151.  While the charge of a phosphate group can be mimicked 
using a charged residue, as in the case of S155D, the replacement does not truly mimic the 
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electrostatic or structural qualities of phosphoserine.  Furthermore, phosphorylation in 
vivo is a transient modification, often only occurring in response to certain stimuli, which 
takes place only post-translationally.  A phospho-mimetic mutant is permanently 
‘stimulated,’ and may therefore not be particularly informative about the role of protein 
phosphorylation.  Incorporation of the charged mimic residue during protein translation 
could also result in protein misfolding, further confounding its study (Stateva et al., 2015).   
Nonetheless, it would be expected that the phospho-mimetic CFP-Mff S155D 
mutant would have increased SUMOylation compared to the WT, in keeping with its role 
as part of a PDSM.  As evident from Figure 5.6, SUMO-1-ylation of Mff was significantly 
increased by the S155D mutation, compared to the WT (B) but SUMO-2/3-ylation, 
interestingly, was significantly decreased compared to the WT (C).  This could be due to an 
occlusion mechanism, whereby the increased SUMO-1-ylation of Mff at K151 out-
competes SUMO-2/3 and hinders Mff SUMO-2/3-ylation.  However, this is unlikely due to 
the 10-fold greater expression of SUMO-2/3 in mammalian cells, compared to SUMO-1 
(Saitoh and Hinchey, 2000).  Another explanation could be the far greater off-on rate of 
SUMO-2/3 compared to SUMO-1 (Flotho and Melchior, 2013, Kolli et al., 2010).  This makes 
SUMO-2/3-ylation far less stable than SUMO-1-ylation and may therefore make it more 
easily lost during immunoprecipitation or more difficult to detect by Western blotting. 
With Mff now shown to have a PDSM, and up-regulated phosphorylation being a 
known marker of cellular stress, we proposed that Mff SUMOylation might also increase 
under conditions of stress (Auciello et al., 2014, Wang et al., 2012b).  Data from ex vivo 
modelling in the whole heart, presented in Chapter 3, identified a ~55kDa SUMO-1-reactive 
species that was significantly increased during ischaemia.  We speculated that this species 
could represent SUMOylated Mff.  Using a cellular model of ischaemia, OGD, the 
experiment detailed in Figure 5.7 sought to determine if Mff SUMOylation could be a stress 
response. 
Although the data presented in Figure 5.7 cannot yet be statistically analysed due to 
insufficient repeats, it appears that OGD does lead to a 2-fold increase in SUMO-1 
conjugation to Mff (B).  In the future, it would be pertinent to see if this increase in 
SUMOylation is indeed due to an increase in phosphorylation.  We know that the kinase 
responsible for phosphorylating Mff at S155 (and S172) is adenosine monophosphate 
(AMP)–activated protein kinase (AMPK), which is activated under conditions of low 
intracellular ATP, usually associated with cellular stress, by binding of AMP (Toyama et al., 
2016).  In future, Western blotting of OGD samples for activation of AMPK, measured as an 
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increase in phosphorylated AMPK, would help to define this pathway.  Samples taken at 
different timepoints in OGD should reveal a spike in AMPK phosphorylation, followed by 
the increase in Mff SUMOylation.   It would also be interesting to test if SUMOylation of 
the phospho-null Mff mutant, S155A, can be increased by OGD; if it cannot, this would 
indicate that the upregulation of SUMOylation is dependent on upregulation of 
phosphorylation as a result of ischaemic stress.     
5.4.3 Fbxo7 ubiquitinates Mff at a site other than 
K151 
Data shown in Chapter 4 indicated that Parkin and Fbxo7 independently ubiquitinate 
Mff WT, with their simultaneous knock down having an additive effect on depletion of Mff 
ubiquitination.  Additionally, data shown in this chapter (Figure 5.2, Figure 5.4) and 
previously published work have detailed a specific SUMO-binding capacity for Parkin (Um 
and Chung, 2006).  We postulated that SUMOylation of Mff could be regulating its 
ubiquitination, by recruitment of one or more SUMO-targeted ubiquitin ligases (STUbLs). 
Parkin knock down was performed in HEK293T cells expressing either WT or K151R 
CFP-Mff.  72 hours post-transfection, cells were lysed, and GFP-Trap used to 
immunoprecipitate CFP-Mff.  These samples were then used for Western blotting and 
probed with a universal ubiquitin antibody.  Figure 5.8 shows a representative blot and 
quantification.  As shown in Chapter 4, knock down of Parkin significantly decreases 
ubiquitination of WT Mff.  However, there was no significant effect on ubiquitination of the 
non-SUMOylatable mutant, K151R.  This could indicate that SUMOylation of Mff is required 
to recruit Parkin, or that Parkin ubiquitinates Mff at K151.  However, given the Parkin-
SUMO binding data, it seemed likely that the former could be true, with Parkin acting as a 
STUbL for Mff. 
Parkin and Fbxo7 contribute independently and equally to ubiquitination of WT Mff 
(Chapter 4).  With Parkin not able to target CFP-Mff K151R, it was hypothesised that Fbxo7 
might compensate, not least because over-expression of Fbxo7 has been previously shown 
to rescue the phenotype of Parkin-null Drosophila melanogaster (Burchell et al., 2013).  We 
proposed that Parkin may target only SUMOylated Mff, while Fbxo7 could preferentially 
ubiquitinate non-SUMOylated Mff.  HEK293T cells were co-transfected with CFP-Mff K151R 
and control sh/siRNA, Parkin-targeted shRNA, Fbxo7-targeted siRNA, or both.  As shown in 
Figure 5.9  (and Figure 5.8), the non-SUMOylatable Mff mutant was insensitive to Parkin 
knock down.  However, knock down of Fbxo7 significantly reduced its ubiquitination ( (B)).  
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These data support a role for Fbxo7 in ubiquitination of Mff that is independent of K151 
and suggest that Fbxo7 targets a different site(s) of Mff. 
    If Fbxo7 were to compensate for loss of Parkin-dependent ubiquitination of Mff 
K151R, it would stand to reason that Fbxo7 would favour this non-SUMOylatable mutant 
over the WT.  To test this, the differences in Mff ubiquitination upon knock down of Fbxo7 
for WT and K151R were compared (Figure 5.10).  Disappointingly, there was no significant 
difference in reduction of Mff ubiquitination upon Fbxo7 knock down between the WT and 
K151R mutant.  The most likely reason for this is that, in the case of Mff, Parkin and Fbxo7 
are neither complementary nor compensatory, but rather they act independently to target 
different lysine residues. 
5.4.4 Parkin as a proposed STUbL 
So far, the only study to have identified a specific lysine residue of Mff targeted for 
ubiquitination showed a single site to be the only Parkin-targeted, and the only 
ubiquitinatable, residue.  In their study, which used a shorter Mff isoform, the authors 
identified K251, which corresponds to K302 in the full-length isoform used in our work (Gao 
et al., 2015).  We therefore proposed a model whereby SUMOylation of Mff at K151 acts 
to recruit Parkin, which then ubiquitinates Mff downstream at K302 (Figure 5.11).  There 
remains no experimentally derived structure for Mff, so the spatial feasibility of this model 
cannot be commented upon.  Additionally, the site of SUMO-binding within Parkin has not 
yet been identified, so it is unclear whether this SIM is sufficiently far from the active 
cysteine (C431) of Parkin for this model to be achievable. 
In the first proposed model, SUMOylation at K151 of Mff is required for binding of 
Parkin, through its as-yet unidentified SIM.  To test this, Parkin binding to Mff was 
experimentally measured.  Free GFP, CFP-Mff WT, K151R, E153A, S155A or S155D were co-
transfected into HEK293T cells with untagged Parkin.  In line with the proposed model, we 
expected that Mff K151R and E153A would be unable to co-immunoprecipitate Parkin, and 
that Mff S155A might have a reduced Parkin-binding capacity.  Similarly, we expected Mff 
S155D to have equal or greater Parkin-binding capacity to WT Mff.  However, as shown in 
Figure 5.12, this was not the case; no significant differences in binding were detected 
between any mutant and the WT Mff.  This indicates the neither SUMOylation nor 
phosphorylation of Mff plays a part in Parkin recruitment/binding. 
In light of this, a new model was proposed in which SUMOylation of Mff K151 is not 
required for binding of Parkin but is required for activation/enhancement of its Parkin-
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dependent ubiquitination (Figure 5.13).  In this newer model, Parkin can bind to Mff via a 
site other than its proposed SIM but cannot efficiently ubiquitinate Mff.  This could be due 
to the spatial arrangement of the proteins, meaning that the active site of Parkin is too far 
away from its target lysine on Mff to efficiently ubiquitinate, or it could be that binding of 
Parkin to SUMO induces a conformational change that makes its active site more readily 
accessible.  In this way, binding of Parkin and Mff is unaffected by the SUMOylation status 
of Mff, but ubiquitination of Mff, at least by Parkin, is enhanced by SUMOylation at K151. 
5.4.5 SUMOylation of Mff enhances its 
ubiquitination and rate of turnover 
Under the newly proposed model, ubiquitination of Mff would depend at least in 
part on its SUMOylation.  We therefore expected that the non-SUMOylatable mutants and 
phospho-null mutant of Mff would have reduced ubiquitination compared to the WT, and 
that the phospho-mimetic would have more.  CFP-Mff WT and mutants were expressed in 
HEK293T cells and GFP-Trap used to immunoprecipitate them 48-hours post-transfection.   
Figure 5.14 shows a representative blot and quantification of endogenous ubiquitination 
of the mutants.  As was expected, CFP-Mff K151R had significantly reduced ubiquitination 
compared to the WT (B).  On its own, this result does not definitively discriminate between 
reduced ubiquitination as a result of replacement of a ubiquitin-targeted lysine residue, or 
reduced ubiquitination due to abolished SUMOylation of K151.  However, the E153A 
mutant also had significantly reduced ubiquitination compared to the WT.  This mutant 
retains the availability of K151 for potential ubiquitination but cannot be SUMOylated 
(Figure 5.6).  This suggests that SUMOylation is required for or enhances ubiquitination of 
Mff, indicating that one or more ubiquitin ligases for Mff could be STUbLs. 
Interestingly, neither the S155A phospho-null nor the S155D phospho-mimetic 
mutant had significantly different ubiquitination compared to the WT.  The phospho-null 
mutant has significantly reduced SUMOylation compared to the WT but is not devoid of 
SUMO.  Given the highly transient nature of SUMO modification, it could be that even this 
reduced level of Mff SUMOylation is sufficient to recruit any STUbL of Mff, due to the mass 
action model outlined in Chapter 1 (The SUMO enigma).  It was expected, in keeping with 
its higher levels of SUMOylation, that the phospho-mimetic mutant might have greater 
levels of ubiquitination.  It is possible that this is not the case due to the nature of the 
mimetic as described previously (5.4.2) and its inability to truly mimic transient 
phosphorylation.  It is also important to note that these experiments were carried out in 
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the absence of any proteasomal inhibitors, so the ubiquitination detected reflects the 
steady-state levels.  This set-up does not account for higher turnover rates of more heavily 
ubiquitinated proteins, so we cannot rule out the possibility that CFP-Mff S155D actually 
does get more heavily ubiquitinated but is then more rapidly degraded. 
Having identified that lack of SUMOylation results in less ubiquitination, it remained 
to be determined if this had any physiological relevance.  We proposed that, owing to its 
reduced ubiquitination, the K151R mutant of Mff may be more stable than the WT.  To 
interrogate this hypothesis, HEK293T cells were transfected with CFP-Mff WT or K151R and 
lysed 72-hours post-transfection.  Prior to lysis, cells were treated with the protein 
synthesis-blocking drug cycloheximide for up to 24 hours, as indicated in Figure 5.15 .  This 
allows the rate of protein degradation to be measured.  Unfortunately, owing to time 
constraints and logistical problems with the experimental set-up, this experiment was not 
repeated sufficient times to apply statistical analyses.  However, over the 24-hour course 
of the experiment, CFP-Mff K151R does appear to be more stable than the WT, being only 
~25% reduced within 24 hours, compared to a ~80% reduction of the WT (Figure 5.15). 
While these data are encouraging, the set-up of this experiment was not ideal.  The 
time-course was insufficient to determine protein half-life and in future would need to be 
longer.  Additionally, degradation rates of over-expressed proteins are unlikely to truly 
reflect the degradation of endogenous levels of the protein, especially in light of their N-
terminal CFP tags, which will undoubtedly affect their degradation via the N-end rule 
(Bachmair et al., 1986).  However, as both the WT and K151R Mff constructs have the same 
N-terminal tag, we can assume that their half-lives will be equally affected by this.  So, 
despite this experiment not necessarily reflecting the true half-life of Mff WT and K151R, 
it can still inform us about the effect of the K151R point mutation, compared to WT.  
Another problem is the use of transiently over-expressed proteins; without a stably 
expressing cell line, there can be no guarantee that all of the conditions had the same level 
of expression of CFP-Mff to begin with, but this must be assumed during quantification.  In 
future work, this experiment would be repeated over a longer time-course, using stable 
knock-down replacement cell lines expressing endogenous levels of WT or K151R Mff.                 
     
5.4.6 K151 of Mff is ubiquitinated by Parkin 
None of the data discussed thus far preclude the possibility that K151 of Mff is the 
target of Parkin ubiquitination.  We reasoned that if both SUMO and ubiquitin could be 
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conjugated to the same residue, this would likely be competitive.  Therefore, reduction of 
one modification might result in an increase of the other.  As shown in Chapter 4, knock 
down of Parkin results in a ~50% decrease in endogenous ubiquitination of Mff.  We 
hypothesised that, in the event of PTM competition, this could induce a similar increase in 
SUMOylation of that site. 
Figure 5.16 shows representative Western blots and quantification of GFP-Trap 
immunoprecipitation of CFP-Mff WT in the presence or absence of Parkin.  Unsurprisingly, 
the SUMO-reactive smear of Mff was significantly reduced by knock down of Parkin (B).  
This smear is more than likely made up of mixed length chains of SUMO and ubiquitin, so 
it stands to reason that knock down of a ubiquitin ligase reduces its intensity.  Interestingly, 
there was no significant difference in the single lower molecular weight SUMO band, that 
we believe to be mono-SUMOylated CFP-Mff, upon knock down of Parkin (C).  This would 
argue that ubiquitin and SUMO do not compete at this site and supports the hypothesis of 
Parkin ubiquitinating Mff at a different residue, but in a SUMO-K151-dependent manner. 
 To definitively determine whether Parkin is recruited to Mff by SUMO or targets the 
SUMOylatable residue of Mff, GFP-Trap was used to immunoprecipitate CFP-Mff WT, 
K151R or E153A from transfected HEK293T cells, in the presence of absence of Parkin 
(Figure 5.17).  As was previously demonstrated (Figure 5.8), knock down of Parkin 
significantly reduces ubiquitination of WT Mff, but has no effect on the non-SUMOylatable 
K151R mutant.  However, knock down of Parkin did significantly reduce ubiquitination of 
CFP-Mff E153A.  This means that it is the lysine residue, rather than its ability to be 
SUMOylated, that is affected by knock down of Parkin, and strongly indicates that, at least 
in this isoform of Mff, K151 is the only site of ubiquitination by Parkin. 
While this was disappointing, the identification of K151 as a Parkin target in Mff is a 
novel finding.  Importantly, the data showing that the non-SUMOylatable E153A mutant is 
significantly less ubiquitinated than the WT (Figure 5.14, Figure 5.17) strongly suggests that 
one or more of the other, as-yet unidentified, ubiquitin ligases of Mff is being recruited by 
Mff SUMOylation.  There remains the possibility that mutation of E153 disrupts a ubiquitin 
consensus, but the ability of Parkin to ubiquitinate the E153A mutant suggests that this is 
not the case.  These findings also pose the question of why Parkin is able to bind to SUMO, 
if not to target it to SUMOylated substrates. 
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5.4.7 Parkin can be SUMOylated 
The experiments defining the non-covalent binding between Parkin and SUMO also 
yielded an unexpected result.  Not only could YFP-SUMO co-immunoprecipitate Myc-
Parkin at its predicted molecular weight from co-transfected HEK293T cells, but also higher 
molecular weight, Parkin-reactive species that were specific to the WT YFP-SUMO 
constructs, and not apparent in co-immunoprecipitations with the non-conjugatable ΔGG 
mutants (Figure 5.18).  As far as we are aware, this is the first indication that Parkin could 
be a SUMO substrate.  To support this finding, a bacterial SUMOylation assay was also 
carried out (Figure 5.19).  Bacteria lack the molecular machinery required for SUMOylation, 
so were co-transformed with plasmids encoding the E1 and E2 SUMOylation enzymes as 
well as the SUMO isoforms, along with Parkin.  In this system as well, T7-tagged Parkin was 
detected at its predicted molecular weight regardless of addition of SUMO and its 
machinery, while higher molecular weight, T7-reactive species were detected only upon 
addition of SUMO machinery and SUMO proteins. 
 If substantiated, this discovery is very interesting.  Parkin is a widely-studied protein 
known to be regulated by myriad PTMs and being a SUMO substrate would add another 
layer of regulation to an already complex network of regulatory pathways.  However, 
validation of this finding would require far more work. 
So far, we have only shown that Parkin can be SUMOylated by over-expressing both 
Parkin and SUMO, in effect forcing the attachment.  While it is unlikely that the SUMO 
machinery will indiscriminately SUMOylate any available lysine residue if the proteins are 
present in large enough concentrations, if this modification cannot be detected at 
endogenous levels, it is unlikely to have any physiological relevance.  Parkin also does not 
contain a consensus SUMOylation motif.  This does not rule it out as a SUMO substrate, as 
>50% of known SUMO substrates lack any kind of consensus motif (Blomster et al., 2009), 
but it does make identification of the SUMOylatable residue(s) more difficult.  Ongoing 
work is aimed at identifying the functional domain of Parkin which can be SUMOylated, by 
use of overlapping truncated Parkin fragments, to narrow down the search for lysine 
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Chapter 6 General Discussion 
6.1 Summary of research 
Western blot analysis of cardiac tissue from an ex vivo model of I/R injury revealed 
changes in the cellular abundance and mitochondrial association of several fission/fusion-
related proteins over the course of ischaemia and reperfusion.  Total amounts of HK2, 
Dyn2, Parkin and MAPL were unchanged by I/R, whereas Drp1, Mfn2, Mff and Fis1 were 
significantly decreased during reperfusion, Mff also decreased by ischaemia, and Fbxo7 
and Fis1 were significantly decreased by ischaemic pre-conditioning (IPC).  Mitochondrial 
association of HK2, Dyn2 and Fbxo7 was significantly decreased by IPC, while association 
of Drp1 was significantly increased by IPC, but decreased by reperfusion.  Association of 
Parkin was by far the largest change, with an increase during ischaemia, followed by a 
decrease upon reperfusion.  Interestingly, IPC partially attenuated the ischaemia-
dependent recruitment. 
Ischaemia and reperfusion significantly increased total cellular and mitochondrial 
ubiquitin-conjugation but had no effect on global or mitochondrial SUMO-conjugation. 
However, we go on to show that Mff is a novel SUMO substrate, and demonstrate that 
ischaemic stress (OGD) increases Mff SUMOylation.  Analysis of point mutants of Mff reveal 
that phosphorylation of Mff regulates its SUMOylation, and SUMOylation, to a lesser 
degree, regulates its ubiquitination and degradation. 
 The scale of the change to mitochondria-associated Parkin during I/R marked it out 
as an interesting target for further study.  Mitochondrial recruitment of Parkin coincided 
with a decrease of Mff during ischaemia, consistent with previous work demonstrating 
Parkin-dependent ubiquitination of Mff during mitophagy (Gao et al., 2015).  In HEK293T 
cells, knock down of Parkin significantly elevated Mff levels, making Mff an ideal candidate 
for a ‘read-out’ of Parkin function.  Parkin, Fbxo7 and mitophagy have previously been 
linked (Burchell et al., 2013), so Fbxo7 was also chosen as a protein for deeper 
investigation. 
Knock down analyses showed that Parkin and Fbxo7 independently and additively 
contribute to ubiquitination of Mff under basal conditions, demonstrating, for the first 
time, a functional link between Fbxo7-containing CRLs and Mff.  Knock down of Parkin 
significantly slowed and blocked the degradation of Mff over 24 hours, whereas knock 
down of Fbxo7 slowed, but did not block, Mff degradation in the same time-period.  
Interestingly, Fbxo7 ablation did appear to alter the ratio of Mff isoforms,  indicating that 
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Parkin and Fbxo7 may regulate Mff in different ways, or primarily target different Mff 
isoforms, though this has not yet been followed up with further investigation. 
Previously published work demonstrated non-covalent binding between Parkin and 
SUMO (Um and Chung, 2006).  I confirmed this interaction by co-immunoprecipitation, 
both from HEK293T cells and in vitro.  Overall, the ischaemia-dependent mitochondrial 
recruitment of Parkin, ischaemia-dependent SUMOylation and loss of Mff from the MOM, 
together with specific SUMO-binding of Parkin, suggest a role for SUMO in Parkin 
recruitment to, and ubiquitination of, Mff.  I show that, while Fbxo7 has no preference 
between SUMOylated and non-SUMOylated Mff, Parkin does not ubiquitinate a non-
SUMOylatable mutant of Mff, K151R.  We therefore initially hypothesised that Parkin could 
be a SUMO-targeted ubiquitin ligase (STUbL).  Subsequent experiments, however, 
indicated that  Parkin directly ubiquitinates Mff at K151, independently of SUMO.  This site 
of Parkin-mediated ubiquitination has not been previously reported.  Additionally, 
immunoprecipitation experiments between Parkin and SUMO indicate the potential for 
Parkin itself to be a SUMO substrate which, if validated, would be a novel and exciting 
discovery. 
 
6.2 The mitochondrial proteome is altered 
during I/R injury 
It is well-established that mitochondria are a major target of the damage incurred 
by ischaemia and reperfusion (Halestrap, 2010, Sanada et al., 2011, Pasdois et al., 2013).  
Building on this work, the focus of my ex vivo experiments was on proteins associated with 
mitochondrial function and dynamics.  IPC is protective against I/R injury but the molecular 
mechanisms underlying this remain poorly-understood (Yellon et al., 1992, Otani, 2004, 
Halestrap, 2010, Kalogeris et al., 2014).  Therefore, particular attention was paid to 
proteins whose expression and/or subcellular compartmentalisation was affected by IPC.  
Summaries of the changes observed in these experiments are given in the tables below 
(Table 6.1 compares pre-ischaemia to ischaemia; Table 6.2 compares ischaemia with I/R or 
IPC). 
6.2.1 Proteins involved in mitochondrial dynamics 
To our knowledge, this is the first study to screen cardiac I/R injured-tissue for 
changes to mitochondrial dynamics-associated proteins. Using mass spectrometry, Oshima 
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et al demonstrated that IPC caused significant up- or down-regulation of several 
mitochondrial proteins compared to I/R in rat liver, while Kim et al identified 25 
mitochondrial proteins that were differentially expressed in IPC or I/R rabbit cardiac tissue, 
which were predominantly proteins of the mitochondrial respiratory chain and proteins 
involved in energy metabolism (Kim et al., 2006b, Oshima et al., 2008).  However, neither 
group included an ischaemic control group, making it difficult to draw conclusions.  Forini 
et al also carried out a proteomics screen on mitochondrial proteins following cardiac I/R 
injury but focussed on proteins associated with metabolic processes (Forini et al., 2015). 
 By far the most marked change was in mitochondrial association of Parkin, which 
increased around 20-fold during ischaemia, an effect which was halved by IPC.  A similar, 
but less pronounced, pattern was observed for Fbxo7.  With regard to mitophagy, it was 
interesting that Parkin and Fbxo7 appear to be regulated in different ways; Fbxo7 was 
degraded during IPC, whereas total Parkin was stable, but less recruited to mitochondria 
during ischaemia following IPC.  These data support the previous report that Fbxo7 is 
required for mitochondrial Parkin translocation (Burchell et al., 2013) - degradation of 
Fbxo7 as a result of IPC contributes to reduced mitochondrial translocation of Parkin.  
Additionally, Mff was lost from the mitochondrial fraction at the same time as Parkin was 
recruited, consistent with a previous study on Parkin-dependent ubiquitination of Mff 
during mitophagy (Gao et al., 2015).  Taken together, this series of experiments suggest 
that Parkin is integral to both Fbxo7-mediated mitophagy and degradation of Mff and 
suggests a direct functional link between Fbxo7 and Mff stability. 
6.2.2    Post-translational modifications 
Hypoxia has been previously shown to up-regulate SUMO conjugation, which is 
thought to be a protective mechanism (Guo et al., 2013, Meller et al., 2014, Lee et al., 2007, 
Luo et al., 2017).  With that in mind, we set out to determine whether SUMOylation was 
increased by IPC, a known cardio-protective mechanism.  While there were no global 
changes to SUMO-2/3-ylation, a small but significant increase was observed in global 
SUMO-1-ylation as a result of IPC, which we propose could contribute to the cytoprotective 
effect of IPC.  Unsurprisingly, global ubiquitination was significantly increased during 
reperfusion, a pattern reflected in the mitochondrial fraction.  We attribute this to 
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substantial upregulation of the UPS as part of the unfolded protein response triggered by 








Stress response   
LC3 II/I = 
Cleaved Caspase-3 = 
LDH            + 
Mitochondria-associated Total Mitochondrial 
HK2 = = 
Dyn2 = = 
Drp1 = = 
Fbxo7 = = 
Parkin = + 
Mfn2  = 
PINK1  = 
MAPL  = 
Mff  - 
Fis1  = 
Post-translational modifications Total Mitochondrial 
Ubiquitin = = 
SUMO-1 = = 
SUMO-2/3 = = 
SUMO-1 55kDa species  + 
Table 6.1 Protein changes observed in ex vivo experiments (1).  Green plus symbol indicates 
increased protein, red minus symbol indicates decreased protein, equal symbol indicates 
no significant change.  Protein levels compared with pre-ischaemia (control). 
 




6.2.3 Parkin and Fbxo7 regulate Mff independently 
and differentially 
Parkin, Fbxo7 and Mff were each identified in the I/R injury screen as targets for 
further investigation, Parkin and Fbxo7 for their similar profiles of mitochondrial 
recruitment and known involvement in mitophagy, and Mff for its ischaemia-dependent 
decrease.  While interactions between these three proteins have not been previously 
reported, they all have been implicated in mitophagy and Parkinson’s disease, which is 
characterised by aberrant mitochondrial dynamics (Wiemerslage and Lee, 2016, Onyango 
Protein Reperfusion Pre-conditioning 
Stress response   
LC3 II/I +  =  
Cleaved Caspase-3 +  =  
LDH     
Mitochondria-associated Total Mito. Total Mito. 
HK2 = = = = 
Dyn2 = = = - 
Drp1 - - = = 
Fbxo7 = = - - 
Parkin = - = - 
Mfn2  =  = 
PINK1  =  = 
MAPL  =  = 
Mff  =  = 
Fis1  -  = 
Post-translational modifications Total Mito. Total Mito. 
Ubiquitin + + = = 
SUMO-1 = = + = 
SUMO-2/3 = = = = 
SUMO-1 55kDa species  =  - 
Table 6.2 Protein changes observed in ex vivo experiments (2).  Green plus symbol indicates 
increased protein, red minus symbol indicates decreased protein, equal symbol indicates 
no significant change.  Protein levels for reperfusion or ischaemic-preconditioning (IPC) are 
compared with ischaemia. 
 
Figure 6.1 Mff is SUMOylation is a stress response.  In response to oxidative stress and low 
intracellular ATP, AMPK is activated by binding of AMP.  AMPK phosphorylates Mff at S155.  
Phosphorylation of S155 enhances SUMOylation of Mff at K151.  The SUMO E3 ligase 
remains unknown.Table 6.3 Protein changes observed in ex vivo experiments.  Green plus 
symbol indicates increased protein, red minus symbol indicates decreas d pro ein, equal 
symbol indicates no significant change.  Protein levels for reperfusion or ischaemic-
preconditioning are compared with ischaemia. 
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et al., 2017).  I therefore explored the relationships between the three proteins, particularly 
focussing on Parkin as the ‘common denominator,’ but also with the goal of investigating 
the potential link between Fbxo7 and Mff.  
6.2.4 Validation of PINK1-dependent 
ubiquitination of Mff by Parkin 
In keeping with the previous work which identified Mff as a target of Parkin-
mediated ubiquitination, loss of Mff from the MOM during ischaemia coincided with Parkin 
recruitment (Gao et al., 2015).  While this was an interesting observation, ex vivo hearts 
are not an easily tractable model for molecular manipulation.  Therefore, I used HEK293T 
cells for the majority of functional experiments because of their ease of culture and 
molecular biological manipulation. 
To complement the ex vivo data, knock down of Parkin was performed in HEK293T 
cells to characterise the effect on Mff.  Consistent with Parkin being a ubiquitin ligase of 
Mff, total levels of Mff were significantly increased by ablation of Parkin.  Previous work 
has cast doubt on the integrity of Parkin over-expression, noting that, like for many E3 
ligases, over-expression can lead to enzyme promiscuity and ‘false positive’ substrate 
identification (Danielsen et al., 2011, Kanner et al., 2017).  Indeed, the study by Gao et al 
relied on over-expressed Parkin to mediate Mff ubiquitination.  In light of this, I used only 
endogenous Parkin for functional studies. 
Endogenous Parkin was sufficient to detectably ubiquitinate CFP-Mff, even in the 
absence of proteasomal inhibitors.  This allowed me to investigate Parkin-mediated Mff 
ubiquitination at steady state.  In support of the study by Gao et al, Parkin knock down 
halved steady state ubiquitination of Mff, complementing the doubling of total 
endogenous Mff with the same treatment. 
Canonically, Parkin is only recruited to damaged or depolarised mitochondria by 
accumulation of PINK1 to initiate mitophagy.  However, recent reports have demonstrated 
that, while Parkin-mediated mitophagy is delayed in PINK1-null cardiac cells, Parkin is still 
recruited to depolarised mitochondria via a PINK1-independent mechanism (Kubli et al., 
2015).  Moreover, PINK1-independent phosphorylation of Parkin at S57, rather than the 
canonical PINK1 site S65, hyperactivates Parkin (George et al., 2017).  As the Parkin knock 
down experiments were performed under basal conditions, I wanted to determine 
whether or not Parkin-mediated ubiquitination of Mff was PINK1-dependent.  Knock down 
of PINK1 in HEK293T cells had no effect on cellular levels of Parkin, but significantly 
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increased total Mff, indicating that PINK1 is required, at least in part, for Parkin activation 
prior to Mff ubiquitination.  This also demonstrates that basal levels of PINK1 expression 
are sufficient to induce Parkin activity, an important factor given that most of the 
experiments detailed in this thesis were performed under basal conditions. 
While the experiments discussed here go a long way toward demonstrating that 
Parkin ubiquitinates Mff in a PINK1-dependent manner, these data would be more 
convincing if extended with further rescue experiments.  For example, the phenotype 
(increased Mff) of Parkin knock down should be rescued by episomal expression of WT, but 
not catalytically dead (C431S mutant) Parkin (Riley et al., 2013).  Similarly, to validate that 
this mechanism is PINK1-dependent, a PINK1-insensitive Parkin mutant such as S65A would 
also not be able to rescue the phenotype (Ordureau et al., 2015).         
6.2.5 Different effects of Mff ubiquitination by 
Parkin and Fbxo7 
As outlined above, immunoprecipitation experiments of CFP-Mff revealed that both 
Parkin and Fbxo7 contributed to Mff ubiquitination.  Interestingly, knock down of Parkin or 
Fbxo7 resulted in equal and additive loss of Mff ubiquitination.  Moreover, knock down of 
Fbxo7 lead to a significant decrease in total Parkin, and vice versa.  Therefore, my initial 
working hypothesis was that the reduction in Mff ubiquitination caused by Fbxo7 knock 
down was due to decreased Parkin.  However, simultaneous knock down of Parkin and 
Fbxo7 caused further significant decrease in Mff ubiquitination, providing strong evidence 
that the two proteins act upon Mff independently. 
I next tested if Parkin- and Fbxo7-mediated ubiquitination of Mff served different 
purposes.  Ubiquitination of Mff by Parkin has already been linked to its degradation (Gao 
et al., 2015).  To validate this finding, degradation of Mff over a 24-hour time-course was 
measured, in the presence or absence of Parkin.  Cycloheximide (CHX) was used to inhibit 
protein synthesis, so that the rate of protein decay could be measured.  In the absence of 
Parkin, degradation of Mff was significantly slower than in the presence of Parkin, and total 
Mff levels decreased by around half as much as in the presence of Parkin over 24 hours.  
This supports the finding by Gao et al.  Together with the decrease in Mff ubiquitination 
observed with Parkin knock down, these data support a hypothesis in which Parkin 
mediates Mff degradation via ubiquitination.  From these experiments, however, the 
mechanism of Mff degradation remains unclear.  The study by Gao et al suggests that 
Parkin targets Mff for autophagic degradation, by showing that a non-ubiquitinatable Mff 
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mutant interacts less strongly with the autophagic adaptor protein p62 (Gao et al., 2015).  
However, they do not include any analysis of interactions with other proteins, such as those 
of the UPS, so other degradative mechanisms cannot be ruled out.  Indeed, a study by 
Tanaka et al provided evidence that known substrates of Parkin-mediated ubiquitination, 
including Mfn2, were selectively decreased during CCCP-induced mitochondrial 
depolarisation, while several other Parkin substrates, including VDAC, Fis1 and the MIM 
transporter protein Tim23, were unchanged.  The lack of global reduction to mitochondrial 
Parkin substrates might indicate that certain proteins are cleared vie selective proteasomal 
degradation, rather than mitophagy (Rojansky et al., 2016, Geisler et al., 2010, Aguileta et 
al., 2015, Tanaka et al., 2010).  In their study, the loss of Parkin substrates like Mfn2 was 
rescued by blocking the UPS using MG132, a well-characterised proteasome inhibitor 
(Tanaka et al., 2010).  This study therefore suggests that at least some Parkin substrates 
are degraded via the UPS, indicating that this could equally be true for Mff.  Repeating the 
Parkin knock down experiments with and without MG132 could go some way toward 
determining the degradative pathway; if Mff is degraded via the UPS, MG132 treatment 
should increase detectable Parkin-induced ubiquitination, as well as increasing total Mff.    
Interestingly, although knock down of Fbxo7 had as much of an effect on Mff 
ubiquitination as Parkin knock down, Fbxo7 ablation did not increase total Mff or decrease 
Mff turnover in 24 hours CHX treatment compared to the control.  However, during the 
earlier stages (6- and 12-hour timepoints) of the time-course, Fbxo7 knock down did 
significantly inhibit Mff degradation.  These data suggest that Fbxo7-mediated 
ubiquitination may have a limited effect on Mff turnover, and that degradation may not be 
the primary function of Fbxo7-mediated modification.  A notable effect of Fbxo7 knock 
down, however, was a significant decrease in abundance of the predominating ~35kDa 
band and a significant increase in presence of ~25kDa lower bands. One explanation for 
these results is that Fbxo7 knock down could affect the ratio between different isoforms 
of Mff.  Very little is known about the roles of different isoforms of Mff, so it is difficult to 
predict what the consequences of this shift in equilibrium could be.  It is also interesting 
that, although Fbxo7 ablation significantly decreased total Parkin, the functional effect of 
Parkin knock down i.e. increased Mff, was not observed.  We propose that the most likely 
reason for this is that complete or near-complete knock down of Parkin is required to 
protect Mff from degradation, which is not achieved by knock down of Fbxo7.  Consistent 
with this, when Parkin and Fbxo7 were simultaneously knocked down, Mff was significantly 
increased. 
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Another plausible explanation could be that, rather than smaller isoforms, the lower 
molecular weight Mff-reactive bands observed upon knock down of Fbxo7 are degradation 
products.  In this were the case, one could argue that Fbxo7 actually opposes the activity 
of Parkin by protecting Mff against degradation, in an epistatic pathway.  In this scenario, 
the observation of the Parkin knock down phenotype (Mff increase) upon knock down of 
both Parkin and Fbxo7 could indicate that Fbxo7 functions upstream of Parkin.  However, 
as discussed in Chapter 4, it is not possible from these data to dissect out the pathway, 
given that knock down of Parkin also reduces Fbxo7, and vice versa.          
6.2.6 Mitochondrial networks are altered by OGD, 
and Parkin and Fbxo7 regulate this 
In H9c2 cells, OGD causes a small but significant decrease in mitochondrial branch 
length, presumably due to an increase in mitochondrial fission.  Mff degradation during 
ischaemia/OGD, which is at least partially mediated by Parkin, is likely to be a protective 
mechanism, designed to stop excessive fission from destroying the mitochondrial network.  
In the absence of Parkin, OGD causes a larger decrease in mitochondrial branch length.  We 
hypothesise that this is due to accumulation of Mff on the MOM as Parkin is not available 
to ubiquitinate it and target it for degradation.  Thus, elevated levels of Mff recruit more 
Drp1, leading to excessive fission and shortening of mitochondrial branches.  However, we 
cannot conclude from these experiments alone that the effects of Parkin in mitochondrial 
networks are via Mff; in future it would be prudent to examine the accumulation of Mff by 
imaging.  
In the presence of Fbxo7, OGD has no effect on the average number of branches 
within a mitochondrial network (network complexity).  However, in the absence of Fbxo7, 
OGD causes a significant increase in the network complexity.  It is unclear whether an 
increase in network complexity is a result of decreased fission or decreased fusion, as logic 
dictates that either could alter the network structure.  A recent publication used 
mathematical modelling to determine that the mitochondrial network complexity of 
control cells is ‘poised at criticality’ (Zamponi et al., 2018).  Zamponi et al concluded that 
promoting either fission or fusion results in a decrease in network complexity, which they 
equate with a decrease in network adaptability.  The increase in complexity observed 
during OGD in the absence of Fbxo7, therefore, could arise from inhibition of fission or 
fusion.  Speculatively, this could be a result of the perturbed equilibrium in Mff isoforms.  
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However, not enough is currently known about the different Mff isoforms or the 
involvement of Fbxo7 in their regulation to draw firm conclusions at this time.    
6.3 Mff is regulated by stress-dependent post-
translational modifications 
SUMOylation has been previously shown to protect cells against ischaemic damage 
(Lee et al., 2007, Guo et al., 2013, Luo et al., 2017).  Despite our ex vivo work not identifying 
any large-scale changes to SUMOylation during I/R injury, this does not rule out the 
possibility of protective changes to the SUMOylation status of subsets of proteins.  A readily 
observable example of this is the ~55kDa mitochondrial SUMO-1-ylated species, which was 
significantly increased during ischaemia. 
6.3.1 Mff is a novel SUMO substrate 
During the course of this study, several of our lab demonstrated for the first time 
that Mff can be SUMO-1- and SUMO-2/3-ylated (Dr Kevin Wilkinson, Richard Seager & 
Laura Lee, unpublished data).  Interestingly, SUMO-1-ylation of GST-Mff in HEK293T cells 
was substantially increased during OGD, indicating that Mff SUMOylation is regulated by 
ischaemic stress (Figure 5.7).  This dataset does not include a free GST control, so it cannot 
be ruled out that this is actually GST SUMOylation, however the molecular weights of the 
co-purified SUMO bands are what would be expected for SUMOylated GST-Mff.  
Additionally, data presented in Figure 3.15 do include a free GST control, which has no 
observable covalent modifications, suggestive that GST cannot be readily SUMOylated. 
The data shown in Figures 3.14 and 3.15 go a long way to establishing Mff as a bona 
fide SUMO substrate.  Figure 3.14 demonstrates that SUMO-reactive species are co-
immunoprecipitated with CFP-Mff, but not GFP alone, thereby ruling out the possibility of 
GFP SUMOylation.  Mutation of a single site in Mff, K151, totally abolishes SUMOylation.  
This demonstrates that either K151 is the sole site of Mff SUMOylation, or that mutation 
of K151 renders Mff incapable of binding to another ~70kDa SUMO substrate, perhaps by 
unfolding the protein.  This cannot be definitely ruled out, as the 0.1% SDS-containing 
buffer used for the pull downs is not totally denaturing.  However, Figures 3.14 (C) and 
Figure 3.15 shows that purification of CFP-Mff or GST-Mff, but not free CFP or GST, also 
purifies a higher, CFP/GST-reactive molecular weight species.  That this upper band is also 
CFP/GST-reactive rules out the possibility of it being another co-purified protein 
modification, regardless of the buffer composition.  This species is also abolished by 
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expression of a SUMO-specific protease, as further evidence for Mff SUMOylation (Figure 
3.15).  Nonetheless, further validation of Mff as a SUMO substrate could be achieved by 
lysing the cells in a completely denaturing buffer, such as one containing 5% SDS or 8M 
urea, which would then have to be diluted out prior to immunoprecipitation.   
Mff is SUMOylated at a single site, K151.  We demonstrate this by mutating K151 
(K151R) and observing total ablation of SUMO-1- and SUMO-2/3-ylation.  Closer 
examination of the region around K151 revealed that K151 of Mff sits within a consensus 
phosphorylation-dependent SUMOylation motif (PDSM).  We confirm that SUMOylation of 
Mff is regulated by phosphorylation at S155; mutation of S155 to a non-phosphorylatable 
site (S155A) significantly reduces SUMO-2/3-ylation of Mff, while mutation to a phospho-
mimetic (S155D) significantly increases SUMO-1-ylation.  S155 (and S172) of Mff are 
phosphorylated by AMP-activated kinase (AMPK).  AMPK is stress-regulated – as 
intracellular ATP concentration falls, the increased AMP binds directly to the regulatory 
subunit of AMPK, facilitating its activation (Toyama et al., 2016).  In this mechanism, 
ischaemic insult depletes cellular ATP, driving cellular AMP levels to reach a critical 
concentration at which AMPK Is activated.  AMPK-mediated phosphorylation of Mff then 
enhances its SUMO-1-ylation, as shown in Figure 6.1.   
 
6.3.2 Parkin binds SUMO 
The finding that Mff is both a substrate for Parkin and is also SUMOylated was 
particularly intriguing, as a previous publication demonstrated that Parkin could bind non-
covalently to SUMO-1, but not SUMO-2 (Um and Chung, 2006).  To confirm this report, I 
Figure 6.1 Mff SUMOylation is a stress response.  In response to oxidative stress and low 
intracellular ATP, AMPK is activated by binding of AMP.  AMPK phosphorylates Mff at S155.  
Phosphorylation of S155 enhances SUMOylation of Mff at K151.  The SUMO E3 ligase 
remains unknown.  
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expressed YFP-SUMO and Myc-Parkin in HEK293T cells and used GFP-Trap beads to 
immunoprecipitate YFP-SUMO.  In support of the work carried out by Um and Chung, YFP-
SUMO-1 was able to co-immunoprecipitate Myc-Parkin.  Surprisingly, the same was 
observed for YFP-SUMO-2.  In their study, Um and Chung used only WT HA-SUMO.  To gain 
more information about the nature of the Parkin-SUMO interaction, I included a -ΔGG 
mutant of YFP-SUMO, in which the absent C-terminal di-glycine renders SUMO non-
conjugatable.  In the case of SUMO-1 and SUMO-2, Parkin preferentially bound to the WT 
form, consistent with the model that Parkin  preferentially interacts with SUMO-modified 
proteins rather than free SUMO. Over the course of my PhD, several findings had hinted at 
an interplay between Parkin, Mff and SUMO.   
• Mff is both a SUMO and a Parkin substrate.   
• During ischaemia, SUMOylation of Mff is increased, recruitment of Parkin to 
the mitochondrial outer membrane is increased, and degradation of Mff is 
increased.   
• Parkin ubiquitinates WT Mff, but not the non-SUMOylatable mutant of Mff, 
Mff K151R.   
• Additionally, Parkin can bind SUMO, and may preferentially bind 
SUMOylated substrates.   
• The only previously published report of Parkin ubiquitinating Mff reported 
that ubiquitination was at a single site, K302 (Gao et al., 2015).   
Taken together, these data provided strong evidence that SUMOylation can recruit 
Parkin to the SUMO-tagged substrate protein i.e. that Parkin can act as a SUMO-targeted 
Ubiquitin ligase (STUbL). 
If Parkin were a STUbL, a reasonable assumption would be that it would bind with 
less affinity to non-SUMOylatable Mff and/or with greater affinity to the highly 
SUMOylated phospho-mimetic mutant.  However, co-immunoprecipitation experiments 
revealed no difference in Parkin binding to any of the mutants used in this study.  
Nevertheless, the interaction between an E3 ligase and its substrate is usually extremely 
transient, so may not be accurately measured by co-immunoprecipitation, especially of 
over-expressed proteins, and substrate binding does not necessarily dictate catalytic 
efficiency.  
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6.3.3 Parkin and Fbxo7 ubiquitinate Mff at 
different sites 
The observation that Parkin does not ubiquitinate the non-SUMOylatable K151R mutant of 
Mff does not necessarily mean that SUMO is required for Parkin activity.  Although Parkin 
has been reported to ubiquitinate Mff only at K302 (Gao et al., 2015), we could not exclude 
the possibility that the lack of Parkin activity on Mff K151R was because Parkin 
ubiquitinates Mff at K151.  To investigate this possibility, we generated a non-
SUMOylatable mutant of Mff that retained the SUMOylatable lysine.  In the Mff E153A 
mutant, K151 is still available for modification, but the SUMO consensus motif is disrupted, 
ablating SUMOylation at K151.  Using this mutant, I could discriminate between the 
requirement for SUMO and the requirement for K151 for Parkin activity.  
Immunoprecipitation of CFP-Mff WT, K151R and E153A revealed that Parkin ubiquitinates 
WT and E153A Mff to the same extent but ubiquitination of K151R is greatly reduced.  This 
provides strong evidence that, contrary to the previously published work, Parkin 
ubiquitinates Mff at K151, as shown in Figure 6.2. 
 
Thus, these data argue against the hypothesis that Parkin is a  STUbL for Mff. 
Nonetheless, it is interesting that the non-SUMOylatable Mff E153A mutant has 
significantly reduced steady state ubiquitination compared to the WT, similar to the K151R 
mutant.  We interpret these results to indicate that an, as-yet unidentified, ubiquitin ligase 
of Mff is recruited via SUMOylation at K151 and does not efficiently ubiquitinate Mff E153A 
despite the availability of K151 because the E153A mutant cannot be SUMOylated.  
Figure 6.2 Parkin ubiquitinates Mff at K151. In response to mitochondrial membrane 
depolarisation, PINK1 accumulates and recruits Parkin from the cytosol by phosphorylation 
at S65.  Activated Parkin ubiquitinates Mff at K151.  Mutation of K151 renders Parkin unable 
to ubiquitinate Mff, suggesting that this is the only site of Parkin-mediated ubiquitination. 
   
Chapter 6 General Discussion 
204 
 
Mutation of E153 blocks SUMOylation as E153 is an essential part of the Ubc9 recognition 
and binding motif, and Ubc9 is the only SUMO E2 enzyme.  However, there are 100s of 
ubiquitin E3 ligases, which do not all have the same substrate recognition 
motif/mechanism, so ubiquitination is not affected by mutation of one residue. 
   As discussed above, our data suggest that Parkin and Fbxo7 act independently of 
one another in their mediation of Mff ubiquitination.  However, it was not clear whether 
they both  ubiquitinate the same lysine residue.  With a site of Parkin-mediated 
ubiquitination determined, it was easy to interrogate this question.  Unlike Parkin, Fbxo7 
was able to mediate ubiquitination of Mff K151R, with no preference for WT or K151R.  This 
indicates that Fbxo7 mediates ubiquitination at a site other than K151 (Figure 6.3). 
That Fbxo7 is involved in ubiquitinating Mff at a different site to Parkin further 
supports the hypothesis that Parkin and Fbxo7 act independently in their regulation of Mff, 
and that Parkin- and Fbxo7-mediated Mff ubiquitination may differ in their effects.  There 
are nine other lysine residues in human Mff; in future systematic mutation of each could 
identify that Fbxo7 target(s). 
 
6.4 Parkin is a potential SUMO substrate 
An unexpected discovery was that Parkin could be SUMOylated.  By expressing YFP-
SUMO and Myc-Parkin and performing co-immunoprecipitations, I showed not only that 
Parkin can non-covalently interact with SUMO, but that it can also be covalently modified 
by SUMO, as demonstrated by the emergence of Parkin- and SUMO-reactive higher 
molecular weight species, which were not present in experiments using non-conjugatable 
ΔGG SUMO mutants.  Analysis of the amino acid sequence reveals that Parkin does not 
Figure 6.3 Fbxo7 mediates Mff ubiquitination at a site other than K151.  Mutation of K151 
has no bearing on the ability of Fbxo7 to mediate Mff ubiquitination, indicating that Fbxo7 
does not ubiquitinate at this site.  There are nine other lysine residues in Mff (indicated). 
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contain a consensus SUMO motif.  However, more than half of the known SUMO substrates 
do not contain a consensus motif, so this does not preclude the possibility that Parkin is a 
bona fide target of SUMOylation (Zhu et al., 2008, Blomster et al., 2009).  Additionally, due 
to difficulties in crystallisation and modelling, a disordered, lysine-containing, portion of 
the 465 amino acid human Parkin protein, amino acids 75-145, remains largely unstudied 
(Gladkova et al., 2018).  While intriguing, more investigation is required to fully validate 
this finding, including observation of endogenously SUMOylated Parkin, identification and 
mutation of the site of SUMOylation, and demonstrating a functional effect at physiological 
levels. 
6.5 Future directions 
Investigation of mechanisms of mitochondrial dynamics under oxidative stress 
 Parkin, Fbxo7 and Mff were chosen for investigation due to the changes observed 
in ischaemic cardiac tissue (Chapter 3).  It was anticipated that the focus of the rest of this 
thesis would therefore also be ischaemia or an ischaemia-like oxidative stress.  However, 
most of the work presented in Chapters 4 and 5 was carried out under basal conditions.  
This is not to say that the data are not important; we need to understand the mitochondrial 
quality control mechanisms that occur basally to be able to critically interpret their 
behaviour under pathological conditions.  Moreover, the basal data obtained here are 
indicative of substantial roles for Parkin and Fbxo7, both usually studied in the context of 
disease or dysfunction, in physiological maintenance of the mitochondrial reticulum, 
through their effects on Mff, a regulator of normal mitochondrial fission. 
 I demonstrate a stress-inducible mechanism of Mff degradation via AMPK 
activation, phosphorylation of Mff and enhanced SUMOylation of Mff leading to its 
ubiquitination.  However, I then demonstrate that this is effected by neither Parkin, which 
ubiquitinates Mff at K151 independently of SUMO, nor Fbxo7, which mediates 
ubiquitination of Mff at a site other than K151.  Additionally, I show that binding of Parkin 
to Mff is not dependent on its phosphorylation or SUMOylation status, making use of non-
SUMOylatable Mff mutants (K151R, E153A) and phospho-mutants (S155A, S155D).  
Examining the roles of Parkin and Fbxo7 in Mff degradation under conditions of oxidative 
stress may therefore not be particularly informative.  A more interesting question would 
be the effect of the, as yet unidentified, SUMO-targeted ubiquitin ligase (STUbL) of Mff 
under conditions of oxidative stress, where we would expect that enhanced Mff 
SUMOylation would enhance STUbL activity.       
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Identification of ischaemia-dependent SUMO substrates 
Changes in protein SUMOylation under conditions of ischaemic stress have been 
reported by several independent studies in various systems, including hypoxic neurons, 
hypoxic embryos, and hibernating ground squirrels  (Lee et al., 2007, Guo et al., 2013, 
Meller et al., 2014).  It was therefore surprising that no global changes in SUMOylation 
were detected in this study.  However, as outlined throughout this thesis, global changes 
in SUMOylation are a relatively crude measure since the dynamics of SUMOylation of 
individual substrates can increase, decrease or remain unchanged. Measures of total 
SUMOylation integrate all of these changes, so nuanced but important detail can be lost, 
as is likely the case in this study.  Furthermore, SUMOylation is a very transient 
modification, and it could be that the 30 minutes ischaemia and 120 minutes reperfusion 
used in this work, while well-established within the cardiac field (Pasdois et al., 2013), were 
sub-optimal to detect global changes in SUMOylation.  Changes in the temporal 
parameters of the ex vivo work may therefore yield more interesting results with regard to 
SUMOylation.  Similarly, it is important to note that the full set of SUMO and associated 
enzymes was not investigated in this study.  Future work should aim to characterise 
changes in SUMO conjugating enzymes SAE1/2 and Ubc9, as well as SUMO proteases, to 
better understand the SUMO response to cardiac I/R injury. 
While global changes in protein SUMOylation were not apparent in our model of 
cardiac I/R injury, a subset of SUMOylated proteins did change in abundance.  Identification 
and analysis of these proteins is an important next step towards understanding any 
protective role(s) SUMOylation has in the response to cardiac I/R injury, and particularly 
during IPC.  To achieve this, SUMO immunoprecipitation experiments from tissue taken at 
the different stages of I/R injury could be performed, to yield samples enriched in SUMO 
substrates.  A landmark publication recently detailed an effective protocol for enriching 
SUMO substrates for quantitative analysis in this way (Barysch et al., 2014).  Following 
immunoprecipitation on an affinity column using SUMO antibodies, SUMOylated 
substrates were specifically eluted using a buffer containing an epitope-specific SUMO 
peptide.  Identification and relative quantitative analysis of SUMOylated proteins could 
then be performed using tandem mass tag mass spectrometry (TMT-MS). 
 
Analysis of Mff turnover 
My PhD research has shed light on some of the regulatory mechanisms underpinning 
Mff function and has opened many intriguing questions.  We have demonstrated that 
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stress-inducible phosphorylation of Mff by AMPK regulates SUMOylation and have 
provided evidence that SUMOylation regulates ubiquitination.  If SUMOylation of Mff 
promotes its ubiquitination, we would predict that non-SUMOylatable mutants of Mff 
(K151R and E153A) may be more stable than WT Mff.  The work presented in this thesis go 
some way towards demonstrating this, but an incomplete dataset precludes the drawing 
of firm conclusions.  On the other hand, we would predict that the hyper-SUMOylated 
phospho-mimetic Mff mutant (S155D) would be less stable, as its increased ubiquitination 
would promote degradation.  This will be the subject of future experiments. 
Further to this, we would predict that, under stressed conditions, WT Mff would be 
more rapidly degraded, while non-SUMOylatable Mff might be unaffected, which could be 
tested in cultured cells through incubation with a mitochondrial uncoupler such as 
rotenone or FCCP. 
It is also important to note that over-expressed WT and K151R Mff mutants were 
used in this work, and that their rates of degradation may not accurately reflect the true 
stability of the proteins.  A starting point for future studies is to repeat this experiment 
using endogenous levels of WT and K151R Mff.  This could be achieved using a knock down 
replacement strategy, or using Mff-null MEF cells, currently available in the Henley lab, to 
express Mff mutants at endogenous levels.  Another way to study the effect of Mff 
SUMOylation on its stability would be using endogenous Mff in conjunction with 
exogenously expressed SUMO mutants.  The Henley lab has a series of SUMO constructs 
to express WT, non-conjugatable -ΔGG mutant and non-de-conjugatable -PQ mutant 
SUMO.  Using cells expressing WT SUMO as a control, we would predict that Mff stability 
would be increased by the expression of SUMO-ΔGG, as Mff would remain largely un-
SUMOylated, and decreased by expression of SUMO-PQ, as Mff would be permanently 
SUMOylated. 
 
Identification and characterisation of the STUbL that ubiquitinates Mff 
The discovery that Mff is a SUMO substrate and that non-SUMOylatable Mff has 
reduced ubiquitination hints at a SUMO-mediated ubiquitination mechanism, potentially 
via the activity of a STUbL.  A diagram of proposed STUbL-dependent mechanisms is given 
in Figure 6.4. 
A hypothesis tested as part of this PhD postulated that this could be Parkin, however 
the data presented here demonstrate that this is not the case.  The identification of a STUbL 
involved in Mff regulation would be very interesting and would contribute to the rapidly 
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expanding field of inter-modification regulation.  Some early and inconclusive experiments 
performed as part of this PhD revolved around the activity of MAPL, the first identified 
mitochondria-specific ligase.  MAPL was first identified as a ubiquitin ligase, but extensive 
research performed by the McBride group has demonstrated the ability of MAPL to also 
conjugate SUMO (Prudent et al., 2015).  Data not presented in this thesis revealed that 
ablation of MAPL resulted in a significant increase in total Mff, hinting that MAPL may be 
involved in the turnover of Mff.  Interestingly, MAPL ablation also lead to a large increase 
in Mff SUMOylation – an unexpected result for a proposed SUMO ligase.  One could 
speculate that the build-up of SUMOylated Mff is the result of a missing STUbL, with MAPL 
being a prime candidate. 
 
 
Figure 6.4 Stress-dependent activation of a STUbL.  As described previously, oxidative stress 
activates AMPK, leading to phosphorylation of Mff at S155.  This promotes SUMOylation at 
K151, which enhances ubiquitination of Mff by an as-yet unidentified STUbL E3 ligase.  It 
remains unclear whether this STUbL would ubiquitinate Mff at another site (top panel), or 
directly ubiquitinate the SUMO moiety at K151 (lower panel). 
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Elucidation of Mff PTM chain composition 
 Some of the data presented in this thesis, and our hypothetic model, suggest that 
Mff is the target of mixed SUMO-ubiquitin chains.  For example, knock down of the 
ubiquitin ligase Parkin removes a significant portion of both the ubiquitin- and SUMO-
reactive Mff species.  I demonstrate that ablation of the Mff SUMOylation consensus 
significantly reduces its ubiquitination, which supports our model in which SUMO is 
conjugated to Mff prior to ubiquitin (Figure 6.4).  to validate this, samples could be 
incubated with a constitutively active SENP catalytic domain moiety (Craig et al., 2012).  If 
Mff ubiquitin conjugating is via SUMO, SENP treatment would remove both SUMO and 
ubiquitin.  In the same way, expression of a de-ubiquitinating peptidase (DUB) would 
remove just ubiquitin, leaving SUMO chains intact.  However, these data would be 
confounded by direct Mff ubiquitination at other sites, such as that mediated by Fbxo7.  All 
other sites of Mff ubiquitination would first need to be mutated/blocked, which requires 
their prior identification.  
 Furthermore, identification of the specific ubiquitin chain linkages present on Mff 
would help to determine the functions of Mff PTMs.  While some linkage-specific ubiquitin 
antibodies have been validated, including those for Lys48- and Lys63-linked chains, it would 
be difficult to accurately analyse the composition of Mff PTMs by Western blotting alone, 
by comparing one ‘smear’ to another  (Newton et al., 2008). 
 A proteomics-based technique could be used, using a ‘bottom up’ approach in 
which samples are trypsin-digested prior to liquid chromatography-tandem Mass 
Spectrometry for peptide identification.  Ubiquitination leaves a signature di-glycine 
moiety of known monoisotopic mass on its substrate following trypsin cleavage, which can 
be used to identify ubiquitination sites within a substrate.  While this allows us to 
determine ubiquitin chain linkage types, it does not reveal information pertaining to 
ubiquitin chain architecture (Peng et al., 2003). 
 A relatively new technique to analyse ubiquitin chain linkages is UbiCRest, in which 
substrates are subjected to parallel reactions with linkage-specific DUBs, followed by 
electrophoretic analysis (Hospenthal et al., 2015).  This technique also allows users to 
determine chain architecture, through digestion of heterotypic poly-Ubiquitin chains with 
different linkage-specific DUBs.  In future, this would be interesting to determine the 
nature (compositional and architectural) of Mff ubiquitination.     
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Regulation and roles of Fbxo7-mediated ubiquitination of Mff 
Data presented here have demonstrated that Parkin-mediated and Fbxo7-mediated 
ubiquitination of Mff are independent of one another.  A site of Parkin ubiquitination has 
been identified as K151.  However, the site of Fbxo7-mediated ubiquitination remains 
unknown.  Systematic replacement of lysine residues of Mff could answer this question; 
knock down of Fbxo7 would have no effect on ubiquitination of a mutant which it could 
not target.  This experiment could also identify other sites of Mff ubiquitination, allowing 
us to generate a non-ubiquitinatable mutant.   
 
Identification of the SIM in Parkin 
The role of the PINK1-Parkin pathway in mitophagy has been extensively described 
in the literature, with a large focus on regulation of Parkin activity and its autoinhibition 
(Burchell et al., 2013, Narendra et al., 2010, Caulfield et al., 2014, Caulfield et al., 2015, 
Wauer et al., 2015b, Seirafi et al., 2015, Ordureau et al., 2015, Wu et al., 2016, Gladkova 
et al., 2018).  Despite this, only one report has functionally linked Parkin and SUMO (Um 
and Chung, 2006).  Data presented in this thesis have validated the finding of Um and 
Chung that Parkin and SUMO can interact non-covalently, however the site of this 
interaction remains unknown.  Parkin does not contain a conventional SUMO-interacting 
motif.  Um and Chung demonstrated that binding was not via the Ubl of Parkin but were 
unable to define the interaction site further.  To resolve this, I have already generated a 
series of overlapping fragments of Parkin, dictated by domain structure (data not shown).  
In the future, co-immunoprecipitation experiments using these fragments could narrow 
down the site of the Parkin-SUMO interaction and allow for in silico modelling of potential 
interaction interfaces. 
 
Validation and analysis of Parkin as a SUMO substrate 
One of the most interesting discoveries of this project was the finding that Parkin 
can be modified by SUMO.  Parkin, like over half of the known SUMO substrates, does not 
contain a SUMOylation consensus motif.  Nonetheless, using the same Parkin fragments 
discussed above, immunoprecipitation experiments could help to narrow down the site of 
potential SUMOylation.  Systematic mutation of lysine residues in the candidate fragment 
could then be used to demonstrate the exact site of SUMOylation.  However, for these data 
to be of importance or physiological relevance, we would need to demonstrate a functional 
outcome of Parkin SUMOylation.  SUMOylation of Parkin could be involved in its 
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autoinhibition, activation, subcellular localisation, degradation or function, but for Parkin 
to be named a bona fide SUMO substrate this would need to be experimentally 
demonstrated, ideally using endogenous levels of both Parkin and SUMO.  
Immunoprecipitation of over-expressed Parkin, like the experiments performed for Mff, 
would be a good starting point, to demonstrate that endogenous levels of SUMO are 
sufficient to modify Parkin. 
 
Potential roles of these pathways in regulating neuronal function and dysfunction in 
disease 
While the roles of Parkin, Fbxo7 and Mff in cardiac tissue remain under-investigated, 
because of the importance of the proteins investigated here in neurodegenerative 
diseases, the natural next step for this project would be re-capitulation of the experiments 
presented here in neurons.  Both Parkin and Mff are strongly implicated in Parkinson’s 
disease (PD) for their role in mitophagy, and Parkin and Fbxo7 have been shown to function 
in a similar pathway in PD (Burchell et al., 2013, Gao et al., 2015).   Parkin is known to be 
mutated in many cases of PD, and there are over 120 known PD-associated pathogenic 
mutations of Parkin (Seirafi et al., 2015).  Data from the Henley lab has shown by mass 
spectrometry that Mff is increased in Fbxo7-depleted neurons (Dr Dan Rocca, unpublished 
data).  As yet, no published work has demonstrated a functional link between all three 
proteins of these proteins in PD.  The Henley lab has acquired post-mortem brain tissue 
from patients who died with PD, as well as controls.  It would be interesting to see whether 
levels of these proteins are altered in these samples.  Furthermore, a cellular model of PD 
has been recently established in the lab using SH-SY5Y cells (Dr Ruth Carmichael, 
unpublished data).  Using this model, it would be interesting to see whether modulation of 
Parkin, Fbxo7 or Mff levels, or Mff SUMOylation status, could be protective against PD.      
6.6 Conclusions and significance 
To our knowledge, this is the first study to systematically characterise changes in 
mitochondrial dynamics proteins and post-translational modifications in cardiac I/R injury.  
The discovery that Parkin and Fbxo7, both mitophagy-associated proteins, are significantly 
less recruited to mitochondria during ischaemia following IPC could go some way towards 
unravelling the illusive molecular mechanisms behind the protective effects of ischaemic 
pre-conditioning. 
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I show that Parkin and Fbxo7 contribute to regulation of mitochondrial morphology 
during ischaemia and demonstrate for the first time that Mff is ubiquitinated by Parkin at 
K151 and an Fbxo7-containing CRL complex, independently of one another.  We show that 
Mff is a novel SUMO substrate and that SUMOylation of Mff is induced by ischaemia, 
probably through AMPK-mediated phosphorylation.  I also show that SUMOylation of Mff 
acts to recruit a SUMO-targeted ubiquitin ligase. 
The implications of interactions and inter-dependent regulation of Parkin, Fbxo7 and 
Mff have far-reaching consequences.  The experimental data presented in this thesis 
contribute not only to understanding of the protective effect of cardiac IPC, but also to 
other pathologies in which aberrant mitochondrial dynamics are a major factor, including 
neurodegenerative diseases such as PD. 
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Chapter 8 Appendix 
8.1 Supplementary Figure 1 
 
Figure 8.1 Mff epitope is present in all 5 human isoforms. Sequence alignment of region 
containing Santa Cruz Mff monoclonal antibody (C-11) epitope with Full length human Mff 
(isoform 1) and isoforms 2-5. Region containing epitope sequence is highlighted (red) and 
present in all Mff isoforms. Alignment produced using ClustalOmega. Uniprot identifiers 
are as shown (Q9GZY8: full length Mff (as used in Mff constructs), Q9GZY8-2-5 are shorter 
isoforms 2-5). 
 
